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Abstract   I 
Abstract 
In this thesis two projects were conducted that had the incorporation of synthetic 
polymers in common albeit at different scales, the nano and the macro scale.  
In the nanoscale project functional polymers were synthesized from initiators bound 
to the interior of a protein cage, the thermosome. The thermosome has pores that are 
large enough for biomacromolecules like nucleic acids or proteins to enter and leave 
the cavity. The synthesized cationic polymers within the thermosome acted as 
anchors through electrostatic interaction and prevented anionic macromolecules from 
diffusing out of the cage. Delivery experiments of biomacromolecules into 
mammalian cells were conducted with the thermosome-polymer conjugates. SiRNA 
and fluorescent proteins were delivered into cells and the results highlight the 
potential of the conjugates for therapeutic drug delivery. Moreover, the entrapped 
molecules were protected from degradation by the local biological environment and 
the cage structure of the thermosome shielded cells from positive charges, which are 
otherwise cytotoxic. 
In the macroscale project a thin water vapor permeable membrane was equipped with 
synthetic polymers forming amphiphilic conetworks. The thin climate membranes 
are widely used in apparel or medical applications. Their drawback is that when 
punctured they cannot close this puncture autonomously. Therefore, the thin 
membrane was equipped with an amphiphilic conetwork in order to add self-closing 
properties while, in addition, being capable to let water vapor pass the membrane. 
The self-sealing properties increased with the thickness of the amphiphilic conetwork 
layer.  
In the two projects, the addition of synthetic polymers allowed generation of new 
functionalities in nano transporters and they provided improvement of the properties 
of synthetic membrane. 
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Chapter 1  1 
Chapter 1 
1 Introduction  
1.1 Aims and motivations for the thesis 
The work for this dissertation is based on two separate projects. The first and main 
project is to synthesize polymers within a protein cage, the thermosome, to obtain 
protein cage-polymer conjugates with the ability to deliver therapeutic 
biomacromolecules into cells. Protein cages show a high uniformity when compared 
with synthetic nanocapsules and a high stability. The thermosome has, in contrast to 
other protein cages, pores that allow the encapsulation of macromolecules like 
proteins or DNA/RNA. Inspired by other researchers working in the field of protein-
polymer conjugates and viral capsids, our motivation was to prepare tailor-made 
polymers within the interior of the thermosome. Those polymers should act as 
anchors for biomacromolecules that reversibly bind the cargo into the cavity and 
have fluorescent labels that allow tracking the cell uptake of the protein-polymer 
conjugate. To this end, ATRP initiators had to be covalently bound to specific sites 
on the inside wall of a mutated thermosome variant. Then, functional homo and 
copolymers had to be synthesized within the cavity of the thermosome by ATRP. A 
methacrylate with a tertiary amine group in the side chain was selected to yield a 
polymer that is cationic at physiological pH, and a fluorescent methacrylate was 
selected as comonomer to yield fluorescently labeled polymers. Another aim of 
polymer synthesis within the cavity was to obtain polymers that do not protrude from 
the cavity, as this can lead to cell toxicity. Moreover, the idea was to create protein-
cage polymer conjugate that could protect the cargo (e.g. siRNA) from degradation 
by enzymes and do not form aggregates in the presence of it. With the developed 
thermosome-polymer conjugates cell uptake and toxicity studies had to be conducted 
as well as binding studies with biomacromolecules. In addition, delivery experiments 
of biomacromolecules (e.g. siRNA, fluorescence proteins) should be performed to 
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show the possibility of the protein cage-polymer conjugate as delivery platform for 
therapeutic cargo. 
The second project was a joined project between the University of Applied Sciences 
Northwestern Switzerland (FHNW) and the company Unico swiss tex GmbH. 
Unicoswiss tex does not have an own research facility, therefore a NanoArgovia-
project was established with the motivation to improve an already existing product of 
this company. The product is a medical cooling laminate based on a polyethylene 
terephthalate fabric sandwiched between two thin semi-permeable membranes. 
Water is filled into this laminate and evaporates through the breathable and water 
proof membranes. The water evaporation reduced the temperature in the vicinity of 
the laminate, and can therefore be used to cool the skin of patients. The drawback of 
such thin membranes is that they become easily damaged and punctured, which 
makes the cooling laminate leaky. Our motivation was to implement self-sealing 
properties into the membranes so that small defects of the membrane are 
autonomously closed by the material. The aim was to coat the membranes with a 
layer of polymer network that swells upon contact with water and that can close 
defects by this swelling. In addition, the material should not hamper the evaporation 
of water through the membrane and should be able to close defects when 
overpressures are applied. 
1.2 Structure of the thesis 
The main focus of this thesis is protein cage-polymer conjugates. For this reason, in 
chapter 1, an introduction to the preparation methods of protein-polymer conjugates 
is given and afterwards the topic of protein cages with synthetic polymers is 
reviewed. The research results and experimental works of the two projects that were 
conducted for this dissertation are presented in chapter 2. A general conclusion of the 
research projects with a brief reflection of the experimental work and an outlook for 
further developments is given in chapter 3. 
 
Chapter 1  3 
1.3 An introduction to preperation methods for protein-
polymer conjugate synthesis 
In this chapter, the different preparation methods of 
protein-polymer conjugates and their applications are 
described. Polymers can either be attached to proteins 
or they can be synthesized from the protein. Moreover, 
functional groups for polymer attachment to a protein, 
possible modifications for selective attachment 
andpolymerization methods for conjugate synthesis in 
aqueous solutions are shown. 
 Protein-polymer conjugates, their properties and their 1.3.1
applications 
Protein-polymer conjugates also termed bioconjugates are hybrid materials in which 
one or more synthetic polymers are covalently bound to a protein.1,2 The idea behind 
this boundary is to profit from the advantages of each compound, while reducing the 
drawbacks.1-3 Thus, creating a synergy between proteins and polymers is of scientific 
interest. Attaching polymers to a therapeutic protein can increase its circulation-
lifetime in the body; decrease its immunogenicity and enzymatic degradation, and 
increase their bioavailability.4-7 Moreover, polymers can stabilize a protein at lower 
pH or higher temperatures8,9 increase their shelf-life9 and increase10 or regulate the 
activity of catalyst-proteins, so called enzymes.10,11 In multimeric enzyme 
complexes, polymers can stabilize their structure and the stability is often a drawback 
of enzymes if intended to be used in large scale biocatalytic applications.12 Most 
proteins denaturate due to disruption of molecular interactions in pure organic 
solvents or in mixtures in which the organic solvent is over 50 %. With attached 
polymers to the proteins, these proteins can be stabilized and remain dissolved in the 
organic solvent.13,14 Recent advancements in protein-polymer conjugate synthesis 
involve polymers that are responsive to external stimuli (e.g. pH, light, temperature) 
so called smart polymer bioconjugates.15 Such conjugates react upon influence of 
external stimuli and have properties like changed thermo and pH-precipitation for 
bioseperation and thermo- and light-responsiveness for biosensing applications.15 On 
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the one hand, synthetic polymers support proteins in many ways. On the other hand, 
proteins were also used to improve and support polymers. In drug delivery 
applications for example, proteins were attached to polymers and promoted the 
cellular uptake of the polymers and polymer-bound drugs and improved the 
circulation of polymeric nanocarriers.16-18  
 Methods of protein-polymer synthesis 1.3.2
In protein-polymer synthesis, the control over the molecular weight of the polymer 
plays an important role, because the length of the polymers can significantly alter the 
properties of a protein-polymer conjugate (e.g. circulation time, enzyme activity, 
disruption of protein-receptor interactions).5,10,19 Therefore polymerization 
techniques are applied that enable the synthesis of polymers with a low molecular 
weight distribution. 20-24 
Protein-polymer conjugates can be synthesized in various ways. The synthesis can be 
achieved either by a grafting-to, a grafting-through or a grafting-from approach 
(Figure 1.1.1a-c). In a grafting-to approach, the polymer chains are attached to the 
protein. In this case, polymers can be synthesized at optimized conditions (e.g. type 
of organic solvent, temperature or type of controlled polymerization (anionic,20 
cationic,21 radical22-24 amongst others25-27) and after synthesis and purification, 
synthetic polymers are attached to the protein (Figure 1.1.1a). The polymer has to 
have a functional group that can bind to an amino acid of the protein to form a stable 
conjugate. Besides the advantage of an optimized synthesis of the polymer, the 
grafting-to method also has disadvanages.28 Attaching a macromolecule to another 
macromolecule mostly leads to low yields of the product due to lower reactivity, 
which is connected with steric hindrance.15,28 Another drawback is the purification of 
the protein-polymer conjugate from the unreacted macromolecules (protein and 
polymer).28 
The grafting-through approach is another method of bioconjugate synthesis (Figure 
1.1.1b).15 In this method, proteins having a polymerizable group (e.g. vinyl, acrylic 
or methacrylic) are embedded in a chain with a carbon backbone. This is in contrast 
to the grafting-to and grafting-from approach, where proteins are not incorporated 
into the polymer chain. In order to avoid low polymerization efficancy due to steric 
Chapter 1  5 
hindrance with larger proteins, comomoners are added for better polymerization 
control.15  
The grafting-from approach starts with the attachment of polymerization initiators to 
reactive amino acids of the proteins (Figure 1.1.2a-g).15,28,29 From those initiators 
polymers are grown by the interconnection of monomers. The advantage of the 
grafting-from strategy is that after the polymerization reaction, separation of the 
products from the reactants is easier than in the grafting-to strategy. Reason for this 
is, that only small molecules (Catalysts, reducing agents and monomers) have to be 
separated from a high molecular weight product. Moreover, the product yield is 
higher because the conjugation reaction occurs between small molecules and the 
protein and thus steric hindrance is lower than for the grafting-to approach.28  
 
Figure 1.1.1. The three most common ways to synthesize protein-polymer conjugates. (a) “Grafting-
to” synthesis: The polymer is synthesized separately and then attached to the protein by interaction of 
functional groups. (b) “Grafting-through” method: In this method, proteins, which contain a 
polymerizable group, are polymerized with other monomers. In this case, the proteins are embedded 
in the backbone of the polymer chain. (c) “Grafting-from” synthesis: Polymers are synthesized from a 
protein-coupled radical initiator or chain-transfer agent. The polymers grow from the protein. Adapted 
with permission from 15. Copyright 2014 Nature Publishing Group. 
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 Functionalization of amino acids   1.3.3
The most common amino acids used for direct attachment of polymers or 
polymerization initiators to proteins are lysines and cysteines (Figure 1.1.2).15 
Conjugation of lysines yields an amide bond between the protein and the attached 
polymer or initiator (Figure 1.1.2a-c).15 Typical reagents for attachment of molecules 
to lysines have following functional groups incorporated: N-succimidyl ester (Figure 
1.1.2a), pentafluorphenyl activated ester (Figure 1.1.2b) or a carboxylic acid (Figure 
1.1.2c). The conjugation of functional molecules to cysteines results in disulphide 
bonds or thioether connections, depending on the reactive group of the conjugation 
partner.15 Molecules can be attached to cysteines by a thiol-disulfide exchange with 
orthopyridyl disulphide, which results in the formation of a disulphide bond between 
the protein and the attached molecule (Figure 1.1.2d).15,28 Thioether formation 
between protein and synthetic polymers or polymerization initiators was achieved by 
reaction of cysteines with molecules bearing a vinyl (Figure 1.1.2e),15 maleimide 
(Figure 1.1.2f)15,28,29 or vinyl sulphone functional group.15 
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Figure 1.1.2. Common functionalization strategies of lysines and cysteines in proteins. For lysines (a) 
N-succimidyl esters, (b) pentafluorphenyl activated ester or (c) carboxylic acid in combination with 1-
ethyl-3-(3`dimethylaminopropyl) corbodiimide (EDC) for amidation in water. Conjugation to 
cysteines is typically conducted by the reaction with (d) pyridyl disulfides, (e) vinyls, (f) maleimides 
or (g) vinyl sulphones. Adapted with permission from 15. Copyright © 2014 Nature Publishing Group. 
For biomedical applications of protein-polymer conjugates, it is desirable to control 
the stoichiometry between protein and polymer chains and also the site of 
modification.28 This control is very difficult to achieve when lysines are intended to 
be used for conjugation because they are ubiquitously present on proteins. Therefore, 
alternative site-selective modifications are desired.28 One strategy for example is the 
selective introduction of cysteines or amino acids with alkyne groups for alkyne-
azide ligation into proteins by genetic methods.15,30 Another example is the selective 
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transamination of the primary amine at the N-Terminus by pydridoxal-5-phosphate 
due to a different pKa-value (7.6-8.0) compared to the primary amines of lysines 
(pKa 10-12).6,28 In addition, molecules can be conjugated to prolines by the reaction 
with o-aminophenols28 and the binding to other amino acids (e.g. thyrosine) was also 
conducted.6,15,28,29,31  
 Controlled radical polymerization methods used for for 1.3.4
protein-polymer synthesis by a grafting-from approach 
There are known issues of proteins in organic solvents like possible denaturation. 
Thus, grafting-from syntheses have to be performed either in buffered solutions, pure 
water or in water with the addition of an organic co-solvent (e.g. methanol, THF or 
DMSO). There are three common ways of conducting controlled polymerization 
reactions, either anionic polymerization20, cationic polymerization21 or radical 
polymerization.22,32,33 Anionic or cationic polymerization can not be applied in 
aqueous solutions due to the reaction of water with either carbanions or carbcations, 
which results in a termination of the polymerization reaction.21,34 In addition, the 
polymerization initiators are inactivated by the reaction with water21,34 Thus, radical 
polymerization methods were applied for the synthesis of protein-polymer 
conjugates, because of the compatibility with aqueous solutions.15,29,35-38 Controlled 
radical polymerization is a method used for synthesis of polymers with low 
polydispersity. The principle behind this technique is that it uses radicals instead of 
cationic21 or anionic20 charges to activate unsaturated double bonds in molecules 
(vinyls, acrylates and methacrylates) allowing their interconnection and constant 
growth into polymers. The two most common controlled, also named reversible-
deactivation, radical polymerization methods, which were applied for bioconjugate 
synthesis are atom transfer radical polymerization (ATRP)32,39 and reversible 
addition-fragmentation chain-transfer (RAFT) polymerization.40 ATRP is a radical 
polymerization technique that uses a transition metal complex in its lower oxidation 
state as catalyst in combination with an alkyl halide (R-X, wheras X = Cl, Br, I) to 
generate radicals in a controlled way.22 The halides are can be bound bound to 
primary, secondary or tertiary carbon atoms, which influences the reactivity and a 
radical stabilizing group (e.g. ester, benzyl, cyanide).39 
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The ligands that form the transition metal complex together with metals (e.g. Cu,41 
Fe,41 Ru,42Ni43) usually contain nitrogen as ligating atom (Figure 1.1.3).44  
 
Figure 1.1.3. Examples of nitrogen-containing ligands used in ATRP. Adapted with permission 
from44. Copyright © 2007 American Chemical Society. 
In ATRP the control over the molecular weight of the polymers relies on an 
equilibrium between propagating radicals (Figure 1.1.4, right side) and a dormant 
species (Figure 1.1.4, left side). The dormant species is the alkylhalide/polymer-X 
(R-X/ Pn-X). It reacts with the transition metal complexes in their lower oxidation 
state (Mtm/L) with an activation rate constant (kact). In this reaction, a halogen 
transfer from the dormant species to the lower oxidation state transition metal 
complex (Mtm/L with e.g. CuI) occurs. This transfer causes the creation of a radical 
on the alkyl halide/polymer, while in parallel, the transition metal complex is 
transformed into its higher oxidation state (X-Mtm+1/L e.g. CuII) due to the binding of 
the halide. The generated radical reacts with meth(acrylate) monomers in the 
solution, which results in constant polymer growth. The halogen transfer is a 
chemical equilibrium and thus reversible with a corresponding kdeact. The halide is 
transferred back to the radical species and this back transfer interrupts the 
polymerization process, until the dormant species/the polymer-halide is activated 
again by the transition metal complex.22 The equilibrium is influenced by many 
factors (e.g. metal-binding capability of the ligand, reactivity of the initiator and their 
concentrations as well as the choice of solvent)22,39  
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Figure 1.1.4. Schematic representation of the ATRP equilibrium. Adapted with permission from22. 
Copyright © 2012 American Chemical Society. 
In classical ATRP copper-catalyts are usually applied and the drawback is that 
usually larger (e.g. equimolar) amounts of copper are used for the reaction. High 
amounts of copper (several mM to M) can cause toxic reactions.45 In order to reduce 
the amount of copper in the synthesis of polymers and therefore make the procedure 
more environmentally friendly, a polymerization method was developed that uses 
low amounts (ppb) of copper. This method is called activators regenerated by 
electron transfer atom transfer radical polymerization (ARGET ATRP).46 In ARGET 
ATRP, a reducing agent is added to the reaction mixture (e.g. sodium ascorbate, 
ascorbic acid, tin(II)ethylhexanoate, glucose) (Figure 1.1.5).22 The reducing agent 
reduces the higher oxidation state catalyst, which is more stable in aqueous solution 
and creates the active lower oxidation state catalyst.22  
 
Figure 1.1.5. ARGET ATRP equilibrium. Adapted with permission from22. Copyright © 2012 
American Chemical Society. 
Reversible-addition fragmentation transfer (RAFT) polymerization47 is another 
technique that is applied for protein-polymer conjugate synthesis.48 Instead of a 
transition metal complex in combination with an alkyl halide like in ATRP, radical 
formation is initiated by a free radical polymerization initiator e.g. 
azobisisobutyrylnitrile (AIBN).49 The control over molecular weight of the polymers 
and their dispersity (Ɖ) is achieved by the addition of a reversible-addition 
fragmentation transfer agent, which is typically based on trithiocarbonates, 
dithiocarbamates or dithioesters.40,50 
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In this thesis the focus was set on ARGET ATRP, due to difficulties with the 
synthesis of a RAFT-transfer agent that could be coupled with proteins. Moreover, in 
ARGET ATRP the copper amount in solution is lowered, which is beneficial for 
biological applications of the conjugates.  
1.4 Protein cages and synthetic polymers: A fruitful 
symbiosis for bionanotechnology 
This chapter will be submitted for publication as an invited review as: Rother M., 
Nussbaumer M. G., Renggli K., Bruns N., Protein cages and synthetic polymers: A 
fruitful symbiosis for bionanotechnology, Chem. Soc. Rev., 2016 
 
Protein cages have been investigated as e.g. 
templates for the synthesis of inorganic and 
organic nanoparticles, as transporter for 
biomedical applications or as nano reactors. In 
this chapter, the recent developments in the field 
of protein cages combined with synthetic 
polymers are reviewed. Polymers can be 
attached on the exterior to extend circulation 
time of the nano vehicles and decrease immunogenicity and, in addition, to promote 
cellular uptake. Polymers in the interior allow the implementation of higher densities 
of cargo for biomedical applications and they allow the modulation of cage 
structures that do not occur in nature. The interior of protein cages can be used as 
reaction vessel for polymer synthesis. Moreover, synthetic materials in which protein 
cages were integrated exhibit enhanced materials properties. 
 Introduction 1.4.1
Hollow nanoparticles play an important role in nanotechnology, materials science 
and in the biomedical field because they can be used as nanoscale reaction vessels,51-
59 as templates for the synthesis of nanostructured inorganic and organic materials60-
64 and as capsules for the delivery and controlled release of therapeutics.53,65-67 
Prominent examples for synthetic nanoscale objects are self-assembled block 
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copolymer vesicles,55,67,68 lipid vesicles69 or layer-by-layer polyelectrolyte capsules.70 
While there is no doubt about the tremendous potential of these systems, they have 
some limitations. It can be cumbersome to equip them with advanced functionalities, 
and it is not possible to modify their shell site-selectively with, e.g. targeting ligands 
or catalysts. Moreover, their wide size distribution can represent a problem for their 
use as templates or in drug delivery. Nature provides us with a rich toolbox of 
functional micro- and nanocompartments, e.g. organelles and lipid vesicles. Protein 
cages, such as the iron storage protein ferritin, viral capsids or chaperonins, are 
particularly interesting types of natural nanocompartments.54,58,71-79 The term ‘protein 
cage’ describes a broad range of proteinaceous structures that share the common 
feature that protein subunits self-assemble into hollow nanoobjects with at least one 
cavity. These cavities are large enough to enclose e.g. inorganic nanoparticles, 
nucleic acids and other proteins. Each kind of protein cage is uniform in size. Protein 
cages are highly symmetric structures. Therefore, only a few different types of 
protein subunits, but many copies of these subunits are needed to form them. For 
example, ferritin is a hollow sphere with an outer diameter of approximately 12 nm 
and an inner diameter of 7–8 nm that consists of 24 copies of a protein.77 The P22 
bacteriophage capsid is 58 nm in diameter and assembled from 420 coat proteins.78 
The interior of protein cages is accessible through pores that are located in between 
protein subunits. These pores are well defined with respect to their size and 
polarity.54 Moreover, some protein cages are dynamic structures that can be 
assembled and disassembled on demand in response to external stimuli,78 or that 
undergo conformational changes that open or close pores.54 A more detailed 
description of the structure and biological function of various protein cages is given 
in the first section of this review. 
Protein cages are ideal building blocks for bionanotechnology because of their well-
defined size and structure. Moreover, they are non-toxic, biodegradable and many 
exhibit chemical and thermal stability.72,75,80,81 
Their pores and their intrinsic functionality make them attractive candidates for 
applications ranging from nanoreactors to materials synthesis and drug 
delivery.54,58,72-74,76-78,82-96 Their most prominent application is the use of viral capsids 
as vectors for gene therapy.97–98,99 
The unique feature of protein cages is, in comparison with synthetic nanocapsules or 
lipid-based compartments, that their subunits can be modified at precisely known 
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locations by genetic engineering100 or by chemical means.74,101-103 Structures of many 
protein cages have been resolved and are available in databases. Thus, it is possible 
to tune the properties of protein cages by modifying them on their outside surface, on 
their inside, i.e. on the surface that lines the cavity and at the interface between 
subunits.13,72,104-106 Genetic engineering of protein cage subunits allows insertion of 
cysteines or non-native amino acids at a desired location in or on protein cages. As 
protein cages consist of many copies of the same protein subunits, one genetic 
modification will result in multiple copies of the modification distributed around the 
protein cage, their location defined by the symmetry of the structure. Such point 
mutations can act as specific attachment points for chemical conjugation102 of, e.g. 
drugs, imaging agents, targeting moieties, (bio) catalysts, polymerization initiators 
and polymers.61,75,105,107-120 Moreover, abundantly present amino acids such as lysine, 
can be chemically modified to introduce a high number of ligands.72,74,101,121,122 The 
exterior of the protein cages represents an ideal surface for multivalent ligand 
display. It was e.g. modified with cell targeting and penetrating moieties such as the 
tripeptide RGD,110,123 TAT peptide,124 LyP-1 peptide,125 EPCR-targeting peptide and 
PAR-1-activating peptides,122 SP94 peptide,126 folic acid,107 hyaluronic acid,127 
biotin,128 the trimeric decoration protein from bacteriophage L129 and aptamers,130 to 
enhance uptake of the protein cages into specific cell lines and, in addition, with 
nanoparticles92,131,132 for nanomaterial synthesis. The interior surface offers the 
possibility to bind catalysts,61,62,120,133 enzymes,90,134-136 nanoparticles,91,137-144 
therapeutic cargo107,110,112,145 and contrast agents119,123,146-148 into the protein cage. 
Moreover, the interface between subunits can be modified to tune the stability of the 
protein cages,106or to change the permeability of the pores.72 Compared with 
synthetic nanocapsules, protein cages offer many advantages. However, also some 
drawbacks have to be mentioned. If intended for use as a drug-delivery vehicle, they 
can be a source of immune reactions, because they are foreign proteins to the human 
body.149-151 Moreover, bare protein cages might be rapidly cleared from circulation or 
neutralized by antibodies.149,150,152 It is not surprising that such problems were 
addressed by attaching PEG chains to the outside of protein cages.152-154 PEGylation 
is a proven method to hide protein therapeutics from the immune system and to 
increase their circulation time.155 Thus, the combination of protein cage delivery 
agents with synthetic macromolecules is highly beneficial. Other combinations of 
protein cages and synthetic polymers have emerged in recent years, either to 
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circumvent intrinsic shortcomings of the protein structures or to obtain 
multifunctional hybrid systems that combine the best of two worlds, the possibility to 
synthesize tailor-made functional polymers with the intriguing structure and 
functionalities of protein cages. Thus, new concepts in 
bionanotechnology,77,102,114,148,156-160 biomedical applications74,75,77,81,101,104,111,113-
115,153,161-165 or materials science52,61,62,77,102,158,166-177 can be pursued. This review will 
summarize the emerging field of protein cage polymer hybrids. After an overview of 
the structure and function of several protein cages, it will cover the modification of 
the exterior surface of protein cages with polymers, embedding protein cages into 
polymeric materials, the adsorption of protein cages onto polymeric surfaces, the 
encapsulation of polymers into protein cages and the synthesis of polymers within 
protein cages (Figure 1.2.1). The reader will be introduced to the basic concepts, and 
potential fields of applications will be highlighted. The focus is set on the beneficial 
combination of protein cages and synthetic polymers. Reports on preparation 
methods of protein-polymer conjugates with either synthetic polymers or natural 
polymers (e.g. glycopolymers, peptides, poly(nucleic acids) and their applications 
have been nicely summarized elsewhere.3,15,28,29,31,178-180 
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Figure 1.2.1. The symbiosis of protein cages with synthetic polymers creates many opportunities for 
nanobiotechnology. This scheme summarizes the main approaches to combine protein cages with 
polymers and highlights properties and applications of the resulting protein–polymer hybrids. 
 Structure and properties of protein cages 1.4.2
1.4.2.1 General aspects 
Protein cages can be categorized into non-viral cages and virus-like particles 
(VLPs).93,181,182 Examples of non-viral protein cages are ferritins,183 vaults,184 heat-
shock proteins,185,186 chaperonins,187,188 lumazine synthase,189 encapsulins108,190,191 
and bacterial microcompartments.192-194 Most of these protein cages are roughly 
spherical in shape. Their size ranges from 9 nm for the spherical DNA-binding 
protein of starved cells (Dps)72 to bacterial microcompartments with a diameter of 
80–150 nm.192-194 Viruses occur in various morphologies. For example the tobacco 
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mosaic virus (TMV)195 and the M13 bacteriophage are rod-shaped viruses, while 
cowpea mosaic virus (CPMV),196,197 cowpea chlorotic mottle virus (CCMV),197,198 
bacteriophage MS2199,200 and adenovirus (Adv)201-203 have icosahedral, i.e. quasi-
spherical structures. Rod-shaped viruses have been extensively investigated as 
templates for inorganic and polymeric materials.116,204-207 However, as they do not 
feature a large internal cavity, they are not protein cages in the sense of this review 
and therefore will not be covered in detail. Icosahedral viral capsids tend to be larger 
than non-viral protein cages. Their diameter ranges from approximately 14 nm to 880 
nm.78,105,208 Icosahedral viruses can be described with a symmetry triangulation 
number T due to their high symmetry. Caspar and Klug developed this concept of a 
specific number of protein repeating units that form regular viruses.209,210 VLPs are 
derived from native viruses, but lack encapsulated viral DNA or RNA.181 VLPs can 
have the same structure as the native viral capsids, but may also differ in 
morphology, size and number of subunits. 
Most protein cages have static pores in their protein shell at the interface between 
subunits. These pores range in diameter from 0.4 nm for ferritin,211 over 
approximately 3 nm for heat-shock proteins212,213 to 10 nm for the P22 capsid in its 
wiffle-ball (WB) structure.214 These pores connect the interior cavity of the proteins 
with the exterior environment. Small molecules (e.g. ions, water, organic molecules) 
can diffuse through them. Thus, the pores act as size-exclusion gates because 
molecules bigger than the pore size cannot enter the cavity.133,215 As some pores 
carry electrostatic potentials or are lined by hydrophobic residues, they can also 
discriminate between molecules according to their polarity and charge.62 
At first sight, protein cages are often perceived as static structures. However, many 
protein cages are dynamic in nature. Some VLPs (e.g. CCMV) reversibly increase in 
size in response to external stimuli, e.g. a change in pH or the presence of metal 
ions.72,198,216,217 This process is caused by subunits moving along symmetry axes to 
larger radii and the concurrent cleavage and formation of contacts between 
subunits.198 It is referred to as swelling as the VLP expands, although this term has a 
different meaning in material sciences. Swelling of protein cages causes their pores 
to widen, thus enabling a better mass transport across their shell. Some protein cages 
(e.g. CCMV, ferritin and thermosomes) can be disassembled into their subunits and 
reassembled into the full cage by pH changes.218-225 This process can be exploited to 
encapsulate guests that are too large to fit through the pores in the wall of the cage.220 
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Chaperonins such as the GroEL–GroES complex, mammalian TRIC/CCT and 
archaeal thermoses have actively gated pores that open and close, using ATP as the 
energy source.226-228 This active gating allows these protein cages temporarily to 
encapsulate guests such as unfolded proteins. Interestingly, the open–close cycle of 
chaperonins can be blocked and the proteins locked into a closed conformation by 
ATP derivatives that mimic the transition state of ATP hydrolysis.229 
A great variety of protein cages exists and only a subset has been explored as 
functional nanoparticles for applications in nanotechnology, drug delivery and 
functional materials. For a comprehensive overview of protein cage structures, 
functions and applications, we would like to refer the reader to several excellent 
reviews published on this topic.54,72,73,78 Here, we will describe those protein cages in 
detail that have been used in conjunction with polymers. 
1.4.2.2 Non-viral protein cages 
1.4.2.2.1 Ferritin 
Ferritins are non-viral protein cages that are ubiquitous in animals, plants and 
bacteria (Figure 1.2.2b). Their natural function is the biomineralization of Fe2+ to 
Fe2O3•H2O, i.e. to store iron in a bioavailable and safe form. They play an important 
role in iron level regulation and in protection against oxidants. Moreover, they 
promote recovery from oxidative stress and help an organism to fight diseases in 
which iron accumulates.183 Mammalian ferritins consist of 24 protein subunits that 
form a spherical cage with an outer diameter of 12 nm and an inner diameter of 8 
nm.211,230 Along the threefold symmetry axes eight hourglass shaped channels with a 
diameter of 0.4 nm, a constriction diameter of 0.33 nm and a length of 1.5 nm 
connect the cavity with the outside, so that Fe2+ ions can enter and exit the protein 
cage. Moreover, six hydrophobic channels exist at the fourfold axes, which are also 
approximately 0.4 nm wide. Native ferritins encapsulate an iron(III) oxide 
nanoparticle that can be easily dissolved by appropriate reagents such as solutions 
containing [S2O4]2–, a mixture of nicotinamide adenine dinucleotide (NADH) and 
flavin mononucleotide (FMN) or dithiothreitol (DTT).183 The empty cage is called 
apoferritin (apo-Fr). Ferritin and apoferritin are robust nanoparticles, i.e. they 
withstand temperatures up to 85 °C,231 pH ranges from 2.0–9.0 and exposure to 6 M 
guanidine at pH 7.232 Moreover, ferritins are readily available by extraction from 
natural sources, by recombinant expression or through commercial suppliers. Thus, 
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they are popular protein cages and have been used in a variety of studies ranging 
from drug delivery to template nanoparticle synthesis and nanoreactors.58,77 
1.4.2.2.2 Heat-shock proteins 
Cells express heat-shock proteins (Hsps) at an increased level when they are stressed, 
e.g. at elevated temperatures (Figure 1.2.2a).185,186 Many Hsps are chaperones, i.e. 
they help to refold (partially) unfolded proteins, or they stabilize newly formed 
proteins. Therefore, they play an important role in protecting cells from 
environmental or physiological stress. Some Hsps have a cage-like structure. For 
example, small heat-shock protein (sHsp) from Methanococcus jannaishii consists of 
24 protein subunits that self-assemble into a hollow sphere.233 It has a diameter of 12 
nm and a cavity that is 6.5 nm in diameter.212 Eight pores with a diameter of 3 nm 
along the threefold symmetry axes and six pores with a diameter of 1.7 nm along the 
fourfold axes make the interior of the protein cage accessible for small organic 
molecules.118,160 
1.4.2.2.3 Chaperonins 
Another subclass of chaperones are chaperonins (Figure 1.2.2d).187,234 They are 
cylindrical protein complexes that feature so-called folding chambers. Non-native 
proteins refold within these cavities, while being protected from interactions with 
other unfolded proteins. Chaperonins are classified as group I and group II 
chaperonins according to their structure and origin. Group I chaperonins feature a 
detachable co-chaperonin as a lid that closes the cavity, whereas group II 
chaperonins have a proteinaceous lid build into their structure.188,226-228,234 Type I 
chaperonins (e.g. GroEL–GroES complex from Escherichia coli) occur in bacterial 
cytosol, chloroplasts and mitochondria, and type II chaperonins are present in 
archaeal cytoplasm (e.g. thermosome from the archaea Thermoplasma acidophilum 
(THS)) or in eukaryotic cytosol (e.g. TRiC/CCT). THS is the only chaperonin that 
has been modified with polymers or used as a nanoreactor for polymerization. Two 
eight-membered rings with alternating α- and β-subunits and pseudo-eightfold 
symmetry stack to form a cylindrical particle, i.e. THS in its fully open 
conformation. The fully closed conformation resembles a sphere with a diameter of 
approximately 16 nm.235 Each hemisphere encloses an ovoid cavity of approximately 
5.4 × 8.6 nm2 and a volume of approximately 130 nm3. The cavities are large enough 
to host globular proteins with a molar mass of up to 5 × 104 g mol–1.235 In contrast to 
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most other protein cages, chaperonins have large pores that allow proteins,234,235 
synthetic macromolecules61,163 and inorganic nanoparticles139 to enter and exit the 
cavities. In the case of THS, this pore is approximately 8–10 nm wide and gated by 
helical pertusions of the subunits.106,236,237 Under consumption of ATP, the subunits 
undergo concerted conformational changes that close and open this built-in lid.227,238 
1.4.2.2.4 Vault particles 
Vault particles (VPs) are ribonucleoprotein particles that occur in higher eukaryotes 
(Figure 1.2.2k).239-241 The name of the particle describes its barrel-like architecture, 
which resembles a vault ceiling of a gothic cathedral. Their size is 41 nm in diameter 
and approximately 73 nm in length.242 VPs are assembled from the major vault 
protein (MVP) with a mass of 1 × 105 g mol–1, the 1.93 × 105 g mol–1 vault 
poly(ADP ribose) polymerase (VPARP), the 2.4 × 105 g mol–1 telomerase-associated 
protein 1 (TEP1) and RNA, resulting in an overall molar mass of about 1.3 × 107 g 
mol–1.241 The function of VPs is unclear, but some studies suggest that they are 
involved in the protection of cells from toxins.242 
1.4.2.2.5 Pyruvate dehydrogenase complex 
The eukaryotic pyruvate dehydrogenase is the largest multienzyme complex known 
(Figure 1.2.2c).243 It converts pyruvate into acetyl-CoA and therefore links the 
glycolysis cycle with the tricarboxylic acid cycle. The complex consists of about 22 
pyruvate dehydrogenases (E1) and about six copies of dihydrolipoamide 
dehydrogenase (E3) that form a shell around a 60-mer complex of dihydrolipoamide 
acetyltransferase (E2). The E2 core is 24 nm in diameter and has pentagonal 
dodecahedron morphology, i.e. 12 pentagons form a spherical hollow particle.244 The 
cavity has a diameter of 12 nm. Small organic molecules can access its interior 
through 12 5.2 nm wide pores along the fivefold symmetry axes. The E2 core is 
stable without the E1 and E3 proteins and can therefore be used as a protein 
nanocapsule.245 
1.4.2.3 Virus-derived icosahedral protein cages 
1.4.2.3.1 Adenovirus 
The human adenovirus (Adv), discovered in 1953,246 is a non-enveloped, double-
stranded DNA (dsDNA) virus with a molar mass of 1.50 × 108 g mol–1 (Figure 
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1.2.2j). It measures about 95 nm from vertex to vertex.202,247,248 The capsid is 
assembled into a pseudo T = 25 icosahedral symmetry by three main proteins 
(capsomers): 720 subunits that form 240 hexon trimers, 12 pentagon-shaped penton-
base pentamers that are all centred on the vertices of the cage, and 12 fibre trimers, 
which are interconnected with the penton-base pentamers.202,247,248 The cage is 
composed of 20 facets and each facet is assembled from 12 hexon trimers and one 
penton-base at each vertex.247 Every penton-base has a central pore of 5 nm, which 
allows the insertion of the fibre shaft protein domain.247 The fibre trimers are 
responsible for interaction of the virus with host cells.247,248 They have a length of 9 
nm.247 In addition, four minor proteins (IIIa, VI, VIII and IX) are incorporated into 
the capsid.202 The minor proteins form networks of interactions, which provide 
additional stabilization to the cage.202,248 On each facet, a network of nine capsomers 
is formed and on each vertex there is a network of six capsomers.202 The minor 
proteins keep them together.202 Human Adv is non-oncogenic and is therefore used in 
gene and cancer therapy.249-252 
1.4.2.3.2 Cowpea mosaic virus (CPMV) 
CPMV is a member of the genus Comovirus in the virus family of	 Comoviridae 
(Figure 1.2.2e).253 Two single-stranded RNA molecules are encapsulated in its 
cavity.253 CPMV is a non-enveloped virus with a diameter of approximately 30 
nm.254 The capsid is composed of two different types of subunits, small subunits that 
are composed of the A-domain and large subunits that are formed from the B + C 
domains.254 Those subunits form pentons (A-domain) and hexons (B + C domains) 
that assemble around the single-stranded RNA into an icosahedral cage with a 
pseudo T = 3 structure.254 Channels of 2 nm in diameter enable the exchange of 
molecules from the exterior to the interior.255 The empty capsid has a molar mass of 
3.94 × 106 g mol–1.254 CPMV is a plant virus, therefore it has no biological hazard 
towards other organisms.254 In addition, it is stable at various conditions. For 
example, the cage is stable for more than two weeks in a solution containing 20% 
DMSO. At 50% DMSO content, the half-life of the cage is still several hours.254 This 
property allows the introduction of relatively hydrophobic molecules into the cage. 
1.4.2.3.3 Brome mosaic virus (BMV) 
BMV is very similar to cowpea chlorotic mottle virus (Figure 1.2.2f). The virus, 
which has a diameter of 28 nm and T = 3 symmetry, is composed of 180 identical 
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polypeptides with different conformations (A, B and C conformation subunits).256 
Pentameric capsomers are formed from the A subunits. The B and C subunits form 
hexameric capsomers.256 Small pores of 0.5 nm in diameter are present in the 
pentamers and 0.6 nm in diameter in the hexamers.256 The cage structure is mainly 
created by protein–nucleic acid interactions of the positively charged inner cavity of 
the capsid with the negative charges of the encapsulated single-stranded RNA.256 
Interactions between single capsid subunits are weak; therefore the RNA is necessary 
for the stability of the cage. At pH < 6.0 and in the presence of Mg2+ ions, the cage 
structure is in its native state.256 If conditions are changed (e.g. the pH is increased to 
7.0) structural transitions of the cage occur that can result in the complete 
disassembly of subunits and release of RNA.256 Disassembled subunits can be 
assembled into different morphologies as well as empty icosahedral cage structures 
(T = 1 and T = 3) at defined conditions.257 
1.4.2.3.4 Broad bean mottle virus (BBMV) 
BBMV is an icosahedral RNA-virus composed of 180 protein subunits, which is 
composed of approximately 190 amino acids and has a molar mass of approximately 
2 × 104 g mol–1.258,259 The subunits are arranged as pentamers and hexamers that 
form a T = 3 capsid structure.258 The external diameter of BBMV is approximately 
26 nm and a central pore of 10–12 nm is integrated in the capsid.258,260 
1.4.2.3.5 Bacteriophage λ procapsid 
The icosahedral bacteriophage λ procapsid is the head of the bacteriophage λ, 
which is missing its flexible, approximately 150 nm long, tail that is used for 
injection of viral dsDNA into the bacterial host (Figure 1.2.2h).261 The capsid is 
composed of 405 capsid proteins that are arranged to capsomers, which form a virus 
with a triangulation number T = 7.262 The immature procapsid has a diameter of 
approximately 54 nm with a shell thickness of approximately 7 nm.263 The immature 
procapsid expands after dsDNA encapsulation in the capsid to the mature capsid.263 
The external diameter increases to approximately 63 nm and the shell thickness 
decreases to 4 nm.263 In addition, the structure changes from a spherical shape to an 
icosahedral shape. As a result of DNA packaging, the inner pressure increases. A 
cement protein is implemented into the capsid structure to prevent the disassembly of 
the capsid caused by the internal pressure.262 Pores of 1.5–2.0 nm in diameter are 
present on many of the mature capsomers.261 
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1.4.2.3.6 MS2 
The MS2 bacteriophage is an icosahedral virus with encapsulated single-stranded 
RNA (Figure 1.2.2i).199 It only infects E. coli bacteria.199 The protein shell, with T = 
3 symmetry, is composed of 180 polypeptide chains (A, B and C chains), which have 
a molar mass of approximately 1.37 × 104 g mol–1 and are arranged as 60 triangular 
monomer units.199,200 The viral capsid has a diameter of approximately 28 nm200 and 
its shell has a thickness of 4 nm.199 Channels of 1.6 nm in diameter are distributed all 
over the capsid.200 In contrast to many other icosahedral viruses, the stability of the 
capsid is not primarily based on protein–nucleic acid interactions.199 The self-
assembly mechanism is mainly controlled by dimer–dimer contacts of the 
polypeptide chains. Therefore, RNA is not necessary for coat protein assembly.199 
1.4.2.3.7 Qβ bacteriophage 
The Qβ bacteriophage is an icosahedral RNA bacteriophage with T = 3 quasi-
symmetry that, like MS2, infects E. coli bacteria (Figure 1.2.2h).264 It is 
approximately 25 nm in diameter. Like MS2, it is composed of capsid proteins with 
different conformations (A, B, C coat proteins).264 The empty capsid has a molar 
mass of 2.7 × 106 g mol–1. It is composed of 180 coat proteins that are arranged as 12 
pentamers and 20 hexamers.265 The viral capsid features pores of approximately 2.5 
nm in diameter.265 The capsid is formed by hydrophobic interactions between the 
subunits and, in addition, is stabilized via disulfide bonds between the subunits.264 As 
in the case of MS2 bacteriophage, RNA is not necessary for capsid assembly.265 
Depending on the conditions, it is possible to form rod-like structures from the 
spherical Qβ bacteriophage.266 
1.4.2.3.8 P22 capsid 
P22 is a dsDNA phage that infects Salmonella bacteria (Figure 1.2.2l).267 The mature 
virion is developed through several maturation processes. The metastable procapsid 
with an external diameter of 58 nm and a T = 7 triangulation number is the first form 
in the development process.268,269 It is assembled from 420 copies of a coat protein 
(CP) with molar mass 4.66 × 104 g mol–1 and about 300 copies of a scaffolding 
protein (SP) with molar mass 3.36 × 104 g mol–1.269 The CPs are assembled to 
pentons and hexons.269 The SP aids the CP in capsid formation. After DNA insertion 
into the capsule, the SPs are removed. Insertion of DNA leads to an expansion of the 
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cage structure to 64 nm and, in addition, the thickness of the capsid wall decreases. 
The hollow procapsid, i.e. the empty cage structure (ES), can be created by removing 
the SP with guanidine hydrochloride. Heating of the empty P22 procapsid shell to 65 
°C expands the cage from 58 nm to 64 nm, forming the expanded capsid (EX).214,269 
The mature capsid possesses a portal that is composed of 12 protein copies.270 The 
portal is used for DNA insertion into the capsid.270 The narrowest part of this portal 
channel is 2.5 nm in diameter.270 Moreover, because of the maturation process, small 
openings of approximately 2.0 nm148 at the centre of the hexons occur.148 Additional 
heating of the expanded structure to 75 °C releases 12 penton subunits, creating the 
P22 WB structure.214,269 It has the same size as the expanded cage but with additional 
larger pores that have a diameter of 10 nm.269 
 
Figure 1.2.2. Structures of protein cages and viruses found in nature. (a) small heat-shock protein 
(HSP) (PDB: 1SHS),213  (b) apoferritin (PDB: 1DAT)211  (c) pyruvate dehydrogenase multienzyme 
complex (PDB: 1EAA),271 (d) thermosome (THS) (PDB: 1A6D),235 (e) cowpea mosaic virus (CPMV) 
(PDB: 1NY7),255 (f) brome mosaic virus (BMV) (PDB: 1JS9),256  (g) cowpea chlorotic mottle virus 
(CCMV) (PDB: 1CWP),198 (h) bacteriophage lambda (rendering of similar bacteriophage Q beta PDB: 
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1QBE), 264  (i) bacteriophage MS2 (PDB: 2MS2),200 (j) human adenovirus (Adv) (PDB: 1VSZ),203 (k) 
vault particle (PDB: 4V60),272  (l) bacteriophage P22 (PDB: 2XYY).273 Structures were rendered 
using the Chimera program.274  
1.4.2.4 Biodistribution of protein cages 
Because many studies with protein cages aim to use them as nanosized drug-delivery 
systems, it is worthwhile to review briefly their fate in vivo. In a study by Young and 
co-workers,149 the biodistribution of two protein cages, namely CCMV and Hsp, was 
analysed. Even though CCMV and Hsp differ in size (28 nm vs. 12 nm), in structure 
(icosahedral vs. octahedral) and in sequence, both protein cages showed a similar 
biodistribution in naïve and immunized mice. The reason could be their similar 
charge at neutral pH. Within one hour of intravenous injection, the protein cages 
were rapidly distributed and found in the majority of the organs. The protein cages 
translocated rapidly and easily through the tissues and extravasated from the 
circulatory system to the interstitial space, then further to the lymphatic system and 
eventually again into the vascular system. After 24 h, the majority of the protein 
cages were cleared from the mice, without any mortality. In contrast, similar studies 
with CPMV showed deposition of this protein cage in certain organs for up to 72 
h.275,276 CCMV and Hsp showed immunogenicity and induced IgG and IgM 
response. However, such side effects, which also occur with other therapeutic 
proteins, could be overcome with PEGylation or other shielding strategies (vide 
infra).75 In general, protein cages are suggested as safe, non-toxic and biocompatible 
drug-delivery platforms.149,150 
 Protein cages with a polymer corona: Polymers bound to 1.4.3
the outside of protein cages 
Protein cages can be easily modified with polymers on their outside, as their surface 
is freely accessible for reagents from solution. Not surprisingly, conjugates of protein 
cages and polymers have been synthesized by many of the well-known methods to 
prepare protein–polymer conjugates,15,29,277-281 such as the binding of preformed 
polymer chains to proteins via chemical linkers (grafting-to approach), the growing 
of polymer chains from protein-bound initiators (grafting-from approach), and the 
non-covalent binding of polymers to proteins, e.g. through multiple electrostatic 
interactions. Reasons to modify the exterior surface of protein cages with polymers 
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are to lower their immunogenicity and antigenicity, to increase the protein particles’ 
circulation time in the body, to stabilize and protect protein cages against degradation 
by proteases and other degrading enzymes and to decrease protein–protein 
interactions.155 Moreover, polymers can be used as flexible spacers to bind targeting 
molecules to the proteins to enhance the interaction of these targeting ligands with 
receptors on the surface of cells.109,282-284 As polymers can be designed to feature 
multiple copies of functional groups along their structure, they can be used to bind a 
high number of contrast agents or drug molecules on the exterior of protein cages.285 
PEGylation, i.e. the conjugation of poly(ethylene glycol) (PEG) to proteins and other 
(macro)molecules, is widely used to ‘mask’ nanoparticles, proteins and drugs from 
the immune system, thus effectively reducing their immunogenicity.286,287 Moreover, 
the presence of PEG increases their hydrodynamic radius and therefore prolongs 
their circulation time. As PEG is biocompatible, non-toxic and FDI-approved, 
several PEGylated drugs have successfully been introduced to the market.288-290 The 
scientific state-of-the-art of PEGylated nanomedicines was recently reviewed by 
Vllasaliu et al.155 
Examples of protein cages that were PEGylated are CPMV,153,154,291 CCMV,292 the 
MS2 bacteriophage,283,293 Adv,152,164,294 ferritin295,296 and the dodecahedral scaffold 
of E2 subunits from pyruvate dehydrogenase.297 The chain length of PEG plays an 
important role in the effectiveness and behaviour of PEGylated protein cages. For 
example, modification of CPMV with PEG of a molar mass of 1 × 103 g mol–1 did 
not inhibit the uptake of the viral capsids into human colon adenocarcinoma cells, 
while PEG with 2 × 103 g mol–1 effectively prevented the capsid from interacting 
with these cells, possibly because the longer polymer shielded key interacting 
regions on the surface of the capsid or because the longer PEG created a sufficient 
hydration shell around the protein.153 In addition to chain length, the number of 
polymer chains per protein subunit, i.e. the modification ratio, plays an important 
role in the interactions of PEGylated protein cages with cells and in the immune 
response they create in vivo. This was investigated by Nakagawa and co-workers 
using Adv.164 They PEGylated Adv (PEG–Adv) with 5 × 103 g mol–1 PEG with 
various modification ratios (30%, 45% and 90%) and investigated their anti-Adv 
antibody and anti-tumour response. To this end, unmodified Adv and PEG–Adv were 
administered to rats. The level of anti-Adv immunoglobulins was determined. 
Immunoglobulin levels were similar when unmodified Adv and PEG–Adv with 30% 
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or 45% modification ratio were administered, while PEG–Adv with 90% 
modification ratio caused a significantly lower immune response. In addition, PEG–
Adv with 90% PEGylation promoted expression of tumour necrosis factor-α and 
lowered the amount of metastatic colonies in the lung compared with unmodified 
Adv. In conclusion, a higher PEG density on Adv can reduce the number of 
antibodies against Adv and improve its efficacy against metastatic cancer. 
PEGylated protein cages were also modified with targeting groups to promote 
specific binding and uptake into cells. PEG–Adv was additionally modified with 
protein subunits from enzymes,282,298 monoclonal antibodies294 or cancer-targeting 
peptide chains284,299 for active targeting strategies. Transferrin-modified PEG chains 
were grafted to lysines on the exterior of bacteriophage λ procapsids (λ-PEG-Tf). 
The aim was to target transferrin receptors, which are overexpressed in some cancer 
cells.109,300 The Tf modification resulted in an enhanced uptake of the capsid by cells 
expressing the Tf receptor. 
Francis and co-workers explored the bacteriophage MS2 as a multifunctional drug-
delivery platform.283,293 They bound fluorescein into MS2 and grafted PEG to the 
outside of the capsid. By using PEG that carried biotin or a fluorescent coumarin at 
one chain end, PEGylated capsids were obtained that displayed small organic 
molecules as models of targeting ligands.283 The fluorescently modified MS2 allows 
tracking of its cellular uptake in cell-based assays. To demonstrate the potential of 
MS2-PEG capsids as delivery agents in in vivo applications, MS2 was modified on 
its interior surface with DOTA chelators that were labelled with 64Cu.293 The protein 
was administered to mice. Its biodistribution was imaged by positron emission 
tomography–computed tomography (PET–CT) and measured by gamma counting of 
organs. PEGylated MS2 showed less cellular uptake into the spleen than bare MS2, 
but otherwise the biodistribution of the two types of capsids was similar. 
In addition to the in vitro, ex vivo153 and in vivo301 advantages of PEGylated protein 
cages in biomedical applications, PEGylation can also be used to modulate the 
adsorption of protein cages on solid surfaces. PEGylation of ferritin reduced the 
adsorption of the protein onto silicon wafers and onto wafers that were modified with 
3-aminopropyltrimethylsiloxane.296 Moreover, the amount and chain length of PEG 
grafted onto ferritin influenced the adsorption behaviour of the protein cage. 
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Only a few research laboratories synthesize PEG in-house due to the difficult and 
dangerous handling of its monomer, ethylene oxide. Moreover, PEG cannot be 
synthesized in the presence of proteins because anionic polymerizations are not 
compatible with the functional groups of proteins. If ethylene glycol-based polymers 
with tailored properties need to be synthesized, it is more convenient to polymerize 
acrylates or methacrylates that have a PEG side chain. Wang and co-workers were 
the first to synthesize poly(oligoethylene glycol methacrylate) (poly(OEGMA)) by 
atom transfer radical polymerization (ATRP) from protein cage-bound initiators.302 
To this end, lysines on the exterior of apoferritin were chemoselectively modified 
with ATRP initiators via N-hydroxysuccinimidyl (NHS) ester conjugation. In a 
similar approach, reported by Hu et al., a NHS ester-functionalized ATRP initiator 
was attached to the exterior of ferritin and poly(OEGMA) chains were synthesized 
by a grafting-from approach with CuBr/bipyridine as catalyst.159 In addition, 
conjugates of poly(methacyryloyloxyethyl phosphorylcholine) (poly(MPC)) and 
ferritin were prepared. Poly(MPC) is a zwitterionic polymer that is hydrophilic and 
biocompatible. As expected for a controlled radical polymerization, the length of the 
polymer chains on ferritin increased with an increasing monomer:initiator ratio 
[M:I]. Moreover, the diameter of the ferritin–polymer conjugates increased with a 
higher [M:I]. The diameter of native ferritin was measured as 12.9 ± 0.8 nm, while 
for ferritin–poly(OEGMA) with [M:I] = 100:1 the diameter was 18.9 ± 0.8 nm and 
for ferritin–poly(MPC) with the same [M:I] the diameter was 19.4 ± 1.2 nm. The 
polymers cover the surface of the protein cage, as shown by in vitro antibody 
recognition experiments. Both types of polymers reduced the amount of anti-ferritin 
antibodies that could bind to the protein nanoparticles by more than 80%. This is 
very important for drug-delivery applications, as the polymers would shield the 
ferritin from the immune system. 
Poly(oligoethylene glycol methacrylate) was also synthesized on the exterior of the 
bacteriophage Qβ by Finn and co-workers (Figure 1.2.3).285 The protein cage has 
720 surface-accessible amine groups of which 180 ± 30 were modified with an azide-
functionalized N-hydroxysuccinimide. Using click chemistry, a triglyme-based 
ATRP initiator with an alkyne end group was bound to the azides on the protein, 
followed by polymerization of OEGMA and OEGMA-N3. The azide-functionalized 
monomer allowed further modification of the resulting polymer. The polymer coat 
increased the diameter of the VLP from 14 nm to approximately 24 nm. To show 
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potential applications of the protein–polymer conjugate, poly(OEGMA-N3) on the 
VLP was modified by click chemistry with gadolinium chelating groups (Gd-
DOTA). The resulting bacteriophage Qβ–poly(OEGMA-Gd-DOTA) could be used 
as a magnetic resonance imaging (MRI) contrast agent. Its high loading capacity 
gave better contrast than established contrast agents. In addition, a doxorubicin (Dox) 
derivative that contained an alkyne group for click reactions and a hydrazine moiety 
for acidic cleavage was bound to Qβ–poly(OEGMA-N3) with the aim of using the 
hybrid particle as a pH-responsive anti-cancer drug. The Dox-carrying protein–
polymer conjugate had a similar cytotoxicity on HeLa cells to free Dox, which 
proves its anti-cancer activity. Further studies could explore the VLP–polymer 
conjugate for imaging applications and targeted drug delivery. 
 
Figure 1.2.3. Polymerization on the exterior of bacteriophage Qβ bacteriophage and the 
characterization of the conjugates. (a) Schematic view of grafting-from ATRP on the exterior of 
bacteriophage Qβ and post-attachment of doxorubicin onto the polymer chains. Characterization of 
conjugates: (b) Size exclusion chromatographs of Qβ VLP (1), Qβ VLP with poly(OEGMA) (8) and 
Qβ VLP with poly(OEGMA-N3) (9). (c) and (d) Transmission electron micrographs of (8) and (9). 
Scale bar is 200 nm. Adapted with permission from 285. Copyright © 2011 American Chemical 
Society 
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While PEGylation with PEG or with poly(OEGMA) remains the most popular 
method to modify proteins and protein cages with polymers on their outside, it has 
some disadvantages.155 PEGylated particles sometimes experience lower uptake by 
targeted cells.303,304 In addition, recent studies indicate that the immune system can 
recognize PEG, as evidenced by the discovery of anti-PEG antibodies.305 This can 
result in an enhanced clearance of PEGylated particles and raises concerns about 
their immunogenicity.306 Moreover, chemical modifications are mostly restricted to 
the chain ends of PEG due to the nature of its polymerization. To overcome these 
drawbacks of PEGylation, other polymers have been bound to the exterior surface of 
protein cages. Poly(2-alkyl-2-oxazolines) (POX) are considered to be good 
alternatives to PEG.307 The properties of poly(2-alkyl-2-oxazolines) make them 
suitable for biomedical applications.308,309 They can be synthesized in a well-defined 
manner by living cationic polymerizations, their chemical composition and 
properties can be easily adjusted during synthesis, e.g. by selecting the hydrophilic 2-
methyl-2-oxazoline or the less polar 2-ethyl-2-oxazoline. Moreover, 
copolymerizations with functionalized oxazolines can introduce functional groups 
into the polymer. Finn and co-workers bound poly(2-alkyl-2-oxazolines) on the 
surface of the bacteriophage Qβ by single-point attachment, and via multiple points, 
using copper-catalysed azide–alkyne cycloaddition click chemistry (Figure 
1.2.4a).310 For single-point attachment, propargyl-poly(2-methyl-2-oxazoline) or 
propargyl-poly(2-ethyl-2-oxazoline) were synthesized that featured a single alkyne at 
the chain terminus. For multiple-point attachments, copolymers of 2-methyl-2-
oxazoline or 2-ethyl-2-oxazoline, and 2-(pent-4-ynyl)-2-oxazoline were prepared. 
The polymers were furthermore end-functionalized with an amine group to attach 
targeting molecules or fluorescent dyes to the polymer chains. The surface-exposed 
amines of the VLP were derivatized with azido-N-hydroxysuccinimide ester and the 
polymers were conjugated to these functional groups. With an increasing ratio 
between polyoxazolines and Qβ, the diameter of the protein–polymer conjugates 
increased from 27 nm (no polymer) to a maximum of approximately 38 nm, i.e. a 
polymer shell of up to 5 nm thickness formed around the protein particle. Multi-point 
attachment of polymers increased the thermal stability of the protein cage to more 
than 100 °C, while VLPs that had polymer chains attached at single points 
disassembled into protein subunits. Unmodified VLPs unfolded at these temperatures 
(Figure 1.2.4b). These results indicate that cross-linking of the protein subunits by 
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polymer chains stabilized the assembly of subunits. The protein–polymer core–shell 
particles could be of interest in materials and biological applications if heat-resistant 
protein cages are desired. It remains to be elucidated, however, if the modification 
with poly(2-alkyl-2-oxazoline) increases the biocompatibility of the protein cage and 
how this modification compares with PEGylated VLPs. 
 
Figure 1.2.4. Different strategies of polymer attachment to Qβ bacteriophage. (a) Schematic view of 
single-point and multiple-point attachment of oxazoline polymers on the exterior of Qβ bacteriophage. 
(b) By attaching poly(oxazolines) via multiple-point attachment, the cage structure remains stable 
upon heating above 100 °C, while the Qβ VLPs without multiple-point attached polymers were 
disrupted. Left side: Comic representation of the description. Right side: TEM image of intact and 
stabilized Qβ bacteriophage (top). TEM image of disrupted Qβ protein cages (bottom). Scale bars are 
200 nm. Adapted with permission from 310. Copyright © 2011 WILEY-VCH Verlag GmbH and Co. 
KGaA, Weinheim. 
Poly(N-isopropylacrylamide) (PNIPAAm) is the most commonly used temperature-
responsive polymer in biomedical research.311,312 It has a lower critical solution 
temperature (LCST) of 32 °C,312,313 i.e. it transforms from a water-soluble polymer at 
room temperature to a water-insoluble polymer at body temperature. This is a useful 
property for many drug-delivery applications. Maynard and co-workers synthesized 
PNIPAAm with a cysteine reactive pyridyl-disulfide group at one polymer chain end 
and a dansyl group for UV–vis spectroscopic analytical purposes on the other chain 
end by RAFT polymerization (Figure 1.2.5). This polymer was grafted to the surface 
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of a cysteine-rich variant of the vault protein cage to create temperature-responsive 
polymer–protein cage conjugates.314 The LCST of the hybrid was 35.9 °C, whereas 
the unmodified vault had no LCST. Heating the conjugate to 40 °C resulted in the 
formation of micrometre-sized aggregates. The aggregation was reversible. Upon 
cooling, the aggregates redissolved completely. Moreover, the protein structure 
stayed intact during the heating and cooling process. This heat-responsive vault–
PNIPAAm conjugate could find application in cancer treatment. Local heating of 
cancer tissue could cause the conjugate to agglomerate and concentrate in cancer 
tissue, to release therapeutic cargo locally from the vault.315,316 
 
Figure 1.2.5. Schematic depiction of vaults that were modified with the thermoresponsive polymer 
PNIPAAm and TEM images showing the reversible aggregation of vault–PNIPAAm conjugates. 
Scale bar is 100 nm. Adapted with permission from 314. Copyright © 2013, American Chemical 
Society. 
Copolymers of NIPAAm and the UV-cross-linkable monomer 2-(dimethyl 
maleinimido)-N-ethyl-acrylamide (DMIAAm) were synthesized on the exterior 
surface of horse spleen ferritin.317 The protein cage was modified with ATRP 
initiator on the exterior via coupling of 2-bromo-isobutyric acid NHS ester to 
primary amines. NIPAAm and DMIAAm were randomly copolymerized under 
ATRP conditions in H2O:DMF (5:1, v:v) at 4 °C with CuBr and Me6TREN as 
catalyst. The ferritin–PNIPAAm-co-poly(DMIAAm) conjugate had a phase 
transition temperature at 32 °C.312,313 At this temperature, the conjugate precipitated 
from aqueous solution and the solution became turbid. Dynamic light scattering 
confirmed a reduction of the hydrodynamic radius of the conjugates from 30 nm at 
20 °C to 12 nm at 32 °C. Further increase of the temperature resulted in an increase 
in hydrodynamic radius due to the formation of aggregates of the collapsed 
conjugates. The ferritin–polymer conjugate was able to stabilize oil-in-water 
emulsions. UV-cross-linking of ferritin–polymer conjugates at the oil–water interface 
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of emulsion droplets led to capsules with an average size of 10 ± 3 µm. Addition of 
ethanol homogenized the oil-in-water emulsion, but the capsules of cross-linked 
ferritin–polymer conjugates remained stable. The high stability of the capsules 
allowed transferring them into solvent of the same polarity as the fluid droplet they 
were formed on.176 By starting from oil-in-water and from water-in-oil emulsions, it 
was therefore possible to create microcontainers that encapsulated hydrophilic 
compounds in a hydrophilic environment and hydrophobic compounds in a 
hydrophobic solvent.176 Extrusion of an emulsion, stabilized by ferritin–polymer 
conjugates, through a track-etch membrane and subsequent UV irradiation allowed 
the production of networks of capsule-containing fibres, capsule assemblies and 
single capsules.177 The capsules of cross-linked ferritin–polymer conjugates and the 
macroscopic materials made thereof could find applications as substrates for cell 
cultivation or as delivery systems, e.g. in cosmetics. Whether the protein remained in 
its native conformation was, however, not investigated in great detail.318 
The chemical diversity of polymers extends well beyond ‘classic’ polymers such as 
PEG, POX, polymethacrylates and polyacrylamides. Tailor-made polymers with 
functional groups in their main chain and in their side chains can add another level of 
functionality. Kim et al. modified Adv with a biodegradable poly(disulfide amine) on 
which arginine was grafted (ABP–polymer) (Figure 1.2.6).161 In addition to the 
biodegradable backbone, the polymer featured primary amines in its side chains. It 
was designed to enhance the protein’s cellular uptake through electrostatic 
interactions and at the same time to minimize the immune response to the virus. Two 
types of Adv were used in this study: Adv that delivered genes for the expression of 
green fluorescent protein (GFP), and YKL-1001, an oncolytic, hepatoma-targeting 
Adv that kills only these cells. GFP expression was approximately threefold higher 
with ABP-modified Adv compared with unmodified Adv. The best GFP expression 
was achieved with an Adv:ABP ratio of 1:5. GFP expression was reduced at a higher 
Adv:ABP ratio (1:10), most likely because the larger number of positive charges 
interfered with the Adv infection pathways following cell binding. The higher charge 
density could also increase cell death, as known from other cationic 
polymers,319which could also contribute to the observed lower GFP expression.319 
Oncologic YKL-1001 with conjugated ABP–polymers remained longer in blood 
circulation and caused an increased hepatoma cell death compared with unmodified 
YKL-1001. The latter is in good agreement with the higher transduction efficiency 
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caused by the ABP–polymer. Concluding, the Adv–polymer conjugate could become 
a powerful gene delivery vector in oncological therapy because of its higher 
efficiency compared with unconjugated virus particles. 
 
 
Figure 1.2.6. Schematic view of Adv–ABP–polymer conjugate. The ABP–polymer contained 
bioreducible disulfide bonds for cleavage and primary amines to promote cellular uptake. Adapted 
with permission from 161. Copyright © 2011, Elsevier Ltd. 
Another approach to coat Adv with polymers containing primary amines was 
reported by Ramsey and co-workers.320 Adv was complexed with synthetic polymers 
used in gene delivery to allow for cellular uptake into cells that lack the receptors for 
Adv. To this end, linear and branched polyethyleneimine (PEI) and poly(ethylene 
glycol)-grafted polyethyleneimine (PEG-g-PEI) were non-covalently bound to the 
viral capsid by electrostatic interactions. The PEI was modified with PEG to 
overcome the intrinsic toxicity and other drawbacks associated with pure PEI.321,322 
Indeed, the complexes of Adv and PEG-g-PEI polymer were less toxic than Adv 
modified with pure PEI, as was shown by cytotoxicity assays. The polymer–Adv 
complexes were able to shuttle their cargo into CAR-negative NIH 3T3 cells, which 
Adv alone cannot infect. Gene transduction efficiency was slightly better for Adv 
with PEG-g-PEI polymers compared with Adv complexed with plain PEI. PEG-g-
PEI copolymers composed of linear PEI showed a better performance than those 
made from branched PEI. 
Later, Adv was also complexed with PEI by Yao et al. with variation of the polymer 
to protein ratio.165 They managed to create Adv–PEI particles that showed no 
cytotoxicity under the investigated conditions and an enhanced cell uptake by 
mesenchymal stem cells compared with unmodified Adv. 
Lyophilized proteins are usually solid materials. However, modification of proteins 
with polymers allows alteration of their state of matter. Mann and co-workers tuned 
the surface of ferritin with a polymer surfactant and were able create protein liquids, 
i.e. solvent-free protein melts.175 The polymer chains were attached to ferritin via 
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electrostatic interactions (Figure 1.2.7a). Ferritin was first cationized on its surface 
by binding N,N-dimethyl-1,3-propanediamine to surface-exposed carboxylic acid 
groups via N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) 
coupling. Then, the anionic polymer poly(ethylene glycol)-4-nonylphenyl 3-
sulfopropyl ether was complexed with the cationized ferritin. Lyophilization (Figure 
1.2.7b) and subsequent annealing at 50 °C yielded a red viscous liquid that remained 
liquid after cooling to room temperature (Figure 1.2.7c). Transmission electron 
microscopy (TEM) indicated that the protein cage retained its structure in this liquid. 
This report opened the door to a new class of protein materials with a huge potential 
in bionanomaterials research.171 For example, protein liquids represent a very 
concentrated form for the storage, handling and modification of proteins. 
 
Figure 1.2.7. Modification of ferritin resulted in liquid proteins. (a) Preparation of a protein liquid by 
cationization of ferritin and electrostatic binding of anionic polymers to the external surface of the 
protein cage. (b) Lyophilized mixture of cationized ferritin and the anionic polymer. (c) After 
annealing at 50 °C, the mixture formed a viscous liquid. It remained liquid even after cooling to room 
temperature. Adapted with permission from 175. Copyright © 2009, Wiley-VCH Verlag GmbH and 
Co. KGaA, Weinheim. 
 Polymer cages as functional additives in polymeric 1.4.4
materials 
Protein cages are robust biological nanoparticles that have a variety of properties that 
are difficult or impossible to achieve with synthetic nanocapsules. Therefore, protein 
cages were incorporated into synthetic polymeric materials with the aim to create 
functional hybrid materials. 
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Self-reporting (or self-sensing) materials can autonomously report micron-scale 
damage and have therefore high potential as safety features in load-bearing 
components in the aerospace, automotive, construction and medical materials 
sectors. Self-reporting materials were achieved by incorporating force-responsive 
molecules or nanostructures into polymeric materials that cause a change in colour, 
fluorescence or electrical conductivity when being deformed.323,324 The well-defined 
three-dimensional (3-D) structure of biological macromolecules results in well-
defined mechanical deformation pathways. Thus, they can be used as force and strain 
sensors if they are intrinsically fluorescent or when combined with fluorescent 
markers.325-327 The first protein that was used to create self-reporting materials was 
the protein cage THS (Figure 1.2.8d).166,328 It encapsulated a pair of fluorescent 
proteins and served as a scaffold to bring enhanced cyan fluorescent protein (eCFP) 
and enhanced yellow fluorescent protein (eYFP) into proximity for fluorescence 
resonance energy transfer (FRET) (Figure 1.2.8a-c). Moreover, the equatorial plane 
of chaperonins is mechanically weak, which allows separating the two hemispheres 
from each other.329 Lysine residues on the THS were modified with acrylamide 
groups so that the protein could be copolymerized with acrylamide and bis-
acrylamide in aqueous solution to form a gel. Upon drying, optically transparent and 
brittle specimens were obtained. Uniaxial deformation of these materials resulted in 
the formation of microcracks and fracture of the material. Fluorescence microscopy 
of the area surrounding the fracture face revealed an increased FRET efficiency in 
the vicinity of cracks, which was additionally confirmed by fluorescence lifetime 
imaging (FLIM) (Figure 1.2.8e). Most likely, polymerization and sample drying 
caused internal stress in the polymers that deformed the protein cage, increased the 
distance between the encapsulated fluorescent proteins and therefore lowered FRET. 
Crack formation allowed the polymer and the protein cage to relax, thus leading to 
the observed increase in FRET. The system proved that the structure and mechanical 
response of protein cages can be exploited to engineer polymer–protein hybrid 
materials with advanced functionalities. 
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Figure 1.2.8. Integration of a protein cage that encapsulated fluorescent proteins into a polymer 
matrix yields materials with self-reporting functionality. (a) Schematic depiction of the chaperonin 
THS (green lines) with a FRET pair of fluorescent proteins embedded into a polymer matrix. Damage 
in the polymer results in relaxation of the polymer matrix and of the disturbed THS, leading to an 
increased FRET signal. (b) UV–vis spectrum of the THS–eCFP/eYFP conjugate in solution: the 
arrows indicate the absorption due to eYFP (513 nm), eCFP (439 nm), bisaryl hydrazone linker 
between THS and the fluorescent proteins (354 nm) and of all proteins (276 nm). (c) Native PAGE of 
the conjugate showing that fluorescent proteins are encapsulated in the THS (left: gel imaged in 
fluorescence mode; right: Coomassie Brilliant Blue stained gel). (d) TEM image of the conjugate with 
particles in top (top arrow) and side view (lower arrow). (e) Microscopy images of self-reporting 
PAAm-THS-eCFP/eYFP hybrid materials after uniaxial deformation and fracture (blue fluorescence 
channel, FRET and FLIM). Adapted with permission from 166. Copyright © 2009, Wiley-VCH Verlag 
GmbH and Co. KGaA, Weinheim. 
Functional hybrid nanofibres can be prepared by electrospinning of polymer–protein 
solutions. For the application of such fibres, e.g. in nanotechnology330 or drug 
delivery,331,332 it is important to know if the incorporated biological compounds 
survive the fabrication procedure of the material. In a study conducted by Zussman 
and co-workers, bacterial viruses (T4, T7 and bacteriophage λ) and bacteria were 
encapsulated into hydrophilic poly(vinyl alcohol) (PVA) nanofibres.333 The 
electrospinning process, which was used for nanofibre fabrication, reduced the 
viability of the incorporated viruses to 1–6% of the value before electrospinning, 
most likely because the tails of the bacteriophages could not withstand the high shear 
forces during spinning. Nevertheless, a portion of the viruses remained biologically 
active and retained this activity during storage for three months at –20 °C and –55 
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°C. This finding let the authors conclude that the electrospinning process is suitable 
for fabrication of nanofibres in which biological material is integrated. Protein cages 
can enhance the mechanical properties of electrospun nanofibres. Lee and co-
workers incorporated ferritin into PVA nanofibres.334 The protein cage was 
homogeneously distributed within the fibre. Ferritin interacted with PVA through 
hydrogen-bond formation between the hydroxyl group of the polymer and amine and 
carboxyl groups of the protein, resulting in a twofold increased elastic modulus 
compared with pure PVA nanofibres, as determined by atomic force microscopy 
(AFM). Electrospinning of hydrophilic polymers can be used to prepare mats of 
nanofibres that are highly porous hydrogels. Hybrid ferritin–PVA nanofibre 
hydrogels showed fast water absorption and had good mechanical properties.173 The 
strength of swollen ferritin–PVA hydrogels increased by 113%, the strain at break by 
227% and the elastic modulus by 151% compared with wet PVA gels that lacked 
ferritin. According to the authors, the mechanical properties were even better than 
those of PVA hydrogels reinforced with carbon nanotubes. Hydrogels with 
incorporated apoferritin instead of ferritin had a similar modulus but lower strength 
and strain at break than ferritin–PVA hydrogels. Thus, the iron core of ferritin is an 
important factor for the reinforcement of these hybrid materials.333,335 Incorporation 
of ferritin into a nanofibre hydrogel results in biocompatible and degradable 
materials with superparamagnetic properties that give good contrast in MRI. The 
advantage of using ferritin, compared with synthetic contrast agents, is that it does 
not pose toxicity risks. 336 3-D porous nanofibre hydrogels were fabricated by 
electrospinning of ferritin–PVA solutions.173 Elevated temperatures (e.g. 80 °C) 
during mixing of the spinning solution were used to denature partially the protein 
cage so that clusters of ferritin formed. Nanofibres with these clusters had enhanced 
superparamagnetic properties and the fibre hydrogels showed a high contrast in in 
vitro and in vivo imaging. In addition to the application as MRI contrast agent, 
ferritin-containing hydrogels have also been applied as an actuator towards the 
development of artificial muscles.168 Electrospun ferritin–PVA and PVA nanofibre 
hydrogels reversibly expanded and contracted when the pH was cycled between pH 4 
and pH 9. In contrast, bulk PVA hydrogels do not show this pH-dependent swelling, 
indicating that the electrospinning process causes the formation of ionizable 
functional groups on the polymer. The pH-induced volume change of the electrospun 
hydrogels was independent of the presence of ferritin. However, ferritin–PVA 
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hydrogels did not show creep-induced elongation during several extension and 
contraction cycles, while the PVA hydrogels gradually increased in length after each 
cycle. Ferritin reinforced the PVA matrix by hydrogen-bond interactions, resulting in 
the superior mechanical properties of the polymer–protein hybrid material. Lack of 
creep is a very important property for artificial muscle development, rendering the 
ferritin–PVA hydrogels interesting candidates for this kind of application. 
Kim and co-workers followed a similar electrospinning approach for the fabrication 
of ferritin-containing nanofibres (Figure 1.2.9).335 Instead of PVA as the polymer, 
they used the polyelectrolyte poly(2-acrylamino-2-methyl-1-propane sulfonic acid) 
(PAMPS). However, ferritin precipitated in PAMPS solution, so that glycerol had to 
be used as a stabilizer for the protein cage. Coaxial electrospinning of a PAMPS and 
a ferritin–glycerol solution allowed fabrication of very thin (<50 nm) nanofibres in 
which ferritin formed the core. Such nanofibres have potential in applications 
ranging from batteries to biosensors and nanoelectronics.335 
 
Figure 1.2.9. The integration of ferritin into PAMPS fibers. Top panels (a) – (c) Transmission 
electron microscopy (TEM) of PAMPS fibers with different widths and incorporated ferritins in the 
fiber core. Bottom panels (a) – (c) Schematic representation of the ferritin distribution in the core of 
the PAMPS fibres in dependence of the fibre width. Adapted with permission from.335 Copyright © 
2008, WILEY-VCH Verlag & Co. KGaA, Weinheim. 
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Carbon nanotubes (CNTs) are known to enhance the mechanical strength of 
polymeric materials.337,338 However, it can be difficult to disperse them 
homogeneously into a polymer. Moreover, low interfacial adhesion between the 
polymer and CNTs can reduce the performance of the materials. Saboungi and co-
workers addressed these problems by covalently attaching ferritin to the sidewalls of 
CNTs.339 The carbon–protein hybrids could be homogeneously incorporated into a 
hydrophilic PVA matrix that was cast into free-standing composite films. The protein 
significantly enhanced the mechanical properties of the material. Compared with 
pure PVA, an increase of 108% in the storage modulus was measured.339 
PVA, PAMPS and PAAm are water-soluble polymers and therefore mix readily with 
protein cages. For many applications it would be desirable, however, to use 
hydrophobic polymers that can be cast from organic solvents. PEGylation is a means 
to render viruses and non-viral protein cages soluble in non-aqueous media.13,295 
TMV was modified with PEG of a molar mass of 2 × 103 g mol–1.13 The resulting 
capsid–polymer conjugates dissolved in chloroform, while the unmodified virus was 
not soluble. TMV solubilized in organic solvents had a markedly increased thermal 
stability of at least 160 °C compared with PEGylated TMV in water. The organo-
soluble virus was cast into polystyrene, opening a route to solid polymer–protein 
hybrid materials.340 While TMV is, strictly speaking, not a protein cage in the sense 
of this review, it is easy to envision that similar strategies could be applied to 
solubilize protein cages in non-aqueous media. Indeed, ferritin was modified with 
750 g mol–1 PEG chains on the exterior carboxylic acid groups.295 The modified 
ferritin was soluble in dichloromethane, whereas the unmodified protein cage was 
not. In addition, ferritin was also alkylated on the exterior (C9 to C14 chains coupled 
to primary amines).341 Both types of modified ferritin were incorporated into a 
polymer blend of PEG and a hydrophobic poly(desaminotyrosyl tyrosine dodecyl 
ester carbonate) (PDTD).295 The PEGylated ferritin accumulated in the PEG polymer 
of the blend due to PEG–PEG interactions, while the alkylated ferritins accumulated 
in PDTD.295 Therefore, it is possible to direct the location of a protein cage in a 
phase-separated material by carefully selecting the type of protein modification. 
Organo-soluble protein–polymer conjugates can alter the morphology of block 
copolymer films, as shown by the interaction of PEGylated ferritin with poly(2-
vinylpyridine)-block-poly(ethylene oxide) block copolymers (P2VP-b-PEO).174 The 
P2VP-b-PEO film had a microphase separated lamellar structure with the lamella 
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oriented parallel to the surface. When ferritin–PEG was added, it interacted with the 
PEO domains of the block copolymer and prevented their crystallization. As a result, 
the microdomains reoriented perpendicular to the surface. In another study, the 
distribution of PEGylated ferritin in thin films of the block copolymer polystyrene-
block-poly(ethylene oxide) (PS-b-PEO) was investigated.159 PS-b-PEO self-
assembled into structures in which the PEO blocks form cylinders that were oriented 
perpendicular to the surface. Ferritin–PEG accumulated in the PEO cylinders. 
Different PEG chain lengths on ferritin changed the centre-to-centre distance 
between the PEO cylindrical domains. 
Another potential application of organo-soluble protein cages would be their use as 
nanoreactors for reactions in non-aqueous media.342 Although this is an intriguing 
possibility to influence, e.g. the selectivity of chemical reactions, the use of 
nanoscale protein-based reaction compartments in hydrophobic media has not yet 
been reported. 
The presented examples show strategies to incorporate protein cages into polymeric 
materials and highlight some interesting properties of the resulting hybrid materials. 
However, many of the intriguing functionalities of protein cages, such as their ability 
to encapsulate and release guests, the electronic and magnetic properties of ferritin 
derivatives and the intrinsic ability of protein cages to self-assemble into 2-D or 3-D 
arrays have not yet been exploited to create functional polymer–protein hybrid 
materials. Thus, opportunities for innovation are plentiful. 
 Protein cages adsorbed to polymer surfaces 1.4.5
Most polymeric materials, when brought into contact with a solution of proteins, will 
adsorb some of the biomacromolecules at their surface. The investigation of this 
phenomenon is important, e.g. for medical device development, as adsorbed protein 
layers determine the biological response towards the material.343 Ferritin is a good 
model protein for such studies because it is very stable and easily imaged by TEM. 
The protein cage was adsorbed on a phase-separated blend of PDTD and poly(ε-
caprolactone) (PCL).344 Both polymers have been studied for medical applications.345 
At physiological pH, native ferritin adsorbed mainly on the hydrophobic PDTD 
areas. Ferritin and partially hydrolysed PCL are both negatively charged at this pH, 
so that the protein is repelled from PCL domains. At pH 3.5, i.e. below the isoelectric 
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point of ferritin, it adsorbed equally well on both polymers.167 To understand the 
influence of protein modification on its adsorption behaviour, the carboxylic groups 
of ferritin were alkylated with dodecylamine.167 As a result, the alkylated ferritin was 
positively charged at pH 5.8, in contrast to native ferritin, which was negatively 
charged at this pH. Alkylated ferritin adsorbed on the PCL phase of the blend due to 
positive charges, while the native ferritin mainly adsorbed on the PDTD phase. 
Selective adsorption of ferritin on a polymer was also observed on thin films of 
polystyrene-block-poly(methyl methacrylate) block copolymers (PS-b-PMMA).169 
The polymer film was treated with UV light and acetic acid, which etched the 
PMMA domains. As a result, trenches and ridges were created on the material. 
Ferritin adsorbed on the PS domains and not on PMMA. This was due to the 
repulsion between the negative charges of ferritin and the negative charges of edged 
PMMA. These studies show that protein adsorption is governed by an intricate 
interplay between the surface properties of the material and of the protein. Moreover, 
they identify polymer morphology as a very important parameter in biomaterial 
development because it can influence the distribution of a protein layer on a surface 
and therefore affect the behaviour of a polymeric material in a biological 
environment. 
 Protein cages that encapsulate polymers 1.4.6
1.4.6.1 General considerations 
Because of their hollow structure, protein cages can encapsulate a variety of guests, 
including polymers. These macromolecules can be either synthesized directly in the 
cavity of a protein cage or preformed polymers can be incorporated into cages during 
self-assembly or through large pores. If the polymers are homogeneously distributed 
within the cavity of the protein cage, core–shell particles with a polymer core and a 
protein shell are obtained. The polymer core can be a cross-linked polymer network, 
a dense polymer particle or a solution of polymer. If the polymers strongly interact 
with the protein’s inner surface or if short polymer chains are attached to it, the 
synthetic macromolecule will form a layer that coats the inner surface of the protein 
cage. The resulting structure is a hollow nanoparticle with a protein–polymer hybrid 
shell. 
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The strength of interaction between protein and polymer can be adjusted by the 
choice of polymer and by engineering the inner protein surface. This allows tailoring 
the inner structure of protein cage–polymer hybrids. While such an approach is 
already state-of-the-art for other hollow nanoobjects, such as polymer-filled lipid 
vesicles,346 deliberate tuning of the inner structure of polymer-filled protein cages 
has not been addressed yet. Another interesting challenge for future research could 
be to prepare stimuli-responsive hybrid particles that transform from a capsule-like 
structure with the polymer lining the cavity to a structure where the polymer is 
homogeneously distributed throughout the cavity. This could result in new 
approaches for the triggered release of therapeutic cargo from protein cages 
1.4.6.2 Non-covalent encapsulation of polymers in protein cages: Tuning the 
size and morphology virus-like particles with polyanionic polymers 
Because viruses are protein cages that encapsulate RNA, i.e. a natural 
macromolecule with anionic phosphate backbone, it is not surprising that successful 
attempts were made to replace nucleic acids with a synthetic polyanionic polymer. 
Already in the 1960s, Hohn used poly(vinyl sulfate) to assemble protein subunits of 
the bacteriophage fr,347 while Bancroft et al. reassembled CCMV, BMV and BBMV 
around poly(vinyl sulfate) and dextran sulfate.348 Their results proved that the 
phosphate backbone of nucleic acids is not required for the assembly of viral coat 
proteins into virus-like structures. Both groups also observed that the reassembled 
particles varied in size, giving a first indication that the structure of reassembled 
VLPs is influenced by the polyanion. However, detailed studies on the interplay of 
synthetic polymers and VLPs were only reported in more recent times, pioneered by 
a study by Douglas and Young. They encapsulated the anionic polymer 
poly(anetholesulfonic acid) into CCMV.197 To this end, CCMV at pH 7.5, i.e. in its 
swollen state, was incubated with the polymer. The pH was lowered to 4.5, which 
caused a deswelling of CCMV, closed the pores in the protein shell and entrapped 
the polymer into the viral capsid. In a control experiment, CCMV was incubated with 
the polymer at pH 4.5 resulting in no encapsulation. 
The interior cavity surface of many viral capsids is highly positively charged, while 
the outer surface of the proteins carries a smaller number of charged residues. Thus, 
electrostatic interactions with polyanions favour their inclusion into the assembling 
protein cage. Moreover, the attraction of oppositely charged residues facilitates and 
Chapter 1  43 
directs the self-assembly of VLPs. Thus, particles that differ from the wild-type 
capsids in their shape, size and number of subunits can be prepared when using 
synthetic polymers as scaffold. Cornelissen and co-workers found that poly(styrene 
sulfonate) (PSS) with a molar mass of 9.9 × 103 g mol–1 induces the formation of 
monodisperse icosahedral CCMV VLPs with a diameter of 16 nm (T = 1). At a pH of 
7.5, the wild-type virus has a diameter of 28 nm (T = 3 particle).196,197,349 Therefore, 
under these conditions the polymer causes the formation of VLPs that are smaller 
than the native capsid. 
Knobler and co-workers investigated the influence of different PSS chain lengths on 
the formation of CCMV VLPs at pH 4.8 (Figure 1.2.10a).157,350 Polymers with a 
molar mass of 3.8 × 104 g mol–1 are small enough to pack more than one chain into 
VLPs. Reassembly of the viral coat proteins around PSS with a molar mass of 3.8 × 
104 g mol–1 resulted in VLPs with a bimodal size distribution.350 By using a 
fluorescently labelled polymer, the number of polymer chains per particle could be 
determined. VLPs with a size of approximately 19 nm (T = 1 structure) encapsulated 
two chains, whereas VLPs with a diameter of 21 nm (T = 2 structure) incorporated 
three polymers. PSS that had a comparable size or were larger than the capsid 
resulted in the formation of larger VLPs.157 PSS with a molar mass between 4 × 105 g 
mol–1 and 1 × 106 g mol–1 yielded VLPs with a diameter of 22–23 nm (T = 2 
particles) (Figure 1.2.10b+c, left diagram), whereas polymers with a molar mass 
between 2 × 106 g mol–1 and 3.4 × 106 g mol–1 induced the formation of VLPs with a 
diameter of 27–28 nm (T = 3 particles) (Figure 1.2.10b, right diagram). Thus, the 
virion adapted to the size of the encapsulated cargo. Larger polymers resulted in 
larger VLPs. A direct comparison of these results to the assembly into T = 1 particles 
reported by Cornelissen349 is difficult because assembly was carried out at a different 
pH and the viral coat proteins differed in their N-terminus. 
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Figure 1.2.10. CCMV size modulation using PSS with different molecular weights.(a) Table of VLP 
size distributions with various PSS that were applied for the formation of CCMV VLPs. (b) 
Normalized capsid size distribution histograms showing the influence of polymer chain length on 
VLP size. Left diagram: CCMV that was assembled with 4 × 105 g mol–1 PSS. Right diagram: CCMV 
that was assembled with 3.4 × 106 g mol–1 PSS. (c) Left image: TEM image showing wild-type (wt) 
CCMV capsids. Right image: TEM image showing CCMV VLPs that were assembled with 3.4 × 106 
g mol–1 PSS. Scale bars are 50 nm. Adapted with permission from 157. Copyright © 2008, The 
Biophysical Society. 
Polymers can control not only the size, but also the shape of VLPs. Icosahedral VLPs 
form when CCMV coat proteins assemble around flexible polyanionic polymers such 
as single-stranded RNA351,352, a combination of RNA and DNA353 or PSS.157,349,350 
However, rigid dsDNA induces the formation of rod-shaped structures.354 These 
different VLP morphologies can be selectively accessed by a single type of polymer 
if it is possible to switch the polymer between a condensed coil and a more expanded 
conformation.355 The water-soluble, fluorescent and semiconducting poly(2-
methoxy-5-propyloxy sulfonate phenylene vinylene) (MPS–PPV) adapts a coiled and 
aggregated conformation in aqueous solutions of high ionic strength due to counter-
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ion condensation, whereas at low ionic strength the coils expand.356 In the absence of 
NaCl, the interplay between MPS–PPV and CCMV coat proteins causes the 
formation of rod-shaped VLPs (Figure 1.2.11a).355 Addition of 0.1 M NaCl to the 
self-assembly buffer resulted in a mixture of spherical and rod-like structures. At 1.0 
M NaCl, mostly spherical VLPs were observed (Figure 1.2.11b). Control 
experiments with PSS as scaffold resulted in spherical structures, independent of the 
ionic strength of the solution. These results suggest that it is not the ionic strength per 
se that is responsible for different VLP structures, but rather that the conformation of 
the polymer dictates the shape of the VLP. Moreover, the protein cage also 
influences the properties of the polymer. The fluorescent properties of 
semiconducting polymers such as MPS–PPV depend on the polymer’s chain 
conformation. In the spherical VLPS the polymer is encapsulated as a coil, resulting 
in blue fluorescence. Rod-shaped VLPs stretch the polymer chains. This leads to a 
red-shift in fluorescence. 
 
Figure 1.2.11. The concentration of NaCl in the presence of an anionic polymer can influence the 
morphology of CCMV VLPs. (a) Rod-shaped VLPs were formed in the presence of MPS–PPV 
without NaCl. Left panel: schematic representation of rod-shaped VLP formation. Right panel: TEM 
image of rod-shaped CCMV VLPs. (b) Spherical VLPs were formed in the presence of MPS–PPV at 
1.0 M NaCl. Left panel: schematic representation of spherical VLP formation. Right panel: TEM 
image of spherical CCMV VLPs. Adapted with permission from 355. Copyright © 2011 American 
Chemical Society. 
Polyanionic polymers such as PSS can be used to promote self-assembly of 
PEGylated CCMV coat proteins.292 The resulting VLPs encapsulate a synthetic 
polymer and carry another type of polymer on their outside. PEG was selectively 
conjugated to the outside surface of coat proteins by reacting fully assembled RNA-
containing viral capsids with NHS-ester PEG. PEGylation caused the virus to 
disassemble slowly, probably because the polymer disrupted interactions between 
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protein subunits. Disassembly was irreversible unless PSS was added to the protein 
solution. After removal of the RNA, PSS with a molar mass of 7 × 105 g mol–1 
yielded fully assembled T = 1 particles with an average diameter of 18 nm (Figure 
1.2.12). In conclusion, the presence of PSS in the interior of the VLP renders it 
robust enough to overcome the destabilization by PEG. The method paves the way 
for multifunctional VLPs, as both the polymer on the outside of the capsid and the 
polymer on its inside could be designed to feature functional groups, such as 
targeting ligands and chelators for contrast agents. 
 
Figure 1.2.12. Self-assembly of CCMV-PEG using PSS (a) Schematic representation of reassembling 
PEGylated and non-modified CCMV coat proteins into VLPs by polyanionic PSS. (b) Left panel: 
TEM image of PSS–CCMV–PEG T = 1 particles. Scale bar is 200 nm. Right panel: zoomed TEM 
image of PSS–CCMV–PEG T = 1 particles. Scale bar is 100 nm. Adapted with permission from 292. 
Copyright © 2013 American Chemical Society.  
The anionic polymers discussed so far as scaffolds for self-assembly of viral capsids 
were linear chains. Recently, de la Escosura and co-workers used anionic Fréchet-
type dendrimers to direct the morphology of CCMV and to add functionality to the 
CCMV–polymer particle.170 The idea was that zinc and ruthenium phthalocyanine 
dendrimers357 could convert molecular oxygen into singlet oxygen and in addition 
drive the self-assembly of CCMV coat proteins to VLPs. Thus, the protein would 
form a capsule around the phthalocyanine catalysts. Zn phthalocyanides with four 
dendrimers attached to the phthalocyanide macrocycle and Ru phthalocyanides with 
two dendrimers axially co-ordinated to the metal centre were tested for their ability 
to assemble coat protein into VLPs. Moreover, dendrimers of different generations 
were used. π -Stacked dimers of Zn phthalocyanides with zero-generation 
Chapter 1  47 
dendrimers and individual Ru phthalocyanides with first-generation dendrimers were 
efficient templates for VLP formation (Figure 1.2.13). A possible explanation is that 
both species carry 16 negative charges, which match the number of positive charges 
on coat protein dimers. T = 1 particles with a diameter of 18 nm were obtained. 
Phthalocyanides can produce singlet oxygen, which is used in photodynamic therapy 
as reactive species. Therefore, these CCMV–phthalocyanine–dendrimer particles 
have a high potential for biomedical applications. 
 
Figure 1.2.13. Schematic representation of VLP formation using Ru phthalocyanine dendrimers. 
Depending on the dendrimer, VLP formation is favoured. Adapted with permission from 170. 
Copyright © 2015 American Chemical Society. 
1.4.6.3 Non-covalent encapsulation of polymers in protein cages other than 
viral capsids 
Non-covalent encapsulation of polymers into the cavity of protein cages is not 
limited to VLPs. Protein cages that have pores wide enough to allow macromolecules 
to enter their cavity can take up polymers from solution. The vault protein has a 
barrel-like structure with a large internal cavity.239 However, the nature and size of 
pores that connect its interior with the surrounding solution are unknown. To explore 
whether polymers can enter into vaults, MPS–PPV of unknown molecular weight 
was incubated with vault particles.158 The photophysical properties of the fluorescent 
polymer depend on the polarity of its environment,356,358 making it a useful tool to 
study its interaction with proteins. Fluorescence intensity measurements, TEM and 
small-angle X-ray scattering (SAXS) suggest that the polymer was encapsulated into 
the vault and did not alter the structure of the protein cage (Figures 1.2.14a–d). 
Encapsulation of the polymer within the native protein cage was furthermore 
confirmed with the cationic fluorescence quencher, methyl viologen. A much lower 
quenching efficacy was observed when the quencher was added to a mixture of 
polymer and vault compared with a polymer solution that did not contain protein 
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cages. Thus, the vault restricted access of the quencher to the fluorescent polymer, 
which implies that the polymer is located inside the protein capsule. For comparison, 
some of the experiments were repeated with vaults composed of cross-linked protein 
subunits. The polymer could not enter into cross-linked protein particles, as 
evidenced by the fact that the fluorescence quenching efficacy with methyl 
viologen,359,360 was similar to pure polymer solution. However, vaults could be first 
loaded with MPS–PPV and then cross-linked, e.g. to prevent leakage of polymer 
from the protein cage. The significance of this study is that fully assembled vaults 
can encapsulate and entrap synthetic polymers. As vaults are of human origin, they 
could become useful delivery vehicles for macromolecular therapeutics. 
 
Figure 1.2.14. Integration of a polymer into a vault protein cage.(a) Schematic representation of a 
vault protein cage (top) and vault protein cage with cross-linked subunits (bottom), showing that non-
cross-linked vaults are able to encapsulate MPS–PPV, while the polymer cannot enter the cavity of 
cross-linked vaults. (b)–(d) TEM images showing (b) vaults in the absence of polymers, (c) vaults that 
encapsulate MPS–PPV and (d) vaults that were loaded with MPS–PPV and subsequently cross-linked. 
Scale bar is 100 nm. Adapted with permission from 158. Copyright © 2008, American Chemical 
Society 
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1.4.6.4 Encapsulated polymers that are covalently bound to the interior of 
the cavity of a protein cage 
Non-covalent encapsulation of polymers into protein cages most often relies on 
electrostatic interactions between the charged inner surface of protein cages and 
oppositely charged  
polymers. Thus, this approach is limited to charged polymers, e.g. polyelectrolytes. 
The scope of polymers can be significantly broadened if polymers are covalently 
bound into protein cages, which prevents them from leaching out of the protein’s 
cavity. To this end, selective attachment points, e.g. cysteine residues, have to be 
genetically engineered to the inner surface of the proteins. These residues allow the 
introduction of initiators for polymerization reactions into the cage, so that polymer 
chains can be grown from the protein within its cavity. Moreover, the attachment 
points can bind preformed polymers via established linker chemistries. In both cases, 
protein–polymer conjugates are obtained that encapsulate the polymer within the 
protein cage. 
The group of Douglas pioneered the synthesis of polymers inside protein cages by a 
‘grafting-from’ approach. Interestingly, their first reports encompassed an 
uncommon method to synthesize polymers, the step-wise growth of polymers by 
repeated click-chemistry reactions.111,160,361,362 Only later they turned to one of the 
routine methods of modern polymer chemistry, atom transfer radical polymerization 
(ATRP).113,115,148,162,172 
The heat-shock protein (Hsp) from Methanococcus jannaishii was used as a scaffold 
to synthesize branched and cross-linked polymers within its cavity.160,361 The aim 
was to prepare drug-delivery and imaging vehicles in which the polymer core 
provides a high density of binding sites for therapeutics. A genetically modified 
variant of Hsp (HspG41C) that features a cysteine residue on the inner surface of 
each subunit was selected.363 This modification allowed selective attachment of 
functional molecules into the protein cage. N-propargyl bromoacetamide was 
conjugated to these cysteines to act as an alkyne initiator for polymerizations.160 
However, bromoacetamides can also react with primary amines (e.g. of lysine 
residues) and the imidazole ring of histidine. There are 11 lysines and one histidine 
on each subunit of Hsp. To limit the reaction sites of N-propargyl bromoacetamide, 
lysines were passivated with N-hydroxysuccinimide acetate before modification of 
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cysteines with the initiator. Step-wise polymer synthesis via click chemistry of 
tripropargyl azide and 2-azido-1-azidomethyl-ethylamine within the cavity was 
performed using a Cu(I) catalyst. Branched and cross-linked polymers that contained 
primary amines as functional handles were obtained (Figure 1.2.15a). Analytical 
results of passivated and non-passivated Hsp–polymer conjugates showed similar 
results in size exclusion chromatography (SEC), dynamic light scattering (DLS) and 
TEM for all generations of step-growth (G0.5–G2.5) (Figures 1.2.15b-d). The size of 
the polymer-filled cage was the same as the empty Hsp, indicating that the polymer 
does not disturb the protein cage structure. The polymer networks increased the 
temperature stability of the protein cage from 70 °C to ≥120 °C because several 
protein subunits were covalently connected through the polymer. 
 
Figure 1.2.15. Step-wise grafting-from approach within Hsp. a) Sectional image of the mutated 
HspG21C variant, showing the interior of the cavity with cysteine residues (red dots) and step-wise 
polymerization of 2-azido-1-azidomethyl-ethylamine and tripropargyl amine within the protein cage. 
(b)–(d) DLS (left panels) and TEM images (right panels) of (b) native HspG41C, (c) non-passivated 
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HspG41C with G2.5 branched polymer and (d) passivated Hsp41C with G2.5 branched polymer. 
Scale bar for TEM images is 100 nm. Adapted with permission from 160. Copyright © 2009 American 
Chemical Society. 
In a next step, functionality was introduced to the Hsp–polymer hybrid particles and 
they were converted into MRI contrast agents.361 Diethylenetriamine pentaacetic acid 
(DTPA) was conjugated to the primary amines of the cross-linked polymer. DTPA is 
a chelator that is capable of binding metal ions such as gadolinium ions (Gd3+). The 
functionalized protein cages contained up to 159 Gd3+ ions per particle with a 
maximum T1 particle relaxivity value of r1 = 4,200 mM–1 s–1. As a comparison, pure 
DTPA–Gd has an r1 value of 4 mM–1 s–1. This was at the time the second highest 
relaxivity that was achieved for contrast agents based on protein cages. A higher r1 
value (r1 = 7,200 mM–1 s–1) was achieved with the MS2 viral capsid by conjugation 
of DTPA ligands to the lysines of MS2.364 However, taking into account that MS2 
has a 12 times bigger volume than Hsp, the relaxivity per volume of the Hsp–
polymer conjugate was seven times bigger than that of MS2. The branched polymer 
network within the cage enabled this high loading capacity for gadolinium ions. 
The Hsp–polymer conjugates were also modified with 1,10-phenanthroline (phen).362 
The ligand allowed complexation of metal ions like Fe2+, generating branched co-
ordinating polymers within the protein cage that contained 0.3 iron ions per protein 
subunit (Figure 1.2.16). The hybrid particles could be used as catalysts365 or in drug-
delivery applications, where drugs could be entrapped within and released from the 
metal–organic networks. 366,367 
 
Figure 1.2.16. Schematic representation of the co-ordination polymers created by modifying a 
branched polymer network with phenanthroline within Hsp G41C. Adapted with permission from 362. 
Copyright © 2010, The Royal Society of Chemistry. 
 
   Chapter 1 
 
52 
The step-wise click-chemistry synthesis of polymers was applied to the P22 viral 
capsid to create a protein–polymer contrast agent with a larger size and therefore a 
greater relaxivity than Hsp.111 The P22 capsid in its WB morphology is 64 nm in 
diameter and therefore much larger than Hsp with a diameter of 12 nm. In addition, it 
has pores that have a diameter of 10 nm.269 It was assumed that bigger pores allow a 
better exchange of molecules between interior and exterior than smaller pores. This 
is beneficial for MRI applications because water molecules have to be exchanged as 
fast as possible between the interior with the Gd3+ complexes and the exterior to 
achieve high relaxivity rates. A branched and cross-linked polymer was synthesized 
in a P22 mutant (K118C), which had a cysteine residue engineered into each of the 
420 subunits. The polymer was synthesized first by introducing alkyne groups to the 
cysteines as initiating site. The bifunctional azide monomer 2-azido-1-
azidomethylethylamine (DAA) with attached 2-(4-isothiocyanatobenzyl)-
diethylenetriamine pentaacetic acid gadolinium (p-SCN-Bn-DTPA-Gd) was coupled 
to the alkynes. Prior to the coupling reaction, the p-SCN-Bn-DTPA-Gd ligand was 
attached to the primary amine of DAA (DAA-DTPA-Gd). Trialkyne as branching 
agent was coupled to the second azide of DAA-DTPA-Gd. The procedure of alkyne–
azide coupling was conducted until theoretically seven ligands (DAA-DTPA-Gd) per 
subunit were introduced. Subsequent modification of the polymer’s primary amines 
with DTPA allowed for complexation of Gd3+ ions. While the mass of the protein 
cage increased due to the presence of the polymer, its size did not change, as 
confirmed by SEC. The polymers enabled a payload of 1900 Gd3+ ions per capsid, 
which resulted in a very high relaxivity of r1 = 41,300 mM–1 s–1 per particle. 
Moreover, the P22-polymer-DTPA construct slows down molecular tumbling due to 
its size, which is important to achieve high relaxivities.368 These results demonstrate 
the potential of virus–polymer MRI contrast agents. The disadvantage of this kind of 
step-growth polymerization is, however, that it takes a lot of effort to synthesize 
larger polymers within the cavity of a protein cage. 
For this reason, Douglas and co-workers switched to ATRP for the synthesis of 
polymers within the P22 capsid,148 as it allows preparation of real polymers in a 
single synthesis step (Figure 1.2.17).22 To ensure that all polymers are within the 
cavity, a new mutant of P22 was created by single-point mutation. Serine on position 
39 of each subunit was exchanged by cysteine (P22S39C). All cysteine residues are 
exposed on the interior of the capsid, in contrast to the K118C mutant, 269 which also 
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has some cysteines on the exterior surface of the capsid. ATRP initiators were 
conjugated to the cysteines of the P22S39C mutant in its expanded morphology. Then, 
2-aminoethyl methacrylate (AEMA) was copolymerized with the cross-linker bis-
acrylamide, resulting in a cross-linked polymer network (xAEMA) that contained 
primary amines (Figures 1.2.17a-c). An additional difference to the previous reported 
study that used the click approach for polymer synthesis, the P22 cage was not 
applied in its WB morphology, but in its expanded (EX) morphology. The diameter 
in both structures is the same, but the WB lacks the penton subunits. The EX form is 
similar to the infectious virus in vivo, therefore it was used in this study. To evaluate 
the number of accessible primary amines on the polymer chains, P22S39C–xAEMA 
conjugates were incubated with FITC. Because FITC attaches to every amine, lysines 
were also modified. To overcome this issue, P22S39C without polymers was incubated 
with FITC. The number of amines from P22S39C was subtracted from the total 
number of P22S39C–xAEMA. Thus, it was possible to calculate the number of 
primary amines in the polymer chains that could be modified. In addition to FITC, 
which was used as an analytical marker and for quantification purposes, Gd-DTPA-
isothiocyanate (Gd-DTPA-NCS) was attached to the amines as MRI contrast agent. 
The number of Gd-DTPA per P22S39C–xAEMA was determined by attaching Gd-
DTPA-SCN to the primary amines and as a control to P22S39C. P22S39C–xAEMA 
revealed a 28 times higher Gd3+ content than P22S39C as determined by inductively 
coupled plasma–optical emission spectroscopy (ICP–OES). Thus, most of the 
contrast agent was bound to the polymers. To exclude electrostatic binding of Gd-
DTPA with the polymer chains, P22S39C–xAEMA was incubated with the contrast 
agent Gd-DPTA (Magnevist, Bayer Schering Pharma). The P22S39C–xAEMA sample 
incubated with Gd-DTPA-NCS showed a shift to higher molecular weight in native 
agarose gel electrophoresis compared with the unmodified P22S39C–xAEMA. The 
P22S39C–xAEMA sample that was incubated with Magnevist on the other hand 
showed the same electrophoretic mobility as the P22S39C–xAEMA conjugate. These 
results led to the conclusion that Gd-DTPA was covalently bound to the polymers 
and not just by electrostatic interaction. The loading capacity of the capsid was 9,100 
± 800 Gd3+ ions and resulted in a particle relaxivity of r1 = 200,000 mM–1 s–1. Thus, 
these ATRP-derived polymers allowed a fivefold higher Gd3+ content and relaxivity 
per VLP than the previously reported click-chemistry-derived polymers.111 
Unfortunately, the WB form of P22 with cross-linked AEMA was not investigated in 
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this study as in the previously reported study. It would be interesting to see the 
differences, because the WB morphology has, due to the lack of capsid pentons, 
larger pores that should allow a better exchange of water molecules between the 
interior of the Gd3+-loaded capsid and the external environment. 
Differences in the location of initiator sites between the K118C and S39C mutants of 
P22 were demonstrated by homopolymerization of the monomer AEMA148 and N-
tris(hydroxymethyl)methyl acrylamide from protein-bound ATRP initiators.172 
Polymerization yielded protein–polymer conjugates in both cases. The size of the 
P22S39C remained constant during polymerization. However, the diameter of the 
K118C mutant increased, indicating that in the first case polymer chains formed 
solely inside the capsid, while in the latter case polymer chains grew on the exterior 
and the interior surface of the protein cage. 
 
Figure 1.2.17. Synthesis and labelling of P22S39C–xAEMA. (a) Schematic representation of ‘grafting-
from’ ATRP inside the protein cage P22 to yield protein–polymer conjugates in which a cross-linked 
polymer (xAEMA) is encapsulated in a protein shell. The polymer bears amine groups that can be 
further modified, e.g. with fluorescent dyes or MRI contrast agents. (b) SDS–PAGE showing P22-
initiator and P22 with cross-linked AEMA (P22–xAEMA). The latter shows cross-linked subunits at 
the top of the gel, and streaking of the subunit band to higher molecular weight, indicating the 
formation of protein–polymer conjugates. (c) TEM images of P22–initiator and P22–xAEMA reveal 
that the protein cage remains intact after polymerization within the cavity. Scale bars are 100 nm. 
Adapted with permission from 148. Copyright © 2012, Nature Publishing Group. 
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A recent study with the P22–xAEMA-DTPA-Gd construct compared the relaxivity 
values r1 and r2 at different MRI field strengths in dependence of the Gd-loading 
capacity of the P22 cage.113 The protein cage gives at least a three times better 
positive contrast (r1 value) than free DTPA-Gd at magnetic fields that are used in 
clinics (≤3 T). Therefore, the P22–polymer conjugate can be applied as T1 contrast 
agent. At high magnetic fields of 7 T and a loading capacity of 10300 Gd3+ per cage, 
the P22–xAEMA-DTPA-Gd has an r2/r1 ratio of approximately 8, which is almost as 
high as for superparamagnetic (T2) contrast agents (r2/r1 > 10). Thus, the P22-capsid 
has high potential as MRI contrast agent. 
Because of its high relaxivity, the VLP was used to image vascular inflammation in 
atherosclerosis mouse models.162 For comparison, experiments with free DTPA-Gd 
complex were also carried out. At the same Gd concentrations (20 µmol Gd/kg in 
mice, corresponding to one-fifth the typical clinical dose), P22–xAEMA-DTPA-Gd 
resulted in a much stronger contrast in magnetic resonance angiography of vascular 
systems.162 In addition, arginine–glycine–aspartic acid (RGD) peptides were attached 
to the exterior of P22–xAEMA-DTPA-Gd for active targeting of αVβ3 integrin, 
which is upregulated on activated macrophages.162 RGD is a proven targeting ligand 
for specific targeting in vascular inflammation (e.g. vascular cancer).369 RGD-
modified P22–xAEMA-DTPA-Gd showed enhanced uptake for the targeted cells, as 
proven by MRI measurements. These results, although so far only published as a 
conference proceeding, show that the ATRP-derived P22–polymer conjugate can be 
applied for in vivo MRI and that it is capable of targeting specific cells when 
modified with a targeting moiety. 
Because gadolinium-based contrast agents are linked with nephrogenic system 
fibrosis due to the possibility of free Gd3+, a less toxic system was developed by 
Douglas and co-workers based on P22–xAEMA.115 The protein–polymer conjugate 
was modified with manganese(III) protoporphyrin (MnPP) on the accessible amines 
of P22–xAEMA (amines of lysines and xAEMA). A relaxivity per particle of 7098 
mM–1 s–1 with a loading of 3646 MnPP molecules per capsid was achieved. 
According to the Solomon–Bloembergen–Morgan theory368 the MnPP containing 
P22 capsid should have a higher ionic relaxivity than free MnPP because molecular 
tumbling is slowed down. However, their relaxivity was similar. A hypothesis for 
this result is that MnPP molecules within the cage interact and block access of water 
molecules to the metal site, slowing down or preventing exchange of water 
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molecules with the complex. The relaxivity of Mn-based systems was lower than that 
of Gd-based systems. Nevertheless, the Mn-based system could be a good alternative 
to the Gd-based systems because of manganese’s lower toxicity. As suggested by the 
authors, targeting moieties on the exterior of the P22 cage could lead to higher 
contrasts at desired places of action.115 Another proposition to enhance the properties 
of the contrast agent is to disrupt interactions between MnPP molecules within the 
cavity of the protein cage to allow better access of water molecules to the Mn sites. 
Furthermore, it would be possible to label the P22–polymer conjugate with Mn–
porphyrin complexes of higher relaxivity (e.g. manganese(III) tetrakis(4-
sulfonatophenyl)porphyrin). 
P22–polymer conjugates that encapsulate cross-linked AEMA were not only 
explored as contrast agents, but also as nanoreactors for photocatalytic 
applications.172 AEMA, bis-acrylamide and [ruthenium(5-
methacrylamidophenanthroline)3]2+ ([(Ru(meth-phen)3]2+) were copolymerized by 
ATRP in P22S39C to create protein–polymer conjugates with photocatalytic activity 
(Figures 1.2.18a+b). Photoreduction of methyl viologen (MV2+), using EDTA or 
ethanol as sacrificial reductants,359,360 was monitored by UV–vis spectroscopy 
(Figure 1.2.18c). Absorbance at 395 nm increased as the reaction proceeded (Figure 
18c). In contrast, P22–xAEMA that lacked [(Ru(meth-phen)3]2+ could not catalyse 
the reduction of MV2+. The results show that copolymerization of functionalized 
monomers inside the P22 capsid can yield core–shell particles in which a 
catalytically active cross-linked polymer core is encapsulated in a protein cage. It 
remains to be elucidated, however, how the catalytic performance of the protein–
polymer conjugates compares with other catalysts. 
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Figure 1.2.18. P22–xAEMA as catalyst for photoreductions. (a) SDS–PAGE of P22S39C initiator after 
0 min and 180 min polymerization time. (b) DLS of P22S39C after 0 min and 180 min polymerization 
shows the same size distribution, indicating that the polymer formed inside the cage. (c) 
Photocatalytic reduction of MV2+ by P22S39C–xAEMA-co-[(Ru(meth-phen)3]2+ as monitored by UV–
vis spectroscopy. In contrast, P22S39C–xAEMA that lacked [(Ru(meth-phen)2+]3 did not reduce the 
substrate. Adapted with permission from 172. Copyright © 2013 Elsevier Ltd. All rights reserved. 
A complementary study to the grafting-from ATRP of amine-containing monomers 
within a viral capsid by Douglas and co-workers,111,148,162,172 was conducted by Finn 
and co-workers (Figure 1.2.19).114 A modified variant of Qβ bacteriophage was 
expressed that had the unnatural amino acid azidohomoalanine (AHA) instead of 
methionine residues on the interior. This mutant (T93AHA) allowed the attachment 
of ATRP initiators to the interior via click chemistry (Figuure 1.2.19a). The viral 
RNA was removed prior to quantification of binding sites and conjugation of 
initiators to AHA. The number of available AHAs was determined by letting the 
capsid react with fluorescein–alkyne dye in a copper-catalysed azide–alkyne 
cycloaddition. A quantity of approximately 147 dye molecules per Qβ  was 
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measured. ATRP initiators with alkyne groups were bound to the AHAs, followed by 
polymerization of 2-dimethyamino ethyl methacrylate (DMAEMA) in the interior of 
Qβ bacteriophage. Two Qβ–poly(DMAEMA) conjugates were synthesized, one 
with 250 monomers per subunit (T93@250×) and another with 1000 monomers per 
subunit (T93@1000×) (Figure 1.2.19b). Qβ–poly(DMAEMA) conjugates increased 
slightly in diameter (17.3 nm for T93@250× and 22.3 nm for T93@1000×) (Figure 
1.1.19c) compared with the protein macroinitiator (16 nm). The increase might be 
caused by disruption of the capsid structure by the polymer chains or by chains that 
protruded from the cage. However, DLS and TEM proved that the cages stayed intact 
after polymerization (Figure 19c). To verify that polymer chains were within the 
interior of the VLP, the terminal bromines on the polymer chains were exchanged 
with azides and then labelled with biotin. Biotinylated polymer–protein particles 
showed weak interaction with streptavidin in an ELISA assay in comparison with Q
β VLPs that were modified on the exterior with biotin, indicating that the majority 
of polymer chain ends was encapsulated in the protein cage. By changing the pH 
from 7.0 to 11.0, the initiator-bearing VLP increased in size, while the T93@1000× 
conjugate decreased in size. This observation could be explained with a transition of 
poly(DMAEMA) from a swollen to collapsed state when the pH is increased.370 As 
additional experiments, a cyclic RGD (cRGD) derivative with a PEG spacer was 
attached to the exterior to enhance cellular uptake. Uptake into HeLa cells was 
enhanced compared with Qβ bacteriophage without cRGD and poly(DMAEMA). 
Surprisingly, Qβ–poly(DMAEMA) conjugates that lacked cRGD on the surface 
showed a similar overall cell uptake to the protein–polymer conjugate with cRGD. 
Thus, it can be concluded that the poly(DMAEMA) in the interior had an influence 
on cellular uptake. A possibility might be that some of the cationic polymer chains 
protruded from the protein cage and improved cellular uptake. A difference between 
cRGD and poly(DMAEMA) uptake was, however, observed. While cRGD-decorated 
VLPs showed a receptor-mediated endolysosomal uptake, Qβ–poly(DMAEMA) 
VLPs were not found in endolysosomes. The Qβ–poly(DMAEMA) conjugates were 
applied as transfection agents for small interfering RNA (siRNA) into HeLa cells 
that expressed GFP. Indeed, a silencing effect of GFP was observed. However, it is 
difficult for a 21-mer siRNA (≈7 nm length, 2 nm thickness)371 to enter and leave the 
cavity through pores with a diameter of 1.5 nm. Moreover, complexes of 40 siRNAs 
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per VLP were formed. It is unlikely that all siRNAs were encapsulated into the 
capsid, as this number of nucleotides does not fit into a 22 nm VLP. It is more likely 
that some siRNA were encapsulated but the major part formed a complex with the 
exterior of Qβ, probably enhanced by the cationic polymer chains that protruded 
from the protein cage. Nevertheless, Finn and co-workers showed that a protein cage 
with polymers in the cavity could be applied for nucleotide delivery. 
 
Figure 1.2.19. Synthesis of polymers in the cavity of Qβ bacteriophage. (a) Schematic representation 
of initiator conjugation in the cavity of the protein cage and subsequent ATRP. (b) SDS–PAGE of the 
protein macroinitiator (T93@init), a sample that was synthesized with 250 monomers per subunit 
(T93@250×) and a sample that was synthesized with 1000 monomers per subunit (T93@1000×). (c) 
DLS (top) and TEM images (bottom) of T93@init, T93@250× and T93@1000×. Scale bars of TEM 
images are 50 nm. Adapted with permission from 114. Copyright © 2014 American Chemical Society. 
Direct polymerization from protein-bound initiators is a versatile approach to prepare 
functional protein cage–polymer conjugates. However, well-controlled 
polymerizations that yield polymers of predetermined molecular weight and narrow 
molecular weight distribution on the surface of proteins can be difficult to achieve.29 
Moreover, characterization of the synthesized polymers by gel permeation 
chromatography or mass spectrometry is hampered by the covalently bound protein. 
An alternative strategy to prepare protein cages that encapsulated polymers is 
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covalently to link preformed polymers to the inside of protein cages. The advantage 
of this ‘grafting-to’ approach is that the polymers are synthesized, purified and 
characterized in solution, so that their molecular characteristics are well defined. Of 
course, this strategy will only work for protein cages that feature large pores in their 
protein shell through which macromolecules can enter into the fully assembled cage, 
or for polymer–protein conjugates that self-assemble into polymer cages. 
The natural function of chaperonins is to refold denatured proteins by providing a 
folding chamber into which proteins can diffuse. Our group took advantage of this 
feature and conjugated dendritic poly(amidoamine) (PAMAM, fourth generation) 
into the cavities of THS, a chaperonin from T. acidophilum to prepare delivery 
agents for siRNA (Figure 1.2.20).163 PAMAM is a common transfection agent in 
gene delivery and can bind and release oligonucleotides and a variety of drugs.372 
However, the high density of positive charges on the surface of PAMAM initiates 
uncontrolled cell uptake and can induce cytotoxicity.373-375 Moreover, PAMAM often 
forms non-defined aggregates with DNA and siRNA, leading to particles that are too 
large for efficient gene delivery.376 To overcome these disadvantages of PAMAM, it 
was incorporated into the cavity of THS. The cage shields cells from the positive 
charges on the polymer, while still allowing the polymer to bind and release siRNA. 
In contrast to other PAMAM-based siRNA transfection systems, the THS–polymer 
conjugate has a well-defined and monodisperse size of approximately 16 nm, which 
is defined by the size of the protein cage. Therefore, it fits well into the therapeutic 
size window (10–200 nm) for nanoparticles.377,378 To bind PAMAM into THS, a 
genetically engineered variant of THS that only carried cysteines on its inside was 
functionalized with maleimido trioxa-6-formyl benzamide (MTFB). In parallel, 
PAMAM was functionalized with succinimidyl-6-hydrazino-nicotinamide (S-
HyNic). Subsequently, PAMAM-S-HyNic and THS-MTFB were mixed. The 
polymer diffused into the protein cage where the linkers reacted to form a bis-aryl 
hydrazone bond, i.e. a resonance stabilized Schiff’s base, between the polymer and 
the protein (Figure 1.2.20a). On average, approximately four PAMAM molecules 
were bound into THS. The THS–PAMAM hybrid was able to bind therapeutic 
siRNA and protect it from degradation by RNase (Figure 1.2.20b). Moreover, it 
could deliver siRNA to U-87 MG cancer cells, inducing siRNA-related inhibition of 
proliferation (Figure 1.2.20c). By modifying the exterior of THS-PAMAM with the 
cell-penetrating peptide TAT, siRNA-loaded THS-PAMAM was also taken up by 
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prostate cancer cells (PC-3) and induced RNA interference in these cells.379 It was 
shown that TAT was crucial to initiate RNA interference in PC-3 cells, as protein 
cage–polymer conjugates that lacked the cell-penetrating peptide did not enter those 
cells. SiRNA has a big potential to tread different diseases, because it can silence 
disease-specific proteins.379 This THS-PAMAM system enables to overcome the 
inherent hurdles in siRNA delivery, such as fast degradation of siRNA in the blood, 
rapid clearing by the kidney due to its small size and the inability of siRNA to cross 
cell membranes.380 
 
Figure 1.2.20. THS-PAMAM as transporter for siRNA into cells. (a) Conceptional view of THS–
PAMAM hybrid as siRNA delivery agent. PAMAM incorporates the sensitive cargo, while the 
protein shell protects cells from positive charges of the polymer. (b) Degradation of siRNA by RNAse 
A, as followed by electrophoresis: 1) Free siRNA, 2) PAMAM-siRNA and 3) THS–PAMAM–siRNA. 
The results show that THS–PAMAM protects its cargo, similar to PAMAM. (c) U-87 MG cells 
transfected with KIF11 siRNA (blue) or scrambled siRNA (red) with either THS-PAMAM or 
Lipofectamine 2000 demonstrate the ability of transfecting siRNA by THS-PAMAM. Adapted with 
permission from 379. 
Nanoreactors are very small reaction vessels that confine chemical reactions into a 
nanoscale reaction volume.54 They can be created by encapsulation of catalysts into, 
e.g. polymer vesicles, inorganic capsules, phase-separated polymer networks and 
protein cages.51-58,61,72,381,382 Reactions in nanoreactors can be controlled in 
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unprecedented ways, allowing for enhanced reaction rates, suppressed side reactions, 
shape- and size-templated synthesis, as well as control of the reaction on a single-
molecule level.51-54,58,72,381 Therefore, nanoreactors have attracted much interest and 
were explored to conduct biocatalytic transformations in non-aqueous media,382 to 
investigate reactions on the single-molecule level220 and as artificial organelles.383 
With their hollow structure and their well-defined pores, protein cages are very 
promising nanoreactors. While most investigations concentrated on the conversion of 
small organic molecules in protein nanoreactors,51-54,58,72 recent reports suggest that 
protein cages can also be used as reaction vessels for the formation of polymers.61,62 
Substituted poly(phenylacetylene)s384,385 are conjugated polymers that can be used 
e.g. as material for active layers in organic light-emitting diodes (OLEDs)386 or as 
dynamic helical polymers to amplify chirality of guest molecules.387 To increase 
control over the polymerization of phenylacetylenes, Watanabe and co-workers 
complexed the catalyst rhodium norbornadiene (Rh(nbd)) to the inside of apoferritin 
(Figure 1.2.21a).62 The 24 subunits bound Rh(nbd) by interaction with cysteine, 
histidine and glutamic acid on the inside surfaces, as revealed by crystal structure 
analysis. Each subunit carried three Rh atoms, as determined by ICP–OES. The 
successful polymerization of phenylacetylene was confirmed by a colour change of 
the reaction mixture from colourless to pale yellow, indicating the presence of 
poly(phenylacetylene). Further, the apo-Fr cage kept its structure during 
polymerization, as indicated by similar elution volumes in size-exclusion column 
chromatography compared with unmodified apo-Fr (Figure 1.2.21b). The polymer 
was extracted from the ferritin by disassembling the protein cage into its subunits at 
pH 2. Poly(phenylacetylene) with a stereoregular cis-transoidal main chain, a 
number-average molar mass (Mn) of 1.31 × 104 g mol–1 and a polydispersity index 
(Ð) of 2.6 was obtained. For comparison, polymerization catalysed by free 
Rh(nbd)Cl2 yielded a stereoregular polymer with Mn = 6.37 × 104 g mol–1 and Ð = 
21.4. These results demonstrate that the discrete reaction space within the protein 
beneficially influences the polymerization of phenylacetylene towards lower Mn and 
smaller Ð compared with polymerization in the absence of apo-Fr. 
Several other derivatives of phenylacetylene were tested as monomers. Although 
phenylacetylene bearing an amino group was polymerized in the protein nanoreactor, 
monomers with carboxylic or phosphonic acid substituents did not react. Most likely, 
this selectivity stems from electrostatic repulsion between anionic molecules and 
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positively charged pores of ferritin, i.e. the anionic monomers were repelled from the 
protein cage. Therefore, it can be envisioned to use apoferritin as a selective 
nanoreactor for neutral and cationic acetylene monomers. 
 
Figure 1.2.21. Apoferritin as nanoreactor for the polymerization of phenylacetylenes. (a) Schematic 
view of complex formation between apo-Fr and [Rh(nbd)Cl2] and subsequent polymerization of 
phenylacetylene. (b) Size-exclusion chromatograms of Rh(nbd)-apo-Fr after polymerization of 
phenylacetylene (top), Rh(nbd)-apo-Fr (middle) and apo-Fr (bottom). The elution was monitored at 
383 nm (red), which is caused by poly(phenylacetylene), and at 280 nm (black) where protein and 
polymer absorb light. Adapted with permission from 62. Copyright © 2009, American Chemical 
Society. 
Polymethacrylates and vinyl polymers are usually prepared by radical 
polymerization. The advent of reversible-deactivation radical polymerization 
(controlled/living radical polymerizations) such as ATRP and RAFT has paved the 
way for the precise synthesis of these polymers.22,47,388 However, conducting ATRP 
in water can be challenging, as several side reactions might occur.44 A possibility to 
increase the performance of ATRP is to conduct the polymerization in 
nanoreactors.389 The first example of a protein cage–catalyst conjugate as a 
nanoreactor for controlled/living radical polymerizations was reported by Bruns and 
co-workers (Figure 1.2.22a).61 They bound an ATRP catalyst covalently to the 
cysteines of an engineered thermosome from T. acidophilum (THS). These 
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attachment points were present on the inside of every beta-subunit of the chaperonin. 
The ligand for the Cu(I) catalyst was synthesized by functionalizing N,N,Nʹ,Nʹ-
tetraethyldiethylenetriamine (TEDETA) with an aromatic aldehyde. In parallel, the 
hetero-bifunctional linker 3-maleimido-6-hydraziniumpyridine hydrochloride 
(MHPH) was reacted with THS. Then, the ligand and the protein were mixed, which 
caused the hydraziniumpyridine to react with the aromatic aldehyde, forming a 
resonance-stabilized bis-aryl hydrazone bond between THS and ligand. The ligand 
was subsequently used to complex copper ions, yielding THS-LxCu. SAXS 
confirmed that the copper complex was only attached on the inside of the protein 
cage. The THS was in an open conformation, allowing the exchange of polymers 
between the inside and outside of the protein cage. This enabled the synthesis of 
polymers inside the THS and their subsequent release into the surroundings. 
Compared with polymerizations in ferritin (vide supra) it was therefore not necessary 
to disassemble the protein cage to extract the polymer from the protein. Having a 
confined reaction space that allows the product to be released into the surrounding 
medium through large pores is an advantage of THS over many other protein cages. 
THS-LxCu was used as a catalyst for ATRP of NIPAAm in water. It resulted in 
PNIPAAm with Mn of 1.5 × 103 g mol–1 and Ð of 1.11. The polymerization of 
oligo(ethylene glycol)methyl ether acrylate (OEGA) in the presence of 30% THF as 
organic co-solvent yielded a polymer of Mn = 1.4 × 103 g mol–1 and Ð = 1.06 (Figure 
1.2.22b). The synthesis of polymers within THS was compared with polymerizations 
in which the globular protein bovine serum albumin (BSA) served as the carrier of 
the copper catalyst (Figure 1.2.22b). BSA-LxCu gave PNIPAAm with Mn = 4.26 × 
105 g mol–1 (Ð = 1.92) and poly(OEGA) with Mn of 1.49 × 105 g mol–1 (Ð of 1.84). 
Thus, polymers synthesized within the protein nanoreactor had a lower molecular 
weight and narrower molecular weight distribution than their counterparts produced 
in solution. These findings are in line with the observations for the polymerization of 
phenylacetylene in ferritin (vide supra).62 Native and SDS–PAGE, as well as TEM 
(Figure 22c) confirmed the integrity of the protein cage also under harsh synthesis 
conditions, i.e. in aqueous solutions that contained 30% organic co-solvent. 
Both examples (Rh(nbd)-apo-Fr and THS-Lx-Cu) demonstrate that polymerizations 
can be confined in protein cages by attaching catalysts to the inner surface of the 
proteins. The nanoscale reaction space within these engineered protein cages results 
in polymers with lower and more narrowly distributed molecular weight compared 
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with polymerizations catalysed by freely accessible catalysts in solution. Reasons for 
this observation could be that the growth of polymer chains is limited by the rate of 
diffusion of monomers into the protein cage and that the nanoreactors hold the 
growing polymer chain and catalyst in close spatial proximity. 
Protein nanoreactors offer the opportunity to gain new insights into polymerization 
reactions. The mechanism of the reactions and the growth of polymer chains could 
be studied with sequestered single polymer chains. Furthermore, triggers to open and 
close pores in protein cages could be used to alter the rate of polymerization or to 
start and stop polymerizations on demand. This could lead to new possibilities to 
influence polymerization reactions. 
 
Figure 1.2.22. Polymer synthesis in the cavity of THS. (a) THS as nanoreactor for ATRP of N-
isopropyl acrylamide and poly(ethylene glycol) methyl ether acrylate. (b) Comparison of GPC traces 
from poly(OEGA) synthesized within THS-LxCu (green) or with BSA-LxCu (brown) in the presence 
of 30% THF. (c) TEM image of THS-LxCu after polymerization, showing that after reaction the 
protein cage is still intact. Adapted with permission from 61. Copyright © WILEY-VCH 2014, 
Weinheim. 
 Conclusion and Outlook 1.4.7
Many of today’s technical and healthcare challenges can be addressed by developing 
functional nanomaterials, e.g. as drug-delivery devices, as templates for electronic 
and energy materials or as advanced catalysts. A fascinating route to novel 
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nanomaterials is to take advantage of the rich variety of functional, self-assembled 
protein structures found in nature. Of particular interest are protein cages, as these 
capsules offer the possibility to host, protect, transport and release therapeutic cargo, 
metal nanoparticles, macromolecules, catalysts and many other guests. Moreover, 
they have very well-defined structures and sizes, which e.g. fit well in the therapeutic 
size window for long circulation time. Protein cages spontaneously self-assemble 
from a small number of protein subunits that can be overexpressed in suitable host 
organisms (e.g. E. coli). Some cages can be obtained from abundant natural sources 
(e.g. certain viral capsids from plants or ferritin from blood). Thus, protein cages are 
easily and widely accessible in sufficient quantities to be useful tools and building 
blocks for bionanotechnology. Although protein cages can be used on their own, 
their full power is unlocked if they are paired with synthetic polymers. In biomedical 
applications, e.g. as drug- or gene-delivery agents, biocompatible polymer chains on 
the surface of protein cages are essential to lower the risk of immunogenic responses 
against the proteins. Moreover, polymers can act as flexible spacers through which 
targeting ligands can be attached to the surface of the proteins. Protein cages can act 
as functional additives in polymeric materials, e.g. to create self-reporting materials 
or to increase the mechanical properties of hydrogels. A major breakthrough in the 
design of protein cage-based therapeutics was to synthesize polymers in their inside 
to enhance greatly their loading capacity for small molecule drugs or for MRI 
contrast agents. In a related approach, cationic polymers were used as anchor groups 
within the cavity of proteins to bind nucleic acids, so that siRNA delivery with non-
viral cages became possible. Synthetic polymers not only increase the potential of 
protein cages in biomedical applications, but can also guide the self-assembly of viral 
subunits into nanostructures that differ in their size or shape from their native 
counterparts. If certain technical applications require a higher heat stability of protein 
cages, polymer chains can be used to achieve this, e.g. by multi-point attachment of 
synthetic macromolecules on the exterior surface or by step-growth polymerization 
and cross-linking of polymers within the cavity of protein cages. Polymerizations 
within protein cages proceed with fewer unwanted side reactions, so that the proteins 
have been used as nanoreactors for the synthesis of polymers or of polymer-filled 
protein nanoparticles. 
This review summarizes and discusses many fascinating protein cage–polymer 
hybrid systems and their (potential) applications. But what lies ahead? The symbiosis 
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of polymers with protein cages opens up new opportunities for creative solutions in 
bionanotechnology and paves the road to novel building blocks for nanomaterials. 
Only a limited number of protein cages have been explored and the selection of 
appropriate cages for a particular application is often guided by their availability in 
the research groups that are active in this field. However, many more hollow protein 
structures are known in the biochemical literature, which can considerably increase 
the range of sizes and shapes of functional protein–polymer conjugates. For example 
bacterial microcompartments192-194 or giant viruses390-395 have not yet been explored 
as scaffolds to create protein–polymer hybrid nanoparticles, although such large 
structures would allow encapsulation of a much higher amount of functional cargo, 
such as polymer-bound catalyst, polymer-bound semiconducting nanoparticles, drugs 
or MRI contrast agents. Polymerization of conducting polymers in rod-shaped 
viruses would create polymer-based nanowires. Another interesting possibility is to 
create designer protein nanostructures from scratch by engineering of protein 
subunits or oligomers.76,396-399 Very recently, this approach has led to highly porous 
protein cubes76 and unilamellar hollow spheres,399 but these structures have not been 
combined with synthetic polymers yet. While most work on protein cages has 
focused on using their intriguing structures as scaffolds or as capsules, the function 
of protein cages has seldom been explored. For example, chaperonins provide a 
folding chamber for unfolded proteins.227 This environment might therefore also fold 
single polymer chains, which would be a major contribution to the field of single-
chain polymer particles.400 Moreover, many cages feature gated pores, but this 
property has not yet been exploited widely to create gated nanoreactors or triggerable 
drug-release vehicles. The pores in protein cages could also be rendered responsive 
to non-native stimuli by blocking them with a stimulus-responsive polymer. This 
would allow, for example creation of controlled drug-delivery cages that release their 
cargo in response to temperature changes, pH changes or any other of the many 
stimuli that are well known in polymer chemistry.401-403 Polymers would also allow 
loading protein cages with a high density of catalyst molecules, so that highly 
reactive nanoreactors can be envisioned. They could be used to conduct cascade 
reactions with improved yield and reduced side reactions. Moreover, such catalyst-
loaded cages could be immobilized on the surface of a lab-on-a-chip device, e.g. for 
biosensing applications. Polymers grafted to the surface of protein cages can render 
them soluble in organic solvents.13 If such proteins could be loaded with catalysts, 
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they could be used as nanoreactors for reactions in organic solvents. A further 
promising field of research is to use protein cage nanoparticles as templates for 
nanostructured materials. Protein cages can be self-assembled into 2-D and 3-D 
arrays. Such arrays could be used as templates to create polymeric materials with a 
highly ordered and well-defined internal structure. This might result in materials with 
novel optical or electronic properties, especially when the protein scaffolds are 
combined with conducting polymers. Engineering of the contact area between 
individual protein cage particles in such arrays would allow self-assembling of the 
protein cages into defined orientations, giving rise for an unprecedented degree of 
control over the position and orientation of encapsulated cargo, such as polymeric or 
inorganic nanoparticles. 
In conclusion, the combination of protein cages with polymers results in novel hybrid 
nanosystems that combine the advantages of these biomacromolecules and of tailor-
made synthetic polymers. Exciting applications, ranging from drug delivery to the 
preparation of advanced materials, have been addressed in the past and a variety of 
protein cage–polymer hybrids have been reported. However, this research field is far 
from maturity, allowing for many new concepts to be developed and explore
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Chapter 2 
2 Research projects 
2.1 Synthesis of functional polymers within a 
chaperonin for encapsulation and release of 
biomacromolecules 
This chapter will be published as: Rother M., Nussbaumer M. G., Duskey J. T., 
Postupalenko V. Meier W., Bruns N., Synthesis of functional polymers within a 
chaperonin by atom-transfer radical polymerization for encapsulation and release of 
biomacrololecules, 2016 
In this chapter, cationic and fluorescent polymers 
were synthesized in the interior of the protein cage 
thermosome, a group II chaperonin. This 
thermosome-polymer conjugate was explored in its 
interaction with biomacromolecules and their 
release into mammalian cells. Moreover, the cage 
structure shielded the cells from toxicity of the 
cationic charges of the polymer. 
 Introduction 2.1.1
Nature provides us with different and versatile types of proteins that carry out 
specific functions such as enzymes,404-406 membrane proteins,407,408 antibodies,409,410 
or protein cages.228,411-413 Protein cages are hollow nanometer sized assemblies from 
protein subunits.228,411-413 They are kept together by covalent and non-covalent 
subunit interactions. Depending on their origin, they play important roles in catalysis, 
nucleic acid storage and delivery, folding of denatured proteins and molecular 
storage and regulation.77,78,234,414-416 Protein cages have recently attracted great 
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interest as functional and structurally well-defined building blocks for 
bionanotechnology77. They are  highly uniform hollow nanoparticles whose structure 
has been, in many cases, resolved with high resolution. Therefore, they can be site-
selectively functionalized on their exterior and their interior via genetic and chemical 
methods.78,101 This is an advantage over hollow nano vehicles based on organic or 
inorganic materials, which have a broader size distribution and cannot be site-
selectively modified with that ease as protein cages.72,81,82 Moreover, they have a 
remarkable high stability81 and are biodegradable and biocompatible.72,149 The 
properties of protein cages make them ideal candidates for development of nano 
carriers that can transport cargo to a specific cellular target,74,82 and as nano reactors 
for the synthesis of inorganic60,137,417 or organic materials.61,62 Protein cages have 
viral or non-viral origin. The most studied ones are virus-like particles (VLPs) that 
are derived from viruses and bacteriophages by removing their cargo 
DNA/RNA.74,95,105,418 Non-viral protein cages are, for example, ferritins77, heat-
shock proteins,185,186,213,234,419 chaperonins187,188,228,235 or vault proteins.242,316  
Protein cages can be combined with synthetic macromolecules in order to create new 
hybrid materials that widen the possible applications of these nanostructures.420,421  
Polymers can be attached on the outside of protein cages to alter the properties of the 
proteins (e.g. prolonged circulation time) or they can be equipped with additional 
functionalities such as targeting ligands to enhance cellular 
uptake.153,154,164,282,283,285,294,297,310,314,322 A constantly growing field are protein cage-
polymer conjugates where the polymers are located in the interior of the cages. This 
allows introducing a higher density of functional molecules into the protein cages, 
e.g. to create highly efficient magnetic resonance contrast agents, protein cage-
polymer conjugates with catalytic activity or gene delivery vehicles.111,113-
115,148,162,163,172,361,362 Commonly used polymerization methods to synthesize protein-
polymer conjugates are atom-transfer radical polymerization (ATRP) and radical-
addition fragmentation chain transfer (RAFT) 
polymerization.15,22,29,33,35,39,40,179,275,422,423  
Many native protein cages have static pores. Ferritin’s pores are 0.4 nm in diamter,211 
the pores of Qβ bacteriophage 2.5 nm264,265 and small heat shock proteins have pores 
with a diameter of approx. 3 nm.212,213 However, these pores are too small to allow 
macromolecular therapeutic cargo, e.g. proteins (~ 50 kDa, approx. 2.5 nm)424 or 
duplex 21-mer siRNA (~7 nm length, 2 nm diameter)371,425-427 to enter the cavity. 
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From all native protein cages, the pores of chaperonins range among the largest. The 
thermosome (THS) from Thermoplasma acidophilum, a group II chaperonin that was 
used in this work, is assembled from alternating α- and β-subunits in an eightfold 
symmetry and has a barrel shape structure, which is approx. 16 nm in outer 
diameter.428 In the open state, THS has two large pores (~ 8-10 nm in 
diameter)236,237,429 that allow macromolecules like globular proteins (up to 50 kDa)235 
or polymers61 to enter and leave the cavity (Scheme 1 a & b).  
Thus, the THS cage is ideally suited for encapsulation, transport and release of 
macromolecules. However, macromolecules do not stay permanently in native THS, 
as they can diffuse out of the cavity when THS is in its open state. In order to address 
this challenge, cationic polymers can be inserted as an anchor into the THS cavity. 
The polymer can bind therapeutic macromolecules via electrostatic interactions and 
therefore prevents the premature release of the cargo from the cavity. A mutated 
variant (K316C) of native THS was used (Figure 2.1.2a+b).30 It carries a cysteine 
(Cys) on the inside of every β-subunit, which allowed covalent attachment of 
functional molecules in the protein cage. In our previous study, poly(amidoamine) 
(PAMAM)430, a cationic dendrimer, was bound to the cysteines via a “grafting-to”-
approach in order to bind siRNA within THS.163 SiRNA was chosen as an example 
for a biomacromolecule because of its therapeutic properties and importance.431-433 
The oligonucleotide was kept within the THS via electrostatic interactions. However, 
the PAMAM-approach has its limitations. Being a presynthesized dendrimer, 
PAMAM cannot include even small amounts of other functional units, is inflexible 
in its folding and has a very limited scope for further modifications. 
In addition, the bulky dendrimer occupies much space in the cavity, limiting the 
amount of macromolecules (e.g. siRNA) that can be encapsulated. Furthermore, the 
THS-PAMAM-siRNA complex formed undesired aggregates, most likely because 
the cargo is not fully encapsulated in the protein cage due to steric reasons. To 
overcome these issues, a different method was applied in which linear polymers were 
synthesized in the cavity by a “grafting-from” approach. Maleimide-ATRP initiators 
were coupled to accessible cysteines (Cys) via Michael-Addition.434 Then, cationic 
2-(dimethylamino)ethyl methacrylate (DMAEMA) was polymerized within the 
cavity of THS via activators regenerated by electron transfer atom transfer radical 
polymerization (ARGET ATRP) (Figure 2.1.1a).46 Copolymerization of DMAEMA 
with the fluorescent monomer methacryloxyethyl thiocarbamoyl rhodamine B 
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(RhBMA) (Figure 2.1.1b) allowed synthesizing a polymer with dual functionality 
within the cage. PDMAEMA is known to bind to negatively charged molecules like 
nucleic acids and is used for their delivery.435 The linear polymer chains allowed the 
entrapment of two times more siRNA into the THS than with the PAMAM-
approach. Moreover, cationic polymers were utilized for intracellular delivery of 
proteins.436 
The THS-pDMAEMA and THS-pDMAEMA-co-RhBMA conjugates were explored 
as a delivery platform for siRNA into mammalian U87 cells (Figure 2.1.2c). In 
addition, enhanced yellow fluorescent protein (eYFP)437 and a modified variant of 
the green fluorescent protein (TurboGFP)438 were complexed to extend our strategy 
to protein delivery.439,440  
 
Figure 2.1.1. Chemical structures. (a) pDMAEMA and (b) methacryloxyethyl thiocarbamoyl 
rhodamine B.  
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Figure 2.1.2. Structure of THS, polymerization within the cavity of THS, and use of the protein-
polymer conjugate to bind and deliver biomacromolecules. Cryo-electron microscopy (cryo-EM) 
density map of a thermosome in its sideview (a) and top view (b). (c) Cross section of the mutated 
variant of the native THS, which had one accessible cysteine (Cys) on every β- subunit. Maleimide 
ATRP-initiators were coupled to the cysteines and the resulting macroinitiator was used for 
homopolymerization of 2-dimethylaminoethyl methacrylate (DMAEMA) or for copolymerization of 
DMAEMA with methacryloxyethyl thiocarbamoyl rhodamine B (RhBMA) under ARGET ATRP 
conditions. Subsequently, siRNA or fluorescent proteins (eYFP, TurboGFP) were complexed within 
the cavity via electrostatic interaction and delivered into U87 cells. 
 Results and Discussion 2.1.2
2.1.2.1 Synthesis and characterization of THS-pDMAEMA and THS-
pDMAEMA-co-pRhBMA conjugate 
Common ATRP reagents with different combinations were tested (Figure 2.1.3), in 
order to find out at which conditions the cage structure is stable and which lead to 
degradation (see Tables 2.1.1-2.1.3 and the experimental section for further details). 
Protein cages were incubated with different single reagents and their combinations in 
degased H2O under argon atmosphere for 48 h. After incubation time, the samples 
were analysed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) and basic native polyacrylamide gel electrophoresis (BN-PAGE). The 
influence of Cu(I) and Cu(II) on the cage structure in presence and absence of two 
different ligands (1,1,4,7,10,10-hexamethyltriethylenetetramine (HMTETA)22 and 
   Chapter 2 
 
74 
tris(2-pyridylmethyl)amine (TPMA)32 was tested (Figure 2.1.3a+b). Then, we 
wanted to know the influence of reducing agents (sodium ascorbate (NaAsc) and 
tin(II)ethyl hexanoate) for Cu(II) complexes, which are commonly applied in 
ARGET ATRP, on the cage structure (Figure 2.1.3a+b). Moreover, to the tested 
reagents in various combinations, monomers (hydroxyethyl acrylate (HEA)), ATRP-
initiators were added in order to test if the cage keeps its structure under ARGET 
ATRP conditions (Figures 2.1.3a-c). The THS subunits did not degrade in the 
presence of Cu(II) (Figure 2.1.2a, lane 2), whereas subunit degradation could be 
observed in the presence of Cu (I) (Figure 2.1.3a, lane 6). Even when Cu(I) was 
complexed with HMTETA, subunit degradation could be observed by the 
appearance of smearing bands (Figure 2.1.3a, lane 8), which was not the case for 
Cu(II) (Figure 2.1.3a, lane 5). In a comparison between the ligands HMTETA and 
TPMA, the samples with HMTETA showed no degradation of subunits (e.g. Figure 
2.1.3c lane 2), while TPMA showed degradation of the subunits by a smearing (e.g. 
Figure 2.1.3c, lane 3) in the SDS-PAGE gels. No difference in cage structure was 
found after treating THS with the reducing agents sodium ascorbate (NaAsc) and 
tin(II)ethylhexanoate in presence of Cu(II) and HMTETA as ligand. When TPMA 
was used as ligand, decomposition of the cage was stronger with 
tin(II)ethylhexanoate (Figure 2.1.3c, lane 9) than with NaAsc (Figure 2.1.3c, lane 8). 
THS is stable in the presence of radicals (ARGET ATRP conditions, Figures 2.1.3a-
c) as well as in 50 vol% dimethylsulfoxide (DMSO) (Figure 2.1.3d) and 5 vol% 
methacrylate monomers (Figure 2.1.3e), which is approx. 75’000 monomer units per 
initiator at 4 initiators per cage (see below). Moreover, a high concentration of Cu 
(I), even when bound to a ligand, caused disruption of the cage structure. As a 
consequence, we used HMTETA as ligand and kept the amount of copper very low. 
At the same time it was desired to generate enough radicals for polymerization 
within the cavity of THS. Thus, we chose activators regenerated by electron transfer 
atom transfer radical polymerization (ARGET ATRP) as our polymerization method 
of choice.41,46,441 DMSO was chosen as a co-solvent, because preliminary 
experiments showed a slightly better control over molecular weight of the polymers 
than with tetrahydrofuran (THF). 
From the stability experiments we derived the ARGET ATRP conditions. Copper 
concentration (as CuBr2 complexed with HMTETA in a 1:1.3-ratio) was chosen to 
be four times higher than initiators to have an adequate amount of copper that can 
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create radicals within the cavity of THS. The concentration of the reducing agent 
NaAsc was chosen to be four times higher than of the Cu-complex. This guaranteed 
a constant generation of radicals even though concentration of reactants, except 
monomers, was kept low. We know that the cage structure is stable at a monomer 
concentration of 5 vol%. For this reason, the monomer concentration was kept below 
5 vol% in order not to eventually disrupt the cage structure at higher concentrations. 
 
Figure 2.1.3. THS protein cage stability tests to find out at which polymerization conditions the cage 
remains intact. (a) SDS-PAGE of THS at different reagent compositions. The influence of Cu(I) + 
Cu(II) in absence and presence of the Ligand HMTETA and reducing agent sodium ascorbate on the 
cage structure was investigated. In addition, it was tested if the cage structure is stable in presence of 
radicals. L = protein ladder. Details of the conditions are shown in table 1(b) SDS-PAGE (top) and 
BN-PAGE (bottom) of THS at different conditions. The influence of Cu (I) + Cu(II) in absence and 
presence of the Ligand TPMA and reducing agent sodium ascorbate on the cage structure was 
investigated also in the presence of radicals. Details of the conditions are shown in table 2  (c) SDS-
PAGE (top) and BN-PAGE (bottom) of THS at different conditions. The ligands HMTETA and 
TPMA were compared at various ATRP-conditions. Moreover, the influence of radicals on the cage 
structure was investigated. Details of the conditions are shown in table 3 (d) THS in DMSO:H2O 1:1 
(v:v). (e) THS in presence of 5 vol% oligo(ethylene glycol) methylether methacrylate (OEGMA, Mn = 
480 g mol-1). 
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T
able 2.1.3 (to Figure 2.1.2c). C
om
parison of the ligands H
M
TETA
 and TPM
A
 at different conditions and their influence on the TH
S cage structure. 
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Prior to polymerization within the cavity, macro-initiators (THS-Br) were prepared 
from mutated THS (K316C) and maleimide functionalized ATRP-initiator,434 which 
reacted with the cysteines in the interior. In order to assess the amount of initiators 
within the cavity, THS and THS-Br were labelled with a cysteine-reactive dye 
(Alexa488 maleimide).  
The labelled samples were purified via spin desalting and spin diafiltration and 
subsequently analysed by fluorescence correlation spectroscopy (FCS) (Figure 
2.1.4a). Fitting of the autocorrelation curves were based on one-population fits 
including triplet state. The obtained diffusion times of THS (408 ±15 µs) and THS-
Br (393 ± 26 µs) were almost equal, while the free dye Alexa488-maleimide had a 
much lower diffusion time (35 µs ± 3.3 µs). Hydrodynamic diameters and molecular 
brightness (counts per molecule (CPM)) were then calculated based on equations 1 
and the equations in the experimental section. Free dye (Alexa488-maleimide) had a 
molecular brightness of CPM = 5.6 kHz, and a hydrodynamic diameter of 1.1 ± 0.1 
nm. In contrast, labelled THS revealed CPM of 31.2 ± 0.9 kHz, and a hydrodynamic 
diameter of 13.1 ± 0.5 nm. For THS-Br a CPM value of 12.0 ± 0.5 KHz, and a 
hydrodynamic diameter of 12.7 ± 0.8 nm was calculated.  The number of dyes within 
the cavity was calculated by comparing CPM values according to equation (1).  𝐶𝑃𝑀!"#$%&𝐶𝑃𝑀!"## !"# =＃ 𝑑𝑦𝑒𝑠 𝑇𝐻𝑆 !!                                  (1) 
5.6 ± 0.2 dye molecules were obtained per THS, whereas THS-Br contained only 2.1 
± 0.1 dye molecules in average (Figure 2.1.4b). From these values we can conclude 
that from the 6 available cysteines from THS, 4 could be modified with ATRP-
initiators (6 cysteines in THS minus 2 that could be modified in the THS-Br). The 
initiators could not be bound to all cysteines in the interior. A possible explanation 
for the deviation from a theoretical value of 8 available cysteines might be that our 
THS was in average not composed of an equal ratio of 8 α- and β-subunits. It rather 
had more α-subunits that did not have an assessable cysteine in the interior. Mass 
spectrometry was unfortunately not conclusive, because the different subunits could 
not be resolved and merged into one signal. 
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Figure 2.1.4. Determination of available cysteines in THS and THS-Br by coupling of Alexa488 
maleimide to Cys and fluorescence correlation spectroscopy (FCS). (a) Normalized autocorrelation 
curve of Alexa488 maleimide dye, THS that was incubated with Alexa488 dye and THS-Br that was 
incubated with Alexa488 dye. (b) Calculated number of bound dyes per THS and THS-Br (as derived 
from the counts per molecule according to equation (1)).  
Polymerizations were conducted with the THS-Br macroinitiator. The monomer-to-
initiator ratio was varied in order to vary the molecular weight of the THS-polymer 
conjugates. The different amounts of monomers that were used for the synthesis of 
the discussed protein-polymer conjugates are combined in Table 4. Homopolymers 
from 2-dimethylaminoethy methacrylate (DMAEMA) and copolymers of DMAEMA 
and methacryloxyethyl thiocarbamoyl rhodamine B (RhBMA) were synthesized with 
the interior. The reaction parameters for the synthesis of protein polymer conjugates 
are summarized in Table 2 in the experimental section. In this study three different 
THS-pDMAEMA conjugates were synthesized with an increasing amount of 
monomers in respect to initiators (from 5’000 monomers per initiator to 15’000) 
(Table 1). As comparison a bovine serum albumin (BSA, Mw ~ 64’000 g mol-1) 
pDMAEMA conjugate (BSA-pDMAEMA) with 15’000 monomers per initiator was 
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synthesized (Table 2.1.4). BSA was chosen, because it is a globular protein that has 
approximately the same molecular weight as a THS-subunit.  
Table 2.1.4. THS-polymer and BSA-polymer conjugates of this study. 
Name 
n(DMAEMA) per initiator ; 
n(RhBMA) per initiator 
amount of initiators: 
4 per THS, 1 per BSA 
THS-
pDMAEMA1 
5’000 ; -- 
THS-
pDMAEMA2 
10’000; -- 
THS-
pDMAEMA3 
15’000; -- 
BSA-
pDMAEMA 
15’000; -- 
THS-
pDMAEMA-co-
pRhBMA 
15’000; 40 
Several methods were applied to determine if the synthesized samples contain 
polymers that are bound to the protein. THS and THS-polymer conjugates were 
analysed by matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-ToF MS) (Figure 2.1.5). The cage structure disassembled 
most likely due to the impact energy of the laser and therefore only subunits could be 
analysed by this method. The MS spectrum of THS (Figure 2.1.5a, red curve) 
doesn`t show two separated masses for the α- and β-subunits as expected, but more 
an averaged spectrum of both. Therefore, it was not possible to show the attachment 
of small molecules (e.g. ATRP-initiators) to the β-subunits by mass spectrometry. 
The presence of polymers attached to the protein subunits could be shown by a clear 
shift of the subunits to higher molecular weight (Figure 2.1.5a, black curve) when 
compared with the MS-spectrum of THS (Figure 2.1.5a, red curve). Moreover, only 
conjugates of reactions in which the molar ratio of DMAEMA to initiator was 50:1 
or less could be evaporated and analyzed. It was possible to calculate the size of the 
polymers by subtracting the MS spectrum of THS from the MS spectrum of the 
conjugates. For the conjugates with a monomer to initiator ratio of 50:1, most of the 
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polymers had a molecular weight between 200 - 1400 g mol-1, which in average 
corresponds to 1.2 to 9 monomers per protein subunit. Higher DMAEMA amounts 
per initiator decreased the signal of the conjugate dramatically that no analysis was 
possible.  
 
Figure 2.1.5. Matrix-assisted laser desorption ionization mass spectroscopy (MALDI-ToF MS) THS 
and THS-poly(DMAEMA). (a) MS spectrum of THS (red curve) and MS spectrum of THS-
poly(DMAEMA) (black curve) with a ratio of DMAEMA: initiator = 50:1 used for reaction.(b) 
Calculated spectrum of poly(DMAEMA). Spectrum was calculated by subtracting the MS spectrum 
of empty THS from THS-poly(DMAEMA). 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to assess the formation of THS-polymer conjugates. Under denaturing conditions, the 
cage is dissembled into its subunits, which have a molecular weight around 60’000 g 
mol-1  (Figure 2.1.6a). In addition, dimers of the subunits can be observed in a less 
pronounced band at approx. 120’000 g mol-1 and tetramers in an even less 
pronounced band at approx. 250’000 g mol-1. The tetramer band is more promiment 
with the THS-pDMAEMA samples (Figure 2.1.6a, lanes 2-4).  Dissembled protein 
cage-polymer conjugate subunits have a higher molecular weight than the subunits 
with no modification. They have a lower electrophoretic mobility, which can be seen 
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on the gel. In addition, conjugate samples moved as streaks under electrophoresis 
conditions due to the attached polymers (Figure 2.1.6a, lanes 3-5).  
THS-pDMAEMA conjugates showed weak streaking towards higher molecular 
weights (Figure 2.1.6a, lanes 3+4), whereas pure THS did not show this smearing of 
bands (Figure 2.1.6a, lane 1).  With an increasing amount of monomers, from 5’000 
monomers per initiator (THS-pDMAEMA1, Figure 2.1.6a, lane 2) to 10’000 (THS-
pDMAEMA2, Figure 2.1.6a lane 3)  and 15’000 (THS-pDMAEMA3, Figure 2.1.6a, 
lane 4), the smearing of bands to higher molecular weights in the THS-polymer 
conjugates increased. The increase of smearing bands can be associated with 
increased polymer chain lengths that are attached to the proteins. This increase is, in 
addition, visualized as a two-dimensional intensity plot in which the sample density 
is plotted against the molecular weight (Figure 2.1.6b). In those two-dimensional 
plots it is visible that the THSpDMAEMA3 sample moved towards higher molecular 
weights when compared with THS-pDMAEMA2 and especially THS-pDMAEMA1. 
A molecular weight range between 50’000 g mol-1 and 100’000 g mol-1 was chosen 
for the samples, because in this range the single subunits with attached polymers are 
located. Like in the mass spectrometry analysis a shift to higher molecular weights is 
visible with the THS-pDMAEMA2 and THS-pDMAEMA3 samples (Figure 2.1.6b). 
The subunits with polymers of THS-pDMAEMA2 shifted less (500 g mol-1) to 
higher molecular weights than THS-pDMAEMA3 (1500 g mol-1) in comparison to 
THS. In addition, the THS-pDMAEMA3 sample covers a higher molecular weight 
range from approx. 62’000 g mol-1 to around 90’000 g mol-1, whereas the THS-
pDMAEMA2 sample ranges from around 60’000 g mol-1 to 80’000 g mol-1. The 
THS-pDMAEMA1 sample did not show any shift or streaking like the other 
conjugate samples. A reason might be that the polymer were so small that gel 
electrophoresis could not resolve the little difference between the conjugate and 
THS. Gel electrophoresis has a limited resolution. 
From these observations we conclude that with an increasing amount of monomer 
per initiator the polymer chain length in the conjugates increased. Thus, for our 
synthesis conditions, the monomer-to-initiator ratio is a parameter that influences the 
chain lengths of the polymers in protein-polymer conjugate synthesis. 
In addition to the monomer-to-initiator parameter that influenced chain growth of the 
polymers, we wanted to know if the cage structure also influenced the 
polymerization reaction. From previous investigations in our group, we knew that the 
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cage structure improved the control of polymer synthesis.61 However, the difference 
to our reported study is that polymers were synthesized in THS or with BSA that 
were not covalently bound to the proteins.61 For this reason, THS-pDMAEMA3 
(Figure 2.1.6a, lane 4) was compared with a BSA-pDMAEMA conjugate (Figure 
2.1.6a, lane 5). Both conjugates were synthesized under same conditions and with the 
same monomer-to-initiator ratio of 15’000:1.  The BSA-pDAMEMA conjugate also 
showed the blurring of bands to higher molecular weights, however, polymers were 
smaller in the THS-pDMAEMA3 conjugate sample. A direct comparison between 
THS-pDMAEMA3 (black line) and BSA-pDMAEMA (purple line) in the two-
dimensional intensity plot confirms this observation (Figure 2.1.6b). From this 
observation we conclude that the cage structure has an influence on the 
polymerization, most likely due to steric hindrance of the protein cage. Access of the 
catalysts and monomers into the cavity is limited when compared with BSA that 
does not have a shielding cage structure. Thus, the confined space of THS influenced 
the polymerization.  
From both analytical methods we can conclude that MALDI-ToF is for conjugates 
with shorter chain lengths. Conjugates with longer chain lengths can not be analysed 
by MALDI-ToF, but with SDS-PAGE. SDS-PAGE, however, has its limitations with 
shorter conjugates due to its limitation in resolution. 
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Figure 2.1.6. SDS-PAGE of THS-poly(DMAEMA) and BSA-poly(DMAEMA) conjugates. (a) Lane 
L = protein ladder, lane 1 = THS, lane 2 = THS-pDMAEMA 1, lane 3 = THS-pDMAEMA 2, lane 4 = 
THS-pDMAEMA 3, lane 5 = BSA-pDMAEMA. The gel was stained with silver nitrate. (b) 
Normalized 2D-plots of the SDS-gels of the analysed conjugates shown in a molecular weight range 
from 50’000 g mol-1 to 100’000 g mol-1, i.e. in the range in which the THS subunit-polymer 
conjugates were located. The calibration curve for determination of molecular weights of the 
conjugates is shown in the experimental section. 
Besides the synthesis of homopolymers also copolymers were synthesized within 
THS. As comonomer, we chose methacryloxyethyl thiocarbamoyl rhodamine B 
(RhBMA). THS and THS-pDMAEMA3 have the same absorbance spectrum, while 
THS-pDMAEMA-co-RhBMA has an additional peak for the RhBMA with an 
absorbance maximum at 560 nm (Figure 2.1.7a). RhBMA is a fluorescent monomer 
and can be quantified by UV/Vis (Figure 2.1.7a). For the THS-pDMAEMA-co-
RhBMA sample with 15’000 DMAEMA and 40 RhBMA monomers per initiator, an 
amount of 5 RhBMA molecules per THS-polymer conjugate was calculated. Like 
THS-pDMAEMA3 (Figure 2.1.7b left gel, lane 2), THS-pDMAEMA-co-RhBMA 
(Figure 2.1.6b left gel, lane 3) shows a shift to higher molecular weights and a band 
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streaking in SDS-PAGE. The fluorescence of the conjugate was proven by 
fluorescence analysis under UV-light of the gel (Figure 2.1.7b right gel, lane 3).  
SDS PAGE analysis was complemented by basic native polyacrylamide gel 
electrophoresis (BN-PAGE) of the conjugates (Figure 2.1.7c). In BN-PAGE proteins 
are not denatured and therefore it can be used to determine if the cage structure 
remained intact after polymerization. The empty THS cage (Figure 2.1.7c, left gel, 
lane 1) had the same electrophoretic mobility than the THS-polymer conjugates 
(Figure 2.1.7c, left gel, lane 2+3). The results show an intact cage structure of the 
conjugates. The fluorescence of THS-pDMAEMA-co-RhBMA was also observed in 
BN-PAGE (Figure 2.1.7c, left gel, lane 3). Furthermore, in BN-PAGE analysis two 
lines of THS occur in every sample. The two lines are more apparent in the THS-
pDMAEMA-co-pRHBMA sample due to the presence of fluorescent molecules 
(Figure 2.1.7c, right gel, lane 3). At certain conditions, THS can occur in two 
different open conformations, a fully opened and half-opened, so-called bullet 
shaped conformation.238 We assume that the bullet shaped THS is less bulky than the 
opened THS. The fully open conformation interacts more with the acrylamide gel. 
Therefore, the bullet-shaped THS migrates further. The band of the bullet-shaped 
THS is more prominent visible in the gels (Figure 2.1.7c, left gel).  
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Figure 2.1.7. Spectroscopic and gel electrophoretic characterization of THS and THS-conjugates. (a) 
UV/Vis of THS, THS-pDMAEMA3 and THS-pDMAEMA-co-pRhBMA. (b) Gel electrophoresis 
characterization of THS and THS-polymer conjugates. L = protein ladder. (1) = THS protein cage, (2) 
THS-pDMAEMA 3 (3) THS-pDMAEMA-co-pRhBMA. (a) SDS-PAGE of THS and THS-polymer 
conjugates. Left gel: Coomassie staining, right gel: fluorescence image (b) BN-PAGE electrophoresis 
of THS and THS-polymer conjugates. Left gel: coomassie staining, right gel: fluorescence image. 
The different cage shapes of the empty THS and THS-polymer conjugates can be 
seen in the transmission electron microscopy images (Figures 2.1.8–2.1.10). Fully 
open and bullet-shaped protein cages can be found in the images of the analysed 
samples. 
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Figure 2.1.8. Transmission electron microscopy images (TEM) of empty THS protein cages. Red 
circles = side views of bullet-shaped THS, white circles = side views of fully open THS. Scale bar is 
200 nm. 
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Figure 2.1.9. Transmission electron microscopy images (TEM) of THS-pDMAEMA3 protein cages. 
Red circles = side views of bullet-shaped THS-pDMAEMA 3, white circles = side views of fully open 
THS-pDMAEMA 3. Scale bar is 200 nm. 
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Figure 2.1.10. Transmission electron microscopy images of THS-pDMAEMA-co-RhBMA protein 
cages. Red circles = side views of bullet-shaped THS-pDMAEMA-co-RhBMA, white circles = side 
views of fully open THS-pDMAEMA-co-RhBMA. Scale bar is 200 nm. 
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Dynamic light scattering (DLS) and transmission electron microscopy (TEM) 
provided  additional proof of an intact cage structure after polymerization (Figure 
2.1.11a-c). The conjugates have the same size and structure than the empty cage. The 
DLS and TEM-results are in good agreement with the size and structure of THS 
reported in literature.428 
DLS shows, in addition, that the polymer chains are mainly located within the cage 
because the size of the cage did not increase after polymerization.  
 
Figure 2.1.11. Dynamic light scattering and transmission electron microscopy of THS and THS-
polymer conjugates. (a) THS, (b) THS-pDMAEMA 3 and (c) THS-pDMAEMA-co-pRhBMA. (a) – 
(c) left panels: DLS measurement of empty THS protein cage (top), THS-pDMAEMA 3 (middle) and 
THS-pDMAEMA-co-pRhBMA (bottom). (a)-(c) right panels: TEM image of empty THS protein cage 
(top), THS-pDMAEMA 3 (middle) and THS-pDMAEMA-co-pRhBMA (bottom). TEM scale bars are 
100 nm. 
 
 
 
 
 
    Chapter 2 
 
92 
2.1.2.2 Interaction of THS-pDMAEMA conjugates with siRNA 
PDMAEMA is known to bind DNA and RNA due to its cationic charges that interact 
with the negative charges of the nucleic acids.435 We confirm findings from literature 
that pDMAEMA (Figure 2.1.12a) is capable to bind siRNA (Figure 2.1.12b).435  
 
Figure 2.1.12. Characterization of the polymer that was used in this study and its binding capacity to 
siRNA. (a) Gel-permeation chromatography curve of pDMAEMA, which was synthesized by 
ARGET ATRP. (b) Agarose gel of pDMAEMA complexed with siRNA. 
Moreover, from our previous investigations we know, that macromolecules like 
siRNA can be encapsulated within THS.379 To follow up with these results, we were 
interested, if our new THS-polymer conjugate can be used as siRNA delivery agent. 
Therefore, we investigated the siRNA binding capacity of the THS-pDMAEMA 
conjugates. With the electrophoretic mobility shift assay (EMSA), the interaction and 
binding capacity of a host (THS-pDMAEMA) towards a guest (siRNA) can be 
estimated.442 In this agarose gel assay, samples with a constant amount of siRNA 
were incubated with increasing amounts of THS-pDMAEMA conjugates. For 
comparison, bare siRNA is shown in lane 1 of the gels. The agarose gels in Figure 
2.1.13a show that THS-pDMAEMA 1 did not bind any siRNA at any of the 
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investigated siRNA-to-THS-pDMAEMA ratios. From a ratio of 1:0.25, THS-
pDMAEMA2 bound siRNA, albeit not completely (Figure 2.1.13a, middle gel, lane 
4). With THS-pDAMEMA3, binding occured already at the lowest molar ratio 
(1:0.06) between siRNA and THS-pDAMEMA used for the experiment. Only very 
little free siRNA was observed in the sample with a siRNA-to-THS-pDAMEMA 
ratio of 1:0.25 and no free siRNA was observed at a ratio of 1:0.5 (Figure 2.1.13a, 
right gel, lanes 4+5) and at higher THS-pDMAEMA concentrations. Therefore, full 
binding of siRNA was achieved with the sample THS-pDMAEMA3. From the 
results we could estimate that between 2 and 4 siRNAs were encapsulated within the 
cavity of THS-pDMAEMA3. This estimation is justified with the argument that in 
the THS-pDMAEMA3 sample with a 1:0.25 ratio, almost no free siRNA could be 
detected. THS-pDMAEMA does not have any functional groups that actively drag 
siRNA into its cavity. This means that in a saturated host-guest system, still free 
species can exist even though most of it could be bound.  In addition, a part of the 
sample migrated in the opposite direction of the normal migration direction of 
nucleotides (Figure 2.1.13a, left gel, lane 4). This indicates that THS-pDMAEMA3 
conjugates in solution existed that had excess in positive charges and did not 
completely bind the siRNA. Eventually after longer incubation time than in the 
performed experiment (30 min.) the equilibrium could be shifted towards more 
binding and thus the disappearing of the weak free siRNA band. The 
overcompensation of positive charges is even more present in the samples with 
higher ratios 1:0.5 and 1:0.85 (Figure 2.1.13a, left gel, lane 5 and 6).  
From the EMSA assay experiments we found out that THS-pDMAEMA can bind 
siRNA. In addition, we wanted to know if the THS itself is capable to encapsulate 
and bind siRNA. This investigation is important to justify the polymers in the cavity 
of THS. Comparing Figure 2.1.13b, left gel (siRNA, gel red stained) and Figure 
2.1.13b right gel (THS, coomassie blue stained) we see that both compounds are 
separated from each other and do not form a complex. Form this experiment we can 
conclude that pDMAEMA is necessary for encapsulation and binding of siRNA. 
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Figure 2.1.13. The presence of polymers and their chain lenght is crucial for siRNA binding. (a) 
Agarose gels of THS-pDMAEMA samples with different siRNA-to-THS-pDMAEMA ratios. 
Samples were run for different duration, thus the different migration lengths. The siRNA was stained 
with GelRed and visualized by fluorescence. The applied ratios between THS-pDMAEMA and 
siRNA are described in the experimental part. (b) Electrophoretic mobility shift assay (EMSA) of a 
mixture of siRNA and THS. Left gel: siRNA, gel red stained and fluorescence imaged. Right Gel: 
THS, coomassie blue stained and imaged with visible light. 
The THS-pDMAEMA 3 conjugate is the most promising sample for further 
investigations. Therefore, we decided to conduct further experiments with this 
sample. THS-pDMAEMA3 was compared with pDMAEMA in the presence of 
siRNA. We wanted to know if any structural changes occur when samples are 
complexed with siRNA. PDMAEMA is a linear polymer and THS-pDMAEMA, in 
contrast, has the cage structure that shields the polymer chains and can prevent 
interaction with neighbouring molecules. Dynamic light scattering (DLS) was 
performed with THS-pDMAEMA3 (Figure 2.1.14a) and for comparison with 
pDMAEMA in presence of siRNA (Figure 2.1.14b). The size of THS-pDMAEMA 3 
complexed with siRNA (14.6 ± 4.0 nm) did not increase in size, compared to THS-
pDMAEMA 3 without siRNA (14.2 ± 3.8 nm, Figure 2.1.11b). This result was, in 
addition, confirmed by TEM (Figure 2.1.15). Another observation from the DLS 
measurement of THS-pDMAEMA complexed with siRNA was that aggregates of 
the protein cage were not formed. In contrast, pDMAEMA complexed with siRNA 
formed larger (~ 600 nm), highly polydisperse aggregates (Figure 2.1.14b). It is 
known from literature that pDMAEMA complexed with e.g. DNA or RNA can form 
inhomogeneous aggregates.443 Aggregate formation was, in addition, observed by the 
formation of a slightly turbid solution. Since no surrounding structure shielded the 
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polymer chains, aggregates were formed in a random fashion. The feature that THS-
pDMAEMA did not form aggregates is beneficial in delivery applications,444 
because the transporter is more defined in its structure. 
 
Figure 2.1.14. The cage structure of THS-pDMAEMA prevented aggregate formation when 
complexed with siRNA. (a) DLS measurement of THS-pDMAEMA3 incubated with siRNA. (b) 
PDMAEMA incubated with siRNA.  
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Figure 2.1.15. Transmission electron microscopy (TEM) image of THS-pDMAEMA3 protein cages 
that were incubated with siRNA. The amount of siRNA was 14 times higher than THS-pDMAEMA3. 
Red circles = side views of bullet-shaped THS-pDMAEMA-co-RhBMA, white circles = side views of 
fully open THS-pDMAEMA-co-RhBMA. Scale bar is 200 nm. 
2.1.2.3 Protection of siRNA by degradation from RNAses 
A further important aspect in siRNA delivery is the protection of siRNA from 
degrading enzymes (RNAses) that are present in extracellular fluids.445 In order to 
assess the protection capability of THS-pDMAEMA3 a digestion experiment was 
conducted in which THS-pDMAEMA3 was first incubated with siRNA and then 
RNAse, a RNA degrading enzyme, was added to the solution (Figure 2.1.16a, top 
gel). As comparison, bare siRNA without any protection was incubated with RNAse 
(Figure 2.1.16a, bottom gel). At particular time intervals, samples were withdrawn 
and the degradation reaction stopped. This allowed the quantification of siRNA 
degradation at specific time points. After 10min. incubation of samples with RNAse, 
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less than 1 % of THS-pDMAEMA3 protected siRNA was degraded (Figure 2.1.16b, 
black curve), whereas at the same time, bare siRNA in presence was degraded 
already to over 80 % of its starting concentration (Figure 2.1.16b, red curve). After 
50 min. incubation time, still 50 % of siRNA was intact in the THS-pDMAEMA3 
sample, while the amount of unprotected siRNA dropped to 6 % of the starting 
concentration after this time. The unprotected siRNA was degraded very fast, as can 
be seen in the graph and also shown by Urban-Klein et al.446 This result is 
comparable to our previous THS-PAMAM approach163 a PAMAM-only approach447 
and with the work of Kong et al,448 who used a PEGylated pDMAEMA for the 
complexation of siRNA.  
 
Figure 2.1.16. THS-pDAMEAM3 can protect siRNA from degradation by RNAse II. (a) Agarose 
gels of siRNA + THS-p(DMAEMA) (upper gel) and of free siRNA (lower gel).  (b) Decay curve of 
siRNA protected by THS-pDMAEMA 3 (black rhomb and line). Decay curve of unprotected siRNA 
(red triangles and line). The error bars represent the standard error of the evaluation method. Standard 
deviation errors are between 0.7 % and 2.3 %.  
2.1.2.4 Cytotoxicity of THS-pDMAEMA3 and THS-pDMAEMA-co-
RhBMA in comparison with  
The test for the toxicity of nano objects is very important, if the objects will be used 
in cell-based assays. A nano transporter that interacts with cells should not cause a 
toxic reaction. We tested our conjugates (THS-pDMAEMA3 and THS-pDMAEMA-
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co-RhBMA) for toxicity and compared them with pDMAEMA (Figures 2.1.17a-c). 
Cells treated with both conjugates showed same viability as the untreated cells 
(Figure 2.1.17a + b). PDMAEMA on the other hand showed high toxicity even at the 
lowest applied concentration (50 µg ml-1), which is consistent with literature (Figure 
2.1.17c).449 From those results we concluded that the cage structure shielded most of 
the positive charges of pDMAEMA from interaction with the cells. 
 
Figure 2.1.17. Toxicity data of THS-polymer conjugates and pDMAEMA. (a) THS-pDMAEMA3 (b) 
THS-pDMAEMA-co-RhBMA and (c) pDMAEMA. 
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2.1.2.5 Cellular uptake of THS-pDMAEMA-co-RhBMA  
From our previous investigations we know that our pDAMEMA-containing 
conjugates can entrap siRNA and that they showed promising results from the 
toxicity assays, which allow going a step further and investigate cellular uptake of 
our THS-polymer conjugates. From our previous investigations379  we know that 
THS-PAMAM is uptaken by U87 cells without further modifications (e.g. cell 
penetrating peptides).450,451 For cellular uptake studies into U87 cells (Figure 
2.1.18a), we used the THS-pDMAEMA-co-RhBMA conjugate (Figure 2.1.18). This 
conjugate has fluorescent monomers integrated into its polymer chains that allow the 
visualization of the particles when uptaken by cells. The conjugate was uptaken by U 
87 cells at different conjugate concentrations (Figure 2.1.18b-d). With an increasing 
concentration from 100 µg ml-1 (Figure 2.1.18b) to 500 µg ml-1 (Figure 2.1.18d), also 
the amount of THS-pDMAEMA-co-RhBMA within the cytosol increased.  
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Figure 2.1.18. Cellular uptake of THS-pDMAEMA-co-pRhBMA into U87 cells after 24h. THS-
pDMAEMA-co-RhBMA (red areas) and  cell nuclei, which were stained with Hoechst 33342 dye 
(blue compartments).  (a) U 87 cells with stained nuclei under the microscope. (b) U87 cells with 100 
µg ml-1 THS-pDMAEMA-co-pRhBMA. (c) U87 cells with 250 µg ml-1 THS-pDMAEMA-co-
pRhBMA. (d) U87 cells with 500 µg ml-1 THS-pDMAEMA-co-pRhBMA.  
2.1.2.6 Complex formation of THS-pDMAEMA-co-RhBMA with 
fluorescent proteins and its cellular delivery 
The thermosome is able to encapsulate macromolecules up to 50’000 g mol-1,235 and 
there are examples where proteins were delivered into cells with cationic 
polymers.436,452,453 Therefore, we explored the capability of THS-polymer conjugates 
to deliver biological macromolecules peptides or proteins440,454,455 into U 87 cells. To 
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show the proof of concept of delivering a protein, we used enhanced yellow 
fluorescent protein (eYFP) and an improved variant of the green fluorescent protein 
(TurboGFP). EYFP has an isoelectric point (pI) of around 6.2,456 and is therefore 
negatively charged at the physiological pH value used for the experiments (7.2-7.4). 
EYFP should therefore interact with positive charges of the pDMAEMA. In addition 
to eYFP, TurboGFP was chosen, because its emission spectrum does not overlap 
with the emission spectrum of RhBMA in our THS-pDMAMEA-co-RhbMA 
conjugate. TurboGFP, in addition, has a higher photostability and brightness.438 Its 
pKa-value of 5.2 indicates that it is also negatively charged at physiological pH.438 
Complex-formation between THS-pDMAEMA-co-RhBMA and the proteins was 
investigated by agarose gel experiments. With a molar excess of THS-pDMAEMA-
co-RhBMA to eYFP of 2:1, no free eYFP could be observed in the gel (Figure 
2.1.19a lane 2). At higher eYFP concentrations, more free eYFP is visible (Figure 
2.1.19a lane3-5). Thus, an excess of conjugate is needed to fully complex eYFP. The 
agarose gel shown in Figure 2.1.19b shows that TurboGFP could not be complexed 
with THS-pDMAEMA-co-RhBMA, even with a molar excess (2:1) of THS-
pDMAEMA-co-RhBMA. This might be due to the size of TurboGFP, which occurs 
in solution as dimer and has a molecular weight of 54’000 g mol-1. This is above the 
maximum molecular weight for proteins that can be encapsulated in the cavity of 
THS.235 Moreover, the synthesized polymer in the cavity occupies additional space. 
 
Figure 2.1.19. Agarose gels of THS-pDMAEMA-co-RhBMA with eYFP (a) and TurboGFP (b) to 
evaluate complex formation. Following conjugate-to-fluorescent protein ratios were applied with a 
constant conjugate concentration. (a) Lane 1: eYFP only, lane 2: (2:1), lane 3: (1:1), lane 4: (1:2), lane 
5: (1:3), lane 6: conjugate only (b) Two separate gels are shown. Lane 1: TurboGFP only, lane 2: 
(2:1), lane 3: (1:1), lane 4: (1:2), lane 5: conjugate. 
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With the agarose gel experiment (Figure 2.1.19a) we could show that THS-
pDMAEMA-co-RhBMA can complex with eYFP and from toxicity experiments we 
know that our conjugates did not decrease cell viability. Therefore, a cellular uptake 
experiment into U87 cells with THS-pDMAEMA-co-RhBMA and eYFP (molar ratio 
1:2) was conducted and the uptake efficiency of the conjugate and eYFP was 
measured by fluorescence-activated cell sorting (FACS) (Figure 2.1.20). The 
fluorescence intensity of cells containing THS-pDMAEMA-co-RhBMA of the 
conjugate/eYFP-complex (Figure 2.1.20a, red curve) increased by a factor of around 
100, compared to the auto-fluorescence of the U87 cells (Figure 2.1.20a, light blue 
curve). The fluorescence intensity of eYFP of the conjugate/eYFP-complex 
increased by a factor of 0.5 (Figure 15b, red curve) compared to the auto-
fluorescence of U87 cells (Figure 2.1.20b, light blue curve) and the fluorescence 
intensity of cells to which only eYFP as sample was added (Figure 2.1.20b, bright 
green curve). Thus, a slight cellular uptake of eYFP was measured. The relative low 
increase in fluorescence intensity of uptaken eYFP might be the result of a weak 
fluorescence of the eYFP-protein in the applied concentrations. Moreover, the 
complex between THS-pDMAEMA-co-RhBMA and eYFP might not be strong 
enough in the cell culture medium, so that uptake of eYFP by U87 cells was not very 
pronounced. Nevertheless, these findings show the potential of the THS-polymer 
conjugate to deliver proteins, but the delivery has to be investigated in more detail. 
For example, with a higher concentration of eYFP and THS-pDMAEMA-co-
RhBMA the signal-shift of eYFP in FACS could be stronger. A delivery of 
TurboGFP promoted by THS-pDMAEMA-co-RhBMA could not be measured 
(Figure 2.1.20c). The signal intensity of TurboGFP (Figure 2.1.20c, red line) is equal 
to the signal of U87 cells (Figure 2.1.20c, light blue line). No cellular uptake was 
measured. However, it is possible that TurboGFP was uptaken by some cells, but in 
the average signal of all cells, the amount of cells with uptaken TurboGFP did not 
change the overall fluorescence intensity. 
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Figure 2.1.20. Fluorescence-activated cell sorting (FACS) of the THS-pDMAEMA-co-
RhBMA/eYFP complex uptaken by U87 cells. (a) Fluorescence intensity of THS-pDMAEMA-co-
RhBMA (red curve) compared with the fluorescence of the U87 cells (light blue curve). (b) 
Fluorescence intensity of eYFP from the THS-pDAMEMA-co-RhBMA/eYFP-complex (red curve), 
eYFP uncomplexed (bright green curve) and fluorescence of U87 cells (light blue curve). (c) 
Fluorescence intensity of TurboGFP (red curve) and U87 cells (light blue curve) in the presence of 
THS-pDMAEMA-co-RhBMA. 
Even though we could not observe strong complex formation with THS-
pDMAEMA-co-RhBMA and TurboGFP (Figure 2.1.19b) and an uptake by FACS, 
further cell uptake experiments were conducted in order to prove if TurboGFP was 
uptaken by cells in presence of THS-pDMAEMA-co-RhBMA (Figure 2.1.21). After 
incubation, cells were imaged by confocal laser scanning microscopy (CLSM). A 
higher amount of TurboGFP was uptaken into selected U87 cells in the presence of 
the conjugate (Figure 2.1.21a), when compared with the control of TurboGFP 
without conjugate (Figure 2.1.21b). A possible explanation for the higher uptake 
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could be that THS-pDMAEMA-co-RhBMA formed a transient complex with 
TurboGFP and enhanced the uptake of TurboGFP. Due to the spectral overlap of 
RhBMA and eYFP, conclusive images could not be recorded by CLSM. This can be 
resolved by using a different protein and label it with e.g. Alexa488 dye (e.g. horse-
radish peroxidase M = 44’000 g mol-1, pI between 3 and 9).457 The complex 
formation between fluorescent proteins and THS-pDMAEMA3 could not be 
observed by gel electrophoresis as well as enhanced cellular uptake with this 
conjugate. By changing the protein to a more negatively charged at physiological pH 
(e.g. fluorescent labelled tyrosine aminotransferase, M = 32’000 g mol-1, pI = 4.1)458,  
it might be possible to form a complex with this conjugate. Although these initial 
experiments are promising, they have to be investigated and proven more in detail by 
repeating experiments and eventually adapt the conditions (e.g. longer incubation 
time, variation of pH) and the protein (pI around 4.0) to clearly show protein 
delivery.  
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2.1.2.7 SiRNA delivery with THS-pDMAEMA3 into mammalian U87 cells 
The ability of THS-pDMAEMA3 to bind and protect negatively charged molecules 
makes it a good candidate for siRNA delivery. Experiments in which siRNA was 
deliverd into U87 cells were conducted. This coding siRNA is capable to bind to a 
specific pattern of the messenger-RNA (mRNA) gene sequence and can knock-down 
the synthesis of proteins that are synthesized according to the gene sequence by 
interfering with the mRNA translation.433,459 This mechanism of silencing a specific 
gene is known as RNA interference (RNAi). RNAi can be useful in the treatment of 
cancer and many other human diseases.460-465 As the silencing target for our 
experiments, glyceraldehyde-3-phosphate dehydrogenase (GAPDH, M ≈ 37’000 g 
mol-1) was chosen, which is a protein that is present in all living cells and plays an 
important role in the cell metabolism.466 While investigations are still ongoing, initial 
results show promise that THS-pDMAEMA3 can deliver siRNA into cells and create 
a maximum knockdown reaching of 80% of intracellular GADPH levels when 5 
pmol of siRNA were delivered, remaining the same with higher amounts (Fig 
2.1.22a+d). The control experiments show that siRNA alone cannot reduce the 
GAPDH protein level by gene-silencing (Figure 2.1.22b). Moreover, the loading 
control protein (M≈ 40’000 g mol-1) was not affected by gene silencing, indicating 
that the specific knock-down of GAPDH worked (Figure 2.1.22.c). While THS-
pDMAEMA3 still required a 5x higher amount of siRNA than the commercially 
available lipofectamine RNAiMAX reagent (5 pmol compared to 1 pmol 
respectively), further optimization could lead to improved results.   
 
 
Chapter 2  
 
107 
 
Figure 2.1.22. Delivery of siRNA into U87 cells by THS-pDMAEMA3. (a) GAPDH gene 
silencing in U87 cells mediated by THS-pDAMEMA3. THS-pDMAEMA3:SiRNA 1:4  with 
an amount of siRNA of lane 1: 0 pmol, lane2: 0.1 pmol, lane 3: 1 pmol, lane 4: 5 pmol, lane 
5: 5 pmol. (b) Control experiments with cell lysate (lane 1), naked siRNA (lanes 2-5) and 
siRNA deliverd with RNAiMAX (lanes 6-7) with an amount of siRNA of lane 1: 0 pmol, 
lane 2: 0.1 pmol, lane 3: 1 pmol, lane 4: 5 pmol, lane 5: 10 pmol, lane 6: 0.1 pmol, lane 7: 1 
pmol. (c) Control experiment showing that the control protein was not affected by gene-
silencing. Samples and lanes correspond to (b). (d) Graph visualizing the data of the different 
experiments. 
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 Conclusion 2.1.3
With the integration of ATRP-initiators into the cavity of THS, it was possible to 
synthesize conjugates with functional polymers that could entrap and form 
complexes with biomacromolecules and enabled particle localization when uptaken 
by cells. We found that the cavity influences on polymerization. Polymers 
synthesized within the cavity of THS were smaller than polymers that were 
synthesized on a protein without having a cage structure.  This is in agreement with 
another study from our group where polymers that were not covalently bound to the 
protein were synthesized in the THS.61 Size measurements showed that the cage 
structure did not increase in size, which is an indication that polymers were in the 
interior and not exterior. PDMAEMA, the polymer synthesized in the interior of 
THS, is toxic as known from literature449 and as confirmed by our own experiments. 
However, the cage shielded cells from the toxic positive charges of the polymers and 
reduced their toxicity. Our THS-pDAMEMA3 and THS-pDMAEMA-co-RhBMA 
conjugates showed same cell viability as the untreated cells in the tested range (≤ 300 
µg ml-1). Another important finding for drug delivery applications is that the THS-
polymer conjugates did not form aggregates in presence of biomacromolecules such 
as siRNA, which is important because aggregate formation could lead to less 
effective delivery.444 For drug delivery applications, it is important that the cargo is 
protected from degrading agents in the local biological environment. THS-
pDMAEMA3 can entrap siRNA and protect it from degradation by enzymes. 
Moreover, the delivery of siRNA into cells by THS-pDAMEMA3 and gene knock-
down was shown. The encapsulation strategy for biomacromolecules was extended 
by complex formation of the THS-polymer conjugates with fluorescent proteins and 
their delivery into cells. We took fluorescent proteins as the proof-of-concept, 
because of their fluorescence and therefore possibility of detection by confocal laser 
scanning microscopy in living cells. The results show that protein delivery into cells 
is possible, but currently has limitations that have to be investigated in more detail. 
We showed the potential behind a protein cage with polymers that are synthesized 
within its cavity. The monomer to be polymerized within the cavity can be chosen to 
suit the desired needs. Polymers allow having a high density of functional groups 
within a protein cage. Therefore, customized bio nano particles can be created for 
applications like drug delivery,114,379 magnetic resonance imaging111,148 or 
catalysis.172 
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 Experimental section 2.1.4
2.1.4.1 Materials 
All Chemicals were purchased from Sigma-Aldrich with the highest purity and used 
as received, unless stated otherwise. Water used for buffers was produced with a 
water purification system (ELGA PureLab DV25). Methacryloxyethyl thiocarbamoyl 
rhodamine B (RhBMA) was purchased from PolySciences Europe (Germany). 
Scrambled siRNA with following sequence delivered as double stranded siRNA (5‘-
AGG UAG UGU AAU CGC CUU GTT-3‘)467 was purchased from Microsynth AG 
(Switzerland). DMEM, optimum, Fetal calf serum (FCS), non-essential amino acids 
(NEAA), and PEN/strep were purchased from Gibco. TEMED, Bovine serum 
albumin (≥ 96 %)Leupeptin, aprotinin, pepstatin, and PMSF were purchased from 
Sigma-Aldrich. The U87 cell line was obtained from ATCC (USA). Sodium dodecyl 
sulphate (SDS) and the TGX stain free acrylamide kit (10%) were obtained from 
Bio-Rad (Switzerland). Supersignal molecular weight protein ladder, lipofectamine 
RNAiMAX reagent, monoclonal mouse antiGADPH antibody and goat anti mouse 
HRP conjugated secondary antibody were purchased from Life Technologies (USA). 
Nitrocellulose membranes and gel-blotting paper were purchased from GE 
Healthcare (USA). Micro BCA protein assay kit and Supersignal west Pico 
chemiluminescent substrate, DMEM, opti-MEM and Silencer select GAPDH siRNA 
as well as 6X MassRuler DNA Loading Dye, Hoechst 33342 and SimplyBlue Safe 
Stain, Alexa 488 maleimide, nuclease free PBS buffer (10x), nuclease free water and 
spin desalting colums (Zeba Spin Desalting Columns, MWCO = 7’000 g mol-1) were 
purchased from Thermo Scientific (USA). Argon used for the glove box (99.998 %, 
Argon 48) was obtained from Carbagas (Switzerland).The centrifugal filters 
(Amicon) with various molecular weight cutoff values (MWCO) were purchased 
from Merck Millipore (Ireland). RNAse A (RNAse II;activity 50 U mg-1) was 
purchased from Roche (Switzerland) and GelRed agarose gel staining from Biotium 
(USA). The nuclease free PBS buffer (10x Ambion) was and diluted with nuclease 
free water Gradient gels with 4 – 20 % acrylamide content (Mini-PROTEAN TGX 
Precast Gels) for electrophoresis were obtained from BioRad (USA). Spin desalting 
colums (Zeba Spin Desalting Columns, MWCO = 7’000 g mol-1) were obtained from 
Thermo Scientific (USA).Recombinant TurboGFP (rTurboGFP) (M = 54’000 g mol-
1, ε482 = 70’000 M-1 cm-1)438 was obtained from Evrogen (Russia). The protein eYFP 
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(M = 27’000 g mol-1, ε514 = 36’500) was expressed in our group according to 
published protocols.468  
2.1.4.2 ATRP-initiator:  
The maleimide functionalized ATRP-initiator was synthesized according to the 
protocol by Le Droumaguet et al.,434 with slight modification. Instead of petrol ether, 
a 1:1 mixture of hexane and ethyl acetate was used for chromatography. 
2.1.4.3 THS expression 
A mutated variant of the thermosome (THS) from Thermoplasma acidophilum was 
expressed and purified as reported by Bruns et al .61,166 The mutated variant (K316C) 
of THS had a Cys residue on the inside of every β-subunit, which allowed covalent 
attachment of functional molecules. For purification and concentration centrifugal 
filters with a MWCO of 100’000 g mol-1 were used. The purified THS stock solution 
was kept at 4°C in a 100 mM sodium phosphate buffer (pH 7.4, 150 mM NaCl, 0.01 
% NaN3) 
2.1.4.4 Methods 
Indicated concentrations are given as end concentrations in the sample/reaction 
mixtures. Structures of protein cages were rendered with UCSF chimera software 
(Version 1.9).274 Since no structural data of the THS cage in its open state is 
available in the databases, as alternative the cryo-electron microscopy structure of 
the similar chaperonin Mn-Cpn from Methanococcus maripaludis (PDB: 3IZH) in its 
open conformation was taken for vizualization.469  
2.1.4.5 UV/Vis spectroscopy 
If not stated otherwise, a Nanodrop 2000c spectrometer (Thermo Scientific, USA) 
was used for concentration determination. Following extinction coefficients were 
used for calculations: THS ε280 = 210 880 M-1 cm-1 30, RhBMA ε552 =  38’460 M-1 cm-
1 ± 1’060 M-1 cm-1 (determined by absorption measurements at different 
concentrations and slope calculation).  
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2.1.4.6 THS stability studies 
Stability studies of the THS in presence of common (ARGET) ATRP reagents and 
organic solvents were performed at a THS concentration of 1.1 µM (1 mg ml-1). 
Experiments were conducted in degased H2O under argon with 48 h incubation time 
at room temperature. After incubation time, samples were analysed by SDS-PAGE 
and BN-PAGE. 
2.1.4.7 Macroinitiator synthesis (THS-Br)   
Prior to maleimide initiator attachment to Cys, the buffer (100 mM sodium 
phosphate pH 7.4) was exchanged to 100 mM sodium phosphate pH 6.5 using 
centrifugal filters with a MWCO of 100 kDa. After buffer exchange, the THS was 
diluted in 100 mM sodium phosphate buffer (pH 6.5 + 150 mM NaCl + 0.01 % 
NaN3) to a concentration of 1 mg mL-1 (1.1 µM, 6.6µM Cys). To the diluted THS 
solution, 4% DMSO (v/v) was added. Afterwards, ATRP-initiator dissolved in 
DMSO (200 mM stock solution) was added with a 40-times molar excess in respect 
to Cys. The solution was incubated over night at room temperature with shaking at 
400 rpm (BioShake iQ, Quantifol Instruments). Unreacted products were removed 
and the buffer was exchanged to 100 mM sodium phosphate buffer (pH 7.4, 150 mM 
NaCl, 0.01 % NaN3) using centrifugal filters (AMICON, MWCO = 100’000 g mol-1) 
with at least 6 dilution-concentration cycles. The bovine serum albumin (BSA) 
macroinitiator (BSA-Br) was synthesized in the same way. The phosphate buffer was 
exchanged to degased water before the macro-initiators were used for conjugate 
synthesis. 
2.1.4.8 Labeling of THS and THS-Br with Atto-488 maleimide for FCS 
measurements: 
THS and THS-Br were diluted in 100 mM sodium phosphate buffer (pH 6.5 + 150 
mM NaCl + 0.01 % NaN3) and 4 % DMSO to a concentration of 1 mg ml-1 (1.1 µM). 
Atto-488 maleimide dissolved in DMSO (200mM) was added in an amount, that was 
40-times higher than the β-subunits of THS (6 per THS, 6.6µM). The sample was 
incubated over night and purified by spin desalting followed by two cycles of spin 
diafiltration.  
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2.1.4.9 THS-pDMAEMA synthesis 
Synthesis of THS-polymer conjugates was performed in a glove box (Labstar, 
MBRAUN, Germany) at < 0.5 - 1 ppm O2-level, < 0.5 - 1 ppm H2O-level, an argon 
over pressure of 1.2 – 1.6 mbar and at a room temperature of 20 ± 2 °C. Solvents and 
reagents were degassed with argon for 30 min. before use. The monomer DMAEMA 
was purified by filtration over basic aluminium oxide and degassed with argon 
before application. The ligand 1,1,4,7,10,10-hexamethyltriethylenetetramine 
(HMTETA) was distilled before use and kept in the fridge at 4°C under argon. The 
macroinitiator (THS-Br) was degassed by at least 5 centrifugation filtration (Amicon, 
MWCO = 30’000 g mol-1) cycles with degassed H2O. 
The tube and filter with THS-Br were filled with argon prior to centrifugation. 
Reducing agent (sodium ascorbate, NaAsc) and catalyst (HMTETA + CuBr2) stock 
solutions were prepared in 10 ml two-neck round bottom flasks connected to a 
Schlenk line. Flasks were evacuated and re-filled with argon in at least 4 cycles 
before dissolving the reagents in 5 ml deoxygenized ELGA water H2O under stirring. 
All reactants were transferred into the glovebox. First H2O was added into the 
reaction tube followed by the addition of the calculated amount of THS-Br. 
Afterwards DMSO was added to a final concentration of 20 % (v/v). The calculated 
amount of DMAEMA was added as well as an aliquot of the catalyst stock solution. 
The reaction was started by the addition of an aliquot of reducing agent stock 
solution. The reaction tubes were shaken at 500 rpm (BioShake iQ, Quantifol 
Instruments, Germany) at room temperature for 16 h. THS-Br concentration was 1 
mg ml-1 (1.1 µM) or expressed in a total concentration of bound initiators: 4 x 1.1µM 
= 4.4 µM. Concentrations of reactants were calculated based on the initiator 
concentrations. The ratios were [Initiator]:[Catalyst]:[Reducing agent]:[Monomer] = 
[1]:[4.1]:[16.1]:[various]. Experimental details are summarized in Table 2.  
The reaction was quenched by addition of non-deoxygenized H2O and exposure to 
air. Polymerization reaction samples were concentrated and the solvent was 
exchanged to 100 mM phosphate buffer (pH 7.4 + 150 mM NaCl + 0.01% NaN3) by 
centrifugal filters (MWCO = 100’000 g mol-1) with at least 6 dilution-concentration 
cycles.  
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2.1.4.10 THS-pDMAEMA-co-pRhBMA: 
Synthesis was performed according to the protocol for THS-pDMAEMA. In 
addition, after 10min. reaction time initiated by addition of Na-Asc, an aliquot of 
RhBMA dissolved in DMSO (cRhBMA = 100 mM) was added. Amount of RhBMA in 
reaction solution corresponded to 40 monomers per initiator. The amount of RhBMA 
in THS-poly(DMAEMA-co-RhBMA) was determined from A(RhBMA552) and with 
ε(RhBMA552). In order to be able to calculate the amount of THS in THS-
poly(DMAEMA-co-RhBMA), first a ratio from A(RhBMA280) / A(RhBMA552) of 
RhBMA was calculated. With this ratio (mean value = 0.370) and the known 
concentration of RhBMA it was possible to calculate the signal amount of RhBMA 
at 280 nm within the total signal intensity at 280 nm. Subtraction of the signal 
amount of RhBMA at 280 nm from the total sample signal at 280 nm gave the 
absorbance of THS at 280 nm. 
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2.1.4.11 SDS-PAGE 
Acrylamide gels were prepared based on the protocol published by Laemmli.470 The 
amount of protein or protein-polymer conjugate per sample well was 5 – 7 µg. If 
necessary, samples were diluted with either water or  PBS buffer. 8 µl  2x loading 
buffer (130 mM Tris/HCl pH 6.8, 200 mM dithiothreitol, 20 % (v/v) glycerine, 4 % 
(w/v) SDS, 0.01 % (w/v) bromophenol blue) was added to 8 µl sample, followed by 
heating at 95°C for 3 min. After denaturing, samples were loaded on a 12 % 
acrylamide SDS-PAGE gel or 4 - 20 % gradient gel if not otherwise mentioned 
(Mini-PROTEAN TGX Precast Gels, BioRad) and run with a constant voltage of 200 
V for 55 min. (Mini Protean Tetra cell, BioRad). The running buffer for these 
experiments was 25 mM Tris, 250 mM glycine pH 8.3 + 0.1 % SDS buffer. For 
Coomassie staining a ready-to-use solution was used (SimplyBlue™ SafeStain, Life 
Technologies) and samples were stained according to the manufacturer’s protocol. 
Silver staining was performed according to the protocol by Nesterenko et al .471  
Conjugate bands were plottet as two-dimensional (2D) plots with the software 
imageJ (1.47v). For the calibration of the molecular weights, the x-y-cooridinates of 
the 2D-plots were converted into into a signal-to-molecular weight relation. With the 
software qTi-plot, an equation was determined that could convert x-coordinates into 
molecular weights. The exponential equation in Figure 2.1.22 below was determined 
by iterative analysis. 
 
Figure 2.1.23. Kalibration curve and equation for molecular weight calculation in SDS-PAGE. 
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2.1.4.12 Basic native PAGE:  
The amount of samples was calculated to have a total mass of 5-7µg of protein or 
protein-polymer conjugate per well and that all wells have equal amounts of protein 
and volumes. If necessary, samples were diluted with H2O or PBS buffer. A volume 
of 2 µL of 5x sample buffer (150mM Tris/HCl pH 6.8, 70 % glycerol, 0.01 % w/v 
bromo phenol blue) was added to 8 µl of samples and mixed. Samples were pipetted 
into the wells of a 4-20% gradient gel and the gel was run at constant 100V for 100 
min. 
Gel imaging: Electrophoresis gels were imaged using an automated imager (Gel 
DocTM EZ system, BioRad) with the Image LabTM software. 
2.1.4.13  Fluorescence correlation spectroscopy (FCS): 
FCS measurements were conducted on a Confocor 2 (Carl Zeiss, Germany) with an 
Ar+-laser for excitation at 488 nm with a LP505 filter. An 40× C-apchromat water 
immersion objective with a numeric aperture of 1.2 was used for laser beam 
focussing. The fluorescence intensity was recorded with an avalanche photodiode 
(APD). Measurements were conducted at a constant temperature of 20 °C and a 
sample volume of 5µl.  Raw data processing was done with the software ConfoCor 
3. Measured samples were fitted with one-component fits including triplet state 
according to the following equation: 
G τ fit = 1+ 1+ 𝑇1− 𝑇 𝑒! !!trip 1𝑁 11+ 𝜏𝜏D 11+ 𝑅! 𝜏𝜏D   
In this equation τD describes the diffusion time. T is the fluorophore fraction that is in 
the triplet state with the appropriate triplet time τtrip. R is the structural parameter that 
is determined after measuring the free dye molecules and N describes the number of 
particles.  
 The diffusion coefficients (D) were calculated according to the relation between the 
diffusion time (τD) and the x-y dimension of the confocal volume ωxy.  𝜏D = 𝜔xy!4𝐷    
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The hydrodynamic radii (RH) of the samples were calculated with the Einstein-
Stokes equation in which kB is the Boltzman constant, η the viscosity of the solvent 
and T the absolute temperature in Kelvin. 𝐷 = kBT6πηRH 
The counts per molecule (CPM) value can be calculated with the count rate (CR), 
which is the amount of photons that reach the detector and the number of molecules 
N with following equation: 𝐶𝑃𝑀 =  𝐶𝑅𝑁  
2.1.4.14 Dynamic light scattering  
Size determination of the THS, poly(DMAEMA), THS-polymer conjugates and 
THS-polymer conjugates with encapsulated siRNA were performed on a Zetasizer 
ZSP (Malvern, UK). Following instrument parameters were used: backscattering 
(173°), dispersant: 1x PBS, equilibrium time: 30 sec. temperature: 25 °C. For 
measurements UV-cuvettes micro (Brand, Germany) with a volume of 70 µl and 
following dimensions (12.5 x 12.5 x 45 mm) were used. Particle size distribution 
(PSD) was calculated according to the number of particles. The mean value of the 
diameter was calculated according to 4 measurement cycles with 14 single 
measurements per cycle. The standard deviations from the mean value were 
calculated the same way. Experiments were performed with a protein concentration 
of 0.7 µM (0.63 mg ml-1) THS or THS-polymer conjugates diluted in nuclease free 
PBS buffer (pH 7.4). Complexation reactions with siRNA were conducted at a THS-
pDMAEMA 3 concentration of 0.7 µM and a siRNA concentration of 10 µM. 
Samples were incubated at 37 °C for 30 min. prior to measurement. Experiments 
with pDMAEMA and siRNA were carried out at a pDMAEMA concentration of 0.5 
mg ml-1 and a siRNA concentration of 10 µM. The pDMAEMA + siRNA sample 
was incubated at room temperature for 10 min. and measured. Incubation time and 
temperature was lower with pDMAEMA because, at longer incubation time and  
higher temperature, larger aggregates were formed that made a measurement 
impossible. The THS-poly(DMAEMA) conjugate did not form any aggregates. It 
stayed intact and kept the cage architecture, whereas the polymer formed aggregates 
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in presence of siRNA. Furthermore, aggregate formation was observed by visible 
turbidity in solution.  
2.1.4.15 Transmission electron microscopy (TEM)  
TEM analysis was done on a FEI Morgani 268D. Sample preparation: A 5 µl drop of 
sample was placed on a glow-discharged specimen grid (Cu 400 mesh, coated with 2 
% palladium and carbon (Stork Veco, Netherlands)) and allowed to be absorbed for 
60 sec. Excess of liquid was gently removed via a filter paper. Afterwards the 
absorbed sample was washed two times with H2O. Samples were two times stained 
with a 2% Uranylacetate solution. For the first staining, the 2 % Uranylacetate drop 
was kept on the sample for 1 sec. and removed with a filter paper. For the second 
staining, the was kept on the sample for 10 sec. and then removed by a filter paper. 
Binding capacity of siRNA and pDMAEMA with Mn = 80080 g mol-1 and PDI = 
1.77 in dependence of increasing N/P-ratios at pH 7.4 . Concentration of siRNA in 
all samples was 2 µM. The used siRNA was a 21-mer doublestrand and had therefore 
42 negative charges. Samples were incubated for 30 min. at 37 °C prior to 
analysis.(1) bare siRNA (2) N/P = 0.1 : 1 (3)  N/P = 0.5 : 1 (4) N/P = 1 : 1 (5) N/P = 
3 : 1 (6) N/P = 6 : 1 (7) N/P = 8 : 1 (8) N/P = 10 : 1 
2.1.4.16 Electrophoretic mobility shift assay (EMSA) with pDMAEMA   
samples and siRNA 
EMSA442,472 were performed at pH 7.4, constant voltage of 100V, but different time 
intervals. Sample volumes were kept at 10 µl, if necessary diluted with PBS buffer 
(pH 7.4) and 2 µl loading dye (6x Mass Ruler DNA loading dye) was added prior to 
electrophoresis. Agarose gels were stained with GelRed dye (Biotinum, USA). 
Concentration of siRNA was kept constant at 2 µM. In all gels, lane 1 was siRNA 
only. Following ratios [siRNA]:[THS-pDMAEMA 3] were used: Lane 2) [1] : [0.06] 
Lane 3) [1] : [0.125] Lane 4) [1] : [0.25] Lane 5) [1] : [0.5] Lane 6) [1] : [0.85].  
For the control reaction with THS and siRNA a molar ratio of 1:1;  [2 µM] : [2 µM] 
was used.  
2.1.4.17 RNAse protection assay  
SiRNA (c = 2 µM) was incubated with or without THS-pDMAEMA 3 (c = 3 µM) 
for 30 min. at 37 °C in a nuclease free PBS Buffer (pH 7.4) in order to encapsulate 
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the siRNA. A slightly higher concentration of THS-pDMAEMA 3 compared to the 
EMSA was chosen to make sure that all siRNA is encapsulated. It was assumed that 
better protection would be achieved by a little excess of THS-pDMAEMA 3 over 
siRNA. A stock solution (10 µl) of RNAse II with an activity of 500 U ml-1 and a 
concentration of 10 mg ml-1 was prepared and incubated for 30 min. at 37°C. (The 
enzymatic activity U ml-1 (1 U = 1 µmol min-1) describes the conversion rate of a 
substrate by an enzyme.) After the incubation time, an aliquot (7 µl) of the RNAse 
stock solution was added to the THS-pDMAEMA 3 + siRNA solution. The RNAse 
concentration in the reaction tube (THS-pDMAEMA 3 + siRNA + RNAse) was 1 
mg ml-1 with an activity of 50 U ml-1. After specific time intervals of incubation at 
37 °C (0 min., 10 min., 15 min., 30 min., 45 min., 60 min., 90 min.), 10 µl aliquots 
were withdrawn from the reaction solution and 1 µl of 4 % SDS was added to the 
samples to a final concentration of approx. 0.4 %. Addition of SDS inactivated the 
RNAse and released encapsulated siRNA from THS-poly(DMAEMA) for better 
analysis. Samples were kept at 4°C until gel electrophoresis. To all samples 2 µl 
loading dye (6x Mass Ruler DNA loading dye) was added. In order to analyse the 
samples an agarose gel electrophoresis (AGE) was performed. Samples were run for 
25 min. at 100 V constant. Afterwards the gels were stained using a fluorescent dye 
(GelRed, Biotium, USA) and an incubation time of 30 min. in the GelRed solution. 
The GelRed staining solution was prepared according to the manufacturers protocol. 
The gels were imaged with a fluorescence imager (GelDoc EZ Imager, Bio-Rad, 
Switzerland). Fluorescence intensity was analysed with the software imageJ 1.47v 
(NIH, USA) by plotting intensity plots of the samples and measuring the area under 
curve (AUC). For the decay graph, the AUC from the sample at 0 min. incubation 
time was normalized to 100 % siRNA content in the reaction mixture. AUCs of the 
other samples were compared to the 100% siRNA sample and proportionate 
calculated. Error bars were calculated according to the analysis method of the gels 
using imageJ (v.147).473 The bands were depicted as 2D-plots. Signal intensity was 
determined by measuring the area under the curve (AUC). Depending on the 
integration, for the same peak, different AUCs were measured. The standard 
deviation of N = 5 AUC measurements represents the error.   
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2.1.4.18 Agarose gel electrophoresis (AGE) of THS-pDMAEMA-co-RhBMA 
conjugates and fluorescent proteins (FPs): 
Prior to analysis, samples of THS-polymer conjugates were incubated in constant 
amounts of THS-pDMAEMA-co-RhBMA and various amounts of fluorescent 
proteins for 3h.  The amount of THS-pDMAEMA-co-RhBMA in the experiments 
was 4.4 pmol for each well. The volume for each sample/well was 10µl. If necessary, 
the sample was diluted with PBS buffer to 10µl. The ratios between conjugate and 
eYFP are summarized in table 6 and between the conjugate and TurboGFP in table 7.  
Table 2.1.6. Molar ratios between THS-pDMAEMA-co-RhBMA and eYFP  
Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 
eYFP (13.2 
pmol) 
THS-poly:eYFP 
2:1 
THS-poly:eYFP 
1:1 
THS-poly:eYFP 
1:2 
THS-poly:eYFP 
1:3 
THS-poly 
(4.4 pmol) 
Table 2.1.7. Molar ratios between THS-pDMAEMA-co-RhBMA and TurboGFP. 
Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 
TurboGFP 
(2.2 pmol) 
THS-
poly:TurboGFP 
2:1 
THS-
poly:TurboGFP 
1:1 
THS-
poly:TurboGFP 
1:2 
THS-poly 
(4.4 pmol) 
2.1.4.19 Cell culture  
U87 glioblastoma cell line was maintained at 37 °C in a 5% CO2 humidified 
atmosphere. Cells were grown in Dulbecco's modified eagle medium (DMEM) with 
10% fetal bovine serum (FBS), 1% non-essential amino acids, 100 units mL-1 
penicillin, 100 µg mL-1 streptomycin and 2 mM L-glutamine. 
2.1.4.20 Cell viability assay  
Cytotoxicity testing was performed using the Promega CellTiter 96 AQueous Non-
Radioactive Cell Proliferation (MTS) assay to determine the number of viable cells 
in culture. An amount of 10’000 U87 cells were cultured in a 96-well plate for 24 h 
prior to the experiment. Thermosome-polymer conjugates (50 – 300 µg ml-1) were 
added to the cells and incubated for 24h at 37°C with 5% CO2. Next, a MTS mixture 
(20 µL/well) was added to the cells and then incubated for 1.5 h. Cell viability was 
calculated by measuring the absorbance at 490 nm using a 96-well plate reader. Two 
internal controls were set up for each experiment: untreated cells and medium 
without cells. Background absorbance due to the non-specific reaction between test 
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compounds and the MTS reagent was deducted from exposed cell values. Each 
experiment was performed in triplicate. 
For THS-pDMAEMA-co-pRhBMA, in addition, wells without the MTS reagent with 
the same concentrations as for the cell viability test were prepared. The absorption 
values from those wells were taken as blank values for each concentration and were 
subtracted from the values that were measured with the samples where the MTS 
reagent was added.  
2.1.4.21 Sample preparation for protein delivery   
To an aliquot of THS-pDMAEMA-co-pRHBMA (10.0 µg, 10.8 pmol), TurboGFP 
(1.16 µg, 21.6 pmol) was added in a molar ratio of 1:2. For eYFP samples the molar 
ratio was also 1:2 (THS-polymer conjugates: 15.0 µg,16.6 pmol and eYFP 0.9µg, 
33.3 pmol). The incubation and complex formation was done in PBS buffer at 4°C 
over night.with a total  sample volume of 10 µl. Control samples had the same 
concentration of either eYFP or TurboGFP,  but were without THS-polymer 
conjugates. For FACS measurements, the sample amount was increased by a factor 
of three. 
2.1.4.22 Cellular uptake  
Freshly trypsinized U87 cells (4x104 cells in 300 µL cell culture medium) were 
seeded into 8-wells chamber 24 h prior to the experiment. The cell culture medium 
was replaced with a cell culture medium without serum (200 µL) followed by 
addition of the different amount of THS-pDMAEMA-co-pRhBMA (100, 250, 500 
µg ml-1) or THS-pDMAEMA TurboGFP complex (50, 100, 250 µg of THS-polymer 
conjugates, formed as described earlier). After 4h incubation, the cell culture 
medium was carefully removed and replaced with serum-containing medium (300 
µL). The cells were incubated for additional 20 h. Immediately before live cell 
imaging, the cell culture medium was replaced with an Opti-MEM. Cell nuclei were 
stained for 10 min with 2 µL of a 50 µg/mL Hoechst 33342 solution in PBS. The 
imaging was performed on a commercial Confocor2 (Carl Zeiss, Jena, Germany). 
Images were taken using a 40x water-immersion objective. The samples were excited 
at 405 nm (Hoechst 33342), 488 nm (TurboGFP), 543 nm (THS-pDMAEMA-co-
pRhBMA) and the emission was collected with a broad pass filter at 420-480 nm 
(Hoechst 33342), a long pass 505 nm filter (TurboGFP) and a long pass 560 nm filter 
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(THS-pDMAEMA-co-pRhBMA), respectively. Images were taken with the same 
acquisition settings for comparison purpose.  
If necessary, cell uptake images were adjusted in contrast/brightness with the 
software imageJ (1.47v). For comparison reasons, settings were the same for each 
experiment. In order to reduce horizontal streaks in LSM images, the LSM 
Transmission deblurring plugin was applied. In some cases, the images were 
deblurred two times with the plugins default settings to remove horizontal streaks. 
2.1.4.23 Flow cytometry analysis  
U87 cells (1x105 cells/well) were plated into 24-well tissue culture plates 24 hours 
prior to the experiment. The cell culture medium was replaced with serum-free 
medium (464 µL) and 36 µl of the eYFP or THS-pDMAEMA-co-pRhBMA eYFP 
complex were added. After 4h incubation, the serum-free medium was carefully 
removed and replaced with 1 ml of medium containing 10% FBS. The cells were 
then incubated 20h. To prepare the sample cells were trypsinized with 200 µl of 
trypsin for 10 minutes at 37 °C and 5% CO2. Following trypsinization, 800 µl PBS 
were added to the cells, gently mixed by pipetting and transferred into 1.5 mL 
microcentrifuge tubes. Cells were then pelleted by centrifugation at 200 RCF for five 
minutes. Subsequently, the media was aspirated and the pellet was resuspended in 
250 µl PBS and put on ice. 6 µL of a 50 µg/mL stock solution of Hoechst 33342 was 
added to each sample. The cells were vortexed gently prior to FACS analysis. FACS 
measurements were performed by measuring at least 30000 cells with a FACS BD 
LSR Fortessa, the cells were excited with lasers at 405 nm (Hoechst 33342), 488 nm 
(eYFP and TurboGFP) and 561 nm (THS-pDMAEMA-co-pRhBMA), the emitted 
light passed through a Band Pass 450/50 (Hoechst 33342), 542/27 (eYFP), 512/25 
(TurboGFP) and 586/15 (THS-pDMAEMA-co-RhBMA) filters, respectively, before 
reaching the detector. The low pass filter was set to 505 nm for eYFP and 
TurboGFP. The data were processed with FlowJo Vx (Tree Star, USA) and a 
histogram of fluorescence intensity of only viable cells was plotted. 
2.1.4.24 Cell cultivation for siRNA knockdown experiments 
U87 cells were grown in DMEM media containing 10% FBS, 1% 
penicilin/streptomycin, and 1% NEAA at 5% CO2 and 37 °C. 
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2.1.4.25 Western blot analysis of THS-pDMAEMA3-mediated siRNA 
GAPDH knockdown 
The procedure was followed from a previously published peptide siRNA delivery 
protocol with several modifications.473 24 hours before the experiment 5000 U87 
cells were plated in 100 µl per well in 96 well plate and incubated at 5 % CO2 and 37 
°C. For every sample 4 wells were plated. After 24 hours, the media was removed 
and replaced with 100 µl opti-MEM media. Samples were prepared by adding 0.4-40 
pmol of siRNA (volume 20 µl) in opti-MEM, and mixing it with either blank opti-
MEM, opti-MEM containing Lipofectamine RMAiMAX, or THS-PDMAEMA3 (in 
a ratio of 4:1 siRNA to THE-PDMAEMA3) in 20 µl (total volume 40 µl) and 
incubated at room temperature for 30 min. 10 µl of sample were added to each well 
(final concentrations of 0.1-10 pmol siRNA per well). After 4 hours 100 µl DMEM 
containing normal cell culture media was added to each well and incubated for 68 
more hours (72 total hours). After 72 hours, the media was removed from cells and 
they were washed with PBS 3x. 60 µl of lysis buffer was added to the first well 
incubated for 5 minutes and then transferred to the second, third, and fourth well of 
each sample with 5 minute incubation in each (final volume of 60 µl containing a 
mixture of the cell lysate of all 4 wells).  The cell lysate protein concentration was 
quantified with the micro BCA protein assay kit. 15 µg total protein of each sample 
were then mixed in 5x SDS protein loading buffer and heated at 95 °C for 10 
minutes. After heating, the samples were loaded into a 10% TGX stain free 
acrylamide gel and electrophoresed at 120 V for 50 minutes. The gel was removed 
from the cassette and imaged on an EZdoc one touch imager (BioRAD) using the 
TGX stain free method activating for 5 min. This image was analysed in imageJ to 
verify consistant loading of each well by quantifying the band at 40’000 g mol-1. The 
gels were then transferred to nitrocellulose membranes via a biometra FASTblot 
semi-dry transfer system at a constant 80 mA for 25 minutes. The membranes were 
then blocked in 5% milk in TBS buffer overnight at 4 °C. The next morning the 
blocking solution was removed and 15 mL of 5% milk in TBS containing 1:10’000 
mixture of primary monoclonal mouse antiGADPH antibody was added to each 
membrane and incubated at room temperature for 2 hours. The membranes were then 
washed in TBST buffer 3x for ten minutes each. The second incubation was also 
done in 15 ml 5 % milk in TBS containing 1:10’000 goat antimouse HRP conjugated 
antibody for 1 hour. The membranes were washed 3 more times at 10 minutes each 
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in TBST buffer and then dried. The supersignal west pico chemiluminescent 
substrate was added as per manufacturer’s directions and imaged on a Bucher biotec 
fluorescence imaging system equipped with s FujiFilm Las-4000 camera. Images 
were recorded with the Las-4000 software and quantified using imageJ to determine 
percent GAPDH-protein level of each sample.  
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2.2 Self-sealing and puncture resistant breathable 
membranes for water evaporation applications 
This work has been published:  Rother, M., Barmettler, J., Reichmuth, A., Araujo, J. 
V., Rytka, C., Glaied, O., Pieles, U. and Bruns, N., Self-Sealing and Puncture 
Resistant Breathable Membranes for Water-Evaporation Applications. Adv. Mater. 
2015, 27, 6620-6624, DOI: 10.1002/adma.201502761.1 
       
In this chapter a composite membrane was 
developed, which was based on a thin non-porous 
poly(ether ester) multi-block copolymer membrane 
that was covalently bound with an amphiphilic 
polymer conetwork (APCN), based on the 
hydrophilic poly(hydroxyl ethyl) acrylate and the 
hydrophobic poly(dimethylsiloxane). This 
composite material was capable to let water vapour pass through the membrane, 
while being capable to seal punctures at applied pressures of at least 1.6 bar. The 
self-closing properties were investigated with two different APCN compositions. 
Moreover the breathability was demonstrated on a cooling pad example.  
 Introduction 2.2.1
Waterproof, but water vapor permeable membranes are thin polymeric membranes 
that are designed to let water vapor pass, while condensed water is retained. Such 
waterproof and breathable membranes can be made out of expanded 
poly(tetrafluorethylene), polyurethane or poly(ether ester) block copolymers.475,476 
They are widely used in the textile industry for weather protective clothing that allow 
body-generated moisture to pass the membrane while preventing wind and rain from 
penetrating the fabric, thus keeping the body dry and warm. Their selective 
                                                
1 Reprinted (adapted) with permission from reference (474) Rother, M.; 
Barmettler, J.; Reichmuth, A.; Araujo, J. V.; Rytka, C.; Glaied, O.; Pieles, U.; Bruns, 
N. Self-Sealing and Puncture Resistant Breathable Membranes for Water-
Evaporation Applications. Adv Mater 2015, 27, 6620-6624. Copyright Wiley-VCH, 
Weinheim 2015 
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permeability for water-vapor is not only interesting for apparel, but can also be used 
in medical applications, e.g. for cooling garments that alleviate symptoms of multiple 
sclerosis.477-480 Their working-principle is based on the evaporation of water through 
a breathable membrane. Evaporative heat loss causes a gentle drop in temperature of 
the skin and the tissue underneath. Moreover, breathable membranes find application 
in pervaporation,481,482 membrane distillation483 moisture regulation of buildings484 
and in humidification for the conservation of art and paper.485 They can also be used 
as part of a sensor for constant electrocardiography monitoring.486,487 A major 
drawback of these membranes is that they are sensitive to punctures and mechanical 
wear and tear. Even a microscopic hole causes the membrane to become leaky for 
liquid water. To overcome this problem, self-sealing membranes that autonomously 
close or heal damage would be desirable. The sealing of holes in rubbery materials is 
well known,488 e.g. in the case of rubber septa,489 in waterproofing construction foils 
that feature a layer of rubberized asphalt,490 or in self-sealing actuators.491 The self-
sealing effect can be enhanced if the material is not only elastic, but also swellable in 
a solvent. The volume gain due to swelling can close reasonable large holes. This 
concept has been used in technical applications, such as bullet proof fuel tank of 
world war II aircrafts492 and in self-repairing car tires.493 Inspiration for self-sealing 
materials can also be drawn from Nature. The plant Aristolochia macrophylla, a 
northamerican liana, has a mechanism to mechanically close defects.494 Its tissue 
expands and swells to seal fissures. Inspired by this phenomenon, Speck and co-
workers developed an airtight pneumatic membrane (as used, e.g. in inflatable boats) 
that is capable to close punctures by the expansion of a polyurethane-foam.495 
Unfortunately, all these materials are not suitable for self-sealing breathable 
membranes, as a sealing layer on a climate membrane has to be permeable for water 
in order to retain the original function of the membrane, i.e. the evaporation of 
moisture.  
Here we present a two-layered composite membrane for water evaporation 
applications that autonomously closes small defects by swelling of a water-swellable 
elastomeric layer. The self-sealing membrane consisted of a waterproof and 
breathable, non-porous poly(ether ester) multi-block copolymer membrane (PEE; 
Sympatex membrane)476,496 onto which an amphiphilic polymer conetwork 
(APCN)497-510 was polymerized. APCNs are water-swellable materials that have 
much stronger mechanical properties than conventional hydrogels due to the 
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presence of a reinforcing hydrophobic phase.497,511-513 Moreover, they have been 
investigated as membranes for pervaporation,514,515 nanofiltration,515,516 chiral 
separation,517 and drug delivery.518,519 We chose APCNs in which hydrophilic 
poly(2-hydroxyethyl acrylate) (PHEA) was cross-linked with hydrophobic 
poly(dimethylsiloxane) (PDMS) because these APCNs are rubbery, elastic materials 
both in dry and wet state.382,519-522 The combination of PHEA-l-PDMS with a PEE 
membrane resulted in a composite material, here named APCN/PEE, that effectively 
closed punctures, while having water evaporation properties similar to unmodified 
PEE membranes.  
 Results and Discussion 2.2.2
A precursor method reported by Bruns. et al. was adapted for the synthesis of PHEA-
l-PDMS.521 The APCN/PEE composite membranes were prepared by synthesizing 
PHEA-l-PDMS conetworks on modified PEE membranes. First, the surface of PEE 
was activated with oxygen plasma and functionalized with methacrylate groups by 
condensation of 3-(trimethoxysilyl)propyl methacrylate. This modification ensures a 
tight bonding between the PEE and the APCN, because the methacrylate groups 
copolymerize with monomers of the APCN.521 UV-initiated free radical 
copolymerization of 2-(trimethylsilyloxy)ethyl acrylate (TMSOEA) with α,ω-
dimethacrylate-terminated poly(dimethylsiloxane) (MA-PDMS-MA; Mn = 5050 g 
mol-1, PDI = 1.11) under argon atmosphere resulted in hydrophobic precursor 
networks that were covalently bound to PEE. The trimethyl-silyl (TMS) groups of 
these networks were cleaved by immersing the composite membranes in acidified 
mixtures of 50% isopropanol (iPrOH) in water, resulting in hydrophilic PHEA chain 
segments. Successful removal of the TMS groups was confirmed via infrared 
spectroscopy (See Figure 2.2.1).521 Our synthesis approach allows to prepare APCNs 
with a wide range of compositions by adjusting the ratio of the TMSOEA to MA-
PDMS-MA in the monomer mixture.521 A higher hydrophilic content results in a 
higher degree of swelling in water.521 As a pronounced swelling should give rise to a 
good self-sealing effect, we chose to synthesize PHEA-l-PDMS conetworks with 75 
wt% and 90 wt% PHEA content. The thickness of the APCN could also influence the 
self-sealing properties of the composite membrane. Therefore, APCN/PEE were 
prepared in casting molds of 200 µm and 400 µm height.  
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Figure 2.2.1. ATR-FT-IR spectra of APCN/PEE composite membrane with a composition of 
PHEA:PDMS 90:10 (w/w). The spectra were recorded on the APCN side of the sample. A) 
PTMSOEA-l-PDMS before treatment in acidified iPrOH:H2O (1:1); B) The same sample after 
incubation for 24 h in acidified iPrOH:H2O (1:1) and subsequent drying. This process cleaved the 
TMS groups from the PHEA chain segments and yielded an amphiphilic PHEA-l-PDMS conetwork. 
Removal of the TMS groups resulted in the appearance of the broad OH-Polymer band at 3390 cm-1 
and disappearance of the –Si-C-band at 836 cm-1. 
2.2.2.1 Imaging of the APCN/PEE composite 
The produced APCN/PEE composite membranes were imaged by scanning electron 
microscopy (SEM). The micrograph (Figure 2.2.2a) shows the two layers of the 
composite material. There is no gap between the PEE-membrane and the APCN, 
which indicates good binding between the materials. SEM also allowed measuring 
the thickness of the APCNs. A 400 µm casting mold resulted in PHEA-l-PDMS 
layers with a thickness of approx. 340 µm, while the 200 µm casting mold yielded 
approx. 170 µm thick APCNs. This decrease in volume is most likely due to 
polymerization shrinkage and the cleavage of TMS groups.  All synthesized APCNs 
were optically transparent. This proves that no macroscopic phase separation 
between the hydrophilic and the hydrophobic polymers occurred, and is consistent 
with literature reports on the nanophase separated morphologies of APCNs.497,521 
However, the hydrophobic phase can accumulate on the surface of APCNs,521 which 
would lead to the formation of a water-impermeable PDMS layer on the surface. 
Such layer would hamper the ability of the composite membranes to take up and 
evaporate water. Therefore, the phase morphology on the surface of an APCN/PEE 
composite membrane was visualized by atomic force microscopy (AFM) in phase 
mode (Figure 2.2.2b). Dark areas represent soft PDMS domains, whereas bright 
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areas show harder PHEA domains.521 AFM revealed a nanophase separated 
cocontinuous morphology with average domain sizes below 70 nm. The area covered 
by PDMS is higher than expected from the overall PDMS content of the sample (10 
wt%), indicating that the hydrophobic polymer enriched on the surface during 
synthesis. However, the PDMS does not form a closed layer, so that water can 
penetrate into the APCN and diffuse through the material.  
 
Figure 2.2.2. SEM and AFM characterization of the APCN/PEE composite. (a) SEM image of a dry 
APCN/PEE composite membrane (side cut). Composition of the material was PHEA:PDMS 90:10 
(w/w) with a thickness of approx. 350 µm. (b) AFM image (phase mode) of the surface of the APCN 
side of an APCN/PEE composite membrane with a composition of (PHEA:PDMS 90:10 (w/w)) and a 
thickness of 340 µm.  
2.2.2.2 Swelling properties of APCN/PEE composites 
As expected, PHEA-l-PDMS conetworks swelled in water. Freestanding samples 
with a composition of PHEA:PDMS 75:25 (w/w) reached an equilibrium degree of 
swelling Q = 1.57 ± 0.02 and samples with a composition of PHEA:PDMS 90:10 
(w/w) swelled to Q = 2.10 ± 0.1. 
2.2.2.3 Mechanical properties of APCN/PEE composites 
The mechanical properties of composite membranes were investigated by tensile 
tests (Figure 2.2.3). APCN/PEE membranes with a composition of PHEA:PDMS 
90:10 (w/w) behaved like an elastomer with a young modulus of 0.05 ± 0.01 MPa 
and a stress of 1.74 ± 0.23 MPa at 250 % strain. In contrast, stress-strain curves of 
neat PEE membranes and of methacrylate-functionalized PEE membranes are typical 
for thermoplastic polymers. Thus, the predominant load-bearing phase in the 
composite membranes is the APCN. The elastic modulus and yield strength of PEE 
   Chapter 2 
 
130 
increased significantly after its surface was functionalization with a methacrylate-
bearing silane, most likely because of the formation of  brittle silica on (and in) the 
PEE. Similar observations were made for other polymer-silicon oxide hybrid 
materials.523,524 PDMS-based APCNs are elastomers.497,511,525 Addition of the APCN 
to the PEE resulted in a composite membrane in which the elastomeric PHEA-l-
PDMS became the predominant load-bearing phase 
 
 c 
 
 
 
 
 
Figure 2.2.3. Mechanical properties of dry membranes. (a) Stress-strain curves of PEE (–––) and 
methacrylate-functionalized PEE (----) membranes; (b) Stress-strain curve of APCN/PEE composite 
membrane with a composition of PHEA:PDMS 90:10 (w/w) and a thickness of 340 µm (·······). * = 
Measurements were stopped before the ultimate tensile strength and elongation at break were reached, 
as the experimental-set-up did not allow to measure at higher strains. (c) Mechanical properties of 
membranes. Average values from at least five tensile tests per type of membrane and standard 
deviations are reported. 
2.2.2.4 Investigation of self-sealing properties 
In order to show that APCN/PEE composite membranes can self-seal small defects, 
dry membranes were punctured with a needle of 0.6 mm diameter. Figure 2.2.4 and 
Figure 2.2.5a show SEM pictures of the resulting holes. When the composite 
membrane was brought into contact with water, the APCN swelled and closed the 
holes (Figure 2.2.5b). The self-sealing capabilities of APCN/PEE membranes were 
 Elastic Modulus[MPa] Yield Strength [MPa] 
PEE 0.20 ± 0.02 1.94 ± 0.09 
PEE-methacrylate  1.96 ± 0.33 15.17 ± 0.69 
APCN/PEE 0.05 ± 0.01 ------ 
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quantified by measuring the water flow through damaged membranes. PEE 
membranes are water-proof to pressures above 4.4 bar, according to the 
manufacturers specifications.526When pierced, a substantial amount of water passes 
through the hole in the membrane (Figure 2.2.5c and Figure 2.2.6). In contrast, the 
APCN/PEE composite membranes show no or only little leaking, i.e. they are self-
sealing materials. In a first set of experiments, the effect of APCN composition on 
self-sealing was investigated at water pressures between 0.02 bar and 0.04 bar above 
atmospheric pressure (Figure 2.2.6). Leaking rates between 8×10-5 ml sec-1 and 
2.2×10-3 ml sec-1 were determined for APCN/PEE membranes with a composition of 
PHEA:PDMS 75:25 (w/w) and a thickness 170 µm. This is 450 times lower than the 
leaking rates of the unmodified PEE-membrane at these pressures (0.035 ml sec-1 to 
0.1 ml sec-1). Composite membranes with an APCN composition of PHEA:PDMS 
90:10 (w/w) had leaking rates that ranged from 0 ml sec-1 to 7×10-4 ml sec-1, i.e. they 
were more than three orders of magnitude lower than those of unmodified PEE. 
APCNs with a PHEA-content of 90% showed a stronger self-sealing effect than 
those with a PHEA-content of 75%, most likely because a higher hydrophilic content 
leads to higher swelling of the APCN in water. For this reason, all further self-
sealing experiments were carried out with APCN/PEE membranes with a 
composition of PHEA:PDMS 90:10 (w/w).  
The influence of the APCN thickness on the self-sealing performance of APCN/PEE 
membranes was evaluated at pressures between 0.1 bar and 1.6 bar. With 170 µm 
thick samples, leaking rates at pressures ≤ 0.5 bar were very low (< 0.006 ml sec-1) 
(Figure 2.2.5d). Above this threshold, leaking rates increased with pressure, i.e. the 
170 µm thick APCN layer was not capable to seal small defects completely. In 
contrast, the water flow through 340 µm thick membrane stayed between 0 ml sec-1 
and 0.003 ml sec-1 for pressures up to 1.6 bar (Figure 2.2.5e). The 340 µm thick 
APCN was therefore capable to seal holes in the investigated pressure range. In 
conclusion, thicker APCN layers lead to a higher pressure tolerance of the self-
sealing effect, because more swollen material covers the defect in the PEE. 
Although water penetrated through the 170 µm thick APCN/PEE membranes at 
pressures ≥ 0.6 bar, it should be pointed out that the observed leaking was 
significantly less than the loss of water through an unmodified PEE membrane. At 
0.5, 1.0 and 1.5 bar, respectively, a leaking rate of 0.85 ml sec-1, 1.1 ml sec-1 and 2.6 
ml sec-1 were measured for pierced PEE. Drying of a damaged APCN/PEE 
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membrane reopens the puncture, because the APCN de-swells. In order to determine 
if this process would impede the ability of the membrane to seal the hole if rewetted, 
a punctured membrane was repetitively dried and exposed to water. A self-sealing 
experiment with a 340 µm thick APCN/PEE was carried out at a pressure of 0.5 bar 
as described above. No leaking of water was observed (Figure 2.2.5f, cycle 1). After 
the measurement, the membrane was dried in air over night. Then, water was refilled 
into the test apparatus, wetting the membrane. Pressure was set to 0.5 bar. The 
material immediately sealed the puncture, and no water passed through the 
membrane. These drying and wetting cycles were repeated four more times (Figure 
2.2.5f, cycles 2 to 5). Leaking rates remained at 0 ml sec-1, i.e. the composite 
membrane sealed the puncture completely. Thus, the self-sealing property of 
APCN/PEE membranes is not affected by repeated drying-swelling cycles.  
 
Figure 2.2.4. SEM image of a puncture in a dry APCN/PEE composite membrane (side cut). 
Composition of the material was PHEA:PDMS 90:10 (w/w). The APCN thickness of this membrane 
was approx. 200 µm. The membrane was damaged with a syringe needle (diameter 0.6 mm) in the dry 
state. Scale bar is 100 µm. 
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Figure 2.2.5. Self-sealing of APCN/PEE composite membranes with a composition of PHEA:PDMS 
90:10 (w/w). (a) Cryo SEM image of a puncture in a dry APCN/PEE membrane with a thickness of 
340 µm. (b) Cryo SEM image of a defect after swelling of the APCN in water (thickness of sample 
340 µm). (c) Measurement of the water flow through punctured unmodified PEE membrane in 
comparison to punctured APCN/PEE composite membranes with thicknesses of 170 µm µm and 340 
µm at a water pressure of 0.5 bar above atmospheric pressure. Such data was used to determine 
leaking rates. (d) Leaking rate in dependence of water pressure for punctured APCN/PEE composite 
membranes with a thickness of 170 µm. (e) Leaking rate in dependence of water pressure for 
punctured APCN/PEE composite membranes with a thickness of 340 µm. The membranes were 
damaged by puncturing them with a syringe needle (diameter 0.6 mm) in the dry state. Variations in 
the leaking rate might be a result of the manual piercing process and small inhomogeneities in the 
materials’ thickness. (f) Effect of repetitive drying/wetting cycles on the ability of an APCN/PEE 
composite membrane to self-seal. A composite membrane with a thickness of 340 µm was punctured 
with a syringe needle (diameter 0.6 mm) in the dry state and leaking rates at 0.5 bar water pressure 
were measured. 
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Figure 2.2.6. Leaking rates of 170 µm thick APCN/PEE composite membranes with different 
compositions and of unmodified PEE at water pressures between 0.02 bar and 0.04 bar. 
2.2.2.5 Evaluation of water vapour evaporation through the APCN/PEE 
Water evaporation through the composite membranes was measured in order to 
assess if the layer of APCN on the PEE hampers the functionality of the membrane 
in cooling garment applications.477,478,480 
To this end, two types of cooling laminates were produced. One was made with the 
unmodified PEE membrane and served as reference sample. The other was made 
using an APCN/PEE composite membrane with a composition of PHEA:PDMS 
90:10 (w/w) and a thickness of 170 µm. The fabrication procedure and experimental 
setup is described in the supporting information. In brief, the membranes were used 
to enclose a hydrophilic polyethylene terephthalate (PET) fabric in a sandwich 
laminate (Figure 2.2.7a). The APCN layer was facing inwards, i.e. towards the 
fabric. Membranes and fabric were glued together with an array of glue spots and the 
laminates were sealed at their edges. Water that was filled into the laminate was 
distributed throughout the laminate by the inner fabric. The two laminates were 
connected to water-reservoirs and placed on a heating plate that was set to the 
average human skin surface temperature of 34 °C.527 Evaporation of water through 
the membranes was measured as loss of water in the reservoirs. In addition, 
temperature of the cooling laminates was monitored by an infrared (IR) camera. Both 
types of cooling laminates evaporated water through the membranes (Figure 2.2.7b): 
APCN/PEE-based laminates with an evaporation area of 20 cm2 at a rate of 0.0162 ± 
0.0006 ml h-1 cm-1 (and PEE reference laminates at 0.0298 ± 0.0003 ml h-1 cm-1).  
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Evaporation of water from APCN/PEE samples was slower, most likely because the 
APCN layer transports water to the PEE membrane by diffusion, while unmodified 
PEE membrane is in direct contact with liquid water. Moreover, the additional 
material could act as heat resistance that reduced energy transfer from the plate to the 
surface of the laminate.  
The infrared camera measured average temperatures on the APCN/PEE-based and 
the PEE-based laminates of 26 ± 1 °C and 30 ± 2 °C, respectively (Figure 2.2.5c). 
The drop in temperature is in accordance with previously reported results for similar 
cooling devices.478 The laminates had a lower surface temperature than the heating 
plate. The temperature was also lower in the middle of the laminates than at their 
sealed edges, indicating that the evaporation of water resulted in cooling. The heat 
transfer resistance of the material also contributed to the decrease in surface 
temperature, which is the reason why the temperature of the thicker APCN/PEE 
membranes was lower than the temperature of the PEE-based laminate, despite the 
higher rate of water evaporation in the latter case. 
 
Figure 2.2.7. Water evaporation and cooling due to evaporative heat loss in APCN/PEE-based, water-
filled laminates. (a) Schematic view of the three-layer laminate. (b) Water evaporation from 
APCN/PEE-based and PEE-based laminates, measured as the loss of water in the reservoirs. The 
laminates had a size of 8 × 7 cm2 and an evaporation area of 5 × 4 cm = 20 cm2 (see supporting 
information for explanation of the evaporation area). (c) Temperature of the cooling laminates during 
a water evaporation experiment as measured with an IR camera. 
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 Conclusions 2.2.3
In conclusion, we have modified a waterproof, but breathable PEE-membrane with 
an amphiphilic polymer conetwork in order to equip the membrane with self-sealing 
properties. When in contact with water, the two-layer APCN/PEE composite 
membrane was able to seal damages by swelling of the APCN. Thicker and more 
hydrophilic APCN layers resulted in a more pronounced self-sealing effect. A 340 
µm thick APCN/PEE prevented leakage through punctures at pressures of at least 1.6 
bar, which corresponds to a water column of >16000 mm. A membrane is considered 
to be waterproof if it can withstand a pressure of 1300 mm.526 Thus, the self-sealing 
effect is strong enough to render the composite membranes waterproof after puncture 
with a sharp object such as a syringe needle. Cooling laminates were assembled from 
these membranes. Water evaporation through the composite membrane was similar 
to the evaporation of water through unmodified PEE membranes and resulted in a 
gentle drop of surface temperature. We demonstrated the functionality of the 
composite membrane in the context of cooling garments. However, it is easy to 
envision that such self-sealing composite membranes can also find applications in 
other areas, e.g. as pervaporation membranes with prolonged life time, 
humidification devices for paper conservation, or as robust climate membrane in 
protective textiles.   
 Experimental section 2.2.4
2.2.4.1 Materials 
All chemicals were used as received unless described otherwise. Isopropanol (iPrOH, 
EP, PhEur) was purchased from Brenntag Schweizerhall (Switzerland). 3-
(Trimethoxysilyl)propyl methacrylate (TMSPMA, ≥98%) was purchased from 
Sigma-Aldrich. Methacryloxypropyl terminated poly(dimethylsiloxane) (α,ω-
dimethacrylate-terminated poly(dimethylsiloxane); MA-PDMS-MA; Mn = 5050 g 
mol-1 (GPC), PDI = 1.11 (GPC), end functionalization ≥ 99 % (1H-NMR)) and 2-
(trimethylsilyloxy)ethyl acrylate (TMSOEA, 97%) were purchased from ABCR 
(Germany). TMSOEA was distilled prior to use in order to remove the 
polymerization inhibitor at 50 °C and 6.2×10-2 mbar. The photoinitiator Irgacure 651 
(2,2-dimethoxy-1,2-diphenylethane-1-one) was kindly provided by BASF 
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(Germany). Self-adhesive poly(propylene)-tape (tesafilm® kristall-klar from Tesa 
AG, Germany) with a thickness of approx. 50 µm was used. Polyester-polyether 
(PEE) membrane with a thickness of approx. 20 µm was obtained from Sympatex 
Technologies (Germany). The polyethylene terephthalate (PET) fabric with a 
thickness of approx. 50 µm and mesh density of 150 dtex was obtained from Serge 
Ferrari Tersuisse AG (Switzerland). 
2.2.4.2 Functionalization of PEE-membrane  
The surface of PEE membrane was functionalized with methacrylate groups in order 
to allow covalent binding of TMSOEA-l-PDMS to the PEE membrane (see Scheme 
S1). For this purpose, the PEE membrane was treated with an oxygen plasma at a 
pressure of 0.0108 mbar and a flow rate of 84.5 × 10-3 Pa m3 s-1 and a radio 
frequency (RF) power of 50 W. The membranes were treated on both sides for 5 min 
each side. Subsequently, the membranes were placed between two glass plates (20 × 
20 cm). TMSPMA was injected between the activated membrane and the glass plate 
on both sides with a concentration of 1.7 × 10-5 mol ml-1. The temperature was 
maintained at 40°C for 2  
hours followed by 1 night at room temperature and ambient pressure allowing the 
condensation of TMSPMA onto the PEE-membrane. The membranes were washed 3 
times with EtOH and then dried.  
2.2.4.3 Synthesis of APCN/PEE composite membranes 
The process of APCN/PEE preparation is depicted in Figure 2.2.8. Synthesis of the 
composite membranes was carried out in a glove box (Labstar Glove Box 
Workstation, MBraun) under argon atmosphere (p(O2) < 1 ppm). MA-PDMS-MA 
was mixed with TMSOEA in a glass vial containing Irgacure 651 with a 
concentration of 5 mg mL-1. The mixture was thoroughly mixed until the initiator 
was completely dissolved. Volume ratios between TMSOEA and PDMS were 
calculated based on the final product after cleavage of the TMS-groups (e.g. 
PHEA:PDMS 90:10 (w/w)). Table 2.2.1 reports the quantity of reagents used for 
APCN/PEE composite membranes with a size of 16.3 cm x 10.3 cm and a mold 
thickness of 200 µm. For the preparation of APCNs in a 400 µm thick mold the 
amount was doubled.  
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Figure 2.2.8. Fabrication process of APCN/PEE composite membranes. PEE membranes were treated 
with oxygen plasma and functionalized with methacrylate groups by condensation of TMSPMA. 
Then, a monomer mixture of TMSOEA, MA-PDMA-MA and photoinitiator Irgacure 651 was casted 
onto the membrane. The monomer mixture was cured by UV-initiated free radical polymerization. 
Casting and UV curing was performed under inert atmosphere. Subsequently, the composite 
membrane was incubated in an acidified H2O:iPrOH (1:1) mixture to cleave TMS groups. The overall 
process yielded PHEA-l-PDMS amphiphilic polymer conetworks that were covalently attached to the 
PEE membrane. 
Table 2.2.1. Quantity of reagents used for APCNs with the size of 16.3 cm x 10.3 cm and a thickness 
of 200 µm. 
Final 
composition 
(PHEA:PDMS, 
(w/w)) 
V 
(MA-
PDMS-
MA) 
[µL] 
m 
(MA-
PDMS-
MA) 
[mg] 
n 
(MA-
PDMS-
MA) 
[µmol] 
V 
(TMSOEA) 
[µL] 
m 
(TMSOEA) 
[mg] 
n 
(TMSOEA) 
[µmol] 
m 
(Irgacure 
651) 
[mg] 
 
n 
(Irgacu
re 651) 
[µmol] 
75:25 831 814 163 4169 3961 21035 25 98 
90:10 311 305 61 4689 4454 23655 25 98 
 
The functionalized PEE-membrane was moistened with EtOH. The edges of the 
membrane were fixed onto a glass plate with self-adhesive tape in a way that the 
membrane was strained after evaporation of EtOH. The tape formed a rectangular 
mold into which monomer mixtures could be casted. By using several layers of tape, 
the APCN thickness could be adjusted in 50 µm steps. The monomer mixture was 
added uniformly onto the PEE-membrane. Curing of the mixture was performed in a 
curing chamber using a 400 W UV curing lamp (UV Light Technology Limited, 
Birmingham, UK). Radiation power of the UV lamp at the surface of the sample was 
10 mW cm-2. The lamp had an output between 315 nm and 405 nm using the 
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suppliers black filter glass. The monomer mixture was exposed to UV light for 1 
min. Then, the sample was then taken out of the chamber for 2 min to cool down the 
material. This cycle was repeated 4 times for each sample. Cooling times were 
important in order to have clear materials with nanoscopic phase seperation. When 
cooling times were not included in the synthesis procedure, the APCNs became 
opaque due to larger domains that phase seperate. After synthesis, the sample was 
incubated for 24 h in a 1:1(v:v) mixture of H2O and iPrOH that had been acidified 
with 2-3 drops of HCl (37%) per liter. HCl was added to increase the cleavage rate of 
TMS-groups.  
Free-standing APCNs were prepared as described above, but with no PEE membrane 
present. 
2.2.4.4 Preparation of cooling laminates  
Cooling laminates with a size of 8 cm × 7 cm were produced. To this end, 
APCN/PEE composite membranes with a composition of PHEA:PDMS 90:10 (w/w) 
and a thickness of 170 µm were glued with an array of dots of Elastosil E43 
(Wacker, Germany) (dot diameter = 2 mm, distance between dots = 5 mm) to both 
sides of a hydrophilic PET fabric with the APCN layers facing towards the PET 
fabric. The result was a three-layer laminate in which the PET fabric is enclosed by 
the composite membrane (Figure 3a). The gaps between the dots of glue in 
combination with the PET fabric allowed water to evenly distribute in the laminate 
and contact the composite membranes. The edges of the sandwich were sealed with 
Elastosil E43. Due to sealed edges, the evaporation area, i.e. the area of the 
membrane that could get in contact with water, was 20 cm2. In addition, two silicone 
tubings (MVQ Silicones, Germany) with different diameters (outer diameter = 4.5 
mm resp. 2.8 mm; inner diameter = 2 mm resp. 0.8 mm) were fixed in between the 
two membrane layers using Elastosil E43. The thinner tube acted as an air outlet the 
thicker as a water inlet.  
Reference cooling laminates were prepared as described above, but replacing the 
APCN/PEE composite membrane with unmodified PEE membrane (thickness ≈ 20 
µm) that had briefly been flame treated (one second butane gas flame with a distance 
of 5 cm to the surface) in order to create reactive groups for a better adhesion of the 
glue.528 
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2.2.4.5 Methods 
Fourier-transform infrared (FT-IR) spectra were recorded on an Alpha FT-IR 
spectrometer with attenuated total reflection (ATR) module (Bruker Optics, 
Germany). Spectra were analyzed using OPUS 6.5 software from Bruker.  
Atomic force microscopy (AFM) images were recorded using an Agilent 5100 
AFM/SPM microscope (PicoLe System, Molecular Imaging, USA) in tapping mode 
at ambient conditions. Silicon cantilevers (PPP-NCHR; Nanosensors, Switzerland) 
with nominal spring constant of 42 N m-1 were used for measurements. Images were 
collected with a resolution of 1024 × 1024 pixels at a scan rate of 0.4 lines s-1.  
For conventional scanning electron microscopy (SEM), samples were cut with a 
scalpel. The sample was mounted onto a 45° sample holder in a way that the area of 
interest did not contact the sample holder. Then, the sample was sputtered with a 20 
nm thick gold layer using a Leica EM ACE600 high vacuum coater. SEM images 
were taken with a FEI NOVA Nano SEM230 Microscope at 5 kV. In order to see the 
edge of the sample from a top view, the sample holder was tilted. For cryo-SEM, an 
APCN/PEE membrane sample was mounted on an aluminum cylinder and 
mechanically fixed with a ring of wire in a way that the APCN side was facing the 
outside. The cylinder had two drilled holes and the composite membrane was pierced 
with a syringe needle (Sterican 0.6 mm × 30 mm; B∣Braun Melsungen AG, 
Germany) from the PEE-side. After mounting the cylinder on the cryo holder, the 
sample was plunge frozen in nitrogen slush and transferred under vaccum to the 
prechamber of the cryo preparation unit Gatan Alto 2500 (Figure 8). There, it was 
sputtered with a gold layer of 20 nm and finally transferred to the cryo stage of the 
SEM, which was cooled to -150°C. Images were taken with a Philips ESEM XL 30 
Microscope at 5 kV. For images of water-swollen APCN/PEE membranes, samples 
were prepared and imaged as described above. In addition, the cylinder with fixed 
membrane was put into a small dish filled with water prior to freezing. The sample 
was allowed to swell for 2 h. Then, surface water was removed using a fiber-free 
tissue and the sample was immersed in nitrogen slush under vacuum. Tensile tests 
were conducted with a Dynamic Mechanical Analyser (DMA-Q800, TA 
Instruments). The samples were cut into rectangular strips of 5 x 15 mm2 and gripped 
using clamps. Tests were performed with dry samples at 26 ºC, with a strain rate of 5 
% min-1, to a final strain of at least 300 % (which represents the maximal strain that 
could be achieved with the experimental set-up). The Young’s moduli for PEE and 
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methacrylate-functionalized PEE membranes were calculated from the slope of the 
initial linear region of stress-stain curves. Yield strength for PEE and PEE-
methacrylate was determined as the maximum stress value after which the materials 
began to deform plastically, i.e. at the yield point. At least five specimens were tested 
for each type of material. Average values and standard deviations are reported. 
 
Figure 2.2.9. Inside view of the prechamber of the cryo preparation unit Gatan Alto 2500 with a 
swollen and frozen APCN/PEE sample that was fixed on a cylindrical sample holder.  
2.2.4.6 Swelling and water content measurements 
The equilibrium degree of swelling (Q) was calculated from 𝑄 = !!"#$$%&!!"# , whereas 𝑚!"#$$%&   represents the mass of a free-standing APCN sample in its swollen state 
and 𝑚!"#  is the same sample in dry state. Samples were dried in a vacuum oven at 
40°C for 48 h until constant weight. Afterwards, samples were immersed in H2O for 
24 h. Excess of water was removed from the surface of the sample by blotting with 
laboratory tissue and the swollen APCN was weighted. For each APCN composition, 
the swelling of at least 3 samples was measured. Average Q and the standard 
deviation are reported. 
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2.2.4.7 Self-sealing experiments 
For each dataset all experiments were performed with samples of the same batch, i.e. 
of the same APCN thickness, to ensure that batch-to-batch variations in sample 
thickness did not influence the measured leaking rates. 
Self-sealing at pressures between 0.02 bar and 0.04 bar was evaluated by tightly 
fixating an APCN/PEE membrane with a rubber band across the cut-of opening of a 
syringe and connecting the syringe as an adapter to a glass column (3 cm diameter) 
via luer connections. The APCN was facing towards the water reservoir. A hole was 
pierced into the membrane in wet conditions from the PEE side using a syringe 
needle with 0.6 mm diameter (Sterican 0.6 mm × 30 mm; B∣Braun Melsungen AG, 
Germany). The glass column was filled with water to a height of 20 cm, 30 cm, or 40 
cm, respectively. The water column defined the applied pressure on the material. 
Leakage through the pierced membranes was measured by collecting the water in a 
beaker on an analytical balance (AL204, Mettler-Toledo, Switzerland). 
Scheme S2 shows the experimental setup for measurements at pressures between 0.1 
bar and 1.6 bar. A small round piece of APCN/PEE membrane (1.00 cm diameter, 
0.79 cm2) was cut out and placed in a custom-made poly(tetrafluoroethylene) (PTFE) 
adapter. This adapter consisted of two rings with an inner diameter of 0.5 cm and an 
inner metal plate with a hole of 0.2 cm in diameter. It prevented coiling up of the 
membrane and undesired leakage. The adapter was placed in a swinny stainless steel 
syringe filter holder (13 mm; Cat. No. XX3001200; Millipore). A hole was pierced 
into the membrane in dry conditions from the PEE side using a syringe needle with 
0.6 mm diameter. Membranes were pierced after placing the membrane into the filter 
holder device. The filter holder was connected to a glass chromatography column 
(height approx. 65 cm, inner diameter 4 cm, max. pressure 2.5 bar) via a syringe 
adapter so that the APCN faced towards the column. The adapter was composed of 
rubber tubing in which a half-cut 1 ml syringe was inserted on one side with the male 
luer part looking out. The adapter was tightened to the column outlet with a clamp. 
The male luer was connected to the filter holder. The column was then filled to a 
height of 45 cm with water and pressurized with air. A pressure reduction valve with 
manometer (DTG-35, Druck & Temperatur Leitenberger GmbH, Germany) was used 
to regulate and determine the pressure. The manometer was connected with the top 
of the column by a tube. Primary air pressure was set to 2.0 bar. Leakage rates were 
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determined by measuring water flow through the membrane using a beaker and an 
analytical balance (see Figure 2.2.10.).  
 
Figure 2.2.10. Schematic depiction of experimental setup for self-sealing experiments. A membrane 
was placed in a PTFE adapter which was then put into a swinny filter holder. The membranes were 
punctured in this holder by means of a syringe needle. Then, the filter holder was connected with a 
flash chromatography column by a piece of rubber tubing in which a syringe adapter was inserted. 
The column was filled with water and connected to a pressure gas system. The pressure was regulated 
by a needle valve in a manometer. Leaking rate was measured by collecting the water in a glass 
beaker on an analytical balance.  
2.2.4.8 Effect of repetitive drying/wetting cycles on self-sealing 
performance of membranes  
In order to assess the materials self-sealing performance, an APCN/PEE composite 
membrane (PHEA:PDMS 90:10 (w/w), thickness 340 m) was punctured in its dry 
state with a syringe needle (0.6 mm diameter) as described above. Then, the sample 
was wetted at 0.5 bar water pressure and the leakaging rate was measured as 
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described above. After the experiment, the swinny filter holder with inserted PTFE-
adapter and APCN/PEE membrane was disconnected from the water reservoir and 
unscrewed. Remaining water drops were gently removed with a lint-free tissue. The 
PTFE-adapter and the APCN/PEE membrane were kept in the filter holder in order 
to guarantee the same position of the puncture in the next leakage measurement, i.e. 
to perform the experiments at same conditions without any changes in the material’s 
position. To ensure drying of the swollen APCN/PEE, the filter holder was left open 
over night, with the APCN-side exposed to the environment, so that the membrane 
could dry in air at ambient conditions. A gentle airflow from the work place 
ventilation aided the drying process. After over night drying, the filter holder was 
screwed together for the next experiment, connected to the water reservoir and the 
leaking rate at 0.5 bar was measured as described above. The drying/wetting cycle 
was performed five times in total with the same sample. 
2.2.4.9 Water evaporation tests 
Evaporation measurements (air humidity = 50 %, temperature = 23 °C) were 
conducted in parallel with an APCN/PEE-based laminate and a PEE-based reference 
laminate. Evaporation tests were performed using a heating plate (Type 0812, Medax 
Nagel GmbH, Germany) on which the laminates were fixed with self-adhesive tape. 
Samples were tested for leaking prior to evaporation experiments to guarantee that 
water loss is only due to evaporation. Water reservoirs were attached to the inlet 
tubes of the cooling laminates. The reservoirs guaranteed a constant water amount 
within the samples. Syringes with 20 ml content were used as reservoirs. They were 
installed on the same height (7 cm) to ensure an equal hydrostatic pressure in both 
laminates. The laminates were filled with approximately 10 ml water each, the outlet 
tubes were closed by means of a metal clamp for tubing and the evaporation test was 
started by setting the heating plate temperature to 34 °C. Monitoring of evaporation 
started after ca. 0.5 h in order to be sure that the experimental set-up had thermally 
equilibrated. The evaporation of water out of the laminates was monitored by the loss 
of water from the water reservoir. Periodically, the water in the reservoirs was 
refilled. Measurement of surface temperature during evaporation experiments was 
performed using a contactless infrared camera (Optris PI 160, Optris GmbH, 
Germany). The temperature was measured with a rectangular IR spot of 2 cm x 2 cm 
in the center of the membrane, as an average of 3 measurements within 10s. 
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Chapter 3 
3 General conclusions and outlooks 
In the first project described in this work, functional homo and copolymers were 
synthesized from polymerization initiators bound to the interior of a protein cage, the 
thermosome. Prior to the polymerization, the cage was tested for its stability in 
presence of different polymerization reagents. From those tests the polymerization 
conditions within the thermosome were derived. The functionality of the polymers 
can be described by the cationic charges of protonated tertiary amine groups and in 
the copolymers with additional fluorescence of Rhodamine B. The polymerization 
process in the confined space of the cavity of the thermosome was compared with a 
protein that does not have a cage structure. The cationic charges of the polymers 
allowed the interaction with negatively charged biomacromolecules. Thus, the 
polymers acted as anchors. The encapsulation of biomacromolecules was possible, 
because the thermosome has two large pores that are big enough for macromolecules 
(up to 50’000 g mol-1) to enter and leave the cavity. The thermosome-polymer 
conjugates and, in addition, their interaction with biomacromolecules were evaluated 
with different analytical methods like gel electrophoresis, dynamic light scattering 
and transmission electron microscopy. As examples for biomacromolecules, siRNA 
and fluorescent proteins (eYFP and TurboGFP) were selected. Cellular uptake 
studies of complexes of the thermosome-polymer conjugate and fluorescence 
proteins or siRNA were conducted. 
The central findings of this project work are: 
a) ATRP conditions were elaborated in which the protein cage remained stable. 
b) Polymers and copolymers were synthesized by ATRP within the protein cage 
using a grafting from approach from thermosome-bound initiators. 
c) With an increasing monomer-to-initiator ratio the polymers within the cavity of 
the thermosome became larger.   
d) Polymers synthesized within the cavity of the thermosome are smaller than 
those synthesized on albumin under the same conditions. This is most probable 
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due to the cage structure of the thermosome that restricts access of reactants 
into the cavity. 
e) The size of the protein cage did not change when homo or copolymers were 
synthesized within its cavities. This finding shows that polymer chains are 
mainly located within that cavity. Binding of siRNA into the polymer-protein 
conjugate did also not affect the size of the cage, indicating that 
macromolecules were and did not stick to the exterior of the protein cage. 
f) The homopolymer conjugates could entrap siRNA and protect it from fast 
degradation by enzymes. 
g) Besides synthesis of homopolymers, it was possible to synthesize copolymers 
of ionizable methacrylate monomers and fluorescent methacrylate monomers. 
This shows the versatility of the grafting-from-approach, which allows 
synthesizing tailor-made polymer chains with different functionalities.  
h) The homopolymer and copolymer conjugates showed similar cell viability as 
the untreated control cells. Thus, the cage structure shielded the cells from the 
cationic charges of the polymers. 
i) Complex formation with eYFP was possible and the first preliminary results 
show a cell uptake of eYFP, which was complexed with the thermosome 
copolymer conjugate. 
j) The delivery of siRNA with thermosome-homopolymer into U87 cells was 
successful and protein expression could be lowered by gene silencing. 
The presented results allow concluding that with the synthesis of polymers within the 
cavity of a protein cage, it is possible to create nano-transporters that are capable to 
encapsulate or interact with cargo and release it into cells. Customized polymer 
synthesis gives a higher flexibility towards the possible applications. The results will 
help in further advancements in the development of the thermosome-polymer 
conjugates as nano-transporter and can be a source of inspiration for other 
researchers to device protein cage-polymer conjugates as drug delivery vehicles. 
In order to advance the developments of the thermosome-polymer conjugates, further 
investigations should look more in detail of the polymerization process. As observed 
during the experimental work, a high amount of monomers (10’000 - 15’000 per 
initiator) was needed in order to synthesize polymers with longer (approx. 60-160 
monomer units) chains. This is different to a reported work in the field of protein 
cage-polymer conjugates in which longer polymer chains could be synthesized with 
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a lower amount of monomers (250 – 1000 per initiator) by classical ATRP with a 
bipyridine ligand instead of ARGET ATRP.114 Another alternative would be AGET 
ATRP in which just a part of the catalysts is generated by the addition of reducing 
agents.32  
Moreover, the temperature of polymer synthesis might be an important parameter in 
the synthesis of THS-pDMAEMA conjugates. In two samples that were synthesized 
during days, when the average room temperature was 5 °C – 7 °C higher than in the 
results reported herein, an additional band at higher molecular weights (300 000 g 
mol-1) was observed in SDS-PAGE. Those samples formed aggregates (approx. 100 
nm) when incubated with siRNA, whereas samples synthesized at normal room 
temperature did not show this property. In addition, samples synthesized at higher 
temperature showed higher toxicity. The data for the conjugates that were 
synthesized at higher temperature was not included in this thesis, because further 
investigations have to be conducted. Therefore, for further developments of synthesis 
of thermosome-polymer conjugates, the polymerization reaction temperature should 
be taken into account.  
For future ideas, it would be desirable to implement more amino acids (e.g. 
cysteines) on each subunit in the interior to which polymerization initiators can be 
bound. This should allow the synthesis of a higher density of polymers within the 
cavity of the thermosome. A higher amount of positively charged polymer chains 
could possibly bind more negatively charged macromolecules or a higher degree of 
functionalities could be implemented. Moreover, the probability of protruding 
polymer chains interacting with the surrounding (e.g. cells) could possibly be 
lowered.  
In this work, the thermosome was in its apo state, i.e. the cage structure remained 
fully open or half-open in all steps. The cage of the thermosome can be completely 
closed with ATP-derivates (e.g. ATP⦁AlFx).238	The	protection	of	 (e.g.	siRNA)	can	eventually	be	improved	with	a	fully	closed	cage.	
Cell experiments with the conjugates in this thesis were conducted with a cell line 
that was previously shown to uptake thermosome. Other cell lines should be tested in 
order to evaluate the uptake of the thermosome-polymer conjugates and the possible 
influence of protruding polymers on the cellular uptake. 
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The uptake experiments with fluorescent proteins have to be investigated more in 
detail by repeating experiments, adapt the complexation conditions or by changing 
the protein to a different one (e.g. fluorescence labeled horseradish peroxidase or 
tyrosine aminotransferase).  
Since polymers can be synthesized within the cavity depending on the application, 
for entrapment purposes also anionic polymer could be synthesized that allow the 
encapsulation of macromolecules with positive charges at physiological pH (e.g. 
anti-HIV and anti-tumor protein MAP30, M ≈ 30’000 g mol-1, pI = 9.12).529-531 
In the second project of this dissertation, a thin semipermeable membrane (poly(ester 
ether)) was equipped with a water-swellable polymer layer (amphiphilic conetwork) 
in order to add a self-closing feature to the composite material without hampering 
water vapor evaporation through it. Prior to composite material synthesis, the 
poly(ester ether membrane)  was functionalized with methacrylate groups for 
covalent binding with the amphiphilic conetwork. The synthesized composite 
membrane was tested for its water-swellability and self-sealing properties at over 
pressures up to 1.6 bar.  With the composite membrane a laminate was fabricated in 
order to show its water evaporation capability. This capability is important in e.g. 
medical applications.477  
The central findings of this project are: 
a) The higher the content of hydrophilic monomers the higher the swelling of the 
amphiphilic conetwork in water. 
b) The self-closing property is related to the thickness of the amphiphilic 
conetwork and becomes more pronounced with thicker amphiphilic polymer 
conetworks. 
c) A punctured membrane keeps its full self-closing property even after five 
drying/wetting cycles. 
d) Water vapour could evaporate through the membrane. 
 
The presented results allow concluding that by the attachment of a polymer layer 
onto a thin climate membrane, properties can be added that extend the field of 
possible applications and make the material more durable. The developed membrane 
showed self-closing properties at overpressures to at least 1.6 bar, therefore it could 
be applied in fields where such features are necessary (e.g. medical applications, 
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membrane filtration). The generated results should give an example of composite 
material development and how to improve an already existing material by the 
addition of another. 
The next step in further development of this composite membrane is to implement 
self-healing properties and keeping the water vapour evaporation feature. This can be 
done by the integration of groups that form donor-acceptor interactions (e.g. nucleic 
acids, boronate-catechol complexation533). Another idea is to integrate subunits of 
viruses or other protein cages into the polymer network material. The interaction of 
virus subunits is very strong and they have to withstand internal pressures of the 
DNA of approx. 50 bar when the virus is fully packed with DNA.534 Thus, the 
integration of virus-like particles or viral subunits into an amphiphilic conetwork 
could add self-healing property. 
   Chapter 4 
 
150 
Chapter 4 
4 Bibliography 
(1) Klok, H. A. Peptide/Protein-Synthetic Polymer Conjugates: Quo Vadis. Macromolecules 
 2009, 42, 7990-8000. 
(2) Grover, G. N.; Maynard, H. D. Protein-polymer conjugates: synthetic approaches by 
 controlled radical polymerizations and interesting applications. Curr. Opin. Chem. Biol. 
 2010, 14, 818-827. 
(3) Jung, B.; Theato, P. Chemical Strategies for the Synthesis of Protein-Polymer Conjugates. 
 Adv. Polym. Sci. 2013, 253, 37-70. 
(4) Abuchowski, A.; McCoy, J. R.; Palczuk, N. C.; van Es, T.; Davis, F. F. Effect of covalent 
 attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver 
 catalase. J. Biol. Chem. 1977,252,3582-3586. 
(5) Grace, M. J.; Lee, S.; Bradshaw, S.; Chapman, J.; Spond, J.; Cox, S.; Delorenzo, M.; 
 Brassard, D.; Wylie, D.; Cannon-Carlson, S.; Cullen, C.; Indelicato, S.; Voloch, M.; Bordens, 
 R. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha 
 antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J. Biol. 
 Chem. 2005, 280, 6327-6336. 
(6) Pelegri-O'Day, E. M.; Lin, E. W.; Maynard, H. D. Therapeutic protein-polymer conjugates: 
 advancing beyond PEGylation. J. Am. Chem. Soc. 2014, 136, 14323-14332. 
(7) Keefe, A. J.; Jiang, S. Y. Poly(zwitterionic)protein conjugates offer increased stability 
 without  sacrificing binding affinity or bioactivity. Nat. Chem. 2012, 4, 60-64. 
(8) Cummings, C.; Murata, H.; Koepsel, R.; Russell, A. J. Dramatically Increased pH and  
 Temperature Stability of Chymotrypsin Using Dual Block Polymer-Based Protein 
 Engineering. Biomacromolecules 2014, 15, 763-771. 
(9) Thilakarathne, V.; Briand, V. A.; Zhou, Y. X.; Kasi, R. M.; Kumar, C. V. Protein Polymer 
 Conjugates: Improving the Stability of Hemoglobin with Poly(acrylic acid). Langmuir 2011, 
 27, 7663-7671. 
(10) Gauthier, M. A.; Klok, H. A. Polymer-protein conjugates: an enzymatic activity perspective. 
 Polym. Chem. 2010, 1, 1352-1373. 
(11) De, P.; Li, M.; Gondi, S. R.; Sumerlin, B. S. Temperature-regulated activity of responsive 
 polymer-protein conjugates prepared by grafting-from via RAFT polymerization. J. Am. 
 Chem.  Soc. 2008, 130, 11288-11289. 
(12) Fernandez-Lafuente, R. Stabilization of multimeric enzymes: Strategies to prevent subunit 
 dissociation. Enzyme and Microb. Technol. 2009, 45, 405-418. 
(13) Schlick, T. L.; Ding, Z.; Kovacs, E. W.; Francis, M. B. Dual-Surface Modification of the 
 Tobacco Mosaic Virus. J. Am. Chem. Soc. 2005, 127, 3718-3723. 
(14) Mabrouk, P. A.: The Use of Poly(ethylene glycol)-Enzymes in Nonaqueous Enzymology. In 
 Poly(ethylene glycol); ACS Symposium Series 680; American Chemical Society, 1997; Vol. 
 680; pp 118-133. 
(15) Cobo, I.; Li, M.; Sumerlin, B. S.; Perrier, S. Smart hybrid materials by conjugation of 
 responsive polymers to biomacromolecules. Nat. Mat. 2015, 14, 143-159. 
(16) Lu, H.; Wang, D.; Kazane, S.; Javahishvili, T.; Tian, F.; Song, F.; Sellers, A.; Barnett, B.; 
 Schultz, P. G. Site-specific antibody-polymer conjugates for siRNA delivery. J. Am. Chem. 
 Soc. 2013, 135, 13885-13891. 
(17) Torchilin, V. P.; Lukyanov, A. N. Peptide and protein drug delivery to and into tumors: 
 challenges and solutions. Drug Discovery Today 2003, 8, 259-266. 
(18) Boyer, C.; Huang, X.; Whittaker, M. R.; Bulmus, V.; Davis, T. P. An overview of protein-
 polymer particles. Soft Matter 2011, 7, 1599-1614. 
(19) Rosendahl, M. S.; Doherty, D. H.; Smith, D. J.; Carlson, S. J.; Chlipala, E. A.; Cox, G. N. A 
 long-acting, highly potent interferon alpha-2 conjugate created using site-specific 
 PEGylation. Bioconjug. Chem. 2005, 16, 200-207. 
Chapter 4 
 
151 
(20) Hirao, A.; Goseki, R.; Ishizone, T. Advances in Living Anionic Polymerization: From 
 Functional Monomers, Polymerization Systems, to Macromolecular Architectures. 
 Macromolecules 2014, 47, 1883-1905. 
(21) Aoshima, S.; Kanaoka, S. A Renaissance in Living Cationic Polymerization. Chem. Rev. 
 2009, 109, 5245-5287. 
(22) Matyjaszewski, K. Atom Transfer Radical Polymerization (ATRP): Current Status and 
 Future Perspectives. Macromolecules 2012, 45, 4015-4039. 
(23) Hill, M. R.; Carmean, R. N.; Sumerlin, B. S. Expanding the Scope of RAFT Polymerization: 
 Recent Advances and New Horizons. Macromolecules 2015, 48, 5459-5469. 
(24) Guegain, E.; Guillaneuf, Y.; Nicolas, J. Nitroxide-Mediated Polymerization of Methacrylic 
 Esters: Insights and Solutions to a Long-Standing Problem. Macrom. Rapid Commun. 2015, 
 36, 1227-1247. 
(25) Aliferis, T.; Iatrou, H.; Hadjichristidis, N. Living polypeptides. Biomacromolecules 2004, 5, 
 1653-1656. 
(26) Huang, J.; Rempel, G. L. Ziegler-Natta Catalysts for Olefin Polymerization - Mechanistic 
 Insights from Metallocene Systems. Prog. Polym. Sci. 1995, 20, 459-526. 
(27) Bielawski, C. W.; Grubbs, R. H. Living ring-opening metathesis polymerization. Prog. 
 Polym. Sci. 2007, 32, 1-29. 
(28) Zhao, W. G.; Liu, F.; Chen, Y.; Bai, J.; Gao, W. P. Synthesis of well-defined protein-polymer 
 conjugates for biomedicine. Polymer 2015, 66, A1-A10. 
(29) Wallat, J. D.; Rose, K. A.; Pokorski, J. K. Proteins as substrates for controlled radical 
 polymerization. Polym. Chem. 2014, 5, 1545-1558. 
(30) Bruns, N.; Pustelny, K.; Bergeron, L. M.; Whitehead, T. A.; Clark, D. S. Mechanical 
 Nanosensor Based on FRET within a Thermosome: Damage-Reporting Polymeric Materials. 
 Angew. Chem., Int. Ed. 2009, 48, 5666-5669. 
(31) Thordarson, P.; Le Droumaguet, B.; Velonia, K. Well-defined protein- polymer conjugates--
 synthesis and potential applications. Appl. Microbiol. Biotechnol. 2006, 73, 243-254. 
(32) Averick, S.; Simakova, A.; Park, S.; Konkolewicz, D.; Magenau, A. J. D.; Mehl, R. A.; 
 Matyjaszewski, K. ATRP under Biologically Relevant Conditions: Grafting from a Protein. 
 ACS Macro Lett. 2012, 1, 6-10. 
(33) Moad, G. Mechanism and Kinetics of Dithiobenzoate-Mediated RAFT Polymerization – 
 Status of the Dilemma. Macrom. Chem. Phys. 2014, 215, 9-26. 
(34) Baskaran, D.; Müller, A. H. E.: Anionic Vinyl Polymerization. In Controlled and Living 
 Polymerizations; Wiley-VCH Verlag GmbH & Co. KGaA, 2009; pp 1-56. 
(35) Averick, S.; Simakova, A.; Park, S.; Konkolewicz, D.; Magenau, A. J. D.; Mehl, R. A.; 
 Matyjaszewski, K. ATRP under Biologically Relevant Conditions: Grafting from a Protein. 
 ACS Macro Lett. 2011, 1, 6-10. 
(36) Sumerlin, B. S. Proteins as Initiators of Controlled Radical Polymerization: Grafting-from 
 via ATRP and RAFT. ACS Macro Lett. 2011, 1, 141-145. 
(37) Liu, J. Q.; Bulmus, V.; Herlambang, D. L.; Barner-Kowollik, C.; Stenzel, M. H.; Davis, T. P. 
 In situ formation of protein-polymer conjugates through reversible addition fragmentation 
 chain transfer polymerization. Angew. Chem., Int. Ed. 2007, 46, 3099-3103. 
(38) Lele, B. S.; Murata, H.; Matyjaszewski, K.; Russell, A. J. Synthesis of Uniform 
 Protein−Polymer Conjugates. Biomacromolecules 2005, 6, 3380-3387. 
(39) Matyjaszewski, K.; Tsarevsky, N. V. Macromolecular Engineering by  Atom Transfer 
 Radical Polymerization. J. Am. Chem. Soc. 2014, 136, 6513-6533. 
(40) Boyer, C.; Bulmus, V.; Davis, T. P.; Ladmiral, V.; Liu, J.; Perrier, S. Bioapplications of 
 RAFT Polymerization. Chem. Rev. 2009, 109, 5402-5436. 
(41) Tsarevsky, N. V.; Matyjaszewski, K. "Green" atom transfer radical polymerization: From 
 process design to preparation of well-defined environmentally friendly polymeric materials. 
 Chem. Rev. 2007, 107, 2270-2299. 
(42) Haas, M.; Solari, E.; Nguyen, Q. T.; Gautier, S.; Scopelliti, R.; Severin, K. A bimetallic 
 ruthenium complex as a catalyst precursor for the atom transfer radical polymerization of 
 methacrylates at ambient temperature. Adv. Synth. Catal. 2006, 348, 439-442. 
(43) Moineau, G.; Minet, M.; Dubois, P.; Teyssie, P.; Senninger, T.; Jerome, R. Controlled radical 
 polymerization of (meth)acrylates by ATRP with NiBr2(PPh3)(2) as catalyst. 
 Macromolecules  1999, 32, 27-35. 
(44) Tsarevsky, N. V.; Matyjaszewski, K. “Green” Atom Transfer Radical  Polymerization: From 
 Process Design to Preparation of Well-Defined Environmentally Friendly Polymeric 
 Materials. Chem. Rev. 2007, 107, 2270-2299. 
(45) Flemming, C. A.; Trevors, J. T. Copper Toxicity and Chemistry in the Environment - a 
 Review. Water. Air. Soil. Poll. 1989, 44, 143-158. 
   Chapter 4 
 
152 
(46) Simakova, A.; Averick, S. E.; Konkolewicz, D.; Matyjaszewski, K. Aqueous ARGET ATRP. 
 Macromolecules 2012, 45, 6371-6379. 
(47) Keddie, D. J. A guide to the synthesis of block copolymers using reversible-addition 
 fragmentation chain transfer (RAFT) polymerization. Chem. Soc. Rev. 2014, 43, 496-505. 
(48) Boyer, C.; Bulmus, V.; Liu, J.; Davis, T. P.; Stenzel, M. H.; Barner-Kowollik, C. Well-
 defined protein-polymer conjugates via in situ RAFT polymerization. J. Am. Chem. Soc. 
 2007, 129, 7145-7154. 
(49) Chiefari, J.; Chong, Y. K.; Ercole, F.; Krstina, J.; Jeffery, J.; Le, T. P. T.; Mayadunne, R. T. 
 A.; Meijs, G. F.; Moad, C. L.; Moad, G.; Rizzardo, E.; Thang, S. H. Living free-radical 
 polymerization by reversible addition-fragmentation chain transfer: The RAFT process. 
 Macromolecules 1998, 31, 5559-5562. 
(50) Mayadunne, R. T. A.; Rizzardo, E.; Chiefari, J.; Chong, Y. K.; Moad, G.; Thang, S. H. 
 Living  radical polymerization with reversible addition-fragmentation chain transfer (RAFT 
 polymerization) using dithiocarbamates as chain transfer agents. Macromolecules 1999, 32, 
 6977-6980. 
(51) Vriezema, D. M.; Aragones, M. C.; Elemans, J. A. A. W.; Cornelissen, J. J. L. M.; Rowan, A. 
 E.; Nolte, R. J. M. Self-Assembled Nanoreactors. Chem. Rev. 2005, 105, 1445-1489. 
(52) de la Escosura, A.; Nolte, R. J. M.; Cornelissen, J. J. L. M. Viruses and protein cages as 
 nanocontainers and nanoreactors. J. Mat. Chem. 2009, 19, 2274. 
(53) Kim, K. T.; Meeuwissen, S. A.; Nolte, R. J. M.; van Hest, J. C. M. Smart Nanocontainers and 
 Nanoreactors. Nanoscale 2010, 2, 844-858. 
(54) Renggli, K.; Baumann, P.; Langowska, K.; Onaca, O.; Bruns, N.; Meier, W. Selective and 
 Responsive Nanoreactors. Adv. Funct. Mater. 2011, 21, 1241-1259. 
(55) Tanner, P.; Baumann, P.; Enea, R.; Onaca, O.; Palivan, C.; Meier, W. Polymeric Vesicles: 
 From Drug Carriers to Nanoreactors and Artificial Organelles. Acc. Chem. Res. 2011, 44, 
 1039-1049. 
(56) Palivan, C. G.; Fischer-Onaca, O.; Delcea, M.; Itel, F.; Meier, W. Protein-Polymer 
 Nanoreactors for Medical Applications. Chem. Soc. Rev. 2012, 41, 2800-2823. 
(57) Marguet, M.; Bonduelle, C.; Lecommandoux, S. Multicompartmentalized polymeric 
 systems: towards biomimetic cellular structure and function. Chem. Soc. Rev. 2013, 42, 512-
 529. 
(58) Maity, B.; Fujita, K.; Ueno, T. Use of the confined spaces of apo-ferritin and virus capsids as 
 nanoreactors for catalytic reactions. Curr. Op. Chem. Biol. 2015, 25, 88-97. 
(59) Priebe, M.; Fromm, K. M. Nanorattles or Yolk-Shell Nanoparticles-What Are They, How 
 Are They Made, and What Are They Good For? Chem. Eur. J. 2015, 21, 3854-3874. 
(60) Li, S.; Lee, A. R.; Park, S. J.; Kim, J. H. Preparation of ZnSe Quantum Dots by Ferritin. Sci. 
 Adv. Mater. 2014, 6, 2590-2594. 
(61) Renggli, K.; Nussbaumer, M. G.; Urbani, R.; Pfohl, T.; Bruns, N. A Chaperonin as Protein 
 Nanoreactor for Atom-Transfer Radical Polymerization. Angew. Chem., Int. Ed. 2014, 53, 
 1443-1447. 
(62) Abe, S.; Hirata, K.; Ueno, T.; Morino, K.; Shimizu, N.; Yamamoto, M.; Takata, M.; 
 Yashima, E.; Watanabe, Y. Polymerization of Phenylacetylene by Rhodium Complexes 
 within a Discrete Space of apo-Ferritin. J. Am. Chem. Soc. 2009, 131, 6958-6960. 
(63) Reichhardt, C.; Uchida, M.; O'Neil, A.; Li, R.; Prevelige, P. E.; Douglas, T. Templated 
 assembly of organic-inorganic materials using the core shell structure of the P22 
 bacteriophage. Chem. Commun. 2011, 47, 6326-6328. 
(64) Priebe, M.; Fromm, K. M. One-Pot Synthesis and Catalytic Properties of Encapsulated Silver 
 Nanoparticles in Silica Nanocontainers. Part. Part. Syst. Charact. 2014, 31, 645-651. 
(65) Tanner, P.; Onaca, O.; Balasubramanian, V.; Meier, W.; Palivan, C. G. Enzymatic Cascade 
 Reactions inside Polymeric Nanocontainers: A Means to Combat Oxidative Stress. Chemistry 
 2011, 17, 4552-4560. 
(66) Gunkel-Grabole, G.; Sigg, S.; Lomora, M.; Lorcher, S.; Palivan, C. G.; Meier, W. P. 
 Polymeric 3D nano-architectures for transport and delivery of therapeutically relevant 
 biomacromolecules. Biomater. Sci. 2014, 3, 25-40. 
(67) Brinkhuis, R. P.; Rutjes, F. P. J. T.; van Hest, J. C. M. Polymeric vesicles in biomedical 
 applications. Polym. Chem. 2011, 2, 1449-1462. 
(68) Egli, S.; Schlaad, H.; Bruns, N.; Meier, W. Functionalization of Block Copolymer Vesicle 
 Surfaces. Polymers 2011, 3, 252-280. 
(69) Mellal, D.; Zumbuehl, A. Exit-strategies - smart ways to release phospholipid vesicle cargo. 
 J. Mater. Chem. B 2014, 2, 247-252. 
(70) Skirtach, A. G.; Yashchenok, A. M.; Mohwald, H. Encapsulation, release and applications of 
 LbL polyelectrolyte multilayer capsules. Chem. Commun. 2011, 47, 12736-12746. 
Chapter 4 
 
153 
(71) Heddle, J. G. Protein cages, rings and tubes: useful components of future nanodevices? 
 Nanotechnol., Sci. Appl. 2008, 1, 67-78. 
(72) Uchida, M.; Klem, M. T.; Allen, M.; Suci, P.; Flenniken, M.; Gillitzer, E.; Varpness, Z.; 
 Liepold, L. O.; Young, M.; Douglas, T. Biological Containers: Protein Cages as 
 Multifunctional Nanoplatforms. Adv. Mater. 2007, 19, 1025-1042. 
(73) Bode, S. A.; Minten, I. J.; Nolte, R. J.; Cornelissen, J. J. Reactions inside nanoscale protein 
 cages. Nanoscale 2011, 3, 2376-2389. 
(74) Ma, Y.; Nolte, R. J. M.; Cornelissen, J. J. L. M. Virus-based nanocarriers for drug delivery. 
 Adv. Drug Delivery Rev. 2012, 64, 811-825. 
(75) Molino, N. M.; Wang, S.-W. Caged protein nanoparticles for drug delivery. Curr. Opin. 
 Biotechnol. 2014, 28, 75-82. 
(76) Lai, Y.-T.; Reading, E.; Hura, G. L.; Tsai, K.-L.; Laganowsky, A.; Asturias, F. J.; Tainer, J. 
 A.; Robinson, C. V.; Yeates, T. O. Structure of a designed protein cage that self-
 assembles into a  highly porous cube. Nat. Chem. 2014, 6, 1065-1071. 
(77) Jutz, G.; van Rijn, P.; Miranda, B. S.; Boker, A. Ferritin: A Versatile Building Block for 
 Bionanotechnology. Chem. Rev. 2015, 115, 1653-1701. 
(78) Putri, R. M.; Cornelissen, J. J. L. M.; Koay, M. S. T. Self-Assembled Cage-Like Protein 
 Structures. ChemPhysChem 2015, 16, 911-918. 
(79) Kushner, D. J. Self-Assembly of Biological Structures. Bacteriol. Rev. 1969, 33, 302-&. 
(80) Kaiser, C. R.; Flenniken, M. L.; Gillitzer, E.; Harmsen, A. L.; Jutila, M. A.; Douglas, T.; 
 Young, M. J. Biodistribution studies of protein cage nanoparticles demonstrate broad tissue 
 distribution and rapid clearance in vivo. Int. J. Nanomedicine 2007, 2, 715-733. 
(81) Maham, A.; Tang, Z.; Wu, H.; Wang, J.; Lin, Y. Protein-based nanomedicine platforms for 
 drug delivery. Small 2009, 5, 1706-1721. 
(82) Molino, N. M.; Wang, S. W. Caged protein nanoparticles for drug delivery. Curr. Opin. 
 Biotechnol. 2014, 28, 75-82. 
(83) Falkner, J. C.; Turner, M. E.; Bosworth, J. K.; Trentler, T. J.; Johnson, J. E.; Lin, T. W.; 
 Colvin, V. L. Virus crystals as nanocomposite scaffolds. J. Am. Chem. Soc.2005, 127, 5274-
 5275. 
(84) Jaafar, M.; Aljabali, A. A. A.; Berlanga, I.; Mas-Balleste, R.; Saxena, P.; Warren, S.; 
 Lomonossoff, G. P.; Evans, D. J.; de Pablo, P. J. Structural Insights into Magnetic Clusters 
 Grown Inside Virus Capsids. ACS Appl. Mater. & Interfaces 2014, 6, 20936-20942. 
(85) Aljabali, A. A. A.; Barclay, J. E.; Cespedes, O.; Rashid, A.; Staniland, S. S.; Lomonossoff, 
 G. P.; Evans, D. J. Charge Modified Cowpea Mosaic Virus Particles for Templated 
 Mineralization. Adv. Funct. Mater. 2011, 21, 4137-4142. 
(86) Kumar, K.; Doddi, S. K.; Arunasree, M. K.; Paik, P. CPMV-induced synthesis of hollow 
 mesoporous SiO2 nanocapsules with excellent performance in drug delivery. Dalton 
 Transactions 2015, 44, 4308-4317. 
(87) Blum, A. S.; Soto, C. M.; Wilson, C. D.; Cole, J. D.; Kim, M.; Gnade, B.; Chatterji, A.; 
 Ochoa, W. F.; Lin, T. W.; Johnson, J. E.; Ratna, B. R. Cowpea mosaic virus as a scaffold for 
 3-D patterning of gold nanoparticles. Nano Lett. 2004, 4, 867-870. 
(88) Douglas, T.; Young, M. Virus particles as templates for materials synthesis. Adv. Mater. 
 1999, 11, 679-681. 
(89) Patterson, D. P.; Schwarz, B.; Waters, R. S.; Gedeon, T.; Douglas, T. Encapsulation of an 
 Enzyme Cascade within the Bacteriophage P22 Virus-Like Particle. ACS Chem. Biol. 2014, 
 9, 359-365. 
(90) Glasgow, J. E.; Capehart, S. L.; Francis, M. B.; Tullman-Ercek, D. Osmolyte-Mediated 
 Encapsulation of Proteins inside MS2 Viral Capsids. ACS Nano 2012, 6, 8658-8664. 
(91) Capehart, S. L.; Coyle, M. P.; Glasgow, J. E.; Francis, M. B. Controlled integration of gold 
 nanoparticles and organic fluorophores using synthetically modified MS2 viral capsids. 
 Abstr. Pap. Am. Chem. Soc. 2013, 245. 
(92) Capek, I. Viral nanoparticles, noble metal decorated viruses and their nanoconjugates. Adv. 
 Coll. Interf. Sci. 2015, 222, 119-134. 
(93) Ludwig, C.; Wagner, R. Virus-like particles-universal molecular toolboxes. Curr. Opin. 
 Biotechnol. 2007, 18, 537-545. 
(94) Teunissen, E. A.; de Raad, M.; Mastrobattista, E. Production and biomedical applications of 
 virus-like particles derived from polyomaviruses. J. Controlled Release 2013, 172, 305-321. 
(95) Garcea, R. L.; Gissmann, L. Virus-like particles as vaccines and vessels for the delivery of 
 small molecules. Curr. Opin. Biotechnol. 2004, 15, 513-517. 
(96) Steinmetz, N. F. Viral nanoparticles as platforms for next-generation therapeutics and 
 imaging  devices. Nanomedicine: Nanotechology, Biology, Medicine 2010, 6, 634-641. 
   Chapter 4 
 
154 
(97) Waehler, R.; Russell, S. J.; Curiel, D. T. Engineering targeted viral vectors for gene therapy. 
 Nat. Rev. Gen. 2007, 8, 573-587. 
(98) Choi, K.-m.; Choi, S.-H.; Jeon, H.; Kim, I.-S.; Ahn, H. J. Chimeric Capsid Protein as a 
 Nanocarrier for siRNA Delivery: Stability and Cellular Uptake of Encapsulated siRNA. ACS 
 Nano 2011, 5, 8690-8699. 
(99) Lilavivat, S.; Sardar, D.; Jana, S.; Thomas, G. C.; Woycechowsky, K. J. In Vivo 
 Encapsulation of Nucleic Acids Using an Engineered Nonviral Protein Capsid. J. Am. Chem. 
 Soc. 2012, 134, 13152-13155. 
(100) Brown, S. D.; Fiedler, J. D.; Finn, M. G. Assembly of Hybrid Bacteriophage Qβ Virus-like 
 Particles. Biochemistry 2009, 48, 11155-11157. 
(101) Schoonen, L.; van Hest, J. C. M. Functionalization of protein-based nanocages for drug 
 delivery  applications. Nanoscale 2014, 6, 7124-7141. 
(102) Lee, L. A.; Niu, Z.; Wang, Q. Viruses and virus-like protein assemblies—Chemically 
 programmable nanoscale building blocks. Nano Res. 2009, 2, 349-364. 
(103) Strable, E.; Finn, M. G.: Chemical Modification of Viruses and Virus- Like Particles. In Curr 
 Top Microbiol; Manchester, M., Steinmetz, N., Eds.; Curr. Top. . Microbiol. Immunol.; 
 Springer Berlin Heidelberg, 2009; Vol. 327; pp 1-21. 
(104) Lee, L. A.; Wang, Q. Adaptations of nanoscale viruses and other protein cages for medical 
 applications. Nanomedicine : Nanotechnology, Biology, Medicine 2006, 2, 137-149. 
(105) Douglas, T.; Young, M. Viruses: making friends with old foes. Science 2006, 312, 873-875. 
(106) Zhang, J.; Baker, M. L.; Schroder, G. F.; Douglas, N. R.; Reissmann, S.; Jakana, J.; 
 Dougherty, M.; Fu, C. J.; Levitt, M.; Ludtke, S. J.; Frydman, J.; Chiu, W. Mechanism of 
 folding chamber  closure in a group II chaperonin. Nature 2010, 463, 379-383. 
(107) Shan, L.; Cui, S.; Du, C.; Wan, S.; Qian, Z.; Achilefu, S.; Gu, Y. A paclitaxel-conjugated 
 adenovirus vector for targeted drug delivery for tumor therapy. Biomaterials 2012, 33, 146-
 162. 
(108) Moon, H.; Lee, J.; Min, J.; Kang, S. Developing Genetically Engineered Encapsulin Protein 
 Cage Nanoparticles as a Targeted Delivery Nanoplatform. Biomacromolecules 2014, 15, 
 3794-3801. 
(109) Koudelka, K. J.; Ippoliti, S.; Medina, E.; Shriver, L. P.; Trauger, S. A.; Catalano, C. E.; 
 Manchester, M. Lysine Addressability and Mammalian Cell Interactions of Bacteriophage λ 
 Procapsids. Biomacromolecules 2013, 14, 4169-4176. 
(110) Zhen, Z.; Tang, W.; Chen, H.; Lin, X.; Todd, T.; Wang, G.; Cowger, T.; Chen, X.; Xie, J. 
 RGD-Modified Apoferritin Nanoparticles for Efficient Drug Delivery to Tumors. ACS Nano 
 2013, 7, 4830-4837. 
(111) Qazi, S.; Liepold, L. O.; Abedin, M. J.; Johnson, B.; Prevelige, P.; Frank, J. A.; Douglas, T. 
 P22 viral capsids as nanocomposite high-relaxivity MRI contrast agents. Mol. Pharm. 2013, 
 10, 11-17. 
(112) Toita, R.; Murata, M.; Abe, K.; Narahara, S.; Piao, J. S.; Kang, J.-H.; Ohuchida, K.; 
 Hashizume, M. Biological evaluation of protein nanocapsules containing doxorubicin. Int. J. 
 Nanomed. 2013,  8, 1989-1999. 
(113) Usselman, R. J.; Qazi, S.; Aggarwal, P.; Eaton, S. S.; Eaton, G. R.; Russek, S.; Douglas, T. 
 Gadolinium-Loaded Viral Capsids as Magnetic Resonance Imaging Contrast Agents. Appl. 
 Magn. Reson. 2015, 46, 349-355. 
(114) Hovlid, M. L.; Lau, J. L.; Breitenkamp, K.; Higginson, C. J.; Laufer, B.; Manchester, M.; 
 Finn, M. G. Encapsidated Atom-Transfer Radical Polymerization in Qβ Virus-like 
 Nanoparticles. ACS Nano 2014, 8, 8003-8014. 
(115) Qazi, S.; Uchida, M.; Usselman, R.; Shearer, R.; Edwards, E.; Douglas, T. Manganese(III) 
 porphyrins complexed with P22 virus-like particles as T1-enhanced contrast agents for 
 magnetic resonance imaging. JBIC 2014, 19, 237-246. 
(116) Moradi, M.; Li, Z.; Qi, J.; Xing, W.; Xiang, K.; Chiang, Y.-M.; Belcher, A. M. Improving the 
 Capacity of Sodium Ion Battery Using a Virus-Templated Nanostructured Composite 
 Cathode. Nano Lett. 2015, 15, 2917-2921. 
(117) Allen, M.; Bulte, J. W. M.; Liepold, L.; Basu, G.; Zywicke, H. A.; Frank, J. A.; Young, M.; 
 Douglas, T. Paramagnetic viral nanoparticles as potential high-relaxivity magnetic resonance 
 contrast agents. Mag. Res. Med. 2005, 54, 807-812. 
(118) Flenniken, M. L.; Liepold, L. O.; Crowley, B. E.; Willits, D. A.; Young, M. J.; Douglas, T. 
 Selective attachment and release of a chemotherapeutic agent from the interior of a protein 
 cage architecture. Chem. Commun. 2005, 447-449. 
(119) Liepold, L.; Anderson, S.; Willits, D.; Oltrogge, L.; Frank, J. A.; Douglas, T.; Young, M. 
 Viral capsids as MRI contrast agents. Mag. Res. Med. 2007, 58, 871-879. 
Chapter 4 
 
155 
(120) Barnhill, H. N.; Claudel-Gillet, S.; Ziessel, R.; Charbonniere, L. J.; Wang, Q. Prototype 
 protein assembly as scaffold for time-resolved fluoroimmuno assays. J. Am. Chem. Soc. 
 2007, 129, 7799-7806. 
(121) Gillitzer, E.; Willits, D.; Young, M.; Douglas, T. Chemical modification of a viral cage for 
 multivalent presentation. Chem. Commun. 2002, 2390-2391. 
(122) Lee, W.; Seo, J.; Kwak, S.; Park, E. J.; Na, D. H.; Kim, S.; Lee, Y. M.; Kim, I. S.; Bae, J. S. 
 A Double-Chambered Protein Nanocage Loaded with Thrombin Receptor Agonist Peptide 
 (TRAP) and gamma-Carboxyglutamic Acid of Protein C (PC-Gla) for Sepsis Treatment. Adv. 
 Mater. 2015, 27, 6637-6643. 
(123) Uchida, M.; Flenniken, M. L.; Allen, M.; Willits, D. A.; Crowley, B. E.; Brumfield, S.; 
 Willis, A. F.; Jackiw, L.; Jutila, M.; Young, M. J.; Douglas, T. Targeting of cancer cells with 
 ferrimagnetic ferritin cage nanoparticles. J. Am. Chem. Soc. 2006, 128, 16626-16633. 
(124) Anand, P.; O'Neil, A.; Lin, E.; Douglas, T.; Holford, M. Tailored delivery of analgesic 
 ziconotide across a blood brain barrier model using viral nanocontainers. Sci. Rep. 2015, 
 5, 1-10. 
(125) Uchida, M.; Kosuge, H.; Terashima, M.; Willits, D. A.; Liepold, L. O.; Young, M. J.; 
 McConnell, M. V.; Douglas, T. Protein Cage Nanoparticles Bearing the LyP-1 Peptide for 
 Enhanced Imaging of Macrophage-Rich Vascular Lesions. ACS Nano 2011, 5, 2493-2502. 
(126) Toita, R.; Murata, M.; Tabata, S.; Abe, K.; Narahara, S.; Piao, J. S.; Kang, J. H.; Hashizume, 
 M. Development of Human Hepatocellular Carcinoma Cell-Targeted Protein Cages. 
 Bioconjug. Chem. 2012, 23, 1494-1501. 
(127) Luo, Y.; Wang, X.; Du, D.; Lin, Y. Hyaluronic acid-conjugated apoferritin nanocages for 
 lung cancer targeted drug delivery. Biomat. Sci. 2015, 3, 1386-1394. 
(128) Suci, P.; Kang, S.; Gmür, R.; Douglas, T.; Young, M. Targeted Delivery of a Photosensitizer 
 to Aggregatibacter actinomycetemcomitans Biofilm. Antimicrob. Agents Chemother. 2010, 
 54, 2489-2496. 
(129) Schwarz, B.; Madden, P.; Avera, J.; Gordon, B.; Larson, K.; Miettinen, H. M.; Uchida, M.; 
 LaFrance, B.; Basu, G.; Rynda-Apple, A.; Douglas,  T. Symmetry Controlled, Genetic 
 Presentation of Bioactive Proteins on the P22 Virus-like Particle Using an External 
 Decoration Protein. ACS Nano 2015, 9, 9134-9147. 
(130) Stephanopoulos, N.; Tong, G. J.; Hsiao, S. C.; Francis, M. B. Dual-Surface Modified Virus 
 Capsids for Targeted Delivery of Photodynamic Agents to Cancer Cells. ACS Nano 2010, 4, 
 6014-6020. 
(131) Love, A. J.; Makarov, V.; Yaminsky, I.; Kalinina, N. O.; Taliansky, M. E. The use of tobacco 
 mosaic virus and cowpea mosaic virus for the production of novel metal nanomaterials. 
 Virology 2014, 449, 133-139. 
(132) Courchesne, N. M. D.; Klug, M. T.; Huang, K. J.; Weidman, M. C.; Cantu, V. J.; Chen, P. 
 Y.; Kooi, S. E.; Yun, D. S.; Tisdale, W. A.; Fang, N. X.; Belcher, A. M.; Hammond, P. T. 
 Constructing Multifunctional Virus-Templated Nanoporous Composites for Thin Film Solar 
 Cells: Contributions of Morphology and Optics to Photocurrent Generation. J. Phys. Chem. C 
 2015, 119, 13987-14000. 
(133) Ueno, T.; Suzuki, M.; Goto, T.; Matsumoto, T.; Nagayama, K.; Watanabe, Y. Size-selective 
  olefin hydrogenation by a Pd nanocluster provided in an apo-ferritin cage. Angew. Chem., 
  Int. Ed. 2004, 43, 2527-2530. 
(134) Patterson, D. P.; Schwarz, B.; Waters, R. S.; Gedeon, T.; Douglas, T. Encapsulation of an 
  Enzyme Cascade within the Bacteriophage P22 Virus-Like Particle. ACS Chem. Biol. 2013, 
  9, 359-365. 
(135) Glasgow, J. E.; Asensio, M. A.; Jakobson, C. M.; Francis, M. B.; Tullman-Ercek, D.  
  Influence of Electrostatics on Small Molecule Flux through a Protein Nanoreactor. ACS  
  Synth. Biol. 2015, 4, 1011-1019. 
(136) Patterson, D. P.; Prevelige, P. E.; Douglas, T. Nanoreactors by Programmed Enzyme  
  Encapsulation Inside the Capsid of the Bacteriophage P22. ACS Nano 2012, 6, 5000-5009. 
(137) Meldrum, F. C.; Wade, V. J.; Nimmo, D. L.; Heywood, B. R.; Mann, S. Synthesis of 
 Inorganic Nanophase Materials in Supramolecular Protein Cages. Nature 1991, 349, 684-687 
(138) Douglas, T.; Strable, E.; Willits, D.; Aitouchen, A.; Libera, M.; Young, M. Protein 
 Engineering of a Viral Cage for Constrained Nanomaterials Synthesis. Adv. Mat. 2002, 
 14,415-418. 
(139) Ishii, D.; Kinbara, K.; Ishida, Y.; Ishii, N.; Okochi, M.; Yohda, M.; Aida, T. Chaperonin-
 mediated stabilization and ATP-triggered release of semiconductor nanoparticles. Nature 
 2003, 423, 628-632. 
   Chapter 4 
 
156 
(140) Suzuki, M.; Abe, M.; Ueno, T.; Abe, S.; Goto, T.; Toda, Y.; Akita, T.; Yamada, Y.; 
 Watanabe, Y. Preparation and catalytic reaction of Au/Pd bimetallic nanoparticles in Apo-
 ferritin. Chem. Commun. 2009, 4871-4873. 
(141) Behrens, S.; Heyman, A.; Maul, R.; Essig, S.; Steigerwald, S.; Quintilla, A.; Wenzel, W.; 
 Bürck, J.; Dgany, O.; Shoseyov, O. Constrained Synthesis and Organization of Catalytically 
 Active Metal Nanoparticles by Self-Assembled Protein Templates. Adv. Mater 2009, 21, 
 3515-3519. 
(142) Huggins, K. N. L.; Schoen, A. P.; Arunagirinathan, M. A.; Heilshorn, S. C. Multi-Site 
 Functionalization of Protein Scaffolds for Bimetallic Nanoparticle Templating. Adv. Funct. 
 Mater. 2014, 24, 7737-7744. 
(143) Malyutin, A. G.; Easterday, R.; Lozovyy, Y.; Spilotros, A.; Cheng, H.; Sanchez-Felix, O. R.; 
 Stein, B. D.; Morgan, D. G.; Svergun, D. I.; Dragnea, B.; Bronstein, L. M. Viruslike 
 Nanoparticles with Maghemite Cores Allow for Enhanced MRI Contrast Agents. Chem. 
 Mater. 2015, 27, 327-335. 
(144) Bedwell, G. J.; Zhou, Z. Y.; Uchida, M.; Douglas, T.; Gupta, A.; Prevelige, P. E. Selective 
 Biotemplated Synthesis of TiO2 Inside a Protein Cage. Biomacromolecules 2015, 16, 214-
 218. 
(145) Ma-Ham, A.; Wu, H.; Wang, J.; Kang, X.; Zhang, Y.; Lin, Y. Apoferritin-based 
 nanomedicine platform for drug delivery: equilibrium binding study of daunomycin with 
 DNA. J. Mater. Chem. 2011, 21, 8700-8708. 
(146) Garimella, P. D.; Datta, A.; Romanini, D. W.; Raymond, K. N.; Francis, M. B. Multivalent, 
 High-Relaxivity MRI Contrast Agents Using Rigid Cysteine-Reactive Gadolinium 
 Complexes. J. Am. Chem. Soc. 2011, 133, 14704-14709. 
(147) Tong, G. J.; Hsiao, S. C.; Carrico, Z. M.; Francis, M. B. Viral Capsid DNA Aptamer 
 Conjugates as Multivalent Cell-Targeting Vehicles. J. Am. Chem. Soc. 2009, 131, 11174-
 11178. 
(148) Lucon, J.; Qazi, S.; Uchida, M.; Bedwell, G. J.; LaFrance, B.; Prevelige, P. E., Jr.; Douglas, 
 T. Use of the interior cavity of the P22 capsid for site-specific initiation of atom-transfer 
 radical polymerization with high-density cargo loading. Nat. Chem. 2012, 4, 781-788. 
(149) Kaiser, C. R.; Flenniken, M. L.; Gillitzer, E.; Harmsen, A. L.; Harmsen, A. G.; Jutila, M. A.; 
 Douglas, T.; Young, M. J. Biodistribution studies of  protein cage nanoparticles demonstrate 
 broad tissue distribution and rapid clearance in vivo. Int. J. of Nanomed. 2007, 2, 715-733. 
(150) Singh, P.; Prasuhn, D.; Yeh, R. M.; Destito, G.; Rae, C. S.; Osborn, K.; Finn, M. G.; 
 Manchester, M. Bio-distribution, toxicity and pathology of cowpea mosaic virus 
 nanoparticles in vivo. J. Controlled Release 2007, 120, 41-50. 
(151) Ranford, J. C.; Coates, A. R. M.; Henderson, B. Chaperonins are cell-signalling proteins: the 
 unfolding biology of molecular chaperones. Expert Rev. Mol. Med. 2000, 2, 1-17. 
(152) O'Riordan, C. R.; Lachapelle, A.; Delgado, C.; Parkes, V.; Wadsworth, S. C.; Smith, A. E.; 
 Francis, G. E. PEGylation of Adenovirus with Retention of Infectivity and Protection from 
 Neutralizing Antibody in Vitro and in Vivo. Human Gene Ther. 1999, 10, 1349-1358. 
(153) Steinmetz, N. F.; Manchester, M. PEGylated Viral Nanoparticles for Biomedicine: The 
 Impact of PEG Chain Length on VNP Cell Interactions In Vitro and Ex Vivo. 
 Biomacromolecules 2009, 10, 784-792. 
(154) Raja, K. S.; Wang, Q.; Gonzalez, M. J.; Manchester, M.; Johnson, J. E.; Finn, M. G. Hybrid 
 Virus−Polymer Materials. 1. Synthesis and Properties of PEG-Decorated Cowpea Mosaic 
 Virus. Biomacromolecules 2003, 4, 472-476. 
(155) Vllasaliu, D.; Fowler, R.; Stolnik, S. PEGylated nanomedicines: recent progress and 
 remaining concerns. Expert Opin. Drug Deliv. 2014, 11, 139-154. 
(156) Minten, I. J.; Ma, Y.; Hempenius, M. A.; Vancso, G. J.; Nolte, R. J. M.; Cornelissen, J. J. L. 
 M. CCMV capsid formation induced by a functional negatively charged polymer. Org. 
 Biomol. Chem. 2009, 7, 4685-4688. 
(157) Hu, Y.; Zandi, R.; Anavitarte, A.; Knobler, C. M.; Gelbart, W. M. Packaging of a polymer by 
 a viral capsid: the interplay between polymer length and capsid size. Biophys. J. 2008, 94, 
 1428-1436. 
(158) Ng, B. C.; Yu, M.; Gopal, A.; Rome, L. H.; Monbouquette, H. G.; Tolbert, S. H. 
 Encapsulation of Semiconducting Polymers in Vault Protein Cages. Nano Lett. 2008, 8, 
 3503-3509. 
(159) Hu, Y. X.; Samanta, D.; Parelkar, S. S.; Hong, S. W.; Wang, Q. A.; Russell, T. P.; Emrick, T. 
 Ferritin-Polymer Conjugates: Grafting Chemistry and Integration into Nanoscale Assemblies. 
 Adv. Funct. Mater. 2010, 20, 3603-3612. 
Chapter 4 
 
157 
(160) Abedin, M. J.; Liepold, L.; Suci, P.; Young, M.; Douglas, T. Synthesis of Cross-Linked 
 Branched Polymer Network in the Interior of a Protein Cage. J. Am. Chem. Soc. 2009, 131, 
 4346-4354. 
(161) Kim, P. H.; Kim, J.; Kim, T. I.; Nam, H. Y.; Yockman, J. W.; Kim, M.; Kim, S. W.; Yun, C. 
 O. Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via 
 systemic administration. Biomaterials 2011, 32, 9328-9342. 
(162) Kosuge, H.; Uchida, M.; Lucon, J.; Qazi, S.; Douglas, T.; McConnell, M. V. High-Gd-
 Payload P22 protein cage nanoparticles for imaging vascular inflammation. J. Cardiovasc. 
 Magn. Res. 2013, 15. 
(163) Nussbaumer, M. G.; Rother, M.; Renggli, K.; Chami, M.; Bruns, N. Chaperonin-dendrimer 
 conjugates for siRNA delivery. submitted 2015. 
(164) Eto, Y.; Yoshioka, Y.; Ishida, T.; Yao, X.; Morishige, T.; Narimatsu, S.; Mizuguchi, H.; 
 Mukai, Y.; Okada, N.; Kiwada, H.; Nakagawa, S. Optimized PEGylated Adenovirus Vector 
 Reduces the Anti-vector Humoral Immune Response against Adenovirus and Induces a 
 Therapeutic Effect against Metastatic Lung Cancer. Biol. Pharm. Bull.2010, 33, 1540-1544. 
(165) Yao, X.; Zhou, N.; Wan, L.; Su, X.; Sun, Z.; Mizuguchi, H.; Yoshioka, Y.; Nakagawa, S.; 
 Zhao, R. C.; Gao, J.-Q. Polyethyleneimine-coating enhances adenoviral transduction of 
 mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2014, 447, 383-387. 
(166) Nabatoff, R. A. Surgical technique for stripping the long saphenous vein. Surg. Gynecol. 
 Obstet. 1977, 145, 81-87. 
(167) Sengonul, M.; Sousa, A.; Libera, M. Selective adsorption of surface-modified ferritin on a 
 phase-separated polymer blend. Coll. Surf. B 2009, 73, 152-155. 
(168) Shin, M. K.; Spinks, G. M.; Shin, S. R.; Kim, S. I.; Kim, S. J. Nanocomposite Hydrogel with 
 High Toughness for Bioactuators. Adv. Mater. 2009, 21, 1712-1715. 
(169) Ibrahim, S.; Ito, T. Surface Chemical Properties of Nanoscale Domains on UV-Treated 
 Polystyrene-Poly(methyl methacrylate) Diblock Copolymer Films Studied Using Scanning 
 Force Microscopy. Langmuir 2010, 26, 2119-2123. 
(170) Setaro, F.; Brasch, M.; Hahn, U.; Koay, M. S. T.; Cornelissen, J. J. L. M.; de la Escosura, A.; 
 Torres, T. Generation-Dependent Templated Self-Assembly of Biohybrid Protein 
 Nanoparticles around Photosensitizer Dendrimers. Nano Lett. 2015, 15, 1245-1251. 
(171) Perriman, A. W.; Mann, S. Liquid proteins--a new frontier for biomolecule-based 
 nanoscience. ACS Nano 2011, 5, 6085-6091. 
(172) Lucon, J.; Edwards, E.; Qazi, S.; Uchida, M.; Douglas, T. Atom transfer radical 
 polymerization on the interior of the P22 capsid and incorporation of photocatalytic 
 monomer crosslinks. Eur. Polym. J. 2013, 49, 2976-2985. 
(173) Shin, M. K.; Kim, S. I.; Kim, S. J.; Kim, B. J.; So, I.; Kozlov, M. E.; Oh, J.; Baughman, R. 
 H. A tough nanofiber hydrogel incorporating ferritin. Appl. Phys. Lett. 2008, 93. 
(174) Lin, Y.; Boker, A.; He, J.; Sill, K.; Xiang, H.; Abetz, C.; Li, X.; Wang, J.; Emrick, T.; Long, 
 S.; Wang, Q.; Balazs, A.; Russell, T. P. Self-directed self-assembly of 
 nanoparticle/copolymer mixtures. Nature 2005, 434, 55-59. 
(175) Perriman, A. W.; Colfen, H.; Hughes, R. W.; Barrie, C. L.; Mann, S. Solvent-free protein 
 liquids and liquid crystals. Angew. Chem., Int. Ed. 2009, 48, 6242-6246. 
(176) van Rijn, P.; Mougin, N. C.; Franke, D.; Park, H.; Boker, A. Pickering emulsion templated 
 soft capsules by self-assembling cross-linkable ferritin-polymer conjugates. Chem. Commun. 
 2011, 47, 8376-8378. 
(177) van Rijn, P.; Mougin, N. C.; Boker, A. Hierarchical structures via self-assembling protein-
 polymer hybrid building blocks. Polymer 2012, 53, 6045-6052. 
(178) Pelegri-O'Day, E. M.; Lin, E. W.; Maynard, H. D. Therapeutic Protein-Polymer Conjugates: 
 Advancing Beyond PEGylation. J. Am. Chem. Soc. 2014. 
(179) Qi, Y.; Chilkoti, A. Growing polymers from peptides and proteins: a biomedical perspective. 
 Polym. Chem. 2014, 5, 266-276. 
(180) Sumerlin, B. S. Proteins as Initiators of Controlled Radical Polymerization: Grafting-from 
 via ATRP and RAFT. ACS Macro Lett. 2012, 1, 141-145. 
(181) Zeltins, A. Construction and characterization of virus-like particles: a review. Mol. Biotech. 
 2013, 53, 92-107. 
(182) Mateu, M. G. Assembly, stability and dynamics of virus capsids. Arch. of Biochem. Biophys. 
 2013, 531, 65-79. 
(183) Theil, E. C. Ferritin: the protein nanocage and iron biomineral in health and in disease. Inorg. 
 Chem. 2013, 52, 12223-12233. 
(184) Rome, L. H.; Kickhoefer, V. A. Development of the Vault Particle as a Platform Technology. 
 ACS Nano 2012, 7, 889-902. 
   Chapter 4 
 
158 
(185) De Maio, A.; Vazquez, D. Extracellular heat shock proteins: a new location, a new function. 
 Shock 2013, 40, 239-246. 
(186) De Maio, A. Heat Shock Proteins: Facts, Thoughts, and Dreams. Shock 1999, 11. 
(187) Dekker, C.; Willison, K. R.; Taylor, W. R. On the evolutionary origin of the chaperonins. 
 Proteins 2011, 79, 1172-1192. 
(188) Horwich, A. L.; Fenton, W. A.; Chapman, E.; Farr, G. W. Two families of chaperonin: 
 physiology and mechanism. Ann. Rev. Cell Dev. Biol. 2007, 23, 115-145. 
(189) Ritsert, K.; Huber, R.; Turk, D.; Ladenstein, R.; Schmidt-Baese, K.; Bacher, A. Studies on 
 the lumazine synthase/riboflavin synthase complex of Bacillus subtilis: crystal structure 
 analysis of reconstituted, icosahedral β-subunit capsids with bound substrate analog inhibitor 
 at 2.4 Å  resolution. J. Mol. Biol. 1995, 253, 151-167. 
(190) Sutter, M.; Boehringer, D.; Gutmann, S.; Guenther, S.; Prangishvili, D.; Loessner, M. J.; 
 Stetter, K. O.; Weber-Ban, E.; Ban, N. Structural basis of enzyme encapsulation into a 
 bacterial nanocompartment. Nat. Struct. Mol. Biol. 2008, 15, 939-947. 
(191) Rahmanpour, R.; Bugg, T. D. H. Assembly in vitro of Rhodococcus jostii RHA1 encapsulin 
 and peroxidase DypB to form a nanocompartment. FEBS Journal 2013, 280, 2097-2104. 
(192) Cheng, S. Q.; Liu, Y.; Crowley, C. S.; Yeates, T. O.; Bobik, T. A. Bacterial 
 microcompartments: their properties and paradoxes. Bioessays 2008, 30, 1084-1095. 
(193) Tanaka, S.; Sawaya, M. R.; Yeates, T. O. Structure and mechanisms of a protein-based 
 organelle in Escherichia coli. Science 2010, 327, 81-84. 
(194) Corchero, J.; Cedano, J. Self-assembling, protein-based intracellular bacterial organelles: 
 emerging vehicles for encapsulating, targeting and delivering therapeutical cargoes. Microb. 
 Cell Fact. 2011, 10, 92. 
(195) Namba, K.; Stubbs, G. Structure of Tobacco Mosaic-Virus at 3.6-a Resolution - Implications 
 for Assembly. Science 1986, 231, 1401-1406. 
(196) Wang, Q.; Lin, T.; Tang, L.; Johnson, J. E.; Finn, M. G. Icosahedral Virus Particles as 
 Addressable Nanoscale Building Blocks. Angew. Chem., Int. Ed. 2002, 41, 459-462. 
(197) Douglas, T.; Young, M. Host-guest encapsulation of materials by assembled virus protein 
 cages. Nature 1998, 393, 152-155. 
(198) Speir, J. A.; Munshi, S.; Wang, G.; Baker, T. S.; Johnson, J. E. Structures of the native and 
 swollen forms of cowpea chlorotic mottle virus determined by X-ray crystallography and 
 cryo-electron microscopy. Structure 1995, 3, 63-78. 
(199) Valegard, K.; Liljas, L.; Fridborg, K.; Unge, T. The three-dimensional structure of the 
 bacterial virus MS2. Nature 1990, 345, 36-41. 
(200) Golmohammadi, R.; Valegård, K.; Fridborg, K.; Liljas, L. The Refined Structure of 
 Bacteriophage MS2 at 2.8 Å Resolution. J. Mol. Biol 1993, 234, 620-639. 
(201) Saban, S. D.; Nepomuceno, R. R.; Gritton, L. D.; Nemerow, G. R.; Stewart, P. L. CryoEM 
 structure at 9Å resolution of an adenovirus vector targeted to hematopoietic cells. J. Mol. 
 Biol. 2005, 349, 526-537. 
(202) Liu, H.; Jin, L.; Koh, S. B. S.; Atanasov, I.; Schein, S.; Wu, L.; Zhou, Z. H. Atomic Structure 
 of Human Adenovirus by Cryo-EM Reveals Interactions Among Protein Networks. Science 
 2010, 329, 1038-1043. 
(203) Reddy, V. S.; Natchiar, S. K.; Stewart, P. L.; Nemerow, G. R. Crystal Structure of Human 
 Adenovirus at 3.5 Å Resolution. Science 2010, 329, 1071-1075. 
(204) Mao, C.; Solis, D. J.; Reiss, B. D.; Kottmann, S. T.; Sweeney, R. Y.; Hayhurst, A.; Georgiou, 
 G.; Iverson, B.; Belcher, A. M. Virus-Based Toolkit for the Directed Synthesis of Magnetic 
 and Semiconducting Nanowires. Science 2004, 303, 213-217. 
(205) Niu, Z.; Liu, J.; Lee, L. A.; Bruckman, M. A.; Zhao, D.; Koley, G.; Wang, Q. Biological 
 templated synthesis of water-soluble conductive polymeric nanowires. Nano Lett. 2007, 7, 
 3729-3733. 
(206) Lee, S.-Y.; Lim, J.-S.; Harris, M. T. Synthesis and application of virus-based hybrid 
 nanomaterials. Biotech. Bioeng. 2012, 109, 16-30. 
(207) Culver, J. N.; Brown, A. D.; Zang, F.; Gnerlich, M.; Gerasopoulos, K.; Ghodssi, R. Plant 
 virus directed fabrication of nanoscale materials and  devices. Virology 2015, 479–480, 200-
 212. 
(208) Fischlechner, M.; Donath, E. Viruses as building blocks for materials and devices. 
 Chem., Int. Ed. 2007, 46, 3184-3193. 
(209) Caspar, D. L.; Klug, A. Physical principles in the construction of regular viruses. Cold. S
 pring. Harb. Symp. Quant. Biol. 1962, 27, 1-24. 
(210) Prasad, B. V. V.; Schmid, M. F. Principles of Virus Structural Organization. Adv. Exp. Med. 
 Biol. 2012, 726, 17-47. 
Chapter 4 
 
159 
(211) Gallois, B.; d'Estaintot, B. L.; Michaux, M.-A.; Dautant, A.; Granier, T.; Précigoux, G.; 
 Soruco, J.-A.; Roland, F.; Chavas-Alba, O.; Herbas, A.; Crichton, R. R. X-ray structure of 
 recombinant horse L-chain apoferritin at 2.0 Å resolution: implications for stability and 
 function. JBIC 1997, 2, 360-367. 
(212) Kim, K. K.; Yokota, H.; Santoso, S.; Lerner, D.; Kim, R.; Kim, S.-H. Purification, 
 Crystallization, and Preliminary X-Ray Crystallographic Data Analysis of Small Heat Shock 
 Protein Homolog from Methanococcus jannaschii,a Hyperthermophile. J. Struct. Biol. 
 1998, 121, 76-80. 
(213) Kim, K. K.; Kim, R.; Kim, S.-H. Crystal structure of a small heat-shock protein. Nature 
 1998, 394, 595-599. 
(214) Teschke, C. M.; McGough, A.; Thuman-Commike, P. A. Penton Release from P22 Heat-
 Expanded Capsids Suggests Importance of Stabilizing Penton-Hexon Interactions during 
 Capsid Maturation. Biophys. J. 2003, 84, 2585-2592. 
(215) Galvez, N.; Sanchez, P.; Dominguez-Vera, J. M. Preparation of Cu and CuFe Prussian Blue 
 derivative nanoparticles using the apoferritin cavity as nanoreactor. Dalton Trans. 2005, 
 2492-2494. 
(216) Basu, G.; Allen, M.; Willits, D.; Young, M.; Douglas, T. Metal binding to cowpea chlorotic 
 mottle virus using terbium(III) fluorescence. JBIC 2003, 8, 721-725. 
(217) Tama, F.; Brooks, C. L. The Mechanism and Pathway of pH Induced Swelling in Cowpea 
 Chlorotic Mottle Virus. J. Mol. Biol. 2002, 318, 733-747. 
(218) Verduin, B. J. M. The preparation of CCMV-protein in connection with its association into a 
 spherical particle. FEBS lett. 1974, 45, 50-54. 
(219) Johnson, J. E.; Speir, J. A. Quasi-equivalent viruses: a paradigm for protein assemblies. J. 
 Mol. Biol. 1997, 269, 665-675. 
(220) Comellas-Aragones, M.; Engelkamp, H.; Claessen, V. I.; Sommerdijk, N. A. J. M.; Rowan, 
 A. E.; Christianen, P. C. M.; Maan, J. C.; Verduin, B. J. M.; Cornelissen, J. J. L. M.; Nolte, 
 R. J. M. A Virus-Based Single-Enzyme Nanoreactor. Nature Nanotech. 2007, 2, 635-639. 
(221) Liu, G.; Wang, J.; Wu, H.; Lin, Y. Versatile Apoferritin Nanoparticle Labels for Assay of 
 Protein. Anal. Chem. 2006, 78, 7417-7423. 
(222) Liu, G.; Wang, J.; Lea, S. A.; Lin, Y. Bioassay Labels Based on Apoferritin Nanovehicles. 
 ChemBioChem 2006, 7, 1315-1319. 
(223) Lin, X.; Xie, J.; Niu, G.; Zhang, F.; Gao, H.; Yang, M.; Quan, Q.; Aronova, M. A.; Zhang, 
 G.; Lee, S.; Leapman, R.; Chen, X. Chimeric Ferritin Nanocages for Multiple Function 
 Loading and Multimodal Imaging. Nano Lett. 2011, 11, 814-819. 
(224) Waldmann, T.; Nitsch, M.; Klumpp, M.; Baumeister, W. Expression of an archaeal 
 chaperonin in E. coli: formation of homo- (α, β) and hetero-oligomeric (α + β) thermosome 
 complexes. FEBS lett. 1995, 376, 67-73. 
(225) Webb, B.; Frame, J.; Zhao, Z.; Lee, M. L.; Watt, G. D. Molecular Entrapment of Small 
 Molecules within the Interior of Horse Spleen Ferritin. Arch. Biochem. Biophys. 1994, 309, 
 178-183. 
(226) Saibil, H. R.; Fenton, W. A.; Clare, D. K.; Horwich, A. L. Structure and Allostery of the 
 Chaperonin GroEL. J. Mol. Biol. 2013, 425, 1476-1487. 
(227) Bigotti, M. G.; Clarke, A. R. Chaperonins: The hunt for the Group II mechanism. Arch. 
 Biochem. Biophys. 2008, 474, 331-339. 
(228) Lopez, T.; Dalton, K.; Frydman, J. The Mechanism and Function of Group II Chaperonins. J. 
 Mol. Biol. 2015. 
(229) Meyer, A. S.; Gillespie, J. R.; Walther, D.; Millet, I. S.; Doniach, S.; Frydman, J. Closing the 
 Folding Chamber of the Eukaryotic Chaperonin Requires the Transition State of ATP 
 Hydrolysis. Cell 2003, 113, 369-381. 
(230) Lawson, D. M.; Artymiuk, P. J.; Yewdall, S. J.; Smith, J. M. A.; Livingstone, J. C.; Treffry, 
 A.; Luzzago, A.; Levi, S.; Arosio, P.; et al. Solving the structure of human H ferritin by 
 genetically engineering intermolecular crystal contacts. Nature 1991, 349, 541-544. 
(231) Stefanini, S.; Cavallo, S.; Wang, C.-Q.; Tataseo, P.; Vecchini, P.; Giartosio, A.; Chiancone, 
 E. Thermal stability of horse spleen apoferritin and human recombinant H apoferritin. Arch. 
 Biochem. Biophys. 1996, 325, 58-64. 
(232) Listowsky, I.; Blauer, G.; Englard, S.; Betheil, J. J. Denaturation of horse spleen ferritin in 
 aqueous guanidinium chloride solutions. Biochemistry 1972, 11, 2176-2182. 
(233) Kim, R.; Kim, K. K.; Yokota, H.; Kim, S.-H. Small heat shock protein of Methanococcus 
 jannaschii, a hyperthermophile. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 9129-9133. 
(234) Hartl, F. U.; Hayer-Hartl, M. Molecular chaperones in the cytosol: from nascent chain to 
 folded protein. Science 2002, 295, 1852-1858. 
   Chapter 4 
 
160 
(235) Ditzel, L.; Löwe, J.; Stock, D.; Stetter, K.-O.; Huber, H.; Huber, R.; Steinbacher, S. Crystal 
 Structure of the Thermosome, the Archaeal  Chaperonin and Homolog of CCT. Cell 1998, 
 93, 125-138. 
(236) Schoehn, G.; Hayes, M.; Cliff, M.; Clarke, A. R.; Saibil, H. R. Domain rotations between 
 open, closed and bullet-shaped forms of the thermosome, an archaeal chaperonin. J. Mol. 
 Biol. 2000, 301, 323-332. 
(237) Booth, C. R.; Meyer, A. S.; Cong, Y.; Topf, M.; Sali, A.; Ludtke, S. J.; Chiu, W.; Frydman, J. 
 Mechanism of lid closure in the eukaryotic chaperonin TRiC/CCT. Nat. Struct. Mol. Biol. 
 2008, 15, 746-753. 
(238) Douglas, N. R.; Reissmann, S.; Zhang, J.; Chen, B.; Jakana, J.; Kumar, R.; Chiu, W.; 
 Frydman, J. Dual action of ATP hydrolysis couples lid closure to substrate release into the 
 group II chaperonin chamber. Cell 2011, 144, 240-252. 
(239) Rome, L. H.; Kickhoefer, V. A. Development of the Vault Particle as a Platform Technology. 
 ACS Nano 2013, 7, 889-902. 
(240) Kedersha, N. L. Vaults. III. Vault ribonucleoprotein particles open into flower-like structures 
 with octagonal symmetry. J. Cell Biol. 1991, 112, 225-235. 
(241) Slesina, M.; Inman, E.; Moore, A.; Goldhaber, J.; Rome, L.; Volknandt, W. Movement of 
 vault particles visualized by GFP-tagged major vault protein. Cell Tissue Res. 2006, 324, 
 403-410. 
(242) Mikyas, Y.; Makabi, M.; Raval-Fernandes, S.; Harrington, L.; Kickhoefer, V. A.; Rome, L. 
 H.; Stewart, P. L. Cryoelectron microscopy  imaging of recombinant and tissue derived 
 vaults: localization of the MVP N termini and VPARP. J. Mol. Biol. 2004, 344, 91-105. 
(243) Zhou, Z. H.; McCarthy, D. B.; O'Connor, C. M.; Reed, L. J.; Stoops, J. K. The remarkable 
 structural and functional organization of the eukaryotic pyruvate dehydrogenase complexes. 
 Proc. Natl. Acad. of Sci. U.S.A. 2001, 98, 14802-14807. 
(244) Izard, T.; Ævarsson, A.; Allen, M. D.; Westphal, A. H.; Perham, R. N.; de Kok, A.; Hol, W. 
 G. J. Principles of quasi-equivalence and Euclidean geometry govern the assembly of cubic 
 and dodecahedral cores of pyruvate dehydrogenase complexes. Proc. Natl. Acad. Sci. U.S.A. 
 1999, 96, 1240-1245. 
(245) Dalmau, M.; Lim, S.; Chen, H. C.; Ruiz, C.; Wang, S.-W. Thermostability and molecular 
 encapsulation within an engineered caged protein scaffold. Biotech. Bioeng. 2008, 101, 654-
 664. 
(246) Rowe, W. P.; Huebner, R. J.; Gilmore, L. K.; Parrott, R. H.; Ward, T. G. Isolation of a 
 Cytopathogenic Agent from Human Adenoids Undergoing Spontaneous Degeneration in 
 Tissue Culture. P. Soc. Exp. Biol. Med. 1953, 84, 570-573. 
(247) Reddy, V. S.; Natchiar, S. K.; Stewart, P. L.; Nemerow, G. R. Crystal  Structure of Human 
 Adenovirus at 3.5 Å Resolution. Science 2010, 329, 1071-1075. 
(248) Martin, C. S. Latest Insights on Adenovirus Structure and Assembly. Viruses-Basel 2012, 4, 
 847-877. 
(249) Jiang, H.; Gomez-Manzano, C.; Lang, F. F.; Alemany, R.; Fueyo, J. Oncolytic Adenovirus: 
 Preclinical and Clinical Studies in Patients with Human Malignant Gliomas. Curr. Gene. 
 Ther. 2009, 9, 422-427. 
(250) Rainov, N. G.; Heidecke, V. Clinical Development of Experimental Virus-Mediated Gene 
 Therapy for Malignant Glioma. Anti-Cancer Agents Med. Chem. 2011, 11, 739-747. 
(251) Castro, M. G.; Lowenstein, P. R. Neuro-Oncology The long and winding road-gene therapy 
 for glioma. Nat. Rev. Neurol. 2013, 9, 609-610. 
(252) Yan, Y.; Li, S. Y.; Jia, T. T.; Du, X. H.; Xu, Y. X.; Zhao, Y. S.; Li, L.; Liang, K.; Liang, W. 
 T.; Sun, H. W.; Li, R. Combined therapy with CTL cells and oncolytic adenovirus expressing 
 IL-15-induced enhanced antitumor activity. Tumor. Biol. 2015, 36, 4535-4543. 
(253) Sainsbury, F.; Canizares, M. C.; Lomonossoff, G. P. Cowpea mosaic Virus: The Plant Virus-
 Based Biotechnology Workhorse. Annu. Rev. Phytopathol. 2010, 48, 437-455. 
(254) Wang, Q.; Kaltgrad, E.; Lin, T. W.; Johnson, J. E.; Finn, M. G. Natural supramolecular 
 building blocks: Wild-type cowpea mosaic virus. Chem. Biol. 2002, 9, 805-811. 
(255) Lin, T. W.; Chen, Z. G.; Usha, R.; Stauffacher, C. V.; Dai, J. B.; Schmidt, T.; Johnson, J. E. 
 The refined crystal structure of cowpea mosaic virus at 2.8 Å resolution. Virology 1999, 265, 
 20-34. 
(256) Lucas, R. W.; Larson, S. B.; McPherson, A. The crystallographic structure of brome mosaic 
 virus. J. Mol. Biol. 2002, 317, 95-108. 
(257) Larson, S. B.; Lucas, R. W.; McPherson, A. Crystallographic structure of the T=1 particle of 
 brome mosaic virus. J. Mol. Biol. 2005, 346, 815-831. 
Chapter 4 
 
161 
(258) Finch, J. T.; Klug, A. Structure of Broad Bean Mottle Virus. I. Analysis of Electron 
 Micrographs and Comparison with Turnip Yellow Mosaic Virus and Its Top Component. J. 
 Mol. Biol. 1967, 24, 289-302. 
(259) Yamazaki, H.; Bancroft, J.; Kaesberg, P. Biophysical Studies of Broad Bean Mottle Virus. 
 Proc. Natl. Acad. Sci. U.S.A. 1961, 47, 979-983. 
(260) Finch, J. T.; Leberman, R.; Berger, J. E. Structure of Broad Bean Mottle Virus. II. X-Ray 
 Diffraction Studies. J. Mol. Biol. 1967, 27, 17-24. 
(261) Bayer, M. E.; Bocharov, A. F. The capsid structure of bacteriophage lambda. Virology 1973, 
 54, 465-475. 
(262) Lander, G. C.; Evilevitch, A.; Jeembaeva, M.; Potter, C. S.; Carragher, B.; Johnson, J. E. 
 Bacteriophage lambda stabilization by auxiliary protein gpD: Timing, location, and 
 mechanism of attachment determined by cryo-EM. Structure 2008, 16, 1399-1406. 
(263) Dokland, T.; Murialdo, H. Structural Transitions during Maturation of Bacteriophage-
 Lambda Capsids. J. Mol. Biol. 1993, 233, 682-694. 
(264) Golmohammadi, R.; Fridborg, K.; Bundule, M.; Valegård, K.; Liljas, L. The crystal structure 
 of bacteriophage Qβ at 3.5 Å resolution. Structure 1996, 4, 543-554. 
(265) Takamatsu, H.; Iso, K. Chemical evidence for the capsomeric structure of phage q beta. 
 Nature 1982, 298, 819-824. 
(266) Cielens, I.; Ose, V.; Petrovskis, I.; Strelnikova, A.; Renhofa, R.; Kozlovska, T.; Pumpens, P. 
 Mutilation of RNA phage Q beta virus-like particles: from icosahedrons to rods. FEBS lett. 
 2000, 482, 261-264. 
(267) Orlova, E. V.: Bacteriophages and their structural organisation. In Bacteriophages; Kurtboke, 
 I., Ed.; InTech: Rijeka, Croatia, 2012; pp 3-30. 
(268) Jiang, W.; Li, Z.; Zhang, Z.; Baker, M. L.; Prevelige, P. E., Jr.; Chiu, W. Coat protein fold 
 and maturation transition of bacteriophage P22 seen at subnanometer resolutions. Nature 
 Struct. Biol. 2003, 10, 131-135. 
(269) Kang, S.; Uchida, M.; O’Neil, A.; Li, R.; Prevelige, P. E.; Douglas, T. Implementation of 
 P22 Viral Capsids as Nanoplatforms. Biomacromolecules 2010, 11, 2804-2809. 
(270) Chang, J.; Weigele, P.; King, J.; Chiu, W.; Jiang, W. Cryo-EM asymmetric reconstruction of 
 bacteriophage P22 reveals organization of its DNA packaging and infecting machinery. 
 Structure 2006, 14, 1073-1082. 
(271) Mattevi, A.; Obmolova, G.; Kalk, K. H.; Teplyakov, A.; Hol, W. G. J. Crystallographic 
 Analysis of Substrate Binding and Catalysis in Dihydrolipoyl Transacetylase (E2p). 
 Biochemistry 1993, 32, 3887-3901. 
(272) Tanaka, H.; Kato, K.; Yamashita, E.; Sumizawa, T.; Zhou, Y.; Yao, M.; Iwasaki, K.; 
 Yoshimura, M.; Tsukihara, T. The Structure of Rat Liver Vault at 3.5 Å Resolution. Science 
 2009, 323, 384-388. 
(273) Chen, D. H.; Baker, M. L.; Hryc, C. F.; DiMaio, F.; Jakana, J.; Wu, W. M.; Dougherty, M.; 
 Haase-Pettingell, C.; Schmid, M. F.; Jiang, W.; Baker, D.; King, J. A.; Chiu, W. Structural 
 basis for scaffolding-mediated assembly and maturation of a dsDNA virus. Proc. Natl. Acad. 
 Sci. U.S.A. 2011, 108, 1355-1360. 
(274) Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; 
 Ferrin, T. E. UCSF Chimera—A visualization system for exploratory research and analysis. 
 J. Comp. Chem. 2004, 25, 1605-1612. 
(275) Moad, G.; Rizzardo, E.; Thang, S. H. Living Radical Polymerization by the RAFT Process – 
 A Third Update. Austr. J. Chem. 2012, 65, 985-1076. 
(276) Lewis, J. D.; Destito, G.; Zijlstra, A.; Gonzalez, M. J.; Quigley, J. P.; Manchester, M.; 
 Stuhlmann, H. Viral nanoparticles as tools for intravital vascular imaging. Nature Med. 2006, 
 12, 354-360. 
(277) Heredia, K. L.; Maynard, H. D. Synthesis of protein-polymer conjugates. Org. Biomol. 
 Chem. 2007, 5, 45-53. 
(278) Lutz, J.-F.; Börner, H. G. Modern trends in polymer bioconjugates design. Prog. Polym. Sci. 
 2008, 33, 1-39. 
(279) Gauthier, M. A.; Klok, H.-A. Peptide/protein-polymer conjugates: synthetic strategies and 
 design concepts. Chem. Commun. 2008, 2591-2611. 
(280) Broyer, R. M.; Grover, G. N.; Maynard, H. D. Emerging synthetic approaches for protein-
 polymer conjugations. Chem. Commun. 2011, 47, 2212-2226. 
(281) Obermeyer, A. C.; Olsen, B. D. Synthesis and Application of Protein-Containing Block 
 Copolymers. ACS Macro Lett. 2015, 4, 101-110. 
(282) Yao, X.; Yoshioka, Y.; Morishige, T.; Eto, Y.; Watanabe, H.; Okada, Y.; Mizuguchi, H.; 
 Mukai, Y.; Okada, N.; Nakagawa, S. Systemic administration of a PEGylated adenovirus 
   Chapter 4 
 
162 
 vector with a cancer-specific promoter is effective in a mouse model of metastasis. Gene 
 Ther. 2009, 16, 1395-1404. 
(283) Kovacs, E. W.; Hooker, J. M.; Romanini, D. W.; Holder, P. G.; Berry, K. E.;Francis, M. B. 
 Dual-Surface-Modified Bacteriophage MS2 as an Ideal Scaffold for a Viral Capsid-Based 
 Drug Delivery System. Bioconjug. Chem. 2007, 18, 1140-1147. 
(284) Yao, X.; Yoshioka, Y.; Morishige, T.; Eto, Y.; Narimatsu, S.; Kawai, Y.; Mizuguchi, H.; 
 Gao, J. Q.; Mukai, Y.; Okada, N.; Nakagawa, S. Tumor vascular targeted delivery of 
 polymer-conjugated adenovirus vector for cancer gene therapy. Mol. Ther. 2011, 19, 1619-
 1625. 
(285) Pokorski, J. K.; Breitenkamp, K.; Liepold, L. O.; Qazi, S.; Finn, M. G. Functional virus-
 based polymer-protein nanoparticles by atom transfer radical polymerization. J. Am. Chem. 
 Soc. 2011, 133, 9242-9245. 
(286) Suh, J.; Choy, K.-L.; Lai, S. L.; Suk, J. S.; Tang, B. C.; Prabhu, S.; Hanes, J. PEGylation of 
 nanoparticles improves their cytoplasmic transport. Int. J. Nanomed. 2007, 2, 735-741. 
(287) Wattendorf, U.; Merkle, H. P. PEGylation as a tool for the biomedical  engineering of surface 
 modified microparticles. J. Pharm. Sci. 2008, 97, 4655-4669. 
(288) Li, W. J.; Zhan, P.; De Clercq, E.; Lou, H. X.; Liu, X. Y. Current drug research on 
 PEGylation with small molecular agents. Prog. Polym. Sci. 2013, 38, 421-444. 
(289) Ginn, C.; Khalili, H.; Lever, R.; Brocchini, S. PEGylation and its impact on the design of 
 new protein-based medicines. Future Med. Chem. 2014, 6, 1829-1846. 
(290) Alconcel, S. N. S.; Baas, A. S.; Maynard, H. D. FDA-approved poly(ethylene glycol)-protein 
 conjugate drugs. Polym. Chem. 2011, 2, 1442-1448. 
(291) Wang, Q.; Raja, K. S.; Janda, K. D.; Lin, T.; Finn, M. G. Blue Fluorescent Antibodies as 
 Reporters of Steric Accessibility in Virus Conjugates. Bioconjug. Chem. 2003, 14, 38-43. 
(292) Comellas-Aragonès, M.; de la Escosura, A. s.; Dirks, A. J.; van der Ham, A.; Fusté-
 Cuñé, A.; Cornelissen, J. J. L. M.; Nolte, R. J. M. Controlled Integration of Polymers into 
 Viral Capsids. Biomacromolecules 2009, 10, 3141-3147. 
(293) Farkas, M. E.; Aanei, I. L.; Behrens, C. R.; Tong, G. J.; Murphy, S. T.; O’Neil, J. P.; Francis, 
 M. B. PET Imaging and Biodistribution of Chemically Modified Bacteriophage MS2. Mol. 
 Pharm. 2013, 10, 69-76. 
(294) Kim, P.-H.; Sohn, J.-H.; Choi, J.-W.; Jung, Y.; Kim, S. W.; Haam, S.;  Yun, C.-O. Active 
 targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. 
 Biomaterials 2011, 32, 2314-2326. 
(295) Sengonul, M.; Ruzicka, J.; Attygalle, A. B.; Libera, M. Surface modification of protein 
 nanocontainers and their self-directing character in polymer blends. Polymer 2007, 48, 3632-
 3640. 
(296) Kulmashiro, Y.; Ikezoe, Y.; Tamada, K.; Hara, M. Dynamic interfacial properties of 
 poly(ethylene glycol)-modified ferritin at the solid/liquid interface. J. Phys. Chem. B 2008, 
 112, 8291-8297. 
(297) Molino, N. M.; Bilotkach, K.; Fraser, D. A.; Ren, D.; Wang, S.-W. Complement Activation 
 and Cell Uptake Responses Toward Polymer-Functionalized Protein Nanocapsules. 
 Biomacromolecules 2012, 13, 974- 981. 
(298) Yao, X.; Yoshioka, Y.; Morishige, T.; Eto, Y.; Narimatsu, S.; Mizuguchi, H.; Mukai, Y.; 
 Okada, N.; Nakagawa, S. Adenovirus vector covalently conjugated to polyethylene glycol 
 with a cancer-specific promoter suppresses the tumor growth through systemic 
 administration. Biol. Pharm. Bull. 2010, 33, 1073-1076. 
(299) Yao, X. L.; Yoshioka, Y.; Ruan, G. X.; Chen, Y. Z.; Mizuguchi, H.; Mukai, Y.; Okada, N.; 
 Gao, J. Q.; Nakagawa, S. Optimization and  internalization mechanisms of PEGylated 
 adenovirus vector with targeting peptide for cancer gene therapy. Biomacromolecules 2012, 
 13, 2402-2409. 
(300) Daniels, T. R.; Bernabeu, E.; Rodriguez, J. A.; Patel, S.; Kozman, M.;  Chiappetta, D. A.; 
 Holler, E.; Ljubimova, J. Y.; Helguera, G.; Penichet, M. L. The transferrin receptor and the 
 targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta 2012, 1820, 
 291-317. 
(301) Bruckman, M. A.; Randolph, L. N.; VanMeter, A.; Hern, S.; Shoffstall, A. J.; Taurog, R. E.; 
 Steinmetz, N. F. Biodistribution, pharmacokinetics, and blood compatibility of native and 
 PEGylated tobacco mosaic virus nano-rods and -spheres in mice. Virology 2014, 449, 163-
 173. 
(302) Zeng, Q.; Li, T.; Cash, B.; Li, S.; Xie, F.; Wang, Q. Chemoselective derivatization of a 
 bionanoparticle by click reaction and ATRP reaction. Chem. Commun. 2007, 1453-1455. 
Chapter 4 
 
163 
(303) Hatakeyama, H.; Akita, H.; Harashima, H. The Polyethyleneglycol Dilemma: Advantage and 
 Disadvantage of PEGylation of Liposomes for Systemic Genes and Nucleic Acids Delivery 
 to Tumors. Biol. Pharm. Bull. 2013, 36, 892-899. 
(304) Pelaz, B.; del Pino, P.; Maffre, P.; Hartmann, R.; Gallego, M.; Rivera-Fernández, S.; de la 
 Fuente, J. M.; Nienhaus, G. U.; Parak, W. J. Surface  Functionalization of Nanoparticles with 
 Polyethylene Glycol: Effects on Protein Adsorption and Cellular Uptake. ACS Nano 2015, 9, 
 6996-7008. 
(305) Verhoef, J. J. F.; Carpenter, J. F.; Anchordoquy, T. J.; Schellekens, H. Potential induction of 
 anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Disc. 
 Today 2014, 19, 1945-1952. 
(306) Yang, Q.; Lai, S. K. Anti-PEG immunity: emergence, characteristics, and unaddressed 
 questions. Interdiscip. Rev. Nanomed. Nanobiotechnol. 2015, 7, 655-677. 
(307) Sedlacek, O.; Monnery, B. D.; Filippov, S. K.; Hoogenboom, R.; Hruby, M. Poly(2-
 Oxazoline)s – Are They More Advantageous for Biomedical Applications Than Other 
 Polymers? Macromol. Rapid Commun. 2012, 33, 1648-1662. 
(308) Adams, N.; Schubert, U. S. Poly(2-oxazolines) in biological and biomedical application 
 contexts. Adv. Drug Delivery Rev. 2007, 59, 1504-1520. 
(309) Lava, K.; Verbraeken, B.; Hoogenboom, R. Poly(2-oxazoline)s and click chemistry: A 
 versatile toolbox toward multi-functional polymers. Eur. Polym. J. 2015, 65, 98-111. 
(310) Manzenrieder, F.; Luxenhofer, R.; Retzlaff, M.; Jordan, R.; Finn, M. G. Stabilization of 
 Virus-like Particles with Poly(2-oxazoline)s. Angew. Chem., Int. Ed. 2011, 50, 2601-2605. 
(311) Alarcon, C. d. l. H.; Pennadam, S.; Alexander, C. Stimuli responsive polymers for 
 biomedical applications. Chem. Soc. Rev. 2005, 34, 276-285. 
(312) Ward, M. A.; Georgiou, T. K. Thermoresponsive Polymers for Biomedical Applications. 
 Polymers 2011, 3, 1215-1242. 
(313) Schild, H. G. Poly (N-Isopropylacrylamide) - Experiment, Theory and Application. Prog. 
 Polym. Sci.1992, 17, 163-249. 
(314) Matsumoto, N. M.; Prabhakaran, P.; Rome, L. H.; Maynard, H. D. Smart Vaults: Thermally-
 Responsive Protein Nanocapsules. ACS Nano 2012, 7, 867-874. 
(315) Xu, J.; Liu, S. Polymeric nanocarriers possessing thermoresponsive coronas. Soft Matter 
 2008, 4, 1745-1749. 
(316) Kickhoefer, V. A.; Garcia, Y.; Mikyas, Y.; Johansson, E.; Zhou, J. C.; Raval-Fernandes, S.; 
 Minoofar, P.; Zink, J. I.; Dunn, B.; Stewart, P. L.; Rome, L. H. Engineering of vault 
 nanocapsules with enzymatic and fluorescent properties. Proc. Natl. Acad. Sci. U.S.A. 2005, 
 102, 4348-4352. 
(317) Mougin, N. C.; van Rijn, P.; Park, H.; Muller, A. H. E.; Boker, A. Hybrid Capsules via Self-
 Assembly of Thermoresponsive and Interfacially Active Bionanoparticle-Polymer 
 Conjugates. Adv. Funct. Mater. 2011, 21, 2470-2476. 
(318) Nash, M. E.; Carroll, W. M.; Nikoloskya, N.; Yang, R. B.; Connell, C. O.; Gorelov, A. V.; 
 Dockery, P.; Liptrot, C.; Lyng, F. M.; Garcia, A.; Rochev, Y. A. Straightforward, One-Step 
 Fabrication of Ultrathin Thermoresponsive Films from Commercially Available pNIPAm for 
 Cell Culture and Recovery. ACS Appl. Mater. Interf. 2011, 3, 1980-1990. 
(319) Lv, H. T.; Zhang, S. B.; Wang, B.; Cui, S. H.; Yan, J. Toxicity of cationic lipids and cationic 
 polymers in gene delivery. J. Controlled Release 2006, 114, 100-109. 
(320) Singarapu, K.; Pal, I.; Ramsey, J. D. Polyethylene glycol–grafted polyethylenimine used to 
 enhance adenovirus gene delivery. J. Biomed. Mater. Res. Part A 2013, 101A, 1857-1864. 
(321) Fischer, D.; Li, Y.; Ahlemeyer, B.; Krieglstein, J.; Kissel, T. In vitro cytotoxicity testing of 
 polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 
 2003, 24, 1121-1131. 
(322) Paul, A.; Eun, C.-J.; Song, J. M. Cytotoxicity mechanism of non-viral  carriers 
 polyethylenimine and poly-l-lysine using real time high-content cellular assay. Polymer 
 2014, 55, 5178-5188. 
(323) Chung, D. D. L. Carbon materials for structural self-sensing, electromagnetic shielding and 
 thermal interfacing. Carbon 2012, 50, 3342-3353. 
(324) Caruso, M. M.; Davis, D. A.; Shen, Q.; Odom, S. A.; Sottos, N. R.; White, S. R.; Moore, J. S. 
 Mechanically-induced chemical changes in polymeric materials. Chem. Rev. 2009, 109, 
 5755-5798. 
(325) Brantley, J. N.; Bailey, C. B.; Wiggins, K. M.; Keatinge-Clay, A. T.; Bielawski, C. W. 
 Mechanobiochemistry: harnessing biomacromolecules for force-responsive materials. Polym. 
 Chem. 2013, 4, 3916-3928. 
   Chapter 4 
 
164 
(326) Makyła, K.; Müller, C.; Lörcher, S.; Winkler, T.; Nussbaumer, M. G.;  Eder, M.; Bruns, N. 
 Fluorescent Protein Senses and Reports Mechanical Damage in Glass-Fiber-Reinforced 
 Polymer Composites. Adv. Mater. 2013, 25, 2701-2706. 
(327) Lörcher, S.; Winkler, T.; Makyła, K.; Ouellet-Plamondon, C.; Burgert, I.; Bruns, N. 
 Mechanical unfolding of a fluorescent protein enables self-reporting of damage in carbon-
 fibre-reinforced composites. J. Mater. Chem. A 2014, 2, 6231-6237. 
(328) Bruns, N.; Clark, D. S. Self-Reporting Materials: Protein- Mediated Visual Indication of 
 Damage in a Bulk Polymer. Chimia 2011, 65, 245-249. 
(329) Valle, F.; DeRose, J. A.; Dietler, G.; Kawe, M.; Plückthun, A.; Semenza, G. AFM structural 
 study of the molecular chaperone GroEL and its two-dimensional crystals: an ideal “living” 
 calibration sample. Ultramicroscopy 2002, 93, 83-89. 
(330) Huang, Z. M.; Zhang, Y. Z.; Kotaki, M.; Ramakrishna, S. A review on polymer nanofibers 
 by electrospinning and their applications in nanocomposites. Compos. Sci. Technol. 2003, 63, 
 2223-2253. 
(331) Hu, X.; Liu, S.; Zhou, G.; Huang, Y.; Xie, Z.; Jing, X. Electrospinning of polymeric 
 nanofibers for drug delivery applications. J. Controlled Release 2014, 185, 12-21. 
(332) Sebe, I.; Szabo, P.; Kallai-Szabo, B.; Zelko, R. Incorporating small molecules or biologics 
 into nanofibers for optimized drug release: A review. Int. J. Pharm. 2015, Ahead of Print. 
(333) Salalha, W.; Kuhn, J.; Dror, Y.; Zussman, E. Encapsulation of bacteria and viruses in 
 electrospun nanofibres. Nanotechnology 2006, 17, 4675-4681. 
(334) Shin, M. K.; Kim, S. I.; Kim, S. J.; Kim, S. K.; Lee, H. Reinforcement of polymeric 
 nanofibers by ferritin nanoparticles. Appl. Phys. Lett. 2006, 88. 
(335) Kim, M. S.; Shin, K. M.; Kim, S. I.; Spinks, G. M.; Kim, S. J. Controlled array of ferritin in 
 tubular nanostructure. Macromol. Rapid Commun. 2008, 29, 552-556. 
(336) Shin, M. K.; Kim, S. I.; Kim, S. J.; Park, S. Y.; Hyun, Y. H.; Lee, Y.; Lee, K. E.; Han, S.-S.; 
 Jang, D.-P.; Kim, Y.-B.; Cho, Z.-H.; So, I.; Spinks, G. M. Controlled Magnetic Nanofiber 
 Hydrogels by Clustering Ferritin. Langmuir 2008, 24, 12107-12111. 
(337) De Volder, M. F. L.; Tawfick, S. H.; Baughman, R. H.; Hart, A. J. Carbon Nanotubes: 
 Present and Future Commercial Applications. Science 2013, 339, 535-539. 
(338) Coleman, J. N.; Khan, U.; Blau, W. J.; Gun'ko, Y. K. Small but strong: A review of the 
 mechanical properties of carbon nanotube-polymer composites. Carbon 2006, 44, 1624-
 1652. 
(339) Bhattacharyya, S.; Sinturel, C.; Salvetat, J. P.; Saboungi, M. L. Protein-functionalized carbon 
 nanotube-polymer composites. Appl. Phys. Lett. 2005, 86. 
(340) Holder, P. G.; Finley, D. T.; Stephanopoulos, N.; Walton, R.; Clark, D. S.; Francis, M. B. 
 Dramatic Thermal Stability of Virus−Polymer Conjugates in Hydrophobic Solvents. 
 Langmuir 2010, 26, 17383-17388. 
(341) Wong, K. K. W.; Colfen, H.; Whilton, N. T.; Douglas, T.; Mann, S. Synthesis and 
 characterization of hydrophobic ferritin proteins. J. Inorg. Biochem. 1999, 76, 187-195. 
(342) Klibanov, A. M. Improving enzymes by using them in organic solvents. Nature 2001, 409, 
 241-246. 
(343) Vogler, E. A. Protein adsorption in three dimensions. Biomaterials 2012, 33, 1201-1237. 
(344) Sousa, A.; Sengonul, M.; Latour, R.; Kohn, J.; Libera, M. Selective protein adsorption on a 
 phase-separated solvent-cast polymer blend. Langmuir 2006, 22, 6286-6292. 
(345) Deshayes, S.; Kasko, A. M. Polymeric biomaterials with engineered degradation. J. Polym. 
 Sci. A 2013, 51, 3531-3566. 
(346) Stauch, O.; Uhlmann, T.; Frohlich, M.; Thomann, R.; El-Badry, M.; Kim, Y. K.; Schubert, R. 
 Mimicking a cytoskeleton by coupling poly(N-isopropylacrylamide) to the inner leaflet of 
 liposomal membranes: Effects of photopolymerization on vesicle shape and polymer 
 architecture. Biomacromolecules 2002, 3, 324-332. 
(347) Hohn, T. Role of RNA in the assembly process of bacteriophage fr. J. Mol. Biol. 1969, 43, 
 191-200. 
(348) Bancroft, J. B.; Hiebert, E.; Bracker, C. E. The effects of various polyanions on shell 
 formation of some spherical viruses. Virology 1969, 39, 924-930. 
(349) Sikkema, F. D.; Comellas-Aragones, M.; Fokkink, R. G.; Verduin, B. J.; Cornelissen, J. J.; 
 Nolte, R. J. Monodisperse polymer-virus hybrid nanoparticles. Org. Biomol. Chem. 2007, 5, 
 54-57. 
(350) Cadena-Nava, R. D.; Hu, Y.; Garmann, R. F.; Ng, B.; Zelikin, A. N.; Knobler, C. M.; 
 Gelbart, W. M. Exploiting fluorescent polymers to probe the self-assembly of virus-like 
 particles. J. Phys. Chem. B 2011, 115, 2386-2391. 
(351) Stockley, P. G.; Twarock, R.; Bakker, S. E.; Barker, A. M.; Borodavka, A.; Dykeman, E.; 
 Ford, R. J.; Pearson, A. R.; Phillips, S. E.; Ranson, N. A.; Tuma, R. Packaging signals in 
Chapter 4 
 
165 
 single-stranded RNA viruses: nature's alternative to a purely electrostatic assembly 
 mechanism. J. Biol. Phys. 2013, 39, 277-287. 
(352) Cadena-Nava, R. D.; Comas-Garcia, M.; Garmann, R. F.; Rao, A. L.; Knobler, C. M.; 
 Gelbart, W. M. Self-assembly of viral capsid protein and RNA molecules of different sizes: 
 requirement for a specific high protein/RNA mass ratio. J. Virology 2012, 86, 3318-3326. 
(353) Garmann, R. F.; Sportsman, R.; Beren, C.; Manoharan, V. N.; Knobler, C. M.; Gelbart, W. 
 M. A Simple RNA-DNA Scaffold Templates the Assembly of Monofunctional Virus-Like 
 Particles. J. Am. Chem. Soc. 2015, 137, 7584-7587. 
(354) Mukherjee, S.; Pfeifer, C. M.; Johnson, J. M.; Liu, J.; Zlotnick, A. Redirecting the coat 
 protein of a spherical virus to assemble into tubular nanostructures. J. Am. Chem. Soc. 2006, 
 128, 2538-2539. 
(355) Ng, B. C.; Chan, S. T.; Lin, J.; Tolbert, S. H. Using Polymer Conformation to Control 
 Architecture in Semiconducting Polymer/Viral Capsid Assemblies. ACS Nano 2011, 5, 7730-
 7738. 
(356) Smith, A. D.; Shen, C. K. F.; Roberts, S. T.; Helgeson, R.; Schwartz, B. J. Ionic strength and 
 solvent control over the physical structure, electronic properties and superquenching of 
 conjugated polyelectrolytes. Res. Chem. Intermediat. 2007, 33, 125-142. 
(357) Setaro, F.; Ruiz-Gonzalez, R.; Nonell, S.; Hahn, U.; Torres, T. Synthesis, photophysical 
 studies and O-1(2) generation of carboxylate-terminated zinc phthalocyanine dendrimers. J. 
 Inorg. Biochem. 2014, 136, 170-176. 
(358) Nguyen, T. Q.; Doan, V.; Schwartz, B. J. Conjugated polymer aggregates in solution: Control 
 of interchain interactions. J. Chem. Phys. 1999, 110,  4068-4078. 
(359) Kaneko, M.; Motoyoshi, J.; Yamada, A. Solid phase photoreduction of methylviologen 
 adsorbed on cellulose. Nature 1980, 285, 468-470. 
(360) Ebbesen, T. W.; Levey, G.; Patterson, L. K. Photoreduction of methyl  viologen in aqueous 
 neutral solution without additives. Nature 1982, 298, 545-548. 
(361) Liepold, L. O.; Abedin, M. J.; Buckhouse, E. D.; Frank, J. A.; Young, M. J.; Douglas, T. 
 Supramolecular Protein Cage Composite MR Contrast Agents with Extremely Efficient 
 Relaxivity Properties. Nano Lett. 2009, 9, 4520-4526. 
(362) Lucon, J.; Abedin, M. J.; Uchida, M.; Liepold, L.; Jolley, C. C.; Young, M.; Douglas, T. A 
 click chemistry based coordination polymer inside small heat shock protein. Chem. Commun.  
 2010, 46, 264-266. 
(363) Flenniken, M. L.; Willits, D. A.; Brumfield, S.; Young, M. J.; Douglas, T. The small heat 
 shock protein cage from Methanococcus jannaschii is a versatile nanoscale platform for 
 genetic and chemical modification. Nano Lett. 2003, 3, 1573-1576. 
(364) Anderson, E. A.; Isaacman, S.; Peabody, D. S.; Wang, E. Y.; Canary, J. W.; Kirshenbaum, K. 
 Viral nanoparticles donning a paramagnetic coat: conjugation of MRI contrast agents to the 
 MS2 capsid. Nano Lett. 2006, 6, 1160-1164. 
(365) Manna, K.; Zhang, T.; Greene, F. X.; Lin, W. Bipyridine- and Phenanthroline-Based Metal–
 Organic Frameworks for Highly Efficient and Tandem Catalytic Organic Transformations 
 via Directed C–H Activation. J. Am. Chem. Soc. 2015, 137, 2665-2673. 
(366) Horcajada, P.; Serre, C.; Maurin, G.; Ramsahye, N. A.; Balas, F.; Vallet-Regi, M.; Sebban, 
 M.; Taulelle, F.; Ferey, G. Flexible porous metal-organic frameworks for a controlled drug 
 delivery. J. Am. Chem. Soc. 2008, 130, 6774-6780. 
(367) Sun, C. Y.; Qin, C.; Wang, X. L.; Su, Z. M. Metal-organic frameworks as potential drug 
 delivery systems. Expert Opin. Drug Deliv. 2013, 10, 89-101. 
(368) Werner, E. J.; Datta, A.; Jocher, C. J.; Raymond, K. N. High-Relaxivity MRI Contrast 
 Agents: Where Coordination Chemistry Meets Medical Imaging. Angew. Chem., Int. Edit. 
 2008, 47, 8568-8580. 
(369) Danhier, F.; Le Breton, A.; Preat, V. RGD-based strategies to target alpha(v) beta(3) integrin 
 in cancer therapy and diagnosis. Mol. Pharm. 2012, 9, 2961-2973. 
(370) Orakdogen, N. pH-responsive swelling behavior, elasticity and molecular characteristics of 
 poly(N,N-dimethylaminoethyl methacrylate) gels at various initial monomer concentrations. 
 Polym. Bull. 2011, 67, 1347-1366. 
(371) Smith, S. B.; Cui, Y. J.; Bustamante, C. Overstretching B-DNA: The elastic response of 
 individual double-stranded and single-stranded DNA molecules. Science 1996, 271, 795-799. 
(372) Menjoge, A. R.; Kannan, R. M.; Tomalia, D. A. Dendrimer-based drug and imaging 
 conjugates: design considerations for nanomedical applications. Drug Discov. Today 2010, 
 15, 171-185. 
(373) Biswas, S.; Torchilin, V. P. Dendrimers for siRNA Delivery. Pharmaceuticals 2013, 6, 161-
 183. 
   Chapter 4 
 
166 
(374) Perumal, O. P.; Inapagolla, R.; Kannan, S.; Kannan, R. M. The effect of surface functionality 
 on cellular trafficking of dendrimers. Biomaterials 2008, 29, 3469-3476. 
(375) Boas, U.; Heegaard, P. M. Dendrimers in drug research. Chem. Soc. Rev. 2004, 33, 43-63. 
(376) Jensen, L. B.; Pavan, G. M.; Kasimova, M. R.; Rutherford, S.; Danani, A.; Nielsen, H. M.; 
 Foged, C. Elucidating the molecular mechanism of PAMAM–siRNA dendriplex self-
 assembly: Effect of dendrimer charge density. Int. J. Pharm. 2011, 416, 410-418. 
(377) Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C. Factors affecting the clearance and 
 biodistribution of polymeric nanoparticles. Mol. Pharm. 2008, 5, 505-515. 
(378) Choi, H. S.; Liu, W.; Misra, P.; Tanaka, E.; Zimmer, J. P.; Itty Ipe, B.; Bawendi, M. G.; 
 Frangioni, J. V. Renal clearance of quantum dots. Nat. Biotechnol. 2007, 25, 1165-1170. 
(379) Nussbaumer, M. The protein cage Thermosome as versatile delivery platform. PhD-Thesis, 
 University of Basel, 2015. 
(380) Kanasty, R.; Dorkin, J. R.; Vegas, A.; Anderson, D. Delivery materials for siRNA 
 therapeutics. Nat. Mater. 2013, 12, 967-977. 
(381) Cotanda, P.; Petzetakis, N.; O'Reilly, R. K. Catalytic polymeric nanoreactors: more than a 
 solid supported catalyst. MRS Commun.2012, 2, 119-126. 
(382) Bruns, N.; Tiller, J. C. Amphiphilic Network as Nanoreactor for Enzymes in Organic 
 Solvents. Nano Lett. 2005, 5, 45-48. 
(383) Tanner, P.; Balasubramanian, V.; Palivan, C. G. Aiding Nature’s Organelles: Artificial 
 Peroxisomes Play Their Role. Nano Lett. 2013, 13, 2875-2883. 
(384) Pauly, A. C.; Theato, P. Control of reactivity of constitutional isomers of pentafluorophenyl 
 ethynylbenzoates for the synthesis of functional poly(phenylacetylenes). Polym. Chem. 2012,  
 3, 1769-1782. 
(385) Lam, J. W. Y.; Tang, B. Z. Functional Polyacetylenes. Acc. Chem. Res. 2005, 38, 745-754. 
(386) Lam, J. W. Y.; Dong, Y.; Kwok, H. S.; Tang, B. Z. Light-Emitting Polyacetylenes:  
 Synthesis and Electrooptical Properties of Poly(1-phenyl-1-alkyne)s Bearing Naphthyl 
 Pendants. Macromolecules 2006, 39, 6997-7003. 
(387) Yashima, E.; Maeda, K.; Furusho, Y. Single- and Double-Stranded Helical Polymers: 
 Synthesis, Structures, and Functions. Acc. Chem. Res. 2008, 41, 1166-1180. 
(388) Braunecker, W. A.; Matyjaszewski, K. Controlled/living radical polymerization: Features, 
 developments, and perspectives. Prog. Polym. Sci. 2007, 32, 93-146. 
(389) Zetterlund, P. B. Controlled/living radical polymerization in nanoreactors: 
 compartmentalization effects. Polym. Chem. 2011, 2, 534-549. 
(390) La Scola, B.; Audic, S.; Robert, C.; Jungang, L.; de Lamballerie, X.; Drancourt, M.; Birtles, 
 R.; Claverie, J. M.; Raoult, D. A giant virus in amoebae. Science 2003, 299, 2033-2033. 
(391) Aherfi, S.; La Scola, B.; Pagnier, I.; Raoult, D.; Colson, P. The expanding family 
 Marseilleviridae. Virology 2014, 466, 27-37. 
(392) Boyer, M.; Yutin, N.; Pagnier, I.; Barrassi, L.; Fournous, G.; Espinosa, L.; Robert, C.; Azza, 
 S.; Sun, S. Y.; Rossmann, M. G.; Suzan-Monti, M.; La Scola, B.; Koonin, E. V.; Raoult, D. 
 Giant Marseillevirus highlights the role of amoebae as a melting pot in emergence of 
 chimeric microorganisms. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 21848-21853. 
(393) Xiao, C. A.; Chipman, P. R.; Battisti, A. J.; Bowman, V. D.; Renesto, P.; Raoult, D.; 
 Rossmann, M. G. Cryo-electron microscopy of the giant mimivirus. J. Mol. Biol. 2005,  353, 
 493-496. 
(394) Van Etten, J. L.; Lane, L. C.; Dunigan, D. D. DNA Viruses: The Really Big Ones (Giruses). 
 Annu. Rev. Microbiol. 2010, 64, 83-99. 
(395) Klose, T.; Rossmann, M. G. Structure of large dsDNA viruses. Biol. Chem. 2014, 395, 711-
 719. 
(396) Glover, D. J.; Giger, L.; Kim, J. R.; Clark, D. S. Engineering protein filaments with enhanced 
 thermostability for nanomaterials. Biotechnol. J. 2013, 8, 228-236. 
(397) Dordick, J. S. Functional nanoscale biomolecular materials. Biotechnol. J. 2013, 8, 165-166. 
(398) Regan, L.; Caballero, D.; Hinrichsen, M. R.; Virrueta, A.; Williams, D. M.; O'Hern, C. S. 
 Protein design: Past, present, and future. Peptide Sci. 2015, 104, 334-350. 
(399) Fletcher, J. M.; Harniman, R. L.; Barnes, F. R. H.; Boyle, A. L.; Collins, A.; Mantell, J.; 
 Sharp, T. H.; Antognozzi, M.; Booth, P. J.; Linden, N.; Miles, M. J.; Sessions, R. B.; 
 Verkade, P.; Woolfson, D. N. Self-Assembling Cages from Coiled-Coil Peptide Modules. 
 Science 2013, 340, 595-599. 
(400) Altintas, O.; Barner-Kowollik, C. Single Chain Folding of Synthetic Polymers by Covalent 
 and Non-Covalent Interactions: Current Status and Future Perspectives. Macromol Rapid 
 Commun. 2012, 33, 958-971. 
(401) Stuart, M. A. C.; Huck, W. T. S.; Genzer, J.; Muller, M.; Ober, C.; Stamm, M.; Sukhorukov, 
 G. B.; Szleifer, I.; Tsukruk, V. V.; Urban, M.; Winnik, F.; Zauscher, S.; Luzinov, I.; Minko, 
Chapter 4 
 
167 
 S. Emerging applications of stimuli-responsive polymer materials. Nat. Mater. 2010, 9, 101-
 113. 
(402) Cabane, E.; Zhang, X.; Langowska, K.; Palivan, C.; Meier, W. Stimuli-Responsive Polymers 
 and Their Applications in Nanomedicine. Biointerphases 2012, 7, 1-27. 
(403) Schattling, P.; Jochum, F. D.; Theato, P. Multi-stimuli responsive polymers - the all-in-one 
 talents. Polym. Chem. 2014, 5, 25-36. 
(404) Urlacher, V. B.; Lutz-Wahl, S.; Schmid, R. D. Microbial P450 enzymes in biotechnology. 
 Appl. Microbiol. Biotechnol. 2004, 64, 317-325. 
(405) Cech, T. R. The Chemistry of Self-Splicing Rna and Rna Enzymes. Science 1987, 236, 1532-
 1539. 
(406) Neurath, H. Evolution of proteolytic enzymes. Science 1984, 224, 350-357. 
(407) Koebnik, R.; Locher, K. P.; Van Gelder, P. Structure and function of bacterial outer 
 membrane proteins: barrels in a nutshell. Mol. Microbiol. 2000, 37, 239-253. 
(408) von Heijne, G. Membrane-protein topology. Nat. Rev. Mol. Cell Biol. 2006, 7, 909-918. 
(409) Woof, J. M.; Burton, D. R. Human antibody - Fc receptor interactions  illuminated by crystal 
 structures. Nat. Rev. Immunol. 2004, 4, 89-99. 
(410) Chen, K.; Xu, W.; Wilson, M.; He, B.; Miller, N. W.; Bengten, E.; Edholm, E. S.; Santini, P. 
 A.; Rath, P.; Chiu, A.; Cattalini, M.; Litzman, J.; J, B. B.; Huang, B.; Meini, A.; Riesbeck, 
 K.; Cunningham-Rundles, C.; Plebani, A.; Cerutti, A. Immunoglobulin D enhances immune 
 surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in 
 basophils. Nat. Immunol. 2009, 10, 889-898. 
(411) Flenniken, M. L.; Uchida, M.; Liepold, L. O.; Kang, S.; Young, M. J.; Douglas, T. A Library 
 of Protein Cage Architectures as Nanomaterials. Curr. Top. Microbiol. 2009, 327, 71-93. 
(412) Ellis, R. J. Molecular chaperones: assisting assembly in addition to folding. Trends Biochem. 
 Sci. 2006, 31, 395-401. 
(413) Hartl, F. U.; Bracher, A.; Hayer-Hartl, M. Molecular chaperones in protein folding and 
 proteostasis. Nature 2011, 475, 324-332. 
(414) Arosio, P.; Levi, S. Ferritin, iron homeostasis, and oxidative damage. Free Radical Bio. Med. 
 2002, 33, 457-463. 
(415) Frydman, J. Folding of newly translated proteins in vivo: The role of molecular chaperones. 
 Annu. Rev. Biochem. 2001, 70, 603-647. 
(416) Theil, E. C.; Behera, R. K.; Tosha, T. Ferritins for chemistry and for life. Coord. Chem.  Rev. 
 2013, 257, 579-586. 
(417) Yamashita, I.; Iwahori, K.; Zheng, B.; Kumagai, S. Nanoparticles Synthesized and Delivered 
 by Protein in the Field of Nanotechnology Applications. Coord. Chem. Protein Cages: 
 Principles, Design, and Applications (eds. T. Ueno and Y. Watanabe) 2013, 305-328. 
(418) Kang, S.; Lander, G. C.; Johnson, J. E.; Prevelige, P. E. Development of Bacteriophage P22 
 as a Platform for Molecular Display: Genetic and Chemical Modifications of the Procapsid 
 Exterior Surface. ChemBioChem 2008, 9, 514-518. 
(419) Saibil, H. Chaperone machines for protein folding, unfolding and disaggregation. Nat. Rev. 
 Mol. Cell Bio. 2013, 14, 630-642. 
(420) Cornelissen, J. J. Chemical virology: Packing polymers in protein cages. Nat. Chem. 2012, 4, 
 775-777. 
(421) Rother, M.; Nussbaumer, M. G.; Renggli, K.; Bruns, N. Protein cages  and synthetic 
 polymers: A fruitful symbiosis for bionanotechnology. to be submitted to Chem. Soc. Rev. 
 2016. 
(422) Klok, H.-A. Peptide/Protein−Synthetic Polymer Conjugates: Quo Vadis. 
 Macromolecules 2009, 42, 7990-8000. 
(423) Averick, S. E.; Bazewicz, C. G.; Woodman, B. F.; Simakova, A.; Mehl, R. A.; 
 Matyjaszewski, K. Protein–polymer hybrids: Conducting ARGET ATRP from a genetically 
 encoded cleavable ATRP initiator. Europ. Polym. J. 2013, 49, 2919-2924. 
(424) Erickson, H. P. Size and Shape of Protein Molecules at the Nanometer Level Determined by 
 Sedimentation, Gel Filtration, and Electron Microscopy. Biol. Proced. Online 2009, 11, 32-
 51. 
(425) Hansen, K. M.; Ji, H. F.; Wu, G. H.; Datar, R.; Cote, R.; Majumdar, A.; Thundat, T. 
 Cantilever-based optical deflection assay for discrimination of DNA single-nucleotide 
 mismatches. Anal. Chem. 2001, 73, 1567-1571. 
(426) Baumann, C. G.; Smith, S. B.; Bloomfield, V. A.; Bustamante, C. Ionic effects on the 
 elasticity of single DNA molecules. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 6185-6190. 
(427) Sinden, R. R.; Pearson, C. E.; Potaman, V. N.; Ussery, D. W.: DNA: Structure and function. 
 Adv. Gen. Biol.; Ram, S. V., Ed.; JAI, 1998; Vol. Volume 5; pp 1-141. 
   Chapter 4 
 
168 
(428) Ditzel, L.; Lowe, J.; Stock, D.; Stetter, K. O.; Huber, H.; Huber, R.; Steinbacher, S. Crystal 
 structure of the thermosome, the archaeal chaperonin and homolog of CCT. Cell 1998, 93, 
 125-138. 
(429) Zhang, J. J.; Baker, M. L.; Schroder, G. F.; Douglas, N. R.; Reissmann, S.; Jakana, J.; 
 Dougherty, M.; Fu, C. J.; Levitt, M.; Ludtke, S. J.; Frydman, J.; Chiu, W. Mechanism of 
 folding chamber closure in a group II chaperonin. Nature 2010, 463, 379-U130. 
(430) Kesharwani, P.; Banerjee, S.; Gupta, U.; Mohd Amin, M. C. I.; Padhye, S.; Sarkar, F. H.; 
 Iyer, A. K. PAMAM dendrimers as promising nanocarriers for RNAi therapeutics. Mater. 
 Today.2015, 18, 565-572 
(431) Whitehead, K. A.; Langer, R.; Anderson, D. G. Knocking down barriers: advances in siRNA 
 delivery. Nat. Rev. Drug Discov. 2009, 8, 129-138. 
(432) Joshi, B. H.; Pachchigar, K. P. siRNA: novel therapeutics from functional genomics. 
 Biotechnol. Genet. Eng. 2014, 30, 1-30. 
(433) Zhou, Y. J.; Zhang, C. L.; Liang, W. Development of RNAi technology for targeted therapy - 
 A track of siRNA based agents to RNAi therapeutics. J. Controlled Release 2014, 193, 270-
 281. 
(434) Le Droumaguet, B.; Velonia, K. In situ ATRP-Mediated hierarchical formation of giant 
 amphiphile bionanoreactors. Angew. Chem., Int. Edit. 2008, 47, 6263-6266. 
(435) Agarwal, S.; Zhang, Y.; Maji, S.; Greiner, A. PDMAEMA based gene delivery materials. 
 Mater. Today 2012, 15, 388-393. 
(436) Coue, G.; Engbersen, J. F. J. Functionalized linear poly(amidoamine)s are efficient vectors 
 for intracellular protein delivery. J. Controlled Release 2011, 152, 90-98. 
(437) Llopis, J.; McCaffery, J. M.; Miyawaki, A.; Farquhar, M. G.; Tsien, R. Y. Measurement of 
 cytosolic, mitochondrial, and Golgi pH in single living cells with green fluorescent proteins. 
 Proc. Natl. Acad. of Sci. U.S.A. 1998, 95, 6803-6808. 
(438) Evdokimov, A. G.; Pokross, M. E.; Egorov, N. S.; Zaraisky, A. G.; Yampolsky, I. V.; 
 Merzlyak, E. M.; Shkoporov, A. N.; Sander, I.; Lukyanov, K. A.; Chudakov, D. M. 
 Structural basis for the fast maturation of Arthropoda green fluorescent protein. EMBO Rep. 
 2006, 7, 1006-1012. 
(439) Tang, R.; Kim, C. S.; Solfiell, D. J.; Rana, S.; Mout, R.; Velazquez-Delgado, E. M.; 
 Chompoosor, A.; Jeong, Y.; Yan, B.; Zhu, Z. J.; Kim, C.; Hardy, J. A.; Rotello, V. M. Direct 
 Delivery of Functional Proteins and Enzymes to the Cytosol Using Nanoparticle-Stabilized 
 Nanocapsules. ACS Nano 2013, 7, 6667-6673. 
(440) Fu, A. L.; Tang, R.; Hardie, J.; Farkas, M. E.; Rotello, V. M. Promises and Pitfalls of 
 Intracellular Delivery of Proteins. Bioconjug. Chem.  2014, 25, 1602-1608. 
(441) Min, K.; Gao, H. F.; Matyjaszewski, K. Use of ascorbic acid as reducing agent for synthesis 
 of well-defined polymers by ARGET ATRP. Macromolecules 2007, 40, 1789-1791. 
(442) Hellman, L. M.; Fried, M. G. Electrophoretic mobility shift assay (EMSA) for detecting 
 protein-nucleic acid interactions. Nat. Protoc. 2007, 2, 1849-1861. 
(443) Verbaan, F. J.; Oussoren, C.; van Dam, I. M.; Takakura, Y.; Hashida, M.; Crommelin, D. J. 
 A.; Hennink, W. E.; Storm, G. The fate of poly(2-dimethyl amino ethyl)methacrylate-based 
 polyplexes after intravenous administration. Int. J. Pharm. 2001, 214, 99-101. 
(444) Rodriguez-Lorenzo, L.; Rothen-Rutishauser, B.; Petri-Fink, A.; Balog, S. Nanoparticle 
 Polydispersity Can Strongly Affect In Vitro Dose. Part. Part. Syst. Char. 2015, 32, 321-333. 
(445) Akhtar, S.; Benter, I. F. Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 2007, 
 117, 3623-3632. 
(446) Urban-Klein, B.; Werth, S.; Abuharbeid, S.; Czubayko, F.; Aigner, A.  RNAi-mediated gene-
 targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. 
 Gene Ther. 2004, 12, 461-466. 
(447) Zhou, J. H.; Wu, J. Y.; Hafdi, N.; Behr, J. P.; Erbacher, P.; Peng, L. PAMAM dendrimers for 
 efficient siRNA delivery and potent gene silencing. Chem. Commun. 2006, 2362-2364. 
(448) Kong, W. H.; Sung, D. K.; Shim, Y. H.; Bae, K. H.; Dubois, P.; Park, T. G.; Kim, J. H.; Seo, 
 S. W. Efficient intracellular siRNA delivery strategy through rapid and simple two steps 
 mixing involving noncovalent post-PEGylation. J. Controlled Release 2009, 138, 141-147. 
(449) Rawlinson, L. A. B.; O'Brien, P. J.; Brayden, D. J. High content analysis of cytotoxic effects 
 of pDMAEMA on human intestinal epithelial and monocyte cultures. J. Controlled Release 
2010,  146, 84-92. 
(450) Raucher, D.; Ryu, J. S. Cell-penetrating peptides: strategies for anticancer treatment. Trends 
 Mol. Med. 2015, 21, 560-570. 
(451) Koren, E.; Torchilin, V. P. Cell-penetrating peptides: breaking through to the other side. 
 Trends Mol. Med. 2012, 18, 385-393. 
Chapter 4 
 
169 
(452) Ayame, H.; Morimoto, N.; Akiyoshi, K. Self-assembled cationic nanogels for intracellular 
 protein delivery. Bioconjug. Chem. 2008, 19, 882-890. 
(453) Lee, A. L. Z.; Wang, Y.; Ye, W. H.; Yoon, H. S.; Chan, S. Y.; Yang, Y. Y. Efficient 
 intracellular delivery of functional proteins using cationic polymer core/shell nanoparticles. 
 Biomaterials 2008, 29, 1224-1232. 
(454) Lu, Y.; Sun, W. J.; Gu, Z. Stimuli-responsive nanomaterials for therapeutic protein delivery. 
 J. Controlled Release 2014, 194, 1-19. 
(455) Sun, W. J.; Lu, Y.; Gu, Z. Advances in Anticancer Protein Delivery using Micro-
 /Nanoparticles. Part. Part. Syst. Char. 2014, 31, 1204-1222. 
(456) Hazarika, P.; Kukolka, F.; Niemeyer, C. M. Reversible binding of fluorescent proteins at 
 DNA-gold nanoparticles. Angew. Chem., Int. Edit. 2006, 45, 6827-6830. 
(457) Shannon, L. M.; Kay, E.; Lew, J. Y. Peroxidase isozymes from horseradish roots. I. Isolation 
 and physical properties. J. Biol. Chem. 1966, 241, 2166-2172. 
(458) Dice, J. F.; Goldberg, A. L. Relationship between in vivo degradative rates and isoelectric 
 points of proteins. Proc. Natl Acad. Sci. U.S.A. 1975, 72, 3893-3897. 
(459) Reynolds, A.; Leake, D.; Boese, Q.; Scaringe, S.; Marshall, W. S.; Khvorova, A. Rational 
 siRNA design for RNA interference. Nat. Biotechnol. 2004, 22, 326-330. 
(460) Devi, G. R. siRNA-based approaches in cancer therapy. Cancer Gene. Ther. 2006, 13, 819-
 829. 
(461) Boudreau, R. L.; Spengler, R. M.; Davidson, B. L. Rational design of therapeutic siRNAs: 
 minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's 
 disease. Mol. Ther. 2011, 19, 2169-2177. 
(462) Wittrup, A.; Lieberman, J. Knocking down disease: a progress report on siRNA therapeutics. 
 Nat. Rev. Genet. 2015, 16, 543-552. 
(463) Wu, S. Y.; Lopez-Berestein, G.; Calin, G. A.; Sood, A. K. RNAi therapies: drugging the 
 undruggable. Sci. Transl. Med. 2014, 6, 240-247. 
(464) Mansoori, B.; Sandoghchian Shotorbani, S.; Baradaran, B. RNA interference and its role in 
 cancer therapy. Adv. Pharm. Bull. 2014, 4, 313-321. 
(465) Joo, M. K.; Yhee, J. Y.; Kim, S. H.; Kim, K. The potential and advances in RNAi therapy: 
 Chemical and structural modifications of siRNA molecules and use of biocompatible 
 nanocarriers. J. Controlled Release 2014, 193, 113-121. 
(466) Tristan, C.; Shahani, N.; Sedlak, T. W.; Sawa, A. The diverse functions of GAPDH: views 
 from different subcellular compartments. Cell Signal. 2011, 23, 317-323. 
(467) Gutwein, P.; Schramme, A.; Abdel-Bakky, M. S.; Doberstein, K.; Hauser, I. A.; Ludwig, A.; 
 Altevogt, P.; Gauer, S.; Hillmann, A.; Weide, T.; Jespersen, C.; Eberhardt, W.; Pfeilschifter, 
 J. ADAM10 is expressed in human podocytes and found in urinary vesicles of patients with 
 glomerular kidney diseases. J. Biomed. Sci. 2010, 17. 
(468) Makyla, K.; Muller, C.; Lorcher, S.; Winkler, T.; Nussbaumer, M. G.;  Eder, M.; Bruns, N. 
 Fluorescent Protein Senses and Reports Mechanical Damage in Glass-Fiber-Reinforced 
 Polymer Composites. Adv. Mater. 2013, 25, 2701-2706. 
(469) Douglas, N. R.; Reissmann, S.; Zhang, J. J.; Chen, B.; Jakana, J.; Kumar, R.; Chiu, W.; 
 Frydman, J. Dual Action of ATP Hydrolysis Couples Lid Closure to Substrate Release into 
 the Group II Chaperonin Chamber. Cell 2011, 144, 240-252. 
(470) Laemmli, U. K. Cleavage of Structural Proteins during the Assembly of the Head of 
 Bacteriophage T4. Nature 1970, 227, 680-685. 
(471) Nesterenko, M. V.; Tilley, M.; Upton, S. J. A Simple Modification of Blums Silver Stain 
 Method Allows for 30 Minute Detection of Proteins in Polyacrylamide Gels. J. Biochem. 
 Bioph. Meth. 1994, 28, 239-242. 
(472) Fried, M. G. Measurement of Protein-DNA Interaction Parameters by Electrophoresis 
 Mobility Shift Assay. Electrophoresis 1989, 10, 366-376. 
(473) Liang, W.; Mason, A. J.; Lam, J. W.: Western Blot Evaluation of siRNA Delivery by pH-
 Responsive Peptides. In Target Identification and Validation in Drug Discovery; Moll, J., 
 Colombo, R., Eds.; Methods in Molecular Biology; Humana Press, 2013; Vol. 986; pp 73-87. 
(474) Rother, M.; Barmettler, J.; Reichmuth, A.; Araujo, J. V.; Rytka, C.; Glaied, O.; Pieles, U.; 
 Bruns, N. Self-Sealing and Puncture Resistant Breathable Membranes for Water-Evaporation 
 Applications. Adv. Mater.  2015, 27, 6620-6624. 
(475) Mukhopadhyay, A.; Vinay Kumar, M. A Review on Designing the Waterproof Breathable 
 Fabrics Part I: Fundamental Principles and Designing Aspects of Breathable Fabrics. J. Ind. 
 Text. 2008, 37, 225-262. 
(476) Gugliuzza, A.; Drioli, E. A review on membrane engineering for innovation in wearable 
 fabrics and protective textiles. J. Membr. Sci. 2013, 446, 350-375. 
   Chapter 4 
 
170 
(477) Meyer-Heim, A.; Rothmaier, M.; Weder, M.; Kool, J.; Schenk, P.; Kesselring, J. Advanced 
 lightweight cooling-garment technology: functional improvements in thermosensitive 
 patients with multiple sclerosis. Mult. Scler. 2007, 13, 232-237. 
(478) Rothmaier, M.; Weder, M.; Meyer-Heim, A.; Kesselring, J. Design and performance of 
 personal cooling garments based on three-layer laminates. Med. Biol. Eng. Comp. 2008, 46, 
 825-832. 
(479) Davis, S. L.; Wilson, T. E.; White, A. T.; Frohman, E. M. Thermoregulation in multiple 
 sclerosis. J. Appl. Physiol. 2010, 109, 1531-1537. 
(480) Personal cooling system by Unico swiss tex GmbH (in German), http://www.unico-swiss 
 tex.ch/personalcoolingsystem/medizin/index.html. (accessed June 2015). 
(481) Hoffmann, E.; Pfenning, D. M.; Philippsen, E.; Schwahn, P.; Sieber, M.; Wehn, R.; 
 Woermann, D. Evaporation of Alcohol-Water Mixtures through Hydrophobic Porous 
 Membranes. J. Membr. Sci.1987, 34, 199-206. 
(482) Tu, C.-Y.; Liu, Y.-L.; Lee, K.-R.; Lai, J.-Y. Hydrophilic surface-grafted 
 poly(tetrafluoroethylene) membranes using in pervaporation dehydration processes. J. 
 Membr. Sci. 2006, 274, 47-55. 
(483) Curcio, E.; Drioli, E. Membrane distillation and related operations - A review. Sep. Purif. 
 Rev. 2005, 34, 35-86. 
(484) Huizing, R.; Merida, W.; Ko, F. Impregnated electrospun nanofibrous  membranes for water 
 vapour transport applications. J. Membr. Sci. 2014, 461, 146-160. 
(485) Dobrusskin, S.; Singer, H.; Banik, G. Humidification with moisture permeable materials. 7. 
 Internationaler Graphischer Restauratorentag, 26.-30. August 1991, Uppsala : IADA 
 Preprints 1991, 68-70. 
(486) Weder, M.; Hegemann, D.; Amberg, M.; Hess, M.; Boesel, L.; Abächerli, R.; Meyer, V.; 
 Rossi, R. Embroidered Electrode with Silver/Titanium Coating for Long-Term ECG 
 Monitoring. Sensors-Basel 2015, 15, 1750-1759. 
(487) Amberg, M.; Rupper, P.; Storchenegger, R.; Weder, M.; Hegemann, D. Controlling the 
 release from silver electrodes by titanium adlayers for health monitoring. Nanomedicine: 
 Nanotechnology, Biology and Medicine 2015. 
(488) Blaiszik, B. J.; Kramer, S. L. B.; Olugebefola, S. C.; Moore, J. S.; Sottos, N. R.; White, S. R. 
 Self-Healing Polymers and Composites. Annu. Rev. Mater. Res. 2010, 40, 179-211. 
(489) Ponto, J. A. Self-sealing capacity of vial stoppers after multiple needle punctures. J. Am. 
 Pharm. Ass. 2013, 53, 58-60. 
(490) Simpson, R. S.; Wright, M. L.; Croft, W. J. Flashing and waterproofing membrane 
 US20110091675A1. 
(491) Shepherd, R. F.; Stokes, A. A.; Nunes, R. M. D.; Whitesides, G. M. Soft Machines That are 
 Resistant to Puncture and That Self Seal. Adv. Mater. 2013, 25, 6709-6713. 
(492) Spenadel, L.; Good, R. Synthetic Rubber for Self-Sealing Fuel Tanks.  Industr. Eng. Chem. 
 1959, 51, 935-936. 
(493) Nagaya, K.; Ikai, S.; Chiba, M.; Chao, X. Tire with Self-Repairing Mechanism. JSME 2006, 
 49, 379-384. 
(494) Busch, S.; Seidel, R.; Speck, O.; Speck, T. Morphological aspects of self-repair of lesions 
 caused by internal growth stresses in stems of Aristolochia macrophylla and Aristolochia 
 ringens. Proc. R. Soc. B 2010, 277, 2113-2120. 
(495) Rampf, M.; Speck, O.; Speck, T.; Luchsinger, R. H. Self-Repairing Membranes for Inflatable 
 Structures Inspired by a Rapid Wound Sealing Process of Climbing Plants. J. Bionic Eng. 
 2011, 8, 242-250. 
(496) Vrouenraets, C. M. F.; Sikkema, D. J. Flexible layered product EP111360A1. 
(497) Erdodi, G.; Kennedy, J. P. Amphiphilic conetworks: Definition, synthesis, applications. 
 Prog. Polym. Sci. 2006, 31, 1-18. 
(498) Patrickios, C. S.; Georgiou, T. K. Covalent amphiphilic polymer networks. Current Op. Coll. 
 Interf. Sci. 2003, 8, 76-85. 
(499) Mespouille, L.; Hedrick, J. L.; Dubois, P. Expanding the role of chemistry to produce new 
 amphiphilic polymer (co)networks. Soft Matter 2009, 5, 4878-4892. 
(500) Béla, I.; Joseph, P. K.; Paul, W. M.: Amphiphilic Networks. In Polymeric Drugs and Drug 
 Delivery Systems; ACS Symposium Series 469; American Chemical Society, 1991; Vol. 469; 
 pp 194-202. 
(501) Lequieu, W.; Du Prez, F. E. Segmented polymer networks based on poly(N-isopropyl 
 acrylamide) and poly(tetrahydrofuran) as polymer membranes with thermo-responsive 
 permeability. Polymer 2004, 45, 749-757. 
Chapter 4 
 
171 
(502) Hu, Z. K.; Chen, L.; Betts, D. E.; Pandya, A.; Hillmyer, M. A.; DeSimone, J. M. Optically 
 Transparent, Amphiphilic Networks Based on Blends of Perfluoropolyethers and 
 Poly(ethylene glycol). J. Am. Chem. Soc. 2008, 130, 14244-14252. 
(503) Lin, C. P.; Gitsov, I. Preparation and Characterization of Novel Amphiphilic Hydrogels with 
 Covalently Attached Drugs and Fluorescent Markers. Macromolecules 2010, 43, 10017-
 10030. 
(504) Fodor, C.; Kali, G.; Ivan, B. Poly(N-vinylimidazole)-l-Poly(tetrahydrofuran) Amphiphilic 
 Conetworks and Gels: Synthesis, Characterization, Thermal and Swelling Behavior. 
 Macromolecules 2011, 44, 4496-4502. 
(505) Rikkou-Kalourkoti, M.; Patrickios, C. S. Synthesis and Characterization of End-Linked 
 Amphiphilic Copolymer Conetworks Based on a Novel Bifunctional Cleavable Chain 
 Transfer Agent. Macromolecules 2012, 45, 7890-7899. 
(506) Kali, G.; Vavra, S.; László, K.; Iván, B. Thermally Responsive Amphiphilic Conetworks and 
 Gels Based on Poly(N-isopropylacrylamide) and Polyisobutylene. Macromolecules 2013, 46, 
 5337-5344. 
(507) Xu, J.; Qiu, M.; Ma, B.; He, C. “Near Perfect” Amphiphilic Conetwork Based on End-Group 
 Cross-Linking of Polydimethylsiloxane Triblock Copolymer via Atom Transfer Radical 
 Polymerization. ACS Appl. Mater. Interf. 2014, 6, 15283-15290. 
(508) Walker, C. N.; Bryson, K. C.; Hayward, R. C.; Tew, G. N. Wide Bicontinuous 
 Compositional Windows from Co-Networks Made with Telechelic Macromonomers. ACS 
 Nano 2014, 8, 12376-12385. 
(509) Liu, D. E.; Dursch, T. J.; Oh, Y.; Bregante, D. T.; Chan, S. Y.; Radke, C. J. Equilibrium 
 water and solute uptake in silicone hydrogels. Acta biomater. 2015, 18, 112-117. 
(510) Qiu, M.; Zhao, X.-Z.; Liu, D.-P.; He, C.-J. pH sensitive amphiphilic conetworks based on 
 end-group cross-linking of polydimethylsiloxane pentablock copolymer and 
 polymethylhydrosiloxane. RSC Advances 2015, 5, 17851-17861. 
(511) Kang, J.; Erdodi, G.; Kennedy, J. P. Third-generation amphiphilic conetworks. III. 
 Permeabilities and mechanical properties. J. Polym. Sci. A 2007, 45, 4276-4283. 
(512) Cui, J.; Lackey, M. A.; Madkour, A. E.; Saffer, E. M.; Griffin, D. M.; Bhatia, S. R.; Crosby, 
 A. J.; Tew, G. N. Synthetically Simple, Highly Resilient Hydrogels. Biomacromolecules 
 2012, 13, 584-588. 
(513) Xu, J.; Bohnsack, D. A.; Mackay, M. E.; Wooley, K. L. Unusual Mechanical Performance of 
 Amphiphilic Crosslinked Polymer Networks. J. Am. Chem. Soc. 2007, 129, 506-507. 
(514) Du Prez, F. E.; Goethals, E. J.; Schue, R.; Qariouh, H.; Schue, F. Segmented network 
 structures for the separation of water/ethanol mixtures by pervaporation. Polymer Int. 1998, 
 46, 117-125. 
(515) Li, X.; Basko, M.; Du Prez, F.; Vankelecom, I. F. J. Multifunctional Membranes for Solvent 
 Resistant Nanofiltration and Pervaporation Applications Based on Segmented Polymer 
 Networks. J. Phys. Chem. B 2008, 112, 16539-16545. 
(516) Zhang, H.; Zhang, Y.; Li, L.; Zhao, S.; Ni, H.; Cao, S.; Wang, J. Cross-linked 
 polyacrylonitrile/polyethyleneimine–polydimethylsiloxane composite membrane for solvent 
 resistant nanofiltration. Chem. Eng. Sci. 2014, 106, 157-166. 
(517) Tobis, J.; Boch, L.; Thomann, Y.; Tiller, J. C. Amphiphilic polymer conetworks as chiral 
 separation membranes. J. Membr. Sci. 2011, 372, 219-227. 
(518) Guiseppi-Elie, A.; Brahim, S. I.; Narinesingh, D. A chemically synthesized artificial 
 pancreas: Release of insulin from glucose-responsive hydrogels. Adv. Mater. 2002, 14, 743-
 746. 
(519) Schöller, K.; Küpfer, S.; Baumann, L.; Hoyer, P. M.; de Courten, D.; Rossi, R. M.; Vetushka, 
 A.; Wolf, M.; Bruns, N.; Scherer, L. J. From Membrane to Skin: Aqueous Permeation 
 Control Through Light-Responsive Amphiphilic Polymer Co-Networks. Adv. Funct. Mater. 
 2014, 24, 5194-5201. 
(520) Scherble, J.; Ivan, B.; Mulhaupt, R. Online monitoring of silicone network formation by 
 means of in-situ mid-infrared spectroscopy. Macromol. Chem. Phys. 2002, 203, 1866-1871. 
(521) Bruns, N.; Scherble, J.; Hartmann, L.; Thomann, R.; Ivan, B.; Mulhaupt, R.; Tiller, J. C. 
 Nanophase separated amphiphilic conetwork coatings and membranes. Macromolecules 
 2005, 38, 2431-2438. 
(522) Dech, S.; Cramer, T.; Ladisch, R.; Bruns, N.; Tiller, J. C. Solid-solid interface adsorption of 
 proteins and enzymes in nanophase-separated amphiphilic conetworks. Biomacromolecules 
 2011, 12, 1594-1601. 
(523) Mauritz, K. A. Organic-inorganic hybrid materials: perfluorinated ionomers as sol-gel 
 polymerization templates for inorganic alkoxides. Mater. Sci. Eng. C 1998, 6, 121-133. 
   Chapter 4 
 
172 
(524) Mauritz, K. A.; Storey, R. F.; Jones, C. K.: Perfluorinated-Ionomer-Membrane-Based 
 Microcomposites. In ACS Symp. Ser. Vol. 395, Multiphase Polymers: Blends and Ionomers; 
 ACS Symposium Series 395; American Chemical Society, 1989; pp 401-417. 
(525) Bruns, N. Design von amphiphilen Conetzwerken zur Generierung von nanoskaligen 
 Reaktionsräumen für Biotransformationen in nichtwässrigen Medien. University of Freiburg, 
 2007. 
(526) Performance of Sympatex Membrane, http://sympatex.com/en/membrane/213/performance. 
 (accessed June 2015). 
(527) Ramanathan, N. L. A new weighting system for mean surface temperature of the human 
 body. J. Appl. Physiol. 1964, 19, 531-533. 
(528) Farris, S.; Pozzoli, S.; Biagioni, P.; Duo, L.; Mancinelli, S.; Piergiovanni, L. The 
 fundamentals of flame treatment for the surface activation of polyolefin polymers - A review. 
 Polymer 2010, 51, 3591-3605. 
(529) Wang, Y. X.; Jacob, J.; Wingfield, P. T.; Palmer, I.; Stahl, S. J.; Kaufman, J. D.; Huang, P. 
 L.; Huang, P. L.; Lee-Huang, S.; Torchia, D. A. Anti-HIV and anti-tumor protein MAP30, a 
 30 kDa single-strand type-I RIP, shares similar secondary structure and beta-sheet topology 
 with the A chain of ricin, a type-II RIP. Protein Sci. 2000, 9, 138-144. 
(530) Meng, Y.; Lin, S.; Liu, S. F.; Fan, X.; Li, G. R.; Meng, Y. F. A Novel  Method for 
 Simultaneous Production of Two Ribosome-Inactivating Proteins, alpha-MMC and MAP30, 
 from Momordica charantia L. PloS one 2014, 9. 
(531) Wang, Y. X.; Neamati, N.; Jacob, J.; Palmer, I.; Stahl, S. J.; Kaufman, J. D.; Huang, P. L.; 
 Huang, P. L.; Winslow, H. E.; Pommier, Y.; Wingfield, P. T.; Lee-Huang, S.; Bax, A.; 
 Torchia, D. A. Solution structure of anti-HIV-1 and anti-tumor protein MAP30: structural 
 insights into its multiple functions. Cell 1999, 99, 433-442. 
(532) Toohey, K. S.; Sottos, N. R.; Lewis, J. A.; Moore, J. S.; White, S. R. Self-healing materials 
  with microvascular networks. Nat. Mater. 2007, 6, 581-585. 
(533) He, L.; Fullenkamp, D. E.; Rivera, J. G.; Messersmith, P. B. pH responsive self-healing 
 hydrogels formed by boronate-catechol complexation. Chem. Commun. 2011, 47, 7497-7499. 
(534) Tzlil, S.; Kindt, J. T.; Gelbart, W. M.; Ben-Shaul, A. Forces and pressures in DNA packaging 
 and release from viral capsids. Biophys. J. 2003, 84, 1616-1627. 
 
 
Chapter 5 
 
173 
Chapter 5 
Acknowledgments 
The work for this thesis would not be possible without the support of many people 
whom I would like to express my sincere thanks. 
First of all, I would like to deeply thank my parents Ursula and Norbert without 
whom I would not be in the place I am today. Thank you very much for your 
support, love and motivation throughout the years and your believing in me. 
I would especially like to thank my supervisor Prof. Dr. Nico Bruns for the very 
inspiring and wonderful research topics and for his advices, enthusiastic guidance, 
his patience and support in all stages of my PhD work. I really appreciated the 
freedom he has given me for my research and how he let me evolve as a researcher.   
Further, I would kindly like to thank my second supervisor Prof. Dr. Wolfgang Meier 
for hosting me in his group, for his support and for the excellent research 
environment. I also want to thank Prof. Dr. Marcus Textor for showing interest in my 
research and being coexaminer of my thesis. Prof. Dr. J. P. Maier is kindly 
acknowledged for being the chair.  
The NanoArgovia-project would not be possible without the collaboration with 
external partners in Switzerland (Prof. Dr. Uwe Pieles, Dr. Olfa Glaied, Christian 
Rytka (FHNW, Muttenz and Brugg-Windisch), Dr. Jose V. Aurajo (AMI, Fribourg) 
and Markus Hess (Unico swiss-tex, Alpnachstad), the helping support of students 
(Sara Freund, Jonas Barmettler and Andreas Reichmuth) as well as the help of 
people from the University of Basel who did an excellent job with the SEM and 
cryo-SEM analysis (Giovanni Morson, Evi Bieler, Carola Alampi) and the AFM 
measurements (Dr. Justyna Kowal). Thank you very much.  
Like other projects, the thermosome-project would not be possible without the help 
of many people. Thank you very much to Vesna Olivieri, Ursula Sauder and 
Gabriele Persy for the beautiful TEM-images of the thermosome and the conjugates. 
Thank you very much to Adrian Najer for help with the FCS measurements and Drs. 
   Chapter 5 
 
174 
Jason Duskey and Viktoriia Postupalenko for their enormous help with the biological 
applications of the conjugates. 
A big thanks to the “Thermosome-Team” Drs. Kasper Renggli and Martin 
Nussbaumer. It was a great time with you in a scientific and non-scientific aspect.  
Thank you to the students I was supervising and advising in a project that is not part 
of this thesis (Kathrin Höhnerlage, Svetlana Stolarov, Sagana Thamboo and Claudio 
von Planta).  
I would like to thank the people who read in parts through my manuscript and helped 
in improving it (Drs. Gesine Gunkel-Grabole, Martin Nussbaumer, Jason Duskey, 
Kasper Renggli, Jens Gaitzsch).  
Further, thanks go to Grischa Martin, Philipp Knöpfel and Georg Holderied from the 
mechanical and electrical workshop and Jean-Pierre Ramseyer. Thank you to Maya 
Greuter and Danni Tischhauser for the administrative support. 
I am also thankful to my colleagues and friends in the Meier and Bruns research 
groups for their support, their friendship and the time outside the university: Severin 
Sigg, Sven Kasper, Samuel Lörcher, Adrian Najer, Pascal Richard, Bernadetta 
Gajewska, Evgeniia Konishcheva and Drs. Fabian Itel, Farzad Seidi, Dalin Wu, Juan 
Liu, Jason Duskey, Jens Gaitzsch, Viktoriia Postupalenko, Justyna Kowal, Adrian 
Dinu, Gergely Kali, Agnieszka Tajchert, Thomas Schuster and all other people.  
Thanks to all people who are involved in the ScienceSlam.  
I would like to acknowledge the University of Basel for the travel grant I received. 
Special thanks go to my family and friends in Germany and Poland. Further special 
thanks go to Michi, Max, Sarah, Artur (Archie), Jens Martin (Madt), Ami and 
Hannes. Besides my parents I am most thankful to my girlfriend Magda for being 
supportive and the time we are spending together.  
 
 
 
 
 
